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Abstract 
Carbohydrates have been heavily exploited in the development of new 
therapeutic agents. Extensively utilized in nuclear medicine, derivatives such as 
[
18
F]-FDG (13)  have gained broad usage in the diagnosis of malignancies. Displaying 
high selectivity and favourable pharmacokinetics, carbohydrates have subsequently 
been incorporated into peptide-based imaging agents, producing diagnostic probes with 
greatly improved physicochemical properties. The efficient radiolabelling of 
glycoconjugate-based imaging agents however represents a significant challenge, with 
many glycoconjugates prone to degradation under current radiolabelling conditions.  
Compatible techniques such as the copper-assited azide-alkyne cycloaddition 
(CuAAC) “click” reaction have found usage in the synthesis of radiolabelled 
glycoconjugates, linking [
18
F]-radiolabelled glycosyl azides to alkyne-containing 
peptides. The wider application of this approach in the labelling of glycoconjugates 
though has been limited by the incongruity of this process with native amino acids,  and 
peptides or proteins. In this thesis, a methodology for the synthesis of glycoconjugates 
amenable to functionalization by the CuAAC “click” reaction is illustrated.  
The concise, 5-step production of glc- and gal-sugar azido acids 60 and 65 
allowed for the formation of “clickable” glycoconjugates 66-73 in 64-96% yield, linked 
to serine, lysine and α-amino containing (Leu, Met, Gln) amino acids. Possessing 
β-azides at the anomeric position, the CuAAC “click” reaction of these with alkyne 
donors produced the functionalized glycoconjugates 78-87 in 52-85% yield, 
representing the first examples of glycosides linked to an amino acid, and derivatized 
using the CuAAC “click reaction. Conjugation of glc-sugar azido acid 60 to the 
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tripeptide Ac.KPV.NH2 resulted in the glycoconjugate (88), which may be 
functionalized by the CuAAC “click” reaction, thus broadening the scope of this 
methodology to the labelling of biologically-relevant substrates. 
Extension of this methodology to the formation of linkages with 
carboxyl-containing amino acids was also investigated, with the key synthon 6-azido-6-
deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucose hydrobromide (103) successfully 
produced in 8 steps from 1,2;5,6-diisopropylidene-α-D-glucofuranose (93). Amide 
coupling at the anomeric amine of 103 by sidechain carboxyl-containing (Asp, Glu) 
amino acids produced the “clickable” glycoconjugates 110 and 111 in 60-70% yield. 
Subsequent CuAAC “click” reaction with 4-pentyn-1-ol yielded the functionalized 
glycoconjugates 112 and 113 in 62-70% yield, the first examples of functionalized 
glycoconjugates formed from carboxyl containing amino acids.  
Using 6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose (114) as a key 
synthon, thioether-linked glycoconjugates bearing an anomeric or 6-azido group were 
also evaluated. Alkylation of the anomeric azide 6-iodo-6-deoxy-1,2,3-tri-O-acetyl-β-D-
glucosyl azide (117; 40% yield in 3 steps from 114), by the thiol-containing amino acid 
(HCys) 120 did not yield the desired glycoconjugate (124).  Alternatively, glycosylation 
of the HCys derivative 130 by the glycosyl donors 6-azido-6-deoxy-1,2,3,4-tetra-O-
acetyl-D-glucose (125) and 6-azido-6-deoxy-1,2,3-tri-O-acetyl-α,D-glucosyl 
trichloroacetimidate (127) yielded the thioether-linked “clickable” glycoconjugate 131, 
however this was present as an anomeric mixture.  
Subsequently, an efficient method for the formation of thioether-linked 
glycoconjugates utilizing the “click” thiol-ene reaction was developed. The maleimide-
xxvii | P a g e  
 
sugar azido acid conjugate 136 was produced from 60 (66% yield), with “click” thiol-
ene reaction with Fmoc.HCys.OMe (130) producing the functionalized derivative 137 
(62% yield). CuAAC “click” reaction resulted in the functionalized thioether-linked 
glycoconjugates 138, which together with amide-linked examples demonstrated the 
versatility of azidosugars in the formation of functionalizable glycoconjugates. 
Beyond “clickable” glycoconjugates, a strategy for the formation of 
orthogonally-protected Type A and B “clickable” neoglycopeptides was also developed. 
Orthogonal protection of the 4-position of a glc-based glycoside yielded the β-azides 
155 and 156 (7 steps). Containing bulky protecting groups (Trt, MMTrt, PMB) though, 
the development of a superior atom-economical approach was sought, with subsequent 
selective TEMPO/PhI(OAc)2 oxidation of the 2,3-OBz diol 154 producing the 
orthogonally-protected sugar azido acid 161 (88% yield). Consequently, amide coupling 
(164, 50% yield) and 4-OTBS protection (165, 36% yield) yielded key intermediates for 
the production of Types A and B “clickable” neoglycopeptides.  
The scope of this strategy was subsequently broadened to those bearing 
orthogonal protection at the 3-position. Formation of the 6,3-lactone intermediate 166 
from 1-azido-1-deoxy-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) and 
nucleophillic ring opening, produced the 3-OH glycoconjugate 169 (42% over 3 steps). 
Subsequent 3-OTBS protection (66% yield) yielded the orthogonally protected 
derivative 170, which alongside 169 represent key intermediates for the production of 
Types A and B “clickable” neoglycopeptides. In conjunction with the developed 
“clickable” glycoconjugates, these derivatives provide a solid platform for the broader 
utilization of the CuAAC “click” reaction in the formation and functionalization of 
bioconjugates encompassing carbohydrates. 
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Chapter 1 : Introduction 
 
1.1 Carbohydrates – Definition and Structural Diversity  
Carbohydrates, synonymously known as saccharides, are a structurally rich class 
of complex molecules. Comprising carbon, hydrogen and oxygen atoms, carbohydrates 
exist in many different forms, ranging from linear non-reducing (ketose) and reducing 
(aldose) species (Figure 1.1, A and B) consisting of three to nine carbons, to cyclic 
hemiacetal-containing species forming five (pentose - furan) or six (hexose - pyran) 
membered ring systems (Figure 1.1, C and D).
1
  
 
Figure 1.1: Examples of non-reducing (D-fructose, A) and reducing (D-glucose, B) linear 
carbohydrates, which in solution cyclize to form furan (C) and pyran (D) glycosides respectively. 
Bearing multiple hydroxyl groups, carbohydrates form a variety of structural 
isomers. For example, cyclic hexoses such as glucose, mannose, allose, galactose, idose 
and talose are structural isomers with the chemical formula C6H12O6, resulting from the 
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alternating stereochemistry of their hydroxyl groups (Figure 1.2). Some examples such 
as glucose (glc) and galactose (gal) can be further classified as epimers of eachother, 
with these isomers bearing at only one position of the molecule (e.g. C4 in glc/gal, 
Figure 1.2).
1
 Likewise, isomers may also have epimers at multiple stereocentres, with 
mannose (C2), allose (C3) and idose (C5) also epimers of glucose (Figure 1.2) 
 
Figure 1.2: Pyran-based isomers of chemical formula C6H12O6. 
Formed by the conversion of linear aldoses to cyclic pentoses and hexoses, 
epimers of individual isomers including glucose and galactose, may also be produced. 
Occurring at the carbon participating in cyclization (or C1), this is known as the 
anomeric carbon, with epimers at this position specifically known as anomers.
1,2
 
Differing in the configuration of the proton linked to the anomeric carbon, the 
stereochemical assignment of a glycoside is directly relative to its absolute 
configuration. In hexose sugars such as D-glucose, the stereochemistry of both the C1 
and C5 carbon defines the assignment, with an axial proton at the C5 and an equatorial 
proton at the C1 denoting an α-anomer, whilst axial proton at both C1 and C5 carbons 
denote a β-anomer.
2 
The anomeric configuration of many carbohydrates is of great 
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importance, as many carbohydrates exist as multimers of individual saccharides, 
including di-, tri-, tetra- and oligosaccharides.
3
 This can produce isomers of saccharides 
conjugated to each other at the same position, such as maltose and cellobiose, which 
represent α- and β-isomers of a (1→4) linked disaccharide respectively.
2
 Additionally, 
saccharides can form linkages at a variety of different positions and can also form 
glycosidic linkages with a number of different C-, O-, S- and N-acceptors. Hence, 
considering the array of structural permutations that carbohydrates may embody, it is of 
little surprise that carbohydrates are amongst the most analysed chemical entities, with 
their roles in biological systems widely studied.
3,4
 
 
1.2 Roles of Carbohydrates in Biological Systems 
1.2.1 Structural Roles of Carbohydrates 
The structural diversity of carbohydrates underlies their importance in a number 
of biological functions. Generally speaking, these roles can be divided into three main 
categories – structural; cellular signalling and recognition; and energy usage 
metabolism.
5 
In plant, algal, fungal and bacterial species, polysaccharides play an 
important role in maintaining cellular structure.
6
 In green plants and algae, the β(1->4) 
glucose polysaccharide cellulose (Figure 1.3, 1) forms a key component of the cell wall, 
with chains of cellulose forming large hydrogen bonding networks that provide strength 
and stability.
7,8
 These fibrils of cellulose are often reinforced with other polysaccharide 
units, including pectins (Figure 1.3, 2), which are rich in poly-galacturonic acids, and 
hemicelluloses such as xylan, which are rich in D-xylose and pentose glycosides.
 6,9
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In fungi, their cell walls consists of the β(1->4)-linked N-acetyl-D-glucosamine 
polysaccharide chitin (Figure 1.3, 3).
10
 Aligned in fibrils akin to cellulose, chitin 
provides many fungi with strength and flexibility.
 
Interestingly, chitin is also present in 
the shells and exoskeletons of many arthropods - including crustacea and insects,
11
 with 
crosslinking by calcium species (primarily CaCO3) in these structures producing chitin 
that is much harder and stronger than that in fungal species.
10,12
 In bacterial species, 
peptidoglycan (or murien) forms the principle component of the organism’s cell wall.
13
 
Consisting of polymeric residues of N-acetylglucosamine and N-acetylmuramic acid 
(NAM), peptide chains linked to NAM residues allow for inter-strand cross-linking, 
producing a matrix that maintains the strength of the cell wall (Figure 1.3, 4).
13 
 
Figure 1.3: Cellulose (1), xylan (2), chitin (3) and murein (4) – important polysaccharides that 
maintain the cellular structure of plant (A), algal (B), fungal (C) and bacterial (D) species.
14–16 
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In mammalian species, the extracellular matrix that lies between individual cells 
is composed of a variety of different glycosylaminoglycans (GAG’s), including 
hyaluronic acid and chondroitin sulphate, in addition to dermatan sulphate and keratan 
sulphate.
3,17
 These negatively charged unbranched polysaccharides are constituents of 
proteoglycans, core proteins that are heavily glycosylated with polysaccharides.
6,18
 
GAG’s display an uncanny ability to coordinate water molecules, producing a matrix 
that can compress and flex when pressure is applied to them.
6
 Displaying such 
flexibility, it is of no surprise that GAG’s form the basis for tissues under constant 
loading and stress, including bone cartilage.
6,19,20 
 
1.2.2 Carbohydrates in Cellular Signalling, Recognition and Growth 
Many carbohydrate-bearing entities hold key positions in the mediation of cell-
cell recognition processes.
21
 Glycoconjugates are species where one or multiple 
glycosides are linked to a biological molecule via a glycosidic bond,
22
 such as 
glycoproteins and glycolipids, which are the most abundant forms of glycoconjugates 
found in nature.
23
 Linked to one or multiple glycans (short oligosaccharides of 
~3-9 units), glycoproteins play important roles in a number of cellular functions, 
including the lubrication and protection of epithelial tissues,
24
 immunological responses 
and defences, cell-cell attachment, and cellular growth and development.
25–28
  
Mucins, a class of 19 highly glycosylated glycoproteins secreted on the surfaces 
of epithelial cells, form a major constituent of important bodily lubricants such as saliva 
and mucous.
29
 High in molecular weight (~250-500 kDa), mucins are composed of 
oligosaccharide chains attached via O-linked amino acid residues including serine and 
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threonine, and to a lesser degree via N-linked asparagine residues.
24,29
 Mucins are 
integral to the body’s defence against external pathogens and key to their role is their 
capacity for gelation, whereby they can expand and coat cell surfaces, providing a 
physical barrier that both lubricates and protects the cell from pathogens.
24,29
  
Immunoglobins, large Y-shaped proteins that are produced by the immune 
system (B cells) to detect and nullify potential pathogens, utilize carbohydrates in their 
protective functions.
30
 Containing two light and heavy polypeptide chains across two 
regions (Fab and Fc), the Fc region of an antibody interacts with the Fc receptor of 
immune cells - including B lymphocytes, natural killer cells and antigen presenting 
cells, eliciting an immune response (Figure 1.4, A), with glycosylation of the Fc region 
by D-fucose, in addition to N-acetylglucosamine and neuraminic acid residues essential 
for immune activity (Figure 1.4, A).
30–32
 In contrast, the Fab region of an antibody binds 
to a number of different antigens (including pathogens), stimulating an immune 
response upon immune cell attachment. Once again glycosylation is important, with the 
Fab regions of many natural antibodies having affinity for the disaccharide motif 
Gal-(α 1->3)-Gal expressed in a number of bacteria and enveloped viruses, thereby 
providing immunity against such pathogens and protecting cells from infection 
(Figure 1.4, A).
33,34
  
Interestingly, many pathogens also exploit the carbohydrate binding affinity of 
cell surface proteins to avoid detection by the immune system, using cell surface 
proteins that bind specific carbohydrate motifs, known as lectins.
6
 The influenza viral 
envelope is coated with membrane-bound glycoproteins including haemagglutinin and 
neuraminidase that are crucial in viral entry and propagation (Figure 1.4, B).
35,36
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Displaying a high affinity for neuraminic acid residues on the exterior of cell-surface 
membranes, influenza haemagglutinin binds to these residues, bringing the viral 
envelope within close proximity of a host cell (Figure 1.4, B). Membrane fusion with 
the viral envelope induces endocytosis, resulting in viral uptake. Following viral 
replication, neuraminidases present on the surface of newly produced virions aid in their 
expulsion from the cell. Targeting neuraminic acid residues bound to hemagglutinin and 
other cell-surface glycoproteins, cleavage of these residues by neuraminidase triggers 
exocytosis, resulting in the release of viral particles that may infect other host cells.
37,38
  
 
Figure 1.4: Roles of carbohydrate-bearing macromolecules in cellular signaling, recognition and 
growth. A: Ig binds disaccharide (Gal(α1->3)Gal) antigens (Fab region) and requires glycosylation 
to bind pathogens (Fc region), B: Influenza viruses utilize carbohydrate-binding glycoproteins 
hemagglutinin and neuraminidase for viral entry and release.
39 
Neuraminic acid residues are also key mediators of cell turnover, coating the 
outer surface of red blood cells (RBCs)
40,41
 and other cells present in the circulatory 
system (thrombocytes, leukocytes and hepatocytes, etc.).
42–44
 Cleavage of these residues 
either by serum neuraminidases or by chemical hydrolysis, unmasks galactose residues 
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underneath the neuraminic acid. As a marker of cellular aging, these residues attract the 
attention of macrophages, which attach to the cells at these residues and subsequently 
induce phagocytosis (Figure 1.5, A).
45,46
 Additionally to cellular clearance, 
carbohydrates also play important roles in cellular growth, with glycoprotein hormones 
such as erythropoietin (EPO) pivotal to the production of red blood cells.
47
 Heavily 
glycosylated with branched saccharide chains, these chains stabilize the protein 
structure of EPO, allowing it to bind to the erythropoietin receptor and stimulate the 
growth of red blood cells in the bone marrow (Figure 1.5, B).
47 
 
Figure 1.5: Roles of carbohydrates in cellular turnover and growth. A – Induction of phagocytosis 
of red blood cells (RBCs) following cleavage of neuraminic acid residues from the cell surface. 
B - Structure of erythropoietin, bearing heavily glycosylated chains provide structural stability.
48 
 
 
 1.2.3 Carbohydrates in Energy Usage, Storage and Metabolism  
The central role of carbohydrates in the regulation of cell structure, recognition 
and protection, is matched by their importance in the production and storage of energy. 
Glycolysis, a key metabolic process that exists in all organisms, converts glycosides 
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into the metabolite pyruvate (Scheme 1.1).
5
 Enzymatically driven and readily occurring 
in the cytosol of cells, glycolysis directly produces two molecules of adenosine 
triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH).
5 
 
 
Scheme 1.1: Glycolysis, a key metabolic pathway in the production of free energy from 
carbohydrates.
5 
Both high energy coenzyme molecules, ATP and NADH are the main providers 
of chemical energy within a cell.
5
 In addition, pyruvate molecules produced as a by-
product of glycolysis can be directly fed into the tricarboxylic acid (TCA) cycle in 
aerobic organisms, which following enzymatic conversion to oxaloacetate and citrate, 
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(in addition to other key intermediate molecules) results in the production of an 
additional ~34 molecules of ATP per hexose sugar consumed. Hence the utilization of 
carbohydrates provides the most readily accessible source of energy to cells.
49,50 
In the absence of available glucose, proteins and lipids may also be converted to 
glucose in order to meet energy requirements via gluconeogenesis. However, the 
catabolism of lipid and protein reserves is energy intensive, with the production of 
glucose from these sources resulting in a 33% decrease in available energy.
51
 Therefore, 
a readily accessible stored form of glucose, known as glycogen is utilized.
 
Glycogen, 
which is
 
present in muscle tissue and the liver as a network of branched glucose 
polysaccharides, is readily formed by the action of the enzyme glycogen synthase.
5
 In 
times of high blood glucose (e.g., postprandial), glycogen synthase can store glucose as 
glycogen via chain addition (Scheme 1.2). In contrast, glycogenolysis – the breakdown 
of glycogen, can be enacted by the enzyme glycogen phosphorylase, liberating glucose 
to curtail low blood glucose levels (Scheme 1.2).
5
 It is this enzyme in addition to the 
hormones insulin and glucagon that modulate the secretion, storage and concentration of 
blood glucose.
5 
 
Scheme 1.2: Pathways for the production and storage of free glucose, highlighting its production 
via gluconeogenesis or glycogenolysis, or its storage as the polysaccharide glycogen.
5
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Beyond the production of free energy from the metabolism of glucose, 
carbohydrates play key roles in other metabolic functions. Processes such as xenobiotic 
metabolism utilize glucuronidation in the breakdown and excretion of substances that 
are foreign to an organism.
52,53
 The 6-carboxyl derivative of glucose, glucuronic acid is 
conjugated to xenobiotic substances in the liver that have been processed by Phase I 
metabolism, with glucuronidation representing the most common detoxifying 
transformation that takes place under Phase II metabolism (Scheme 1.3).
54
 Ionisable at 
physiological pH, substitution of molecules linked to glucuronic acid following reaction 
with uridine diphosphate glucuronate - a carrier of glucuronic acid, produces 
metabolites that are significantly more polar, allowing for their excretion in urine or 
bile.
55
 The importance of this process is exemplified in drug metabolism, where the rate 
of clearance may have a pronounced influence on the effectiveness of a dosage.
53,55
    
 
Scheme 1.3: Xenobiotic metabolism, a key process in the metabolism and removal of foreign 
substances, including pharmacologically active species.
53
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1.3 Carbohydrates in Medicinal Chemistry 
 The integral role of carbohydrates in such a vast array of biological systems has 
attracted the attention of researchers keen to exploit their therapeutic potential. Whilst 
beyond the scope of the current discussion, the range of conditions and diseases that are 
targeted by carbohydrate-based or containing entities is truly diverse (Figure 1.6). These 
range from aminoglycoside and glycopeptide antibiotics such as streptomycin and 
vancomycin (5 and 6)
56–58
 through to cardiac glycosides for the treatment of heart 
failure such as digoxin,
59
 and glycosidase inhibitors for the treatment of influenza (e.g. 
Zanamivir (Relenza 
®
)
60
 7 and Oseltamivir (Tamiflu 
®
 (8)) 
61
 and also for diabetes 
(e.g. Miglitol (9) and Voglibose (10)).
62,63
 
  
Figure 1.6: Carbohydrate-based therapeutic agents used as antibiotics (5 and 6), and in the 
treatment of influenza (7 and 8) and diabetes (9 and 10).
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In addition to treating the above conditions, carbohydrate-containing species 
have also displayed potential in the treatment of a number of malignancies, targeting 
glycoproteins upregulated by metastatic cells. Many of these play important roles in 
cellular structure and growth, with examples such as the heparan sulphate mimetic 
PI-88 (Muparfostat, 11) that inhibits angiogenesis, reaching phase III clinical trials for 
the treatment of post-resectional hepatocellular carcinoma (Figure 1.7).
64,65
   
 
Figure 1.7: Heparan sulphate mimetic PI-88 (11) and pentavalent conjugate vaccine 12, bearing 
antigens for tumour-upregulated glycoproteins (MUC-1 – Tn, TF, STn), glycolipids (Globo-H) and 
gangliosides (GM2), agents under evaluation for their treatment of malignancies.
 
Chapter 1: Introduction 
14 | P a g e  
 
 Furthermore, a number of other heavily glycosylated glycoproteins are over-
expressed in tumour cells, including a number of mucins.
66 
MUC-1 is a mucin 
glycoprotein that is bound to the apical surface of epithelial cells present in the tissues 
of the lungs, stomach and intestines, and represents an excellent tumour marker, with 
the targeting of mucins and other markers using tumour associated carbohydrate 
antigens (TACAs) representing a promising strategy towards the development of new 
anticancer vaccines.
66–68
 A number of vaccines bearing these antigens have been 
developed, with many bearing multiple carbohydrate-based antigens targeting MUC-1 
(e.g Tn, TF and STn). Additionally, many of these vaccines also target glycolipids (e.g 
Globo-H), glycophospholipids and gangliosides (e.g, GM2), which are also 
overexpressed on the surfaces of a range of cells.
68
 This work has been pioneered by 
Danishefsky and co-workers, who have developed a number of mono, tri and 
pentavalent cancer vaccines.
69,70 
Linked to an immunogenic protein such as keyhole 
lymphet haemocyanin (KLH),
71
 pentavalent vaccines such as 12 (Figure 1.7) have 
displayed great promise in providing targeted, selective treatment to specific metastases, 
reaching Phase I clinical trials.
69,70
 
 
 
1.4 Carbohydrates in Nuclear Imaging 
Whilst carbohydrate-based medicines have been developed for the treatment of a 
variety of different illnesses, their greatest impact has been in the diagnosis of a number 
of different malignancies. In Australia, cancer is a leading cause of mortality and 
morbidity accounting for around 30% of deaths in 2011, with approximately 1 in 2 men, 
and 1 in 3 women expected to be diagnosed with cancer by the age of 85.
72
 However, 
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whilst a major cause of death in Australia, the actual rate of morbidity from cancer has 
decreased over the last thirty years, with 16% fewer people dying from cancer today as 
opposed to thirty years ago.
72
 The survival rate for sufferers of the most common 
cancers has also improved dramatically, with 30% more people surviving cancer than 
twenty years ago, and the survival rate for sufferers five years after diagnosis rising 
by 60%.
72
 Beyond the development of new and improved cancer therapies, the 
improvement in cancer survival can be attributed to three main factors: 
 A push towards earlier detection of malignancies 
 The development of tumour-targeting diagnostic probes/imaging agents 
 More accurate means of detecting malignancies (PET/SPECT) 
Greater public awareness of the warning signs and symptoms of particular 
cancer types have dramatically decreased the time between occurrence and diagnosis, 
resulting in the treatment of cancer in the early stages and limiting the spread and 
proliferation of tumours to other tissues.
72
 However, it can be equally said that the 
development of new molecular probes that specifically target tumours has had a 
profound impact on the diagnosis of malignancies.
73
 Incorporating radionuclides linked 
to a probe that targets specific features of different malignancies, these probes are 
delivered to, and accumulate in the targeted tumour.
73
 When coupled with techniques 
that quantify the radiation emitted by the attached radionuclide, such as Positron 
Emission Tomography (PET) or Single Photon Emission Computerized Tomography 
(SPECT),
74,75
 the use of diagnostic probes provides an accurate 3D depiction of the size, 
shape and distribution of metastases, allowing for their treatment or removal.
76 
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1.4.1 
18
F-Fluorodeoxyglucose ([
18
F]-FDG) 
Of the diagnostic probes developed over the last 40 years, the radiolabelled 
glucose derivative [
18
F]-fluorodeoxyglucose ([
18
F]-FDG, 13, Figure 1.11) is by far the 
most widely used and regarded, revolutionizing the diagnosis of metastatic tumours.
77
 
First described in 1969,
78
 and developed for nuclear imaging in 1976 at the Brookhaven 
National Laboratory,
79
 [
18
F]-FDG is fluorinated at the 2-position with radioactive 
fluorine-18 (T1/2 = 109 minutes), a positron-emitting radionuclide.
80
 Taken up by tissues 
that maintain a high rate of glucose metabolism, the 2-fluoro group prevents the initial 
metabolism by glycolysis, with eventual radioactive decay of fluorine-18 to oxygen-18 
allowing for the fast metabolism and clearance of 13 identical to that of naturally 
occurring hexoses.
81
 As metastatic tissues require high quantities of glucose to maintain 
their growth, and [
18
F]-FDG is not metabolised until radioactive decay occurs, the 
localization of [
18
F]-FDG in these tissues ensues. Using PET/SPECT methods, contrast 
differences of tissues containing [
18
F]-FDG to those that don’t (signal to noise ratio) are 
quantified to highlight the presence of high glucose-metabolizing tissues, which are 
subsequently used to diagnose the presence of malignancies (Scheme 1.4).
81 
 
Scheme 1.4: Injection of [
18
F]FDG into a patient and analysis using Positron Emission Tomography 
(PET), allowing for the 3D visualization of the size, shape and distribution of malignancies. 
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Whilst the use of [
18
F]-FDG has significantly improved the diagnosis of a 
number of cancer types, for some its use has been rather problematic. As [
18
F]-FDG 
exploits the high glucose metabolism of metastatic tissues, a lack of target selectivity 
has been encountered, with this phenomenon primarily observed in tissues that would 
normally exhibit a high rate of glucose metabolism.
82
 This particularly relates to 
neuroendocrine tumours of the brain,
83,84
 gastrointestinal tract
85
 and pancreas,
86
 where 
the presence of metastatic tissues in close proximity to naturally high glucose-
metabolizing tissues has made accurate diagnosis difficult, leading in some cases to 
false positives and misdiagnosis.
85
 Though the use of [
18
F]-FDG in the diagnosis of 
metastases at these sites still bears some clinical significance, efforts have been made to 
develop more selective means of  tumour diagnosis in these tissues.
87
  
 
1.4.2 Peptide Imaging Agents  
In addition to the exploitation of high glucose metabolism by [
18
F]-FDG in the 
diagnosis of malignancies, a large number of non-carbohydrate imaging agents have 
also been developed.
87
 Accompanying the upregulation of cell surface glycans in 
tumour cells, a number of different cell-membrane receptors are also upregulated that 
promote tumour growth and proliferation.
87 
Appearing in much larger numbers in 
tumour cells compared to healthy cells, these receptors represent good diagnostic 
markers for defining the presence and spread of malignancies.
87
 Consequently, a 
number of peptide imaging agents have been developed that target receptors associated 
with one or multiple forms of cancer.
88
 These peptides include mimetics of the 
endogenous peptides somatostatin,
89,90
 α-melanocortin stimulating hormone (α-MSH)
91
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and neuropeptide-Y,
92
 which are associated with, and whose receptors are upregulated 
in neuroendocrine, skin and breast cancers respectively (Table 1.1, Entries 1-3). 
 
Table 1.1: Native peptides upregulated in various cancers and their mimics used as diagnostic 
probes in nuclear imaging.
88
 
Native Peptide Tumour/Cancer Type Probes 
Somatostatin 
α-MSH 
Neuropeptide Y 
Bombesin/GRP 
Neuroendocrine, melanoma, breast 
Melanoma 
Breast 
Lung, colon, glioblastoma, prostate 
Octreoscan® 
[
111
In]DOTA-NAPamide 
(Cu/DOTA)
4
]BVD-15 
[
99m
Tc]Bombesin 
 
These also include derivatives of exogenous peptides such as 
Bombesin (Table 1.1, Entry 4), which is derived from the toad Bombina bombina.
93
 A 
homologue of the mammalian Gastrin-releasing Peptide (GRP), Bombesin binds to 
GRP receptors, which are overexpressed in lung, colon and prostate cancer.
94,95
 Peptide 
imaging agents targeting overexpressed receptors have been highly beneficial as 
diagnostic tools. Radiolabelled cyclic peptides imcluding  In-111-Octreotide 
(Octreoscan®, Mallinckrodt), an octapeptide derivative of somatostatin-14 that shows 
high affinity for somatostatin receptors (sst) upregulated in neuroendocrine tumours, has 
found broad clinical use.
96
 However, despite such promise the clinical utility of these 
imaging agents has been fraught with a number of challenges. A common problem 
encountered with their use is in vivo degradation, with many peptide imaging agents 
susceptible to the actions of intracellular proteases.
73
 Additionally, the reabsorption of 
small peptides by glomerular filtration in the kidneys often limits the quantity of 
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radiotracer that reaches the desired target, thereby exposing the kidneys to potential 
nephrotoxicity, and large doses of radiation.
97
 Finally, if the utilized imaging agent does 
indeed reach the desired target they often suffer from poor tumour retention, which has 
the effect of reducing the quality of the diagnostic scan performed by reducing the 
signal to noise ratio.
98
 Considering these issues, in addition to those encountered in the 
use of [
18
F]-FDG, it is evident that their problems with both selectivity and clearance 
are balanced by their opposing properties. The high selectivity for metastatic tissues 
possessed by peptide imaging agents, in addition to the high tumour retention and 
clearance exhibited by [
18
F]-FDG together impart properties that would be ideal for a 
diagnostic agent. Thus, a number of researchers have worked to develop strategies that 
would combine these properties of peptide imaging agents and [
18
F]-FDG.
 
  
1.4.3 Glycoconjugation – Improving the Pharmacokinetics of Peptide 
Imaging Agents 
1.4.3.1 Iodine-125 Radiolabelled Imaging Agents 
As a result of their complimentary properties, a number of carbohydrate-
containing peptide imaging agents have been developed. These include cyclic 
glycoconjugates bearing the peptide motif RGD (Arg-Gly-Asp), that display a high 
affinity for the αvβ3 integrin.
99
 A heterodimeric transmembrane glycoprotein that 
mediates cell to cell matrix interactions, αvβ3 is upregulated in metastatic tissues and is 
an important mediator of tumour invasion and angiogenesis.
100
 Initial derivatives of 
RGD developed by Wester and co-workers incorporated a cyclic pentapeptide also 
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bearing (Lys; K) and tyrosine (Tyr; Y) residues, with the presence of a sugar on the 
sidechain 
ε
NH2 of the lysine modulating the peptides’ lipophilicity.
99
 The presence of 
the tyrosine residue allowed for radioiodination with iodine-125, producing the 
radiolabelled glycosylated RGD derivative 14 (Figure 1.8).
99 
 
 
Figure 1.8: Iodine-125 radiolabelled glycoconjugate imaging agents, based on the cyclo-RGD (14) 
and octreotide (15 and 16) peptide scaffolds.
99,101–104 
The marked reduction in lipophilicity of 14 compared to the non-glycosylated 
derivatives inspired the translation of this approach to other diagnostically relevant 
peptides. This is demonstrated by the [
125
I]-labelled derivatives 15 and 16, and the 
maltotriose-containing derivative 17, which incorporate the octapeptide somatostatin 
derivative Octreotide (Figure 1.8).
102
 Whilst the lipophilicity of αvβ3 and sst-targeting 
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imaging agents 14-17 has been significantly decreased by glycosylation, the use of 
iodine-125 as a radionuclide for labelling in these examples limits their usability, with 
the long-half life (T1/2 = 59.4 days) and requirement of a tyrosine residue for 
introduction being limiting factors.
105
  
 
1.4.3.2 Fluorine-18 Radiolabelled Imaging Agents 
To overcome these hurdles, Wester and co-workers developed a strategy that 
allowed for the glycosylation and radiolabelling of peptides with fluorine-18
106
. 
Utilizing a galacturonic acid-derivative linked via the terminal lysine NH2 of the cyclic 
peptide (-RGDFK-), acylation with p-nitrophenyl-2-[
18
F]fluoropropionate ([
18
F]-NPFP) 
resulted in the [
18
F]-radiolabelled glycoconjugate 18, which is more commonly known 
as [
18
F]GalactoRGD (Figure 1.9).
99,107–109
 Radiolabelled on the carbohydrate as opposed 
to the peptide chain, the shorter half-life of fluorine-18 has led to an increase in the 
translation of cyclic-RGD derivatives to the clinic, with [
18
F]GalactoRGD considered 
the “gold standard” for the detection and diagnosis of angiogenesis.
108
 Furthermore, the 
use of the 2-[
18
F]fluoropropionate method essentially allows for the introduction of 
fluorine-18 at any site bearing a free amino group.
 
As a direct result of the success of 
[
18
F]GalactoRGD, p-nitrophenyl-2-[2-[
18
F]fluoropropionate has also been used to 
introduce fluorine-18 into octreotide derivatives, resulting in the [
18
F]-radiolabelled 
derivative 19 (Figure 1.9).
76
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Figure 1.9: Fluorine-18 radiolabelled imaging agents 18 and 19 based on the cyclo-RGD and 
octreotide peptide scaffolds, with both agents glycosylated and labelled at lysine.
76,109  
 
1.4.3.3 Alternative Methods for the Introduction of Fluorine-18 
 A variety of different radiofluorination methods exist in addition to the use of 
p-nitrophenyl-2-[
18
F]fluoropropionate (20). For the introduction of fluorine-18 into 
derivatives such as 18 and 19, this includes the use of different prosthetic groups (akin 
to [
18
F]-NPFP), and electrophilic and nucleophilic fluorination methods.
110
 Introducing 
a fluorine-18 atom to a respective amine through acylation, the actions of [
18
F]-NPFP 
have been mirrored by other [
18
F]-bearing prosthetic groups, such as N-succinimidyl-4-
[
18
F]fluorobenzoate ([
18
F]-SFB; Figure 1.10, 21). Additionally, prosthetic groups that 
label via a different ligation method have also been used, with imidation and alkylation 
by 3-[
18
F]fluoro-5-nitrobenzimidate ([
18
F]-NFB; Figure 1.10, 22) and 
4-[
18
F]fluorophenacyl bromide ([
18
F]-FPB; Figure 1.10, 23) are also common.
77,106   
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Figure 1.10: [
18
F]-Containing prosthetic groups utilized in the synthesis of 
18
F-radiolabelled probes.
106 
The exploitation of these prosthetic groups and their respective conjugative 
techniques provides a means for utilizing fluorine-18 in the radiolabelling of peptides 
and proteins.
 
However,
 
a major disadvantage of these methods is their synthetic 
complexity, with the prosthetic groups described requiring numerous synthetic steps and 
long reaction times for their production. Often, these factors result in the isolation of 
prosthetic groups containing fluorine-18 in yields much lower than what could be 
expected based on the initial amount of radionuclide available, which is also known as 
radiochemical yield  (Table 1.2).
106
 Additionally, bar a small number of examples,
111–113
 
the use of nucleophilic and electrophilic radiofluorination methods have largely been 
avoided in the development of radiofluorinated peptides. The diversity of reactive 
groups present on a peptide limit the use of nucleophilic radiofluorination methods, with 
electrophilic radiofluorination also limited by the need for the use of carriers with 
agents such as [
18
F]-F2.
106
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Table 1.2: Efficiency of prosthetic groups commonly used in the radiolabelling of peptides and 
glycoconjugates with fluorine-18.
106
 
Method 
18
F Labelling Agent # Steps Time 
(min) 
RCY(%) 
Acylation 4-nitrophenyl-2-[
18
F]fluoropropionate 
N-succinimidyl-4-[
18
F]fluorobenzoate 
3 
3 
90 
30-35 
60 
18 
Imidation 3- [
18
F]fluoro-5-nitrobenzimidate 3 45 20-33 
Alkylation 4- [
18
F]fluorophenacyl bromide 
N-(p-[
18
F]fluorophenyl)maleimide  
3 
4 
75 
100 
28-40 
15 
 
Hence, considerable research has been undertaken into the further development 
of more efficient labelling methods for glycopeptide imaging agents. One method that 
has emerged is the labelling of peptides using [
18
F]-5-fluoro-5-deoxyribose ([
18
F]-FDR, 
24) through oxime linkages. Developed by Xiang-Guo Li and David O’Hagan from the 
University of St Andrews, [
18
F]-FDR is synthesised from a tosylated, protected 
furanoside by nucleophilic radiofluorination and deprotection (Scheme 1.5).
114
 Isolated 
in high purity, 24 can be incorporated into peptides bearing an oxime via furan ring 
opening, with 95% conversion of 24 to an oxime-linked 
18
F-radiolabelled glycopeptide 
observed (Scheme 1.5).
114
 Directly labelling the glycoside used prior to peptide 
conjugation, this method provides an alternative to the use of prosthetic groups, limiting 
the exposure of the radiolabelled glycoconjugate to harsh reaction conditions. One issue 
that remains with this method though is the potential formation of cis and trans (E/Z) 
isomers from peptide conjugation, a result of labelling via ring opening at the anomeric 
carbon of 24.
115,116
 A relatively minor issue though, the promise of this strategy has 
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supported its wider usage in the fluorine-18 radiolabelling of peptides. Beyond this 
example though, significant attention is still being paid to approaches that could be 
utilized in tthe production radiolabelled glycoconjugates encompassing fluorine-18 and 
other radiolabels commonly used in nuclear medicine.  
 
 
 
Scheme 1.5: Oxime-linkage method for the synthesis of 
18
F-radiolabelled glycoconjugates developed 
by Li and O’Hagan.
114–116 
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1.5 The Copper Assisted Azide-Alkyne [3 + 2] Huisgen 
Cycloaddition (CuAAC).  
1.5.1 Background and Mechanism 
 One method that has been widely exploited for its labelling potential is the 
copper-assisted azide-alkyne [3 + 2] cycloaddition (CuAAC). Initially reported 
seperately in 2001 by the groups of Barry Sharpless and Valery Folkin from the Scripps 
Research Institute, and Morten Meldal from the Carlsberg Laboratory,
117–119 
the CuAAC 
reaction builds on the Huisgen 1,3-dipolar cycloaddition developed by Rolf Huisgen in 
1961 to produce 1,2,3-triazoles from azide and alkyne precursors.
120
 The catalysis of 
this reaction by Cu(I) species results in the selective production of 1,2,3-triazoles 
bearing a 1,4-substitution pattern (Scheme 1.6), allowing for the preparation of complex 
molecules from fairly simple synthons. The CuAAC reaction is often discussed 
alongside other modular ligation methods, with this field of reactions referred to 
collectively as “click chemistry”. Subsequently, as the CuAAC is the most popular of 
these reactions, it is often described as the quintessential “click” reaction.
117 
 
Scheme 1.6: Regioselective comparison of the Huisgen 1,3-dipolar azide-alkyne cycloaddition to the 
copper-assisted and ruthenium-assisted azide-alkyne cycloadditions (CuAAC and RuAAC). 
118,120,121
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Mechanistically, metallation of an alkyne by Cu(I) ions, results in the Cu-alkyne 
intermediate A and the release of a proton (Scheme 1.7). Next, the dissociation of 
ligands associated with the Cu(I) ion (not shown) and secondary metallation of an 
azide-bearing group to the copper ion via the proximal nitrogen of the azide, result in 
the formation of the alkyne-Cu-azide intermediate B (Scheme 1.7). Within close 
proximity to each other, the distal nitrogen of the azide group of B undergoes 
intramolecular attack of the distal carbon (C2) of the alkyne, resulting in the unusual 
six-membered ring intermediate C (Scheme 1.7). Under immense steric strain, a 
rearrangement occurs whereby the six-membered ring undergoes ring contraction, 
resulting in a 5-membered triazole ring with the Cu(I) bound to the 5-position (D, 
Scheme 1.7). Subsequently, exchange between the Cu(I) ion and a proton results in the 
formation of a 1,4-substituted-1,2,3-triazole, with recycling of the Cu(I) species into the 
catalytic cycle allowing for the propagation of the reaction (Scheme 1.7).
122
 
Alternatively to the CuAAC reaction, the selective formation of 1,5-substituted-
1,2,3-triazoles may also be achieved, with ruthenium complexes 
such as pentamethylcyclopentadienylbis(triphenylphosphine)ruthenium(II) chloride 
[Cp*RuCl(PPh3)2].
121
 This variation of the Huisgen 1,3-dipolar cycloaddition is known 
as the ruthenium-catalysed azide-alkyne cycloaddition (RuAAC, Scheme 1.6).
121
 The 
rate-limiting steps in both the CuAAC and RuAAC reactions are the specific formation 
of the triazole ring, with the transformation of 6-membered energetically unfavourable 
metallocycles resulting in a significant increase in reaction kinetics compared to the 
Huisgen 1,3-dipolar cycloaddition. In particular, the CuAAC reaction experiences a 10
7
 
to 10
8
-fold increase in the overall rate of reaction at room temperature compared to the 
uncatalysed reaction.
122
 Considering that the CuAAC “click” reaction utilizes a catalytic 
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quantity of Cu(I) ions, and is susceptible to further rate enhancements through the 
modulation of catalyst loading (1-10%) and temperature, the CuAAC “click” reaction 
represents a flexible, efficient and quick method for the conjugation of different 
chemical entities.
122  
 
Scheme 1.7: Proposed mechanism for the formation of 1,4-substituted-1,2,3-triazoles via the 
CuAAC “click” reaction.
122 
 
1.5.2 Utilization of the CuAAC “Click” Reaction with Carbohydrates 
 As a result of the convenience of the CuAAC “click” reaction in the conjugation 
of small molecules, its use in the development of new carbohydrate-containing entities 
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has been extensive.
123–125
 Azides are widely used in carbohydrate chemistry, with the 
first examples of glycosyl azides (glycosides bearing azides at the anomeric position) 
produced in 1930, pre-dating both the discovery of the CuAAC “click” reaction and the 
Huisgen 1,3-dipolar cycloaddition.
126
 Subsequently, glycosyl azides comprise the bulk 
of the literature utilizing the CuAAC “click” reaction in carbohydrate chemistry, with 
their ease of access through anomeric azidonation allowing for their efficient 
derivatization with a plethora of alkyne-containing molecules.
127
 The ability to 
efficiently produce diverse libraries has supported their use in medicinal chemistry, 
where the utility of this reaction has enabled the production of diverse libraries of 
biologically active compounds. This has been illustrated previously by those such as 
Poulsen and co-workers, who successfully demonstrated the utility of the CuAAC 
“click” reaction in the generation of multiple libraries of sulphonamide-containing 
glycoconjugates.
128–130
 Utilizing CuSO4 and sodium ascorbate to generate Cu(I) from 
Cu(II) in situ for catalysis of the “click” reaction, the synthesised glycoconjugates 
inhibit cancer-associated carbonic anhydrase (CA) enzymes at nanomolar 
concentrations (Scheme 1.8).
128,129
 
 
 
Scheme 1.8: Synthesis of carbonic anhydrase inhibitors by Poulsen and co-workers, utilizing the 
CuAAC “click” reaction.
128–130
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 Moreover, the use of glycosyl azides and the CuAAC “click” reaction has been 
investigated in the development of new glycoconjugation methods with biologically 
relevant molecules, including amino acids. Rutjes and co-workers have illustrated the 
versatility of glycoconjugates in mimicking linkages found in nature. Linking glycosyl 
azide (25) and alkyne-containing amino acids/dipeptides together using the CuAAC 
“click” reaction, they have produced triazole-linked glycosylamino acids and 
glycopeptides such as 26 (Scheme 1.9).
131
 Alternatively, triazole-linked glycosylamino 
acids utilizing glycosides bearing C-linked alkynes at the anomeric centre have also 
been developed. These include the α- and β-acetylenic glucose derivatives 27 and 28, 
which were linked to azide-bearing amino acids to produce the triazole-linked 
glycosylamino acids 29-32 (Scheme 1.9).
131
  
 
 
Scheme 1.9: Synthesis of triazole-containing glycosylamino acids via the CuAAC “click” reaction.
131
 
 In addition to these methods that utilize carbohydrates bearing azides or alkynes 
directly conjugated to the sugar backbone, a number of examples have been produced 
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where these moieties are linked to a respective carbohydrate via a prosthetic group. This 
ligation strategy has found particular use in cellular imaging, where glycosides may be 
fed to an organism (or cells) and subsequently expressed in cell surface 
glycoproteins.
132 
This work has been pioneered by Carolyn Bertozzi and co-workers, 
who have utilized acetylated mannosamine derivatives bearing a 2-linked pentynoyl 
group (such as 33) to label Chinese hamster ovary (CHO) cells.
133
 Taken up by these 
cells and converted to alkynylneuraminic acid, these alkynyl-containing species are 
incorporated into cell-surface glycoproteins (Scheme 1.10). When cells bearing these 
groups are washed with Cu(I) species, a chelating ligand that specifically stabilizes the 
Cu(I) oxidation state (TBTA, Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine)  and 
an azide-bearing fluorescein, the CuAAC “click” reaction ensues. This reaction 
produces cells labelled by triazole-linked fluorosceins, that can be visualized using 
fluorescence microscopy (Scheme 1.10).
133 
 
Scheme 1.10: In vivo CuAAC “click” reaction of Chinese hamster ovary (CHO) cells fed 33, 
allowing for their visualization under fluorescence microscopy.
133 
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 A consideration in the usage of this method, is the impact of Cu toxicity to the 
organism, resulting from the potential generation of reactive oxygen species (ROS).
134
 
Accordingly, methods that limit the need for the use of copper catalysis in the formation 
of triazoles have been investigated, with the most well known utilizing strained alkynes 
in the formation of triazole-linked glycoconjugates. Again pioneered by Carolyn 
Bertozzi and co-workers, this approach has been widely used in the labelling of cell 
surface glycoproteins.
135
 The utility of these synthons is exemplified by the work of 
Kevin Brindle and co-workers at the University of Cambridge, who have used a strain-
promoted “click” approach to label mouse tumour cells.
136
 Following the injection of a 
galactosamine derivative bearing an azide group into live mice, incubation of the mice 
and cellular uptake of the probe, resulted in incorporation and externalization of it in 
cell-surface glycoproteins.
136
 Subsequent injection of a strained cyclooctyne derivative 
resulted in Cu-free triazole formation, which upon further conjugation allowed for the 
visualization of labelled tumour cells by fluorescence microscopy (Scheme 1.11).
136 
 
Scheme 1.11: In vivo strain-promoted Cu-free “click” reaction of mouse tumour cells fed an 
azidogalactosamine, allowing for their visualization under fluorescence microscopy.
136 
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1.5.3 Fluorine-18 Labelling of Carbohydrates utilizing the CuAAC 
“Click” Reaction 
Based on the utility of the CuAAC “click” reaction in the synthesis of 
glycoconjugates, the potential of this method to develop biologically-relevant probes 
labelled with fluorine-18 has been evaluated. Initial work in this area by Kim and 
co-workers focussed on the production of 
18
F-radiolabelled derivatives of D-glucose.
137
 
Starting from 2,3,4,6-tetra-O-acetyl-β-D glucopyranosyl azide (25), a CuAAC “click” 
reaction with 3-butyn-1-ol was performed, resulting in the 1,4-triazole containing 
glycoside 34, Subsequent tosylation of the primary alcohol group (35), radiofluorination 
using nBu4N[
18
F]F and Zemplén deacetylation resulted in the 
18
F–radiolabelled triazole-
bearing glycoside 36 in 21% radiochemical yield from 25 (Scheme 1.12).
137 
 
 
 
Scheme 1.12: Synthesis of 
18
F-radiolabelled glucose derivative 36 from direct radiofluorination of a 
triazole-containing derivative 35.
137
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Using SN
2
 nucleophilic displacement of a tosylate group to introduce 
fluorine-18, the synthesis of 36 directly from β-D-glucopyranosyl azide (37) has also 
been performed, with the CuAAC “click” reaction of [
18
F]-4-fluoro-1-butyne (produced 
from 4-butyn-1-ol, Scheme 1.13) and 37 resulting in the 
18
F-radiolabelled triazole-
bearing glycoside 36 in 30% radiochemical yield (Scheme 1.13).
137
 This efficiency of 
the CuAAC “click” radiofluorination has also been replicated in our research group, 
using 2-deoxy-2-N-acetyl-3,4,6-tri-O-acetyl-β-D-glucopyranosyl azide and 
[
18
F]-4-fluoro-1-butyne, resulting in the isolation of the desired radiolabelled glycoside 
in 22% radiochemical yield (unoptimised).
138
 In comparison to the acylation and 
imidation methods previously described, the radiochemical yield gained for 36 
represents a decrease from those previously observed, with the high volatility of 
[
18
F]-4-fluoro-1-butyne (b.p 45°C) believed to be a major contributor to these results. 
Thus, the use of less volatile alkynes is key to the utilization of this methodology for 
18
F-radiolabelling. 
 
Scheme 1.13: Synthesis of 
18
F-radiolabelled glucose derivative 36 from CuAAC “click” reaction of 
azido sugar 37 with a 
18
F-fluorinated alkyne.
137 
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 The strategy described above allows the labelling of sugar molecules, but is not 
amenable to the 
18
F-radiolabelling of peptide-based molecular probes. Furthermore, the 
efficiency of this method in the 
18
F-radiolabelling of the protected azido sugar 25 or 
unprotected azido sugar 37 is much lower than that observed in the production of 
[
18
F]FDG (~50% RCY).
79
 Because of this, alternative methods that utilize the CuAAC 
“click” reaction in the synthesis of 
18
F-radiolabelled glycoconjugates for use as 
molecular probes have been evaluated. 
 
1.5.4 Fluorine-18 Labelled Glycoconjugates Synthesised using the 
CuAAC “Click” Reaction 
 Following in the footsteps of probes such as [
18
F]FDG, in which fluorine-18 is 
introduced by nucleophilic displacement of a mannosyl triflate, methods that utilize 
glycosides radiolabelled in this way have been investigated.
139
 The versatility of the 
CuAAC “click” reaction as a ligation method has resulted in the development of 
[
18
F]-radiolabelled glycoconjugates linked via a triazole at the anomeric centre of the 
glycoside. Initially developed by Olaf Prante and co-workers, preliminary nucleophilic 
radiofluorination of 2-trifluoromethanesulfonyl-3,4,6-tri-O-acetyl-β-D-mannopyranosyl 
azide (38) using K[
18
F]F and Kryptofix 2.2.2 resulted in the production of 2-[
18
F]-2-
deoxy-β-D-glucopyranosyl azide (39) in 71% radiochemical yield (Scheme 1.14).
139
 An 
azide-bearing derivative of [
18
F]FDG, deprotection of the acetyl groups followed by 
CuAAC “click” reaction with an Fmoc-protected L-propargylglycine resulted in the 
production of the 
18
F-radiolabelled glycosylamino acid 40 in 60% radiochemical yield 
from 39 (Scheme 1.14).
139 
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Scheme 1.14: Synthesis of 
18
F-radiolabelled triazole-containing glycosylamino acid 40 in 60% 
radiochemical yield via the CuAAC “click” reaction. 
139 
The production of 39 and its subsequent conjugation via the CuAAC “click 
reaction provided impetus for the further utilization of this methodology in the synthesis 
of [
18
F]-labelled glycoconjugate probes. Building on this work, Prante and co-workers 
utilized 39 to glycosylate and radiolabel a propargylglycine-bearing cyclic 
RGD-containing peptide, producing the radiolabelled derivative 41, which in addition to 
other [
18
F]-glycosylated derivatives have been evaluated for their diagnostic potential in 
the quantification of angiogenesis (Figure 1.11).
140,141
 In addition, this methodology has 
been extended to the development of probes targeting neurotensin receptor 1 (NST1), a 
G-protein coupled receptor upregulated in a number of tumour types, including those of 
the breast, lung, pancreas and prostate.
142
 Examples of probes developed include those 
containing both peptidic and non-peptidic scaffolds, with the non-peptidic derivative 42 
(Figure 1.11) displaying low nanomolar affinity for NST1, and 70-fold selectivity for 
this receptor over the related neurotensin receptor 2 (NST2).
142
  
Such has been the worth of this method in the development of radiolabelled 
glycoconjugates, that it has been adopted by researchers investigating other biological 
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targets. Schibli and co-workers have utilized 39 and the CuAAC “click” reaction to 
target the folate receptor.
143
A membrane-anchored protein that binds folic acid as its 
natural substrate, the folate receptor is upregulated in a variety of different tumour types 
in addition to a number of autoimmune and inflammatory diseases, positioning it well 
as a diagnostic target.
143
 Subsequently, the CuAAC “Click” reaction of 39 with a 
propargylglycine-bearing folate derivative, resulted in the [
18
F]-glycosylated derivative 
43 (Figure 1.11), which showed high affinity for the folate receptor. 
 Beyond the production of diagnostic probes (such as 43), the CuAAC “click” 
reaction has also been used in the evaluation and analysis of glycoprotein interactions. 
This is exemplified by the group of Benjamin Davis at the University of Oxford, who 
have selectively synthesised proteins bearing fluorosugars.  Incorporating non-natural 
amino acids (such as L-homopropargylglycine (Hpg)) into proteins,
144
 these residues 
may participate in the CuAAC “click” reaction in mild conditions, with linkage at these 
sites providing a mechanism for the production of [
18
F]-radilabelled glycoproteins. This 
is illustrated by the triazole-linked glycoprotein 44, that was formed by the CuAAC 
“click” reaction of 39 and the protein SsβG, a beta-glycosidase derived from the 
hyperthermophilic bacteria Sulfoolbus solfataricus (Figure 1.11).
144 
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Figure 1.11: 
18
F-containing glycopeptides radiolabelled using 39 and the CuAAC “click” 
reaction.
140–144 
The utilization of azide-bearing [
18
F]-labelled sugars such as 39 have resulted in 
the development of diagnostically-relevant [
18
F]-labelled glycoconjugate probes. 
However, the current methodology for the synthesis of the required fluorosugars (39), 
and ligation to the desired peptide or protein using the CuAAC “click” reaction, present 
some challenges. Firstly, access to 39 from a commercially-available starting material in 
high yield is difficult, with the production of the precursor 38(β-anomer) from 
D-mannose yielding only 8.2% yield over 5 synthetic steps (Scheme 1.15).
139
 Much of 
this is due to the need for the use of an orthogonal protection strategy, allowing for the 
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selective conversion of the mannosyl triflate derivative 38(β-anomer) into the glucosyl 
fluoride.
139
 Also, the requirement of a β-azide that can undergo the CuAAC “click” 
reaction significantly lowers the efficiency of this process, with the presence of a 
pentafluorophenyl (Pfp) group in 46 and 47 prior to azidonation significantly decreasing 
the selectivity of this reaction, producing both α- and β-anomers of 48 (Scheme 1.15).  
 
 
 
Scheme 1.15: Synthesis of 2-OTf-containing derivative 38 from D-mannose, a key precursor in the 
synthesis of 2-[
18
F]fluoro-2-deoxy-β-D-glucopyranosyl azide (39).
139
  
However, one of the largest issues with the current methodology is the need for 
an alkyne group in the macromolecule or peptide to be labelled. Whilst in the previously 
described examples 41-43 this approach is used efficiently, it isn’t really appropriate for 
use in the synthesis of larger peptides and proteins. As illustrated by the work of Davis 
and co-workers (44), in order to introduce an alkyne-bearing amino acid changes to the 
peptide or protein of interest at specific positions in the amino acid sequence are 
required.
144
 This represents both a synthetic and structural challenge, as the introduction 
Chapter 1: Introduction 
40 | P a g e  
 
of the required alkyne-containing amino acid must be performed in a way that is 
synthetically efficient.  Also, it is important that the modifications made do not alter the 
structural characteristics of the peptide or protein in question, maintaining the biological 
activity of the probe.  
 
1.5.5 Alternative Strategies for the Fluorine-18 Labelling of 
Glycoconjugates using the CuAAC “Click” Reaction 
Considering the potential complications of this approach and how these may 
affect the broader utilization of this strategy, the development of an alternative method 
to the labelling of glycoconjugates via the CuAAC “click” reaction is warranted. We 
propose that an alternative methodology that utilizes azide-bearing glycosides that can 
be readily conjugated to proteinogenic amino acids would be advantageous.  Containing 
an azide group, these glycosides would by definition be azidosugars. If a number of 
azidosugars were produced that contained different functional groups forming linkages 
with amino acids (such as carboxylic acids, amines, leaving groups, etc), these could be 
incorporated into peptides or conjugates (Scheme 1.16). The use of a protecting group 
strategy utilizing acetyl protecting groups would allow for the installation of the 
required azide groups, in addition to amino acid coupling. Simple and easily installed, 
these groups also have the benefit of being easily cleaved in the cellular environment, 
due to pH and the presence of intracellular esterases.
145
 
 These glycoconjugates could thus be described as being “clickable,” with the 
corresponding free azide group of the glycoside available for use in the CuAAC “Click” 
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reaction. In conjunction with alkynes akin to the previously discussed [
18
F]-4-fluoro-1-
butyne, this could be utilized to produce 
18
F-radiolabelled glycoconjugates 
(Scheme 1.16).
137
 This represents a methodology that allows for the introduction of 
fluorine-18 into a glycoconjugate in the final step, an important feature when working 
with radioisotopes with short half lives. Also, as non-proteinogenic amino acids are not 
required, it allows for the use of unmodified native peptides and proteins that may 
display ideal radiopharmaceutical properties, thus limiting the need for the installation 
of prosthetic groups (such as alkynes) for conjugation (Scheme 1.16). 
 
 
 
Scheme 1.16: Comparison of methods that may be used to produce 
18
F-radiolabelled glycosylamino 
acids using the CuAAC “click” reaction. A: Previously described strategy developed by Prante and 
co-workers, B: Postulated method using “clickable” glycosylamino acids radiolabelled by a 
[
18
F]-fluoroalkyne using the CuAAC “click” reaction.
 
 Therefore, in order to produce 
18
F-radiolabelled glycoconjugates of this form, 
“clickable” glycosylamino acids consisting of an azidosugar linked to an amino acid 
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must be produced. However, an evaluation of the relevant literature has highlighted a 
clear lack of structures of this form. Of those previously synthesised, many are ether-
linked conjugates between azidosugars and hydroxyl-containing amino acids, including 
serine, threonine, tyrosine and hydroxylproline, and as demonstrated by the 
threonine-linked derivatives 49 and 50 (Figure 1.12).
146,147 
 
Figure 1.12: Threonine-linked derivatives 50 and 51, examples of “clickable” 
glycosylamino acids.
146,147
 
 
Interestingly, the formation of glycoconjugates between azidosugars and other 
amino acids used in the synthesis of glycoconjugates, including serine (Ser; via 
ester linkages), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu) and cysteine (Cys) 
be performed. Also, the majority of “clickable” glycoconjugates previously synthesized 
either pre-date the development of the CuAAC “click” reaction, or instead have been 
used as precursors in the synthesis of other glycoconjugates, including 
N-acetylglycosylamino acids.
146,147
 Thus, there lies the opportunity to develop and 
synthesise a host of “clickable” glycosylamino acids and demonstrate the applicability 
of the CuAAC “click” reaction in their further derivatization. Conjugated together via 
ester linkages initially, before being utilized in the formation of conjugates formed 
through more stable amide and thioether linkages, the synthesis of these derivatives 
could then be extended to other glycopeptides, neoglycopeptides and glycoconjugates. 
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The development of this approach would further expand the use of the CuAAC “click” 
reaction in the production 
18
F-radiolabelled glycoconjugates for nuclear imaging. 
 
 
1.6 Project Aims  
The CuAAC “click” reaction represents a useful method for the synthesis of 
18
F-
radiolabelled glycoconjugates. Utilizing “clickable” glycosylamino acids and 
glycopeptides, this method would allow for the efficient production of a range of 
18
F-
radiolabelled diagnostic probes. In order to evaluate this approach, azidosugars that can 
ligate to a number of different proteinogenic amino acids must be developed and 
optimised (Scheme 1.17). Subsequent ligation would produce the desired “clickable” 
glycoconjugates, which would be open to evaluation with the CuAAC “click” reaction 
(Scheme 1.17). The success of this process may then be ported to the synthesis of 
“clickable” glycopeptides and neoglycopeptides, paving the way for the development of 
18
F-radiolabelled glycoconjugates for use as probes in nuclear imaging (Scheme 1.17). 
Therefore, the specific aims of this project were: 
1. To synthesise a range of different azidosugars (sugar azido acids and 
azidoglucopyranosyl amines) that could form linkages with proteinogenic 
amino acids commonly used in bioconjugation (serine, lysine, 
aspartic/glutamic acid, homocysteine, etc.) (Goal 1, Scheme 1.17).  
2. To synthesise a range of “clickable” glycoconjugates bearing ester, amide and 
thioether linkages to various amino acid residues (Goal 2, Scheme 1.17). 
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3. To demonstrate the utility of the synthesised glycoconjugates in the 
CuAAC “click” reaction (Goal 3, Scheme 1.17). 
4. To extend this methodology towards the synthesis of glycopeptides and 
neoglycopeptides that may be functionalized via the CuAAC “click” reaction 
(Goal 4, Scheme 1.17). 
In Chapter 2, 3 and 4, the synthesis and functionalization of “clickable” 
glycoconjugates will be discussed. These chapters will focus on examples linked to 
serine, lysine and α-amino groups (Chapter 2), aspartic acid and glutamic acid 
(Chapter 3) and homocysteine (Chapter 4). In Chapter 5, the development of methods 
toward the synthesis and functionalization of “clickable” neoglycopeptides will also be 
discussed. 
 
Scheme 1.17: General scope of the synthesis and functionalization of “clickable” glycoconjugates 
performed in this project. 
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Chapter 2 : Synthesis and Functionalization of 
Serine, Lysine and α-Amino Linked “Clickable” 
Glycoconjugates. 
  
Carbohydrates that can be incorporated into peptides and functionalized using the 
CuAAC “click” reaction have a wide range of potential applications. In the following 
chapter, the synthesis and functionalization of serine, lysine and α-amino linked 
“clickable” glycoconjugates will be described. Conjugates of sugar azido acids linked 
to proteinogenic amino acids are useful compounds that can be incorporated into 
peptides and are also freely available for functionalization using the 
CuAAC “click” reaction. 
2.1 Synthetic Rationale 
Azidosugars are highly amenable to the CuAAC “click” reaction. If the same 
azidosugars could also be coupled to amino acid residues then they would have great 
potential for use in the synthesis and labeling of glycopeptides.
139
 However, currently 
there is limited literature precedence on the development of azidosugars that can both 
couple to amino acids or peptides, and also be free to undergo the CuAAC “click” 
reaction.
 
Hence, a methodology that provides a comprehensive, wide-ranging approach 
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towards the introduction (and labeling) of carbohydrates into linear and/or cyclic 
peptides would be highly advantageous. 
Previously in our research group, work had been performed towards the 
development of acid-labile cytotoxic isatin prodrug models for conjugation to the cancer 
relevant protein plasminogen activator inhibitor-2 (PAI-2), whereby the acid-labile 
prodrug was tethered by a carboxylic acid group to a N
α
/C-protected lysine 
residue.
148,149
 Conjugates that are tethered together through an amide linkage hold a 
distinct advantage over those formed through other methods, particularly due to their 
strength and chemical resistance under a wide variety of conditions, and ease of 
synthesis through peptide coupling conditions.
150
 Whilst conjugates to lysine may be 
linked via its N
ε
-sidechain, it could be envisaged that amino acid residues containing 
chemically inert sidechains may also form amide linkages, through coupling to 
carboxylic acid containing moieties through their terminal α-amino group (Scheme 2.1). 
Moreover, using this coupling strategy could result in conjugates with other amino acid 
residues commonly used as linkers in peptide conjugation and labeling, including ester 
linkages when coupled to the amino acids serine or threonine. 
 Therefore, if a glycosyl coupling partner that included a carboxylic acid group 
(uronic acid); such as a sugar azido acid was employed, and coupled to a variety of 
different proteinogenic amino acids, this could produce a library of “clickable” 
glycoconjugates that could be employed in the CuAAC “click” reaction (Scheme 2.1). 
The synthesis and functionalization of conjugates of this type would provide further 
insight into the feasibility of this approach in producing glycoconjugates that could find 
future utility in the synthesis and labeling of glycopeptides (Scheme 2.1). 
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Scheme 2.1: Proposed scheme for the synthesis of "clickable" glycoconjugates. 
 
2.2 Initial Synthetic Targets 
2.2.1 Conjugate Criteria 
In order to synthesize a library of diverse “clickable” glycoconjugates, it was 
recognized that a few key design principles were required. The synthetic approach 
undertaken should be: 
 Divergent in nature, allowing for the production of a variety of different 
“clickable” glycosyl-amino acids from one or two precursor molecules, and; 
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 Synthetically efficient, with easy installation and access to the azide and 
carboxylic acid functional groups required for coupling and the CuAAC 
reaction. 
Whilst not a definitive requirement, it was also decided that the glycosides used 
would be pyran-based (6-membered ring). By using a pyran ring as a scaffold, it would 
ultimately leave the 6-position as the most synthetically viable site for the introduction 
of the required carboxyl group. This is an attractive option, allowing the carboxyl group 
to be introduced via oxidation of a 6-OH group. Alternatively, it would be highly 
advantageous to utilize uronic acid precursors in which the carboxylic acid is already 
installed if possible. If the azido group of the sugar azido acid was installed at the 
anomeric centre, and ester protecting groups such as acetyl (OAc) groups were utilized, 
this would provide a versatile, stereoselective method for the synthesis of sugar azido 
acids. Additionally, this methodology would be portable, and hence could be used in the 
synthesis of sugar azido acids based on different glycosyl isomers (Scheme 2.2). 
 
 
Scheme 2.2: Key design principles required in the synthesis of "clickable" glycoconjugates, utilizing 
a uronic acid precursor. 
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2.2.2 Synthetic Approaches 
 Based on the criteria described in section 2.2.1, a review of sugar azido acids 
reported in the literature was undertaken. To date, all sugar azido acids previously 
synthesized can be classified into one of four different stereochemical isomer classes; 
glc,
151
 gal,
152
 manno
153
 or allo
153
 (Figure 2.1), with a β-configuration at the anomeric 
position the most common. Of these, sugar azido acids based on D-glucuronic acid were 
the most prominent, with multiple methods previously used in the synthesis of 
D-glucuronic acid based derivatives with either α- or β-stereochemistry present at the 
anomeric centre. Hence, commercially available D-glucuronic acid was employed as the 
scaffold for the synthesis of the sugar azido acids described herein.  
 
 
Figure 2.1: Examples of sugar azido acids previously reported in the literature.
151–153 
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The selection of D-glucuronic acid-based derivatives was further rationalized by 
the prominent role of D-glucuronic acid in living systems, such as glucuronidation 
described in Chapter 1.
53
 D-Glucuronic acid is also present as a constituent in a number 
of different biologically relevant glycosaminoglycans, including hyaluronic acid and 
chondroitin sulfate, where they are important constituents in connective tissues such as 
cartilage.
19
  
D-Galacturonic was chosen as a second scaffold for the synthesis of sugar azido 
acids. Varying only by the axial stereochemistry of the hydroxyl group attached to the 
C4 position of the pyran ring, D-galacturonic was selected as it was thought that this 
distinction would not affect the further functionalization of the molecule, but would 
impart a stereochemical difference into the “clickable” glycoconjugates. Furthermore, 
akin to D-glucuronic acid, D-galacturonic acid displays a variety of roles in nature, 
particularly as a structural element of plant gums such as pectin.
154
 D-Galacturonic acid 
is present in many different food stuffs, thus it is likely that conjugates containing 
D-galacturonic acid would be well tolerated if used in nuclear imaging agents in the 
future.
155
 In addition to D-glucuronic acid and D-galacturonic acid, D-mannuronic acid 
was also considered as a sugar azido acid scaffold. However, the axial stereochemistry 
at the C2 position on the pyran ring increased the potential risk of side reactions due to 
the closer proximity of the C2 hydroxyl group to the carboxylate group.
 
Hence no SAAs 
based on mannuronic acid were synthesized herein. 
In selecting an approach for the synthesis of the required glc- and gal- sugar 
azido acids, three potential methodologies were considered (Scheme 2.3). The first of 
these, described by Von Roedern et al.,
156
 was the synthesis of 1-azido-2,3,4,-tri-O-
acetyl-β-D-glucuronic acid methyl ester (53) from the corresponding 1,2,3,4-tri-O-
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acetyl-β-D glucuronic acid methyl ester (52) (Pathway A, Figure 2.4). Utilizing 
glucuronolactone (51) as a precursor, this pathway was deemed not suitable in this 
instance due to the long duration/low yielding nature of the process. Also, this method 
would not be able to be ported to the synthesis of a gal-based sugar azido acid. 
 
 
Scheme 2.3: Three potential pathways en route to the synthesis of sugar azido acids based on the 
Glc scaffold.
156–158
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An alternate strategy previously developed by D’Onofrio et al.,
158
 that was 
considered also commenced from a previously synthesized precursor, 
β-D-glucopyranosyl azide (37, Scheme 2.3 Pathway 2), where selective protection of 
the primary 6-OH, peracetylation of the remaining 2-,3- and 4-OH groups (54), 
followed by the one pot selective deprotection of a silyl ether and oxidation of the 
primary 6-OH, resulted in the required SAA. However, the utilization of the 
CrO3/H2SO4 reaction cocktail in the one-pot deprotection/oxidation of 54 posed some 
safety concerns,
158
 reducing the scalability of the synthesis considerably. 
 Instead, a strategy whereby the target SAAs were synthesized from D-
glucuronic/or galacturonic starting materials was employed (Scheme 2.3, Pathway 3). 
Utilizing cheap, readily available precursor molecules of D-glucuronic and 
D-galacturonic acid, this methodology would allow for the stereoselective introduction 
of an azido group at the anomeric position, with β-stereochemistry. Furthermore, this 
concise four step synthesis allows for the utilization of a number of different protecting 
groups for the 6-carboxyl group, including the methyl protecting group utilized by 
Von Roedern et al.,
156
 and other commonly used protecting groups such as the ethyl, 
allyl, tert-butyl or benzyl groups;
159
 providing versatility in the deprotection procedure 
that would yield the required sugar azido acids. 
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2.3 Synthesis of Glc- and Gal-Sugar Azido Acids. 
2.3.1 Synthesis of 1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60)
 
 For the production of glc- and gal- sugar azido acids, protection of both the 
secondary hydroxyl groups and the carboxylic acid was required. Based on the protocol 
reported by Bergeon et al.,
160
 D-glucuronic acid (55) was peracetylated using I2 as a 
Lewis acid, with slow, cold addition of methanol resulting in the cleavage of the 
intermediate anhydride, which after recrystallization produced 56 in 58% yield 
(Scheme 2.4). 
 
Scheme 2.4: Synthesis of peracetylated glucuronic acid allyl ester 57 from D-glucuronic acid.
 
Analysis of the 
1
H NMR spectrum highlighted the β-configuration of the OAc 
group at the anomeric centre, with a doublet at 5.79 ppm (J = 7.6 Hz) indicative of a 
shielded proton of α- or axial anomeric configuration. Subsequently, the free carboxylic 
acid of 56 was protected using the method of Tosin et al. to form an allyl ester.
157
 The 
allyl ester was chosen over other options due to its stability under both acidic and basic 
conditions. Furthermore, the selective deprotection of an allyl ester in the presence of an 
azido group would allow for the efficient production of the required glc- sugar azido 
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acid. Installation of the allyl ester began with the formation of a glucuronyl chloride 
from 56, utilizing oxalyl chloride and catalytic DMF. Substitution of the glucuronyl 
chloride with allyl alcohol, followed by scavenging of the alcohol proton by pyridine, 
resulted in the peracetylated glucuronic acid allyl ester 57 in 93% yield over two steps 
(Scheme 2.4).
157
 In the 
1
H NMR spectrum, multiplets at 5.89 ppm and 5.37 ppm 
integrating for one and two protons respectively, and  a doublet at 4.61 ppm 
(J = 6.1 Hz) integrating for two protons were consistent with the allyl group in 57. 
Accordingly, with 57 in hand the synthesis of the β-azidosugar 59 was 
investigated. In comparison to tin (IV) chloride-catalyzed azidonation reactions 
presented in the literature in the formation of the previously described β-azide 25,
157
 it 
was identified that variations in the coordinating group at the C6 position of the 
protected glycoside (OAc group versus COOMe) could result in a noticeable decrease in 
the yield of product. Therefore, an alternate strategy employing a two-step process was 
initially used. Firstly, acid-catalyzed bromination of the anomeric centre of 57 using 
33% HBr in acetic acid, produced the α-brominated compound 58 in 67% yield 
(Scheme 2.5). 
 
Scheme 2.5: Synthetic pathways towards the production of the protected sugar azido acid 59. 
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In the following reaction in dichloromethane, the anomeric OAc group of 57 
dissociates, producing an oxocarbenium intermediate (Scheme 2.6). Stabilization of this 
intermediate produces an anomeric-centred carbocation, which in the presence of a 
bromide undergoes nucleophilic substitution. Formation of the α-bromo compound 58 is 
highly favoured, due to hyperconjugation resulting from the orbital overlap present 
between the lone pair of electrons of the ring oxygen, and the anti-bonding orbital of the 
anomeric carbon (Scheme 2.6). α-Bromo compound 58 was then subjected to 
nucleophilic substitution at the anomeric centre employing NaN3, producing the sugar 
azido acid 59 in 68% yield (Scheme 2.5). The use of a polar aprotic solvent such as 
DMF allowed the nucleophilic substitution to proceed smoothly without the formation 
of potentially hazardous side products. This is in contrast to the use of CH2Cl2, which 
when used with ionic azides is known to result in the production of diazidomethane – a 
highly unstable, shock sensitive species.
161
 To this end, the use of NaN3 in chlorinated 
solvents during azidonation reactions was completely avoided in this work. 
 
Scheme 2.6: Proposed alternative mechanistic pathway for the synthesis of 1-azido-2,3,4-tri-O-
acetyl-β-D-glucuronic acid allyl ester (59). 
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Whilst this methodology produced the required protected sugar azido acid 59, 
the yield for this product proved to be significantly less than that expected (44% versus 
~70% as described in the literature).
157
 Furthermore, the sensitivity of the intermediate 
α-bromo compound 58 to degradation hindered the scalability of this process. Hence, 
the procedure of Tosin et al. was utilized (Scheme 2.5, pathway B), where the azido 
group was directly introduced to 57, using TMSN3 as a soft azide donor and catalyzed 
by tin(IV) chloride (Figure 2.8).
157
 Workup and subsequent recrystallization generated 
the fully protected sugar azido acid 59 in 63% yield (Scheme 2.5). Mechanistically, 
tin(IV) chloride forms a coordinate complex with the carbonyl oxygen of the carboxylic 
acid and that of the anomeric OAc group. This coordination induced 
neighbouring-group participation from the carbonyl of the OAc group attached to the 
C2 of the pyran ring results in the formation of a carbocation-containing acetal 
intermediate, and the release of an acetate ion (Scheme 2.7). The axial stereochemistry 
of the acetal intermediate allowed for the SN
2
 nucleophilic substitution at the anomeric 
centre with the azide anion, forming the required β-sugar azido-acid 59. 
 
 
 
 
Scheme 2.7: Mechanism for the SnCl4-catalyzed azidonation that formed 59.
151 
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The 
1
H and 
13
C NMR spectra of 59 highlight the distinct difference in electron 
density surrounding the anomeric centre, with a doublet (J = 9.1 Hz) in the 
1
H NMR at 
4.71 ppm and a singlet in the 
13
C NMR at 88.3 ppm respectively, with the correlation of 
these signals confirmed by a 2D gHSQC NMR experiment. These appear noticeably 
upfield from those signals for the peracetylated precursor 57 (5.79 ppm and 91.6 ppm 
respectively), and are indicative of the inductive electron-withdrawing effects of the 
anomeric OAc group in 59, which deshields the nuclei of H1 and C1. Even further 
upfield from the H1 doublet in the 
1
H NMR spectrum of 59 is a doublet representing the 
H5 proton (4.14 ppm, J = 9.8 Hz). The difference between these protons (~0.6 ppm) and 
their relative positions was a consistent feature of the 
1
H NMR spectra of all derivatized 
sugar azido acids synthesised in this project. 
 The protected sugar azido acid 59, was then subjected to deprotection, in order 
to yield the required 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60). The utilization 
of the allyl ester allowed for the selective “unmasking” of the carboxylic acid through 
mild palladium(0)-catalyzed deallylation. Mechanistically, when in the presence of 
Pd(0) catalysts such as Pd(PPh3)4 the allyl ester is cleaved, forming a free carboxylate 
and Pd-π complex between the catalyst and the liberated allene. In the presence of a 
“scavenger” molecule such as pyrrolidine, piperidine or morpholine, the allene is 
sequestered from the catalyst, which is reintegrated into the catalytic cycle, producing 
the free carboxylic acid product (Scheme 2.8).
157 
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Scheme 2.8: Catalytic cycle for the deprotection of allyl esters.
162 
  Hence, using this approach and the methodology of Tosin and co-workers, the 
allyl ester of 59 was deprotected, to form the target sugar azido acid 60. Utilizing 
Pd(PPh3)4 as a catalyst and pyrrolidine as an allyl scavenger, 60 was synthesized in 66% 
yield (Scheme 2.9).
157
  
 
 
Scheme 2.9: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid 60. 
In comparison to the literature, this yield was somewhat less than that previously 
achieved (83-93%) when performed on the same scale.
151,157 
Furthermore, this yield 
proved inconsistent when synthesized on larger scales, with yields ranging from 
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49-66%. Considering the catalyst (Pd(PPh3)4) used, the high loading of catalyst 
(10 mol%) and the proposed mechanism of this reaction, one likely reason for these 
variances is the potential side reaction of the starting material with triphenylphosphine 
(PPh3) leached from the catalyst. In the presence of PPh3, the azide at the anomeric 
centre of 59 can undergo a Staudinger reduction, resulting in the release of N2 gas and 
upon aqueous work-up the formation of triphenylphosphine oxide and a sugar amino 
acid derivative (Scheme 2.10).  
 
Scheme 2.10: Proposed mechanism of the Staudinger reduction that occurs in the synthesis of 60. 
The leaching of PPh3 from the catalyst is supported by the presence of signals in 
both the 
1
H and 
13
C NMR spectrum between 7.40 and 7.80 ppm, respectively in a 
number of the crude reaction samples of 60, which are indicative of the presence of an 
aromatic ring, of which PPh3 or O=PPh3 are the only potential contributors in this 
protocol. In addition, signals of m/z 301 present in the low resolution electrospray 
ionization mass spectrum (LR-ESIMS) of the reaction mixture are indicative of 
O=PPh3 + Na. To combat the potential interference of PPh3 in this reaction, freshly 
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recrystallized Pd(PPh3)4 was used, and removal of the catalyst was performed via 
filtration over a thick pad of celite, to prevent any leaching. Whilst no amine formation 
was detected in the worked-up solution, the following approach to the use of catalyst 
resulted in generally higher yields of 60, compared to when no recrystallization of the 
catalyst was performed. In this manner, starting initially from D-glucuronic acid, 
1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60) was successfully synthesized in a 
total yield of 23% over four steps. 
 
2.3.2 Synthesis of 1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65) 
 Based on the convenient synthesis of 60 from D-glucuronic acid, it was 
envisaged that this methodology would prove quite useful in the synthesis of 1-azido-
2,3,4-tri-O-acetyl-β-D-galacturonic acid (65). Hence, the synthesis of this sugar azido 
acid initiated with the peracetylation of commercially available D-galacturonic 
monohydrate. Utilizing the protocol developed by Vogel and co-workers, acetic 
anhydride and perchloric acid were employed to produce 1,2,3,4-tetra-O-acetyl-α-D-
galacturonic acid (61) in 35% yield (Scheme 2.11).
163
 Mechanistically, the perchloric 
acid-catalyzed protocol proceeds in a comparable manner to the use of I2 in the 
acetylation of D-glucuronic acid, with an in depth examination of the literature 
illustrating the similarities in yield when either method is used to synthesise 61.
164
 The 
α-stereochemistry of the anomeric centre is highlighted by the 
1
H NMR spectrum of 61, 
where a doublet integrating to one proton at 6.47 ppm indicates the deshielded, 
equatorial nature of H1. Furthermore, the small coupling constant of J = 2.9 Hz 
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emphasizes the small dihedral angle that exists between H1 and H2 when H1 is in the 
equatorial position. 
 
 
Scheme 2.11: Synthesis of peracetylated allyl ester 62 from D-galacturonic acid monohydrate.  
 The presence of α-stereochemistry at the anomeric centre of 61 is in stark 
contrast to the β-stereochemistry present in the D-glucuronic acid derivative 56. To 
understand and reason this difference further, a brief conformational analysis was 
undertaken using the molecular modeling program ChemBio3D 11. Using the AM1 
semi-empirical level of theory, the heat of formation (ΔHf) for both α- and β-anomers of 
56 and 61 was calculated (Figure 2.2).  
 
Figure 2.2: Heat of formation (ΔHf) of the α- and β- anomers of 56 and 61, calculated using 
ChemBio3D 11.0. 
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Interestingly, there were noticeable differences between the different uronic 
acids, with the β-anomer of 56 calculated to have a ΔHf 11.4 kcal/mol less than its 
counterpart α-anomer. This is indicative of the greater stability of the β-anomer, as seen 
by the resulting ratio of the β-anomer of 56. In contrast, the calculated ΔHf values for 
the respective anomers of 61 show negligible differences between them (0.1 kcal/mol, 
Figure 2.2), suggesting an even likelihood of the formation of both α- and β-anomers. 
Considering the low yield of 61 and the use of recrystallization in its isolation, it is 
entirely possible that the production of the β-anomer of 61 could have occurred in equal 
quantities to the isolated α-anomer. 
 With 61 in hand, the free carboxylic acid could be protected. Utilizing the 
protocol optimised in the synthesis of 57, the peracetylated galacturonic acid allyl ester 
derivative 62 was synthesized via the acid chloride intermediate in 85% yield 
(Scheme 2.11). Similarly to the previously synthesized 57, signals in the 
1
H NMR 
spectrum at 5.75 ppm (1H), 5.15 ppm (2H) and 4.70 ppm (2H) were indicative of the 
presence of the allyl ester. Subsequently, 62 was subjected to azidonation at the 
anomeric centre. Based, on the experience gained during the synthesis of 59, the 
peracetylated galacturonic acid allyl ester 62 was subjected to reaction under 
TMSN3/SnCl4 conditions. Interestingly though, compared to the moderate yielding 
synthesis of 59, an initial reaction attempted over 4 hours yielded the anticipated 
product 64 in only 18% yield.  Increasing reaction time to 20 hours only mildly 
increased the yield of product (29%), with no further gains in yield observed after 
72 hours of reaction time.  
Mechanistically, the α-stereochemistry of the parent molecule appeared to 
impede the kinetics of this reaction, as a result of the large distance between the OAc 
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group at the C1 position, and the carbonyl group of the allyl ester (Scheme 2.12). 
Hence, when SnCl4 is dissolved in dichloromethane and in the presence of 62, it instead 
preferentially forms an interaction between the carbonyl group of the allyl ester, and the 
oxygen of the pyran ring. This interaction can destabilize the pyran ring, leading to ring-
opening at the anomeric centre, resulting in the formation of a C1-centred carbocation 
intermediate. Mutarotation of the C-C bond between C1 and C2, and subsequent ring 
closing of this intermediate results in the formation of the β-anomer of 62, which can 
undergo OAc elimination, neighbouring group participation and nucleophilic 
substitution to form the protected sugar azido acid 64 (Scheme 2.12).
151
  
 
 
Scheme 2.12: Mechanism for the synthesis of 64 from 62 in the presence of SnCl4.
165 
 As a consequence of the inefficiencies present in this process, it was determined 
that the synthesis of the α-bromo intermediate en route to 64 would provide the most 
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viable procedure towards the synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-galacturonic 
acid (see Scheme 2.6). Furthermore, the oxocarbenium transition state is formed 
independent of the stereochemistry present at the anomeric centre. 
 
 
Scheme 2.13: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65) 
Hence, the peracetylated allyl ester 62 was subject to bromination utilizing the 
conditions developed in the preparation of 58 (33% HBr/Acetic acid in 
dichloromethane), resulting in the α-bromo compound 63 in 66% yield.  Next, 63 was 
subjected to NaN3 azidonation, producing the β-azide derivative 64 in 70% yield 
(Scheme 2.13, pathway B). The structure of 64 was confirmed using 2D NMR 
spectroscopy, with the gCOSY spectral plot displaying correlations between the H5 and 
H4, H4 and H3, and H2 and H1 (Figure 2.3). The axial stereochemistry of the proton at 
the anomeric centre of 64 was identified using the NOESY spectral plot, where through-
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space correlations between the H1 and H3 of 64 were detected. Hence, the azido group 
present at the anomeric centre possessed β-stereochemistry (Figure 2.3). 
 
 
Figure 2.3: The gCOSY (left) and NOESY (right) 2D 
1
H 
 
NMR spectral plots for 64. 
 Subsequently, the carboxylic acid group was unmasked through the 
Pd-catalyzed deprotection of the the allyl ester of 64, producing 1-azido-2,3,4-tri-O-
acetyl-β-D-galacturonic acid (65) in 67% yield (Scheme 2.13).
157
 This was evident by 
the 
1
H and 
13
C NMR spectra of 65, where the disappearance of signals from the allyl 
group of 64 highlighted the deallylation. Therefore, the novel, target sugar azido acid 65 
was synthesized from D-galacturonic acid monohydrate in 9% over 5 steps. Comparable 
in yield to the synthesis of the glc sugar azido acid 60, this synthesis allowed for the 
timely, scalable synthesis of SAAs without the need of chromatography. Thus, 
sufficient material for the synthesis of a library of “clickable” glycoconjugates was 
procured. 
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2.4 Synthesis of “Clickable” Glycoconjugates 
2.4.1 Synthesis of Sidechain-linked Derivatives (66-69) 
 With the key glc- and gal- sugar azido acids 60 and 65 in hand, our attention 
turned to the synthesis of “clickable” glycosyl amino acids. Initially, the synthesis of 
conjugates formed through the coupling of our synthesized sugar azido acids with serine 
was targeted, with Boc.Ser.OMe selected as the protected serine donor. The general 
reactivity of primary alcohols in peptide coupling conditions, positioned serine ideally 
as a coupling amino acid in the development of “clickable” glycoconjugates. The 
formation of serine-linked glycoconjugates was also validated by the importance and 
prevalence of serine glycosylation in the production of biologically important 
glycoconjugates.
166
 Hence, utilizing a classical  Steglich 
N,N’-1,3-dicyclohexylcarbodiimide (DCC)-based esterification protocol, Boc.Ser.OMe 
was coupled to the glc- sugar azido acid 60, successfully producing the novel serine-
based “clickable” glycosyl amino acid 66 in 80% yield (Scheme 2.14).
167
 
 
 
 
Scheme 2.14: Synthesis of serine-based “clickable” glycoconjugates 66 and 67. 
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Mechanistically, in the presence of a non-nucleophilic base such as DMAP, the 
free carboxylic acid of 66 reacts with the carbodiimide of DCC to form an activated 
ester (Scheme 2.15). Driven by electron donation into the pyridine ring, DMAP can 
subsequently attack the activated ester resulting in the acyl iminium intermediate and 
the displacement of dicyclohexylurea as a by-product. Relatively unstable, the acyl 
imminium intermediate is subsequently prone to nucleophilic substitution by the 
hydroxyl group of the Boc.Ser.OMe sidechain, resulting in the formation of desired 
ester product 66 (Scheme 2.15). Subsequently, the success of this procedure was 
mirrored by its use in the synthesis of the novel gal-based sugar azido acid 67, which 
was produced from Boc.Ser.OMe and 65 in 64% yield (Scheme 2.14).  
 
Scheme 2.15: Mechanism of the synthesis of esters using a Steglich DCC/DMAP coupling approach. 
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The 
1
H NMR spectra of both 66 and 67 highlighted the presence of signals  each 
integrating for 2 protons at 4.58 and 4.47 ppm,  respectively, with both of these 
indicative of the CH2 protons adjacent to the ester on serine. This is in comparison to 
the corresponding protons in the parent amino acid (Boc.Ser.OMe, 3.80 - 3.95 ppm), 
which are more shielded due to the presence of the adjacent hydroxyl group. In addition, 
the 
13
C NMR spectra of 66 and 67 highlighted the formation of the esters in each, with 
signals at 173.2 and 167.8 ppm in 60 and 65 replaced by signals at 165.9 and 165.0 ppm 
in 66 and 67. Furthermore, the LR-ESIMS of both 66 and 67 highlighted signals at 
m/z 639, indicative of a [M + Na]
+
 signal. As far as the novelty of 66 and 67, both of 
these compounds represent the first examples of “clickable” glycoconjugates produced 
from sugar azido acids and amino acids. 
Considering the ease in using the DCC/DMAP coupling protocol, this 
methodology was utilized in the synthesis of conjugates containing protected lysine 
amino acids. In comparison to the previous serine-based examples however, the 
synthesis of these conjugates proved less efficient using this protocol, with the coupling 
of glc- sugar azido acid 68 to Ac.Lys.OMe.HCl yielding only 31% after 48 hours 
(Table 2.1). It is likely that the poor solubility of the lysine donor in dichloromethane, in 
addition to the reduced nucleophilicity of the primary amine of the lysine sidechain with 
respect to the serine hydroxyl group, significantly impeded the progress of the reaction. 
These conclusions are further illustrated by the significant quantity of DCC-activated 
ester that was left unreacted as observed by TLC. Hence, in an attempt to improve the 
efficiency of this reaction, a modified procedure was employed utilizing 
hydroxybenzotriazole (HOBt) as an activator and DIPEA as a base in DMF.
150,168
 This 
procedure resulted in a significant improvement in reaction time and yield, producing 
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the novel glc- and gal- lysine-based conjugates 68 and 69 in 75% and 60% yield, 
respectively (Table 2.1).  
 
Table 2.1: Reaction conditions for the synthesis of lysine-based “clickable” glycoconjugates 
68 and 69 
 
 
 
An important constituent of coupling reagents such as N,N,N′,N′-Tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), N,N,N′,N′-Tetramethyl-
O-(1H-benzotriazol-1-yl)uranium tetrafluoroborate (TBTU) and (benzotriazol-1-yl)- 
tripyrrolidinophosphonium hexafluorophosphate (PyBOP); HOBt in the presence of a 
DCC-activated ester will displace N,N’-dicyclohexylurea and form an unstable HOBt-
activated ester. The sidechain -NH2 group of Ac.Lys.OMe.HCl is a suitable nucleophile, 
and in the presence of this activated ester will displace HOBt, undergoing coupling to 
form the amide-linked conjugates 68 or 69 (Scheme 2.16).
150
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Scheme 2.16: Mechanism of the synthesis of amides using a DCC/HOBt coupling approach. 
The identity of both 68 and 69 were confirmed by their HR-ESIMS with signals 
at m/z 552.1918 and 552.1935 (calculated for C21H31N5O11Na [M + Na]
+
: 552.1918)  
indicative of the desired products. Furthermore, the NMR spectra of glc-68 and gal-69 
highlighted the contrasting stereochemistry at the C4 position between these conjugates, 
and the steric consequences that result from this variation. In the 
1
H NMR spectrum of 
68, two matching signals present at 3.40 ppm and 3.15 ppm each displaying an 
integration of 1H are present (Figure 2.4). A gCOSY 2D NMR experiment of 68 
suggested that both of these protons were those of the CH2 group bound directly to the 
amide bond formed during the coupling reaction (H
ε
).  
The different chemical environments of the two geminal protons are potentially 
indicative of hydrogen bond stabilization resulting from the neighbouring amide bond. 
It is possible that under the conditions of the 
1
H NMR experiment performed (CDCl3, 
25°C) the proton of the newly-formed amide nitrogen of 68 may be in close proximity 
to the C4-linked oxygen of the pyran ring. Though the  amide itself is an sp
2
 hybridized 
system, if this were the case the proton would be in close enough proximity to the ring-
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bound oxygen at the 4-position to form a pseudo six-membered ring. Whilst the 
presence of this interaction is completely speculatory, if present the ring would display a 
configuration close to that of a “chair,” with the stability of this interaction effectively 
limiting the rotation by the C-C bond at the C5 position (Figure 2.4).   
 
 
 
 
Figure 2.4: 
1
H NMR spectrum of 68, highlighting the pseudo 6-membered ring formed through 
hydrogen bonding, inducing rigidity at the C4 position. 
In contrast, the 
1
H NMR spectrum of 69 displays two asymmetrical signals – 
two multiplets at 3.25-3.49 ppm integrating for the two hydrogens bound to C
ε
 
(Figure 2.21). The axial C4 stereochemistry of 69 produces a “cis” configuration in the 
C-C bond linking the C4 and C5 of the pyran ring, resulting in a shorter relative 
distance between the C4-OAc group and the C5-amide linkage. When aligned in a 
manner akin to that described for the 
1
H NMR of
 
68 (CDCl3, 25°C), it can be speculated 
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that the amide proton of 69 is facing in an opposing direction to the ring-bound oxygen 
at the 4-position. The greater distance between these groups would limit their 
interaction, and thus likelihood of forming a hydrogen bond. Hence, near-free rotation 
of the C-C bond present at the C5 would occur, resulting in a greater degree of chemical 
equivalence for the C
ε
 compared to the corresponding protons in 68 (Figure 2.5). 
 
 
 
Figure 2.5: 
1
H NMR spectrum of 69, highlighting the chemical equivalence of the two protons 
bound to C
ε
, allowing for bond rotation at the C5 position. 
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2.4.2 Synthesis of Leucine, Methionine and Glutamine α-Amino linked 
Derivatives (70-73) 
Based on the success of coupling 60 and 65 to lysine and serine residues, this 
methodology was next applied to the coupling of amino acid residues via their α-amino 
group. Leucine (Leu), methionine (Met) and glutamine (Gln) were selected as ideal 
coupling amino acids, with these residues comprising a range of sidechain functional 
groups that are resistant to coupling conditions (aliphatic chain, thioether and amide). In 
addition to this trait, the synthesis of derivatives including glutamine, leucine and 
methionine would be highly advantageous, as previous studies have highlighted the 
utility of these amino acids in targeting of amino acid transport.
169–172
  
Glutamine has been targeted primarily for magnetic resonance imaging of 
tumour cells,
173,174
 with some studies utilizing fluorinated derivatives of glutamine in 
the metabolic imaging of tumour cells.
175
 Leucine has been investigated for ultrasonic 
imaging of tumour angiogenesis as part of the cell binding tripeptide arginine-arginine-
leucine.
176
 Methionine (Met) is the most widely used [
11
C]-labelled amino acid in 
clinical PET imaging,
170,177
 with derivatives also labelled with fluorine-18 under current 
investigation for use in the imaging of tumours.
169,171,178
 The linkage of these amino 
acids to either 60 or 65 would generate a novel class of N-α-linked “clickable” 
glyococonjugates that could be evaluated potentially in the development of 
radiolabelled glycoconjugates formed using the CuAAC “click” reaction.
179
   
Contrasting the previously used DCC and DCC/HOBt coupling protocols in the 
syntheses of 66-69, HBTU was selected as the coupling reagent. Possessing milder 
reactivity than carbodiimide-based coupling reagents such as DCC and DIC, HBTU and 
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related coupling reagents (HATU, TBTU, HCTU) display a lower propensity to induce 
racemization in the coupling amino acid residue – an important attribute considering the 
position of the unhindered α-amino group adjacent to the stereocentre of the amino 
acid.
150
 Hence, using HBTU in the presence of DIPEA in DMF, attempts were 
undertaken to couple glc-sugar azido acid 60 to H.Leu.OMe.HCl, producing the novel 
conjugate 70 in 84% yield (Figure 2.22). This method was extended to the synthesis of 
the novel gal- sugar azido acid leucine conjugate 71, which was produced from 65 and 
H.Leu.OMe.HCl in 78% yield (Scheme 2.17).  
 
 
 
Scheme 2.17: Synthesis of leucine-based “clickable” glycoconjugates 70 and 71 
The presence of doublets at 6.70 and 6.82 ppm in the 
1
H NMR spectra of 70 and 
71,  respectively is indicative of the amide-bond formed during the coupling procedure, 
with further signals at 4.57 and 4.70 ppm correlating to the proton at the α-carbon of the 
leucine each integrating for one proton (Figure 2.6). 
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Figure 2.6: 
1
H NMR spectra of leucine-based “clickable” glycoconjugates 70 and 71, highlighting 
the deshielded amide nitrogen and proton of the α-carbon of leucine 
Following on from the efficient coupling of H.Leu.OMe.HCl to 60 and 65, this 
procedure was extended to the coupling of glc- sugar azido acid 60 with 
H.Met.OMe.HCl and H.Gln.OtBu.HCl, producing the glycosyl amino acids 72 and 73 
in 95% and 96% yields, respectively (Scheme 2.18).  
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Scheme 2.18: Synthesis of “clickable” glycoconjugates 72 and 73. 
Containing thioether and amide functional groups, the coupling of both 
H.Met.OMe.HCl and H.Gln.OtBu.HCl were both well tolerated under the conditions 
used, with clean coupling occurring. This is verified by the 
13
C NMR spectrum of 72, 
where a signal at 165.7 ppm indicates coupling of the carboxylic acid to form an amide 
bond (Figure 2.7). In the 
13
C NMR spectrum of 73, coupling was verified by the 
presence of a signal at 167.5 ppm, with a downfield signal 174.9 ppm highlighting the 
shielding effect imposed on the carbonyl carbon by the α-amino group as opposed to the 
amide present on the sidechain (Figure 2.8). 
 
Figure 2.7: 
13
C NMR spectrum of methionine-based “clickable” glycoconjugate 72, highlighting the 
shielded carbonyl signal resulting from amide bond formation. 
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Figure 2.8: 
13
C NMR spectrum of glutamine-based “clickable” glycoconjugate 73, highlighting the 
shielded signal resulting from amide bond formation in comparison to the sidechain amide bond 
carbonyl. 
 
2.5 Synthesis of Functionalized Glycoconjugates 
2.5.1 Optimisation of CuAAC “Click” Reaction Conditions 
With the production of “clickable” glycoconjugates 66-73 successfully achieved, 
efforts were subsequently made to demonstrate the versatility of the CuAAC “click” 
reaction towards this class of compounds. In order to optimize reaction conditions for 
all “click” reactions to be performed, the previously synthesized allyl ester intermediate 
59 was utilized as an azide bearing glycoside, with the cheap and widely available 3-
butyn-1-ol used as an alkyne donor. Using varying quantities of different copper salts 
(CuSO4, Cu(OAc)2) and sodium ascorbate,
131,180
 different solvent conditions, reaction 
times and the use of copper-stabilizing additives (e.g TBTA),
181
 the CuAAC “click” 
reaction between 59 and 3-butyn-1-ol was successfully optimized, producing the 
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triazole-containing glycoconjugate 74 in 88% yield after 24 hours of reaction time 
(Table 2.2, Entry F).  
Table 2.2: Optimization of CuAAC “Click” reaction conditions, producing the triazole-bearing  
functionalized glycoconjugate 74. 
 
 
TLC monitoring of the reaction mixture highlighted the formation of a spot at 
significantly reduced Rf (0.18, 1:1 Hexane: EtOAc), which was indicative of  the 
formation of a more polar product than the starting material, due to the presence of the 
terminal alcohol present on the alkyne.  It is interesting to note that during our 
evaluation of different reaction conditions, the utilization of the known additive TBTA 
provided some increase in reaction yield, but was not ultimately used further (Table 2.2, 
Entry E). This is a result of the extra purification required to isolate 74 from the reaction 
mixture in the presence of TBTA, which during chromatographic isolation co-eluted 
with the product. In addition to visualization using TLC, the formation of 74 was 
highlighted in the 
1
H NMR spectrum, where the presence of a singlet at 7.74 ppm was 
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indicative of the proton present at the 5’-position of the newly-formed triazole ring 
of 74, with multiplets at 2.92 and 3.87 ppm each integrating for two protons indicative 
of the CH2 groups linked to the triazole and hydroxyl groups, respectively (Figure 2.9).  
 
 
Figure 2.9: 
1
H NMR spectrum of the functionalized triazole-bearing glycoconjugate 74. 
Following on from the formation of 74, the CuAAC “click” reaction was further 
evaluated against a variety of alkyne donors. In the presence of 4-pentyn-1-ol, 59 and its 
respective gal-analogue 64 underwent successful “click” reaction, producing the 
triazole-bearing glycoconjugates 75 and 76 in 84% and 80% yields, respectively 
(Scheme 2.19). Compared to 74, the 
1
H NMR spectrum of 75 was quite similar except 
for the presence of a multiplet at 1.95ppm, which was indicative of the central CH2 
group of the ligated alkyne. This too was represented in the 
1
H NMR spectrum of 75 
at 1.95 ppm. Following on from these examples, 59 was subjected to CuAAC “click” 
reaction with phenylacetylene, producing the glycoconjugate 77 in 85% yield 
(Scheme 2.19). A very different alkyne donor to those used in the production of 74-76, 
the formation of the triazole was distinguished in the 
1
H NMR by a signal at 8.08 ppm, 
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with the deshielding of the triazole proton compared to 74-76 likely due to the 
deshielding effect of the neighbouring phenyl ring. 
 
 
Scheme 2.19: Synthesis of triazole-bearing functionalized glycoconjugates 75-77.  
 
2.5.2 Synthesis of Functionalized Glycoconjugates (78-87) 
With reaction conditions for the CuAAC “click” reaction optimized, the 
functionalization of “clickable” glycoconjugates was undertaken. Initially evaluating 
sidechain-linked derivatives, the serine-based glc “clickable” glycoconjugate 66, 
CuAAC “click” reaction with 3-butyn-1-ol resulted in the functionalized glycoconjugate 
78 in 62% yield (Scheme 2.20). Similarly to 59 and 64, this was extended to 4-pentyn-
1-ol, where “click” reaction with 66 and the gal serine-based “clickable” glycoconjugate 
67 resulted in the production of functionalized glycoconjugates 79 and 80 in 58% and 
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69% yield, respectively (Scheme 2.20), with LR-ESIMS of 79 and 80 (m/z 653, 
molecular formula C26H38N4O14 + Na) confirming their production.  Similarly, the glc 
and gal lysine-based “clickable” glycoconjugates 68 and 69 were subjected to the 
CuAAC “click” reaction. In the presence of 3-butyn-1-ol, “click” reaction with 68 
resulted in the production of the functionalized glycoconjugate 81 in 70% yield 
(Scheme 2.20). The presence of a singlet in the 
1
H NMR spectrum of 81 at 7.87 ppm 
was indicative of triazole formation. Subsequently, 68 and 69 were subject to the 
CuAAC “click” reaction in the presence of 4-pentyn-1-ol, producing the functionalized 
glycoconjugates 82 and 83 in 63% and 75% yields, respectively (Scheme 2.20).   
 
 
Scheme 2.20: Synthesis of triazole-bearing functionalized glycoconjugates 78-83. 
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As a result of the successful production of functionalized glycoconjugates 78-83, 
our focus turned to the synthesis of analogues derived from the previously synthesized 
α-amino derivatives 70-73. Beginning with the glc and gal-linked leucine derivatives 70 
and 71, in the presence of 4-pentyn-1-ol both of these underwent CuAAC “click” 
reaction to produce the triazole-bearing functionalized glycoconjugates 84 and 85 in 
80% and 75% yield, respectively (Scheme 2.21).  HR-ESIMS of both 84 and 85 
displayed molecular ions of m/z 579.2271 and 579.2273 respectively, which 
corresponded to a molecular formula of C24H36N4O11 + Na (579.2278) confirming the 
formation of the desired products. 
 
 
Scheme 2.21: Synthesis of triazole-bearing functionalized glycoconjugates 84 and 85  
Subsequently, the CuAAC “click” reaction was extended to the methionine and 
glutamine-based derivatives 72 and 73, whereby reaction with 4-pentyn-1-ol under the 
previously optimized conditons produced the triazole-bearing functionalized 
glycoconjugates 86 and 87 in 85% and 63% yields, respectively (Scheme 2.22).   
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Scheme 2.22: Synthesis of triazole-bearing functionalized glycoconjugates 86 and 87  
The 
1
H NMR spectra of 86 and 87 displayed the presence of signals at 7.63 ppm 
and 8.15 ppm, both indicative of the triazole protons present in 86 and 87. Furthermore, 
a desielded signal at 2.86 ppm in the 
1
H NMR spectrum of 86 is indicative of a CH2 
adjacent to an aromatic ring, indicative of the H
α
 protons introduced into 86 post “click” 
reaction (Figure 2.10). These protons are readily distinguished from the more shielded 
H
β
, and the more deshielded H
γ
 protons of 86 (Figure 2.10). 
 
 
Figure 2.10: 
1
H NMR spectrum of the functionalized glycoconjugate 86, highlighting the formation 
of the triazole ring. 
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2.6 Towards the Synthesis and Functionalization of 
“Clickable” Glycopeptides  
2.6.1 Synthesis of Sugar Azido Acid-Ac.Lys-Pro-Val.NH2 
Considering the success achieved in the synthesis and functionalization of 
“clickable” glycoconjugates 78-87, the methodology was next investigated for 
expansion to the production and functionalization of “clickable” glycopeptides. Hence, 
in order to evaluate this possibility, our focus turned to the replication of this 
methodology on a small peptide system. In evaluating a peptide for coupling, it was 
recognized that a few key criteria would be important in selecting the peptide, 
including: 
 Relevance to bioconjugation 
 Contains a number of different functional groups that would be stable to the 
condition of the CuAAC “click” reaction 
With these criteria in mind, an analysis of the literature was undertaken to discover a 
suitable candidate for this study. During this investigation, the protected tripeptide 
analogue Ac.Lys-Pro-Val.NH2 (Ac.KPV.NH2) (Figure 2.11) drew considerable 
attention. Forming the C-terminus of the naturally-occurring peptide α-melanocortin 
stimulating hormone (α-MSH) (Figure 2.11), Ac.KPV.NH2 and its parent peptide have 
been found to display anti-inflammatory and antimicrobial activities, with Ac.KPV.NH2 
displaying activity comparable to the parent α-MSH.
100,182,183
 Furthermore, in respect to 
the compatibility of Ac.KPV.NH2, the variety of functional groups it encompasses 
aligned well with those present in previously functionalized “clickable” 
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glycoconjugates, suggesting that the peptide would be stable to the CuAAC “click” 
reaction conditions previously optimized. 
 
 
Figure 2.11: Primary structure of α-melanocortin stimulating hormone (α-MSH), and N
α
-acetyl 
lysine-proline-valinamide (Ac.KPV.NH2), a tripeptide analogue of the C-terminus of α-MSH 
Therefore, in order to evaluate the CuAAC “click” reaction on a small 
glycopeptide, the glc- sugar azido acid 60 was coupled to the commercially available 
tripeptide Ac.Lys-Pro-Val-NH2.HCl, which in the presence of HBTU and DIPEA in 
DMF produced the β-azide containing glycopeptide 88 in 53% yield (Scheme 2.23).  
 
 
Scheme 2.23: Synthesis of Ac.KPV.NH2-based “clickable” glycopeptide 88 
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Evaluation of the 
1
H NMR spectrum of 88 showed clear evidence of the desired 
coupled product, with a signal 6.83 ppm indicative of the sidechain NH2 of the lysine of 
Ac.KPV.NH2.HCl (Figure 2.35). Furthermore, two multiplets integrating for one proton 
each at 3.38 and 3.05 ppm indicate splitting of the two geminal protons present on the 
C
ε
 of the lysine of the peptide – a result of their significantly different ”environments” 
resulting from hydrogen bond stabilization (Figure 2.12). The correlations between 
these protons – similarly to the previously synthesized “clickable” glycoconjugate 68, 
were exemplified in a gCOSY 2D NMR experiment of 88, displaying a clear three-bond 
coupling between the geminal protons linked to the C
ε
 of the lysine of 
Ac.KPV.NH2.HCl and the neighbouring NH (Figure 2.13).  
 
 
Figure 2.12: 
1
H NMR spectrum of the glc-Ac.KPV.NH2-based “clickable” glycopeptide 88, 
highlighting the pseudo 6-membered ring formed through hydrogen bonding, and three-bond 
coupling correlation.  
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Figure 2.13: 2D 
1
H NMR gCOSY experiment of the glc-Ac.KPV.NH2-based “clickable” 
glycopeptide 88, highlighting the pseudo 6-membered ring formed through hydrogen bonding, and 
three-bond coupling correlation. 
With the synthesis and isolation of 88 achieved, the functionalization of the 
azide-bearing glycopeptide is expected to be straightforward. However, the production 
of 89 using the CuAAC “click” reaction was not performed due to time restraints. 
(Figure 2.24). 
 
 
Chapter 2: Serine, lysine and α-amino linked “clickable” glycoconjugates 
 
89 | P a g e  
 
 
 
Scheme 2.24: Postulated synthesis of the glc-Ac.KPV.NH2-based functionalized glycopeptide 89 
Herein, the synthesis and functionalization of a range of sidechain and α-amino 
linked glycoconjugates utilizing the CuAAC “click” reaction, has been described. 
Furthermore, the synthesis of the biologically-relevant glycopeptide 88 has provided an 
opportunity for the production of functionalized glycopeptides (such as 89) via the 
CuAAC “click” reaction. In chapter 3, the synthesis and functionalization of “clickable” 
glycoconjugates will be further discussed, encompassing sidechain carboxyl-containing 
amino acids. 
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Chapter 3 : Synthesis and Functionalization of 
Sidechain-Linked “Clickable” Glycoconjugates 
 
As illustrated in Chapter 2,”clickable” glycoconjugates represent a class of 
molecules that can be readily incorporated into biologically-active peptides, whilst 
retaining free handles for use in the CuAAC “click” reaction. In this chapter, the 
development of sidechain-linked “clickable” glycoconjugates will be examined. 
 
3.1 Synthetic Rationale 
In Chapter 2, the development of serine and lysine sidechain and leucine, 
methionine and glutamine α-amino linked “clickable” glycoconjugates, and their 
functionalization using the CuAAC “click” reaction, highlighted the potential of these 
species for utilization in the labelling of biologically-active peptides. Exploiting ester 
and amide-coupling chemistry in the preparation of these conjugates,
150
 this platform 
methodology allows for the conjugation of sugar azido acids to a variety of different 
compatible amino acid residues used in bioconjugation, as highlighted by the synthesis 
of the “clickable” glycopeptide 88. This strategy is highly advantageous in the synthesis 
of conjugates with free hydroxyl and amino groups, however it would also be useful to 
expand this methodology to other amino acid residues used in labeling and 
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bioconjugation. These include those bearing sidechain carboxyl groups, such as aspartic 
acid and glutamic acid.
 
Carboxyl-containing amino acid residues can be readily coupled to a 
glycosylamine to give rise to stable amide linkages formed using peptide-coupling 
chemistry. Hence, in consideration of the research detailed in Chapter 2, if a 
methodology utilizing amide coupling was developed to form conjugates between 
carboxylic acid-containing amino acids and azido glycosylamines, such analogues 
would be examples of amide-linked “clickable” glycoconjugates.  Analogous to the 
glucuronic acid derivatives 66-73 described in Chapter 2, these conjugates would be 
amenable to the CuAAC “click” reaction, allowing for their use in the labelling and 
conjugation of biologically-active peptides (Scheme 3.1). 
 
 
Scheme 3.1: Proposed synthesis of sidechain carboxyl-linked "clickable" glycoconjugates. 
 
3.2 Synthetic Approach 
It was recognized that the pronounced reactivity of the anomeric and 6-positions 
of a pyranoside would favour azidonation or amination/conjugate formation, compared 
to other positions on the pyran ring. Using a simple glycosyl precursor containing a 
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suitable leaving group (Ts, etc) at the 6-position, in stallation of an azide moiety via SN
2
 
nucleophilic substitution would be highly favourable. Such 6-azidonated glycosides 
may then be subjected to reduction, producing an amine at the 6-position that could be 
coupled to carboxylic acid-containing derivatives to produce 6-amide linked sugar 
derivatives.
146,184
 Accordingly, a second azide group could be introduced at the 
anomeric centre, resulting in 6-linked azido sugar derivatives that may be amenable to 
the CuAAC click reaction (Scheme 3.1).  
Conversely, an azide could be introduced at the 6-position of a relevant 
furanoside or pyranoside, and left available for utilization in the CuAAC reaction, with 
the introduction of an amine at the anomeric position, and subsequent protection and 
coupling of a sidechain carboxyl-containing amino acid would produce anomeric 
amide-linked conjugates (Scheme 3.1).
185,186
 The literature precedence for the synthesis 
of 6-azidoglycosylamines, endorses this strategy in the production of sidechain-linked 
“clickable” glycoconjugates (Scheme 3.1). 
 
3.3 - Synthesis and Functionalization of Anomeric-linked 
“Clickable” Glycoconjugates 
Thus, to further extend the library of “clickable” glycoconjugates to those linked 
via an acidic sidechain or α-carboxyl group, derivatives linked via the anomeric centre 
were investigated. As mentioned, an evaluation of the literature showed precedence for 
the preparation of glycoconjugates based upon glucopyranosylamines, including those 
bearing azide groups at a variety of different positions on the pyran ring.
187,188
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Stereoselective amination of the anomeric centre of pyranoside has been thoroughly 
investigated, with the early work of Likhosherstov and coworkers utilizing either 
ammonium carbonate, ammonium bicarbonate and ammonium carbamate in the 
production of β-glucopyranosylamines.
189
 As a result, the tandem use of azidosugars 
encompassing an anomeric amine, such as the azidoglucopyranosylamines  prepared by 
Garcia Fernandez and coworkers, have been used to great effect, providing synthons 
(such as 90) that can readily undergo reaction at the anomeric centre, whilst maintaining 
an additional handle for derivatization (Scheme 3.2).
188
  
 
 
Scheme 3.2: Further derivatization of an azidoglucosylamine (90) previously described by Garcia 
Fernandez and Co-workers.
188 
In the current context, azidoglucopyranosylamines can be accessed concisely 
from the known precursor 6-azido-1,2-α-D-glucofuranose (96), with protecting group 
manipulation providing synthons that can be coupled to both an acidic sidechain or 
α-carboxyl containing amino acid derivatives, and be available for use in the CuAAC 
“click” reaction (Scheme 3.3). Furthermore, the convergent nature of this approach 
allows for the utilization of a variety of different amino acid protecting group strategies, 
making such molecules amenable to further amino acid coupling (Scheme 3.3). 
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Scheme 3.3: Approach towards the synthesis of amide-linked “clickable” glycoconjugates linked at 
the anomeric position. 
 
3.3.1 Synthesis of Key β-Azidoglycosylamine Intermediate 103 
As a starting point for the production of amide-linked “clickable” 
glycoconjugates, the synthesis of the known 6-azido-1,2-isopropylidene-α-D-
glucofuranose (96) was initiated. Starting from the commercially available, 1,2:5,6-di-
isopropylidene-α-D-glucofuranose (93), cleavage of the primary acetonide under mild 
70% acetic acid was effected,  resulting in the production of 1,2-isopropylidene-α-D-
glucofuranose (94) in 90% yield (Scheme 3.4), which was confirmed by 
1
H and 
13
C NMR spectroscopy.
190
 Subsequently, 94 was subjected to standard tosylation 
conditions, with selective tosylation of the primary 6-OH resulting in the production of 
6-p-toluenesulfonyl-1,2-isopropylidene-α-D-glucofuranose (95) in 73% yield 
(Scheme 3.4). The presence of two doublets at 7.79 and 7.33 ppm (J = 7.9 Hz) in the 
1
H 
NMR spectrum, each integrating for two protons is indicative of the formation of the 
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mono-tosylated product, with the LR-ESIMS spectrum of 95 highlighting a signal at m/z 
397, which was indicative of the product. The selectivity observed is a result of the 
steric hinderance encountered by the 3- and 5-OH groups, with the additional freedom 
of rotation experienced by the primary 6-OH providing a greater level of selectivity 
towards the 6-OH of 94. 
 
 
Scheme 3.4: Synthesis of 6-azido-1,2-isopropylidene-α-D-glucofuranose (96). 
With 95 in hand, a modified procedure of Fleet et al. was trialled in the 
production of 96.
191 
SN
2
 nucleophilic substitution of the 6-tosyl group by NaN3 in DMF 
resulted in the requisite 6-azido-1,2-isopropylidene-α-D-glucofuranose (96) in 74% 
yield (Scheme 3.4). This was confirmed in the 
1
H NMR spectrum of 96, where 
disappearance of the aromatic protons of 95 indicated substitution with the azide group 
(Figure 3.1). Furthermore, the HR-ESIMS displayed a signal of m/z 280.0710 of 
chemical formula C9H15N3O5+ Cl (280.0700), which was indicative of the formed 
product. 
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Figure 3.1: 
1
H NMR spectrum of 6-azido-1,2-isopropylidene-α-D-glucofuranose (96). 
Following the successful production of 96, our focus next shifted to the 
synthesis of the key 6-azido-β-D-glucopyranosylamine intermediate 118. Conversion of 
the furan ring to a pyran ring initially began with cleavage of the 1,2-isopropylidene 
group, using 80% acetic acid at 80°C, to yield the lactol intermediate 97 (Scheme 3.5). 
Subsequently, the glycoside was subject to prolonged heating in a saturated solution of 
NH4HCO3 at 40°C over four days. In this aqueous solution, it is proposed that the 
furanose intermediate underwent interconversion to its respective reducing sugar, which 
in the presence of NH3 (formed from the decomposition of NH4HCO3) resulted in the 
formation of the aminal intermediate 98. Driven forward by the abstraction of dissolved 
CO2 from the solution, 98 could then cyclize through the 5-OH of the reducing sugar, 
forming the pyranose carbamate ammonium salt 99 (Scheme 3.5). Indeed, the potential 
presence of this intermediate was suggested by the presence of a signal in the 
LR-ESIMS of the reaction mixture (m/z 265). Key to the formation of 99 was the 
maintenance of a saturated NH4HCO3 solution at precisely 40°C, with dissolved NH3 
and CO2 gas essential for the reaction. Furthermore, if heated above 50°C, significant 
dimerization to form the bisglycosylamine compound 100 (m/z 409, M + NH4
+
) was 
observed (Scheme 3.5).  
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Scheme 3.5: Proposed mechanism for the production of 99 utilizing an NH4HCO3-promoted 
anomeric amination. 
Following lyophilisation, the ammonium salt 99 was subjected to protection of 
the anomeric amine using diethyl (ethoxymethylene)malonate, which as an excellent 
Michael acceptor that readily underwent nucleophilic substitution, liberating CO2, NH3 
and EtOH to produce the required enamine-protected 6-azido-β-D-glucopyranosylamine 
101 in 53% yield from 6-azido-1,2-isopropylidene-α-D-glucofuranose (Scheme 3.6). 
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Scheme 3.6: Synthesis of enamine-protected 6-azido-β-D-glucopyranosylamine 101. 
Evaluation of the 
1
H and 
13
C NMR spectra of 101 (Figure 3.2, A and B) were 
inconclusive in their identification of the stereochemistry at the anomeric centre,  with 
only the 
13
C NMR spectrum displaying an upfield signal at 91.6 ppm suggesting that the 
stereochemistry around the anomeric centre of 101 may be beta (β-). The sole 
β-stereochemistry present at the anomeric carbon of 101 was however confirmed by a 
NOESY 2D 
1
H
 
NMR experiment, highlighting correlations between the H1 and H5 of 
101, suggesting they are both axially configured (Figure 3.3). 
 
 
Figure 3.2: A: 
1
H NMR spectrum of 101, highlighting signals indicating H1 and H3, B: 
13
C NMR 
spectrum of 101, highlighting the downfield C1 carbon. 
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Figure 3.3: NOESY 2D 
1
H 
 
NMR experiment of 101, showing weak H1/H5 correlation.  
Following the installation and protection of the required anomeric β-amine, 101 
was then subject to peracetylation of the free 2-,3- and 4-OH groups under standard 
Ac2O/pyridine conditions, yielding the fully protected glycoside 102 in 92% yield 
(Scheme 3.7). Subsequently, the anomeric enamine of 102 was cleaved under aqueous 
Br2, unmasking the anomeric amine, which was stabilized as a hydrobromide salt, 
producing 103 in 73% yield (Scheme 3.7). 
 
 
Scheme 3.7: Synthesis of the 6-azido-2,3,4-tri-O-β-D-glucopyranosylamine hydrobromide salt 103. 
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In the presence of Br2, the enamine 102 is subject to Markovnikov addition 
across the double bond, resulting in the formation of an iminium intermediate 
(Scheme 3.8). The presence of water in the reaction mixture drives nucleophilic 
substitution of the imine, which following proton transfer results in the formation of a 
α-hydroxy intermediate. Subsequently, the presence of bromide ions in situ from the 
initial use of Br2 drive the formation of an aldehyde, resulting in the production of the 
desired ammonium hydrobromide salt 103 (Scheme 3.8). Whilst the synthesis of the 
corresponding hydrochloride salt (90) of 103 has previously been detailed,
188 
the use of 
Br2 represents a more readily accessible, safer option compared to the Cl2 gas 
previously utilized.
 
 
Scheme 3.8: Proposed mechanism for the formation of 103 through enamine cleavage mediated by 
wet Br2. 
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The formation of 103 was indicated in the 
13
C NMR spectrum, where the 
disappearance of the signal for the methylene carbon of 102, and the shielding of the 
anomeric carbon from 95.2 ppm in 102 to 79.1 ppm in 103 due to the unmasking of the 
free amine, verified the cleavage of the anomeric protecting group (Figure 3.4).  
 
 
Figure 3.4: 
13
C NMR spectra of 102 and 103, highlighting the deprotection of the anomeric 
enamine.  
 
3.3.2 Synthesis of Boc-protected Amino Acids 108 and 109 
With the required 6-azido-β-D-glucopyranosylamine 103 in hand, our focus now 
shifted to the synthesis of amino acids that could be coupled with 103. Considering the 
widespread use of both aspartic and glutamic acid residues in the synthesis of 
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bioconjugates,
192
 it was decided that conjugates between 103 and protected aspartic and 
glutamic acid residues would be synthesised to broaden the scope of our current studies.  
Hence, the synthesis of both protected aspartic acid and glutamic acid 
derivatives was performed, with the known Boc.Asp.OMe (108) and Boc.Glu.OMe 
(109) chosen.  Starting from the Boc-N-protected benzyl ester derivatives 104 and 105, 
using our own developed method methyl iodide and K2CO3 were employed to protect 
the α-carboxylic acid group of 104 and 105, with successful esterification producing 
Boc.Asp(OBn).OMe (106) and Boc.Glu(OBn).OMe (107) in 85% and 92% yields, 
respectively (Scheme 3.9). Subsequently, reduction of the sidechain benzyl ester 
protecting groups of 106 and 107 produced the required Boc.Asp.OMe (108) and 
Boc.Glu.OMe (109) in 84% and 86% yields, respectively (Scheme 3.9).  
 
 
Scheme 3.9: Synthesis of Boc.Asp.OMe (108) and Boc.Glu.OMe (109). 
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3.3.3 Synthesis of Sidechain Carboxyl-linked “Clickable” 
Glycoconjugates 110 & 111 
 With our key building blocks synthesized, coupling between these protected 
amino acids 108 and 109 commenced. Utilizing HBTU as a coupling reagent in the 
presence of DIPEA, Boc.Asp.OMe (108) was successfully coupled to 103, with reaction 
over 24 hours resulting in the “clickable” glycoconjugate 110 in 74% yield 
(Scheme 3.10).  
 
 
Scheme 3.10: Synthesis of sidechain carboxyl-linked “clickable” glycoconjugates 110 and 111. 
In the 
1
H NMR spectrum of 110, the presence of a deshielded doublet at 
6.55 ppm with coupling of 9.0 Hz was suggestive of a proton present on an amide 
nitrogen, indicative of the amide bond formed through the coupling (Figure 3.5, A). 
Furthermore, evaluation of a gCOSY experiment of 110 displays a correlation between 
this signal and a multiplet at 5.26 ppm, representing the three bond coupling present 
between H1 and the anomeric-linked NH (Figure 3.5, B). In addition to these, signals at 
3.74 and 1.44 ppm integrating for three and nine protons respectively, and a signal in 
the HR-ESIMS of m/z 582.2029 representing a chemical formula 
C22H33N5O12+Na (582.2023), definitively illustrated the production of 110.  
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Figure 3.5: 
1
H NMR spectrum (A) and gCOSY 2D 
1
H NMR experiment (B) of the sidechain 
carboxyl-linked “clickable” glycoconjugate 110, highlighting the correlation between the H1 and 
NH resulting from amide bond formation. 
The success achieved in the formation of 110 was subsequently extended to the 
coupling of Boc.Glu.OMe. Reaction of 103 with under HBTU-mediated coupling 
conditions resulted in the production of the Glu-linked “clickable” glycoconjugate 111 
in 79% yield (Scheme 3.10). Similarly to 110, the presence of a deshielded doublet at 
6.85 ppm in the 
1
H NMR spectrum of 111 was indicative of the proton bound to the 
anomeric amide nitrogen, with a gCOSY experiment of 111 showing a correlation 
between the NH proton and a multiplet at 5.31 ppm representing the H1 proton. In the 
13
C NMR spectrum of 111, a signal at 172.7 ppm was indicative of the carbon of an 
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amide linkage, indicative of the coupling of 100 and 106. Furthermore, the HR-ESIMS 
displayed a signal of m/z 596.2204 representing a chemical formula of 
C23H35N5O12+Na (596.2180), indicative of the desired product. Examples of sidechain 
carboxyl-linked “clickable” glycoconjugates, 110 and 111 represent the first instances 
of sidechain carboxyl-linked “clickable” glycoconjugates described. 
 
3.3.4 Synthesis of Functionalized Sidechain Carboxyl-linked 
Glycoconjugates 112 & 113 
 With the production of carboxyl sidechain-linked “clickable” glycoconjugates 
110 and 111 successfully achieved, our attention now turned to their functionalization 
via the CuAAC “click” reaction. Utilizing the conditions previously described in 
Chapter 2 for the functionalization of “clickable” glycoconjugates 66-73, aspartic acid 
derivative 110 was subject to the CuAAC “click” reaction with 4-pentyn-1-ol. 
Subsequently, after work up and flash column chromatography the functionalized 
derivative 112 was isolated, in 70% yield (Scheme 3.11).  
 
Scheme 3.11: Synthesis of functionalized sidechain carboxyl-linked “clickable” glycoconjugates 
112 and 113 through the CuAAC “click” reaction. 
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 An evaluation of the 
1
H NMR spectrum of 112 illustrated the formation of the 
desired triazole-bearing product, with a singlet at 7.54 ppm ascribed to the triazole 
proton (Figure 3.6). Interestingly, two signals at 4.55 ppm and 4.61 ppm were 
suggestive of the H6/H6’ protons adjacent to the triazole ring, with the electron-rich 
nature of the neighbouring triazole ring deshielding these protons by approximately 
1.1 ppm compared to the parent glycoconjugate 110 (Figure 3.5). Furthermore, 
HR-ESIMS of 112 displayed a signal of m/z 666.2621, which was indicative of the 
product with a molecular formula of C27H41N5O13 + Na (666.2599). 
 
 
Figure 3.6: 
1
H NMR spectrum (4.0 ppm – 8.0 ppm) of functionalized
 
glycoconjugate 112, 
highlighting the formation of a 1,4-substituted triazole. 
Subsequently, following on from the successful production of 112, the glutamic 
acid derivative 111 was also subjected to the CuAAC “click” reaction with 
4-pentyn-1-ol, which up on work up and isolation yielded the functionalized derivative 
113 in 62% yield (Scheme 3.11). Similarly to 112, a downfield singlet in the 
1
H NMR 
spectrum of 113 at 7.72 ppm was indicative of the desired product, representing the 
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triazole proton. Furthermore, a more deshielded doublet at 4.31 ppm was ascribed to the 
H6/6’ protons of 113, with the HR-ESIMS of 113 displaying a signal for the desired 
product of m/z 680.2793, corresponding to the formula C28H43N5O13+ Na (680.2755).  
To summarize, the synthesis of the azidoglucosylamine 103 has provided access 
to the development of “clickable” glycoconjugates 110 and 111 through amino acids 
coupled to sidechain-carboxyl groups. Further derivatization of these glyconjugates 
utilizing the CuAAC “click” reaction has broadly extended the uility of this 
methodology beyond the ester and amide-linked conjugates produced in chapter 2. In 
chapter 4, the extension of this approach to the synthesis and functionalization of 
thioether-linked “clickable” glycoconjugates will be discussed. 
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Chapter 4 : Synthesis and Functionalization of 
Thioether-linked “Clickable” Glycoconjugates 
 
Chapters 2 and 3 detailed the development of ester and amide linked azido 
sugar amino acid derivatives attached through either sidechain groups such as NH2, 
OH or COOH, or via the N-terminus. These ”clickable” glycoconjugates could be 
readily incorporated into biologically-active peptides, whilst retaining free handles for 
use in the CuAAC “click” reaction. In this chapter, the development of thioether-linked 
“clickable” glycoconjugates will be presented. 
 
4.1 Synthetic Rationale 
 In Chapters 2 and 3, the synthesis of “clickable” glycoconjugates exploiting 
amide-coupling chemistry was highlighted. Demonstrating the coupling of sugar azido 
acids to a variety of different amino acid residues (e.g. Ser, Lys, Asp and Glu), the 
following approach provides a highly advantageous method for the synthesis of 
bioconjugates.
 
However,
 
beyond the following amide and ester-linked examples, there 
are a number of different conjugate types that are incompatible with this approach. 
These include thioesters formed through the coupling of thiol-containing amino acids 
such as cysteine or homocysteine to carboxylic acids, which are less stable than their 
corresponding esters.
193
 Thioesters are susceptible to degradation under acidic or basic 
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conditions and prone to substitution in the presence of stronger oxygen and nitrogen-
based nucleophiles. Although their use has been widely applied in areas of peptide and 
ligation chemistry, such as native chemical ligation,
193,194
 the lability of these linkages 
has made their use in the development of stable bioconjugates unsuitable.  
In contrast, thioethers represent linkages which provide excellent chemical 
stability under a range of different conditions. Widely accessible through alkylation, 
they have been commonly used in the developments of conjugates with thiol or alcohol-
containing amino acids.
195
 If a class of azidosugars were developed that had the capacity 
to form thioether linkages, these could produce glycoconjugates with amino acids such 
as cysteine and homocysteine. Comparable to the examples described in Chapter 2 and 
Chapter 3, these glycoconjugates would be “clickable,” and could therefore be utilized 
to functionalize biologically-active peptides via “click” chemistry (Scheme 4.1). 
 
 
 
Scheme 4.1: Proposed synthesis of thioether-linked "clickable" glycoconjugates. 
 
4.2 Initial Synthetic Approach 
Building upon the earlier strategies that produced “clickable” glycoconjugates 
bearing azides at the anomeric (Chapter 2) and 6-position (Chapter 3) of the glycoside, 
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respectively, a divergent synthetic strategy that could produce both of these types of 
glycoconjugates was initially undertaken. Using a simple precursor such as D-glucose 
would allow for the introduction of the required azide moiety.  Also, the presence of a 
suitable leaving group would allow for the installation of a thioether-linkage through 
alkylation. A p-toluenesulfonyl (tosyl; Ts) group, when utilized in a fully-protected 
glycoside (such as 114, Figure 4.3), provides a strategy whereby an azide moiety can be 
introduced into the molecule by a number of different ways (Scheme 4.2, pathway A).  
 
 
Scheme 4.2: Pathways towards the synthesis of thioether-linked “clickable” glycoconjugates. 
Akin to examples described in chapter 2 (cf earlier synthesis of 58 and 63, 
section 2.3), bromination of the anomeric acetate of 114 using HBr in acidic conditions 
could be utilized to produce an anomeric α-bromide intermediate (115). Based on Hard 
Acid Soft Base (HSAB) theory, both the anomeric α-bromide and OTs groups represent 
soft leaving groups. The bromide of 115 however is a better leaving group than the 
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6-OTs moiety, with this judgement based on the pKa of the conjugate acid of each 
leaving group (pKa: HBr = -9, TsOH = -2.8). As a result of this difference, in the 
presence of NaN3 selective SN
2
 nucleophilic substitution of the anomeric centre of 115 
would be favoured, resulting in the production of the β-azide 116.  Subsequently, the 
replacement of the stable 6-OTs of 116 with a more labile leaving group (e.g. halide - 
Br, I) would produce a glycoside that could be alkylated to yield thioether-linked 
glycoconjugates (Figure 4.2, pathway A). This judgement is based on the soft nature of 
a thiol nucleophile, with a softer leaving group (for example, pKa HI = -10), more likely 
to undergo nucleophilic substitution in the presence of a relatively soft nucleophile. 
Alternatively to this approach, the tosyl group of 114 could be subjected to directly 
nucleophilic substitution in the presence of NaN3, resulting in the production of the 
6-azidonated glycoside 125. The subsequent introduction of an anomeric leaving group 
would allow for the formation of the desired glycoconjugates through glycosylation 
chemistry (Scheme 4.2, pathway B).  
 
4.3 Attempted Synthesis of 6-Thioether-linked “Clickable” 
Glycoconjugates 
4.3.1 Synthesis of 6-Iodo-2,3,4-tri-O-acetyl-β-D-glucosyl azide (117) 
With the following options available, the synthesis of thioether-linked 
“clickable” glycoconjugates initially focused on the synthesis of derivatives 
incorporating amino acids linked to the glycoside at the 6-position. The lack of a 
stereocentre at the 6-position of these glycosides would remove problems regarding 
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stereoselectivity in these conjugates, and the potential formation of epimers during 
alkylation. Hence, D-glucose was initially subject to p-tosylation at the 6-position using 
p-touenesulfonyl chloride and pyridine, with the subsequent addition of acetic 
anhydride resulting in the acetylation of the remaining alcohols, producing 
6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose (114, Scheme 4.3) in 
40% yield.
196
 The moderate yield of this reaction is a direct result of the lack of 
selectivity of the p-tosylation step, which in comparison to the previously synthesized 
furanose p-tosylate 95 is much less hindered. The inefficiency of this process however, 
was offset by the high scalability and simple purification of this process, in addition to 
the divergent nature of the synthesis to be performed from this key intermediate. 
With 114 in hand, installation of the anomeric β-azide to produce the required 
6-p-toluenesulfonyl-β-D-glucosyl azide 116 was undertaken. In comparison to the 
synthesis of β-azides previously described in chapter 2, SnCl4-mediated azidonation was 
not considered, due to the likely cleavage of the tosyl group in the presence of the tin 
catalyst. Hence, 114 was instead subjected to anomeric α-bromination conditions by 
reaction with 33% w/v HBr/AcOH in dichloromethane producing the anomeric bromide 
intermediate 115 (Scheme 4.3). Under subsequent SN
2
 nucleophilic azidonation using 
sodium azide in DMF, 6-p-toluenesulfonyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyl azide 
was isolated in 65% yield over the two steps (116, Scheme 4.3).  
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Scheme 4.3: Synthesis of 6-iodo-2,3,4,tri-O-acetyl-β-D-glucopyranosyl azide (117).
196 
The production of 116 was confirmed by the 
1
H NMR spectrum, where a 
shielded doublet at 4.56 ppm (J = 9.8 Hz) indicated the introduction of a β-azide into 
the molecule. Whilst in its own right the p-tosyl group represents a good leaving group, 
it was believed that the stability of this group (compared to more labile, soft leaving 
groups) would prevent the formation of 124 under mild alkylating conditions. Hence, 
the introduction of a more labile leaving group was investigated. A halide, such as an 
iodo group, would be more inclined to undergo elimination in the presence of a suitable 
nucleophile, negating the requirement for stronger basic conditions to drive alkylation. 
Furthermore, it is possible that nucleophilic substitution of the iodo group could be 
favoured over the dimerization of the alkylating thiol, a common side reaction in the 
presence of base. Hence, utilizing classical Finkelstein iodination conditions employing 
4.0 equivalents of sodium iodide in acetone,
196
 the p-tosyl containing azidosugar 116 
was iodinated at the 6-position, to produce 6-iodo-2,3,4-tri-O-acetyl-D-glucosyl azide in 
62% yield (117, Scheme 4.3). In the 
1
H NMR spectrum of 117, the disappearance of 
two doublets at 7.80 ppm and 7.36 ppm were indicative of substitution of the tosyl 
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group, with a more shielded signal at 3.60 ppm in the 
13
C NMR spectrum of 117 
indicative of the formation of a C-I bond at the 6-position. 
 
4.3.2 Synthesis of Thiol-bearing Amino Acid Boc.HCys.OtBu (120) 
With the requisite carbohydrate building block in hand, the synthesis of the 
thiol-containing amino acid was attempted, with the homocysteine (HCys) derivative 
N-tertbutoxycarbonyl-L-cysteine-t-butyl ester (Boc.HCys.OtBu) chosen as the thiol-
containing amino acid. Starting from L-homocystine, Boc-protection of the α-amino 
groups using aqueous Na2CO3 yielded 118 in 90% (Scheme 4.4), which in the presence 
of an excess of t-butyl-2,2,2-trichloroacetimidate yielded the t-butyl diester 119 in 
near-quantitative yield (Scheme 4.4).
197
 Subsequently, the disulfide bond of 119 was 
reduced to the thiol using n-tributylphosphine, yielding Boc.HCys.OtBu in 85% yield 
(120, Scheme 4.4), with an analysis of the 
1
H NMR spectrum of 120 highlighting a new 
triplet at 1.55 ppm (J = 5.7 Hz) that was indicative of the free thiol group present in 120. 
 
 
Scheme 4.4: Synthesis of Boc.HCys.OtBu (120) from L,L-homocystine.
178,197 
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4.3.3 Attempted Alkylation of 6-Iodo-2,3,4-tri-O-acetyl-β-D-
glucosyl azide (117) 
With the 6-iodosugar 117 and Boc.HCys.OtBu in hand, efforts were made 
towards the alkylation of thioether-containing amino acids. In endowing 117 with a 
better leaving group in our attempts to form thioether–linked “clickable” 
glycoconjugates, it was recognized that the iodo group may be susceptible to cleavage 
under the alkylation conditions proposed. This premise was based on the previous work 
of Murphy and co-workers, who en route to the production of glc, gal and manno 
iminosugars 121-123 produced the hex-5-enopyranosides from 6-iodopyranosides, with 
DBU catalysis resulting in HI elimination (Scheme 4.5).
198 
 
 
Scheme 4.5: Proposed mechanism for the elimination of hydrogen iodide from 121-123 in the 
presence of a non-nucleophillic base. 
Considering that the reported conditions in the glc example (121) required much 
higher temperatures to induce elimination (reflux, >110°C)
198
 than the conditions we 
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proposed, it was believed that the competing process of alkylation would occur 
favorably with an amino acid containing a good nucleophile. Hence, alkylation of 
Boc.HCys.OtBu by 117 was attempted, utilizing a range of different non-nucleophilic 
bases to catalyse alkylation. However, under these conditions the formation of the 
desired product (124) was not observed, with the azidosugar side product 121 instead 
procured in moderate quantities (Table 4.1, Entries 1-3).  
Table 4.1: Attempted alkylation of 6-iodo-2,3,4-tri-O-acetyl-β-D-glucopyranosyl azide (117) by 
Boc.HCys.OtBu (120). 
 
Comparison of the 
1
H NMR spectra of 117, Boc.HCys.OtBu and the crude 
reaction mixture when Cs2CO3 was used as the alkylating base (Figure 4.1, A-D 
respectively), highlighted the degradation of 117 and the near-quantitative conversion of 
Boc.HCys.OtBu to the dimerized precursor (Boc.HCys.OtBu)2 (Figure 4.1). This also 
was clearly illustrated by LR-ESIMS, with a signal of m/z 603 (M + Na) indicative of 
Boc.HCy.OtBu dimerization. The disappearance of signals from 3.0-4.0 ppm in A 
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ascribed to the H5 and H6/H6’ protons of 117, the downfield shift of a CH2 signal (120) 
to ~2.75 ppm in B, and the appearance of methine protons between 4.5-5.0 ppm in C, 
are indicative of the elimination of HI from 117, the reformation of (Boc.HCys.OtBu)2 
(119) and the formation and isolation of the unwanted glc hex-5-enepyranoside 121 
(Figure 4.1, D).  
 
Figure 4.1: Comparison of the 
1
H NMR spectrums of 117 (A), Boc.HCys.OtBu (120, B) and the 
crude alkylation reaction mixture (C), highlighting reformation of (Boc.HCys.OtBu)2 (119) and the 
glc hex-5-enepyranoside 121 (D).  
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Based on the observed dimerization of 120, it is the plausible that the bases used 
in the attempted alkylations were too strong for the thiol-containing amino acid used. 
The pKa values for NEt3 (~10.45), DBU (~12) and Cs2CO3 (~10.3) are all much higher 
than that of the thiol of the amino acid used (~8.5), thus it is likely that in solution the 
thiol of 120 may have been more readily present as a thiolate. A good nucleophile, it is 
possible (but speculatory) that the presence of this species may have encouraged 
nucleophilic attack of the thiol of another amino acid in solution, resulting in the 
observed dimerized amino acid.  
Interestingly, TLC analysis of the reaction mixture highlighted the presence of 
significant quantities of the starting iodide (117), with 25-35% recovered across the 
three approaches used. Whilst the undesired hex-5-enopyranoside (121) was also 
isolated in significant quantities, its rate of formation was much slower compared to the 
dimerization of 120, which was observed over 4-6 hours of reaction time compared to 
the 48 hours for the HI elimination. The lack of desired product formed, in addition to 
the slow rate of by-product formation and the presence of significant quantities of 
starting material, suggested that lower temperature would not inhibit elimination.  
Thus, a base-free alternative approach using the halide scavenger Ag2O was 
trialled to catalyze the alkylation of Boc.HCys.OtBu by 117. Exhibiting a strong affinity 
for halides, it was believed that Ag2O would act to promote the alkylation without 
promoting side product formation through proton scavenging.
199
 However, whilst this 
methodology was effective in preventing the formation of the side product 121, after 
stirring for 4 days in the presence of 4.0 equivalents Ag2O in DMF no reaction was 
observed (Table 4.1, entry 4). To further evaluate this reaction, the reaction time was 
extended to 8 days, and THF was utilized as a reaction solvent. Similarly though, this 
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non-reaction proved unsuccessful, with only a trace amount of 121 detected (Table 4.1, 
Entry 5). Thus, after multiple attempts to produce 6-thioether-linked “clickable” 
glycoconjugates, the synthesis of these was discontinued, and focus shifted to the 
synthesis of conjugates linked to the anomeric position of a pyranoside. 
 
4.4 Synthesis of Anomeric Thioether-linked “Clickable” 
Glycoconjugate 131 
Akin to the carboxyl-linked glycoconjugates synthesized in Chapter 3, attempts 
to produce thioether-linked derivatives through linkages at the anomeric centre were 
investigated. Utilizing the previously synthesized acetyl protected 6-tosyl bearing 
glycoside 114, SN
2
 nucleophilic substitution with an azide donor (such as NaN3) would 
produce an azidosugar such as 125 that could be directly glycosylated (using SnCl4 or 
BF3.OEt2). Alternatively, the introduction of a better leaving group (e.g bromide, 
trichloroacetimidate, etc.) at the anomeric centre, would provide a better glycosyl donor 
that could undergo steroselective glycosylation.
200 
If a thiol-containing glycosyl 
acceptor such as cysteine or homocysteine were utilized, these molecules would 
represent anomeric thioether-linked “clickable” glycoconjugates, and thus would be 
amenable to further functionalization using the CuAAC “click” reaction.  
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4.4.1 Synthesis of 6-Azido-2,3,4-tri-O-acetyl-α-D-glucopyranosyl 
trichloroacetimidate (127) 
The synthesis of the target thioether-linked glycoconjugates commenced using 
6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucopyranose (114) as a key synthon. In 
the presence of NaN3 in DMF, and under mild heating over 24 hours, 114 was 
converted into the requisite 6-azido-6-deoxy-1,2,3,4-tetra-O-acetyl-D-glucopyranose 
(125) in 57% yield (Scheme 4.6), as a ~1:1 mixture of α- and β-anomers. Compared to 
previous azidonations discussed in this work, the yield of 125 was somewhat reduced 
due to the competing azidonation of the anomeric centre of 114, as opposed to the 
p-tosyl group. The formation of this side product was initially indicated by TLC 
analysis, with LR-ESIMS of the reaction mixture displaying a signal of m/z 379 
(M + Na) indicative of the side product. As a result, additional recrystallization from 
EtOAc/Hexane following chromatography was required to yield spectroscopically pure 
125, the structure of which was confirmed from the 
1
H NMR spectra, where the loss of 
two doublets at 7.80 and 7.36 ppm (J = 8.2 Hz), indicated the loss of the p-tosyl group. 
This was further confirmed by the LR-ESIMS of 125, where a value of m/z 396 was 
indicative of the desired product plus sodium (C14H19N3O9Na). 
 
 
Scheme 4.6: Synthesis of 6-azido-6-deoxy-1,2,3,4-tetra-O-acetyl-D-glucose 125. 
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In order to evaluate glycosylation at the anomeric centre, a suitable glycosyl 
donor was required. As mentioned previously (section 2.3), anomeric acetates have been 
known for their susceptibility to glycosylation under Lewis acid catalysis – utilizing 
SnCl4 and BF3.OEt2.
200
 However, the potential formation of epimers in using these 
methods limits their favourability in these reactions. Alternatively, glycosyl 
trichloroacetimidates represent a class of compounds that have historically been used as 
glycosyl donors. Developed by Schmidt and co-workers,
201
 the versatility of these 
glycosyl donors to undergo stereoselective glycosylation using Lewis acids such as 
TMSOTf, in the presence of a range of O- and S-acceptors has validated their 
widespread use in chemical glycosylation.
202
 Considering the breadth of literature into 
anomeric glycosylation via both of these methodologies, they were both evaluated in the 
production of the target anomeric-linked glycosyl azides. 
Therefore, with peracetylated 6-azidoglycoside 125 in hand the synthesis of the 
desired azidosugar bearing an α-trichloroacetimidate at the anomeric position was 
initiated. Commencing from 125, selective deacetylation at the anomeric position using 
hydrazine acetate resulted in the lactol intermediate 126 in 75% yield (Scheme 4.7). 
This isolated intermediate was then subjected to reaction with trichloroacetonitrile and 
DBU, producing the desired α-trichloroacetimidate bearing compound 127, isolated 
solely as the α-anomer in 78% yield (Scheme 4.7).
146 
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Scheme 4.7: Synthesis of α-trichloroacetimidate bearing azidosugar 127.
146
 
Confirmation of the formation of 127 was highlighted by the 
1
H NMR spectrum, 
where a singlet at 8.76 ppm corresponded to the imidate proton present on the 
trichloroacetimdate (Figure 4.2). Furthermore, a doublet at 6.63 ppm (J = 3.7 Hz) 
signified the equatorial H1 proton of 127,  suggesting a small dihedral angle between 
H1 and H2,  indicative of  the α-stereochemistry of the trichloroacetimidate present at 
the anomeric position, with no signal indicating the presence of the β-anomer observed 
(Figure 4.2).
146
 
 
 
Figure 4.2: 
1
H NMR spectrum of 127, highlighting the small coupling constant (J = 3.7 Hz) between 
the H1 and H2 protons, indicative of the α-stereochemistry present in 127. 
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4.4.2 Synthesis of Fmoc.HCys.OMe (130) 
With the trichloroacetimidate 127 inhand, our attention tuned to the required 
thiol-containing amino acid. Previously utilizing Boc.HCys.OtBu (120), it was 
recognized that the acid-sensitive Boc and tBu protecting groups would not be 
compatible with the current Lewis acid-catalysed strategy. Therefore as an alternative, a 
homocysteine derivative protected with groups compatible with Lewis acid-mediated 
glycosylation conditions (Fmoc, OMe groups) was chosen for use in this strategy. Thus, 
commencing from L,L-homocystine, esterification using thionyl chloride (SOCl2) in dry 
methanol resulted in the formation of the dimethyl ester dihydrochloride derivative 128 
in near quantitative yields (Scheme 4.8).
203
  
 
 
Scheme 4.8: Synthesis of Fmoc.HCys.OMe (130) from L,L-homocystine. 
203 
The α-amino groups of 128 were subsequently protected using Fmoc-Cl in 
aqueous K2CO3, yielding the protected derivative (Fmoc.HCys.OMe)2 (129) in 
74% yield (Scheme 4.8). Finally, disulfide bond reduction of 129 utilizing Zinc 
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dust/TFA conditions, resulted in the isolation of the requisite thiol-containing amino 
acid Fmoc.HCys.OMe  (130) in 71% yield respectively (Scheme 4.8), with 
1
H and 
13
C NMR spectra in accordance with those previously described elsewhere.
203 
 
4.4.3 Synthesis of Thioether-Linked “Clickable” Glycoconjugate 131 
With both the glycosyl donors 125 and 127, and the amino acid acceptor 130 
prepared, the synthesis of the desired thioether-linked glycoconjugate was attempted. As 
previously discussed in section 2.3, the utilization of contrasting non-stereoselective and 
steroselective Lewis acid-mediated glycosylation strategies was trialled. In the first 
instance, the anomeric acetate-bearing azidosugar 125 was subjected to SnCl4-mediated 
glycosylation by Fmoc.HCys.OMe (130). As a result, the target compound 131 was 
synthesised, as ~2:1 α- to β-anomeric mixture in 51% yield (Scheme 4.9). 
 
 
Scheme 4.9: Synthesis of thioether-linked “clickable” glycoconjugate 131 from anomeric 
acetate 125.
 
Isolable individually by flash column chromatography, both α- and β-anomers of 
131 displayed m/z values of 707 (C32H36N4O11S+Na), which were both indicative of the 
desired product plus sodium. The 
1
H NMR spectra for both α- and β-anomers of 131 
also highlighted their differing conformations (Figure 4.3). For the α-anomer, a 
Chapter 4: Thioether-linked “clickable” glycoconjugates 
 
127 | P a g e  
 
deshielded doublet at 6.35 ppm (J = 3.6 Hz) was indicative of the equatorial H1 proton, 
with the small coupling constant between the H1 proton and the neighbouring axial 
H2 proton highlighting their “cis” configuration (Figure 4.3, A). Comparably, in the 
1
H NMR spectrum of the β-anomer of 131, the presence of a doublet (J = 9.9 Hz) at 
4.51 ppm was indicative of the H1 proton (Figure 4.3, B), with the larger coupling 
constant highlighting the “trans” relationship that exists between the axial H1 and H2 
protons (Figure 4.3, B).  
 
Figure 4.3: 
1
H NMR spectra for both α- and β-anomers (A and B) of the thioether-linked 
“clickable” glycoconjugate 131. 
Additionally, variations between the signals for the H
γ
 of the amino acid portion, 
and H6/H6’ protons of the pyran ring portion of 128 highlighted the different anomeric 
configurations. In the β-anomer, two multiplets each integrating for one proton at 
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2.69 ppm and 2.79 ppm represented the geminal H
γ
 protons (Figure 4.12, B). The 
different signals for each proton in the β-anomer of 131 indicated that in the 
1
H NMR 
conditions utilized (CDCl3, 25°C) these geminal protons may be in different chemical 
environments. Considering the adjacent 2-OAc group, it is possible that one of these 
protons may be sterically hindered by this neighbouring group, with the β-configuration 
of the thioether at the anomeric centre placing one of these protons in close proximity to 
the neighbouring ring-bound oxygen. Such hinderance would limit free rotation of the 
C-S bond, resulting in the diastereotopic signals observed in the 
1
H NMR spectrum of 
131(Figure 4.4). This phenomenon is specific to the β-anomer of 131, as the 
corresponding protons of the α-anomer do not display the same divergence (Figure 4.3, 
A). The non-stereoselective synthesis of 131 represents the second instance where a 
thiol-containing amino acid has been utilized in the glycosylation of an azidosugar, 
producing thioether-linked “clickable” glyococnjugates.
204 
 
 
Figure 4.4: Proposed steric hinderance between the amino acid H
γ
 methylene protons and 
neighbouring acetate group of 131, resulting in different chemical environments for the two H
γ 
protons in the 
1
H NMR spectrum (CDCl3, 25°C) of 131. 
With the non-stereoselective production of 131 successfully achieved, efforts to 
replicate these results utilizing a steroselective strategy were attempted. As with the 
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previously described glycosylation, Lewis acid catalysis provided the best opportunity 
to catalyse this glycosylation, with TMSOTf widely used for such a procedure.
205
 In the 
presence of a trichloroacetimidate (such as the synthesised 127), coordination of the 
imidate by TMSOTf results in the elimination of trichloroacetamide (Scheme 4.10). 
Equilibration between the formed oxocarbenium ion, and the formation of a stable 
anomeric carbocation, results in neighbouring group participation by the 2-OAc group, 
forming a stable acetal intermediate (Scheme 4.10). Subsequently, in the presence of an 
O- or S-containing acceptor the anomeric centre is susceptible to nucleophilic 
substitution, with the α-stereochemistry of the acetal intermediate favouring the 
stereoselective formation of a β-substituted product (Scheme 4.10).  
 
 
Scheme 4.10: Proposed mechanism for the stereoselective formation of β-glycosides from an 
α-trichloroacetimidate. 
In respect to the proposed mechanism for glycosylation, the resonance 
stabilization of the oxocarbenium ion provides an opportunity for glycosylation to occur 
via either an SN
1
-mediated mechanism (kinetic control - direct glycosylation) or an 
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SN
2
-mediated mechansm (thermodynamic control - neighbouring group participation), 
potentially producing both α- and β-anomers of the desired glycoconjugates.
200,206
 
Whilst the potential formation of both anomers was a concern, previous literature had 
highlighted that the selective formation of azido-β-thioglycosides via this methodology 
was feasible, with Gouin and co-workers successfully utilizing 127 and TMSOTf to 
produce the β-thioglycoside 132 en route to tethering fluorescein to heptyl 
α-D-mannosides.
207
 This work highlights the importance of reaction temperature in 
stereoselectively producing β-thioglycosides via this methodology, suggesting that a 
reaction temperature of less than -20°C would be sufficient to maintain kinetic control, 
and thus produce the desired β-glycoconjugate.  
 
 
Scheme 4.11: Synthesis of azido-β-thioglycoside 132 performed by Gouin and co-workers.
207 
Thus, based on this literature precedence the stereoselective synthesis of 
thioether-linked 131 was attempted. After being thoroughly dried under vacuum, 127 
and Fmoc.HCys.OMe (130) were subjected to TMSOTf catalysis in dichloromethane. 
After 1 hour at -20°C, subsequent work up resulted in the isolation of the desired 
glycoconjugate 131 in a moderate yield of 38% (Scheme 4.12). Monitored by TLC, 
unfortunately the appearance of two spots at Rf 0.23 and Rf 0.30 (2:1 Hexane:EtOAc) 
represented the presence of both α-and β-anomers, with the 
1
H and 
13
C spectra of these 
samples in agreement with those previously produced using SnCl4.  
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Scheme 4.12: Synthesis of thioether-linked “clickable: glycoconjugate 131 from 
α-trichloroacetimidate 127.
 
The stringent requirement of moisture and oxygen-free conditions made the 
synthesis of 131 via this method precarious, with the TMSOTf used in each reaction 
highly susceptible to degradation. Forming triflic acid as a by-product, it is likely that 
this occurred in both these instances, with the presence of spots on the baseline of the 
TLC of each reaction suggesting the degradation of the trichloroacetimidate 127, 
contributing to the moderate yields gained for 131. In regards to the lack of 
stereoselectivity observed, it is likely that in our hands at -20°C, neighbouring group 
participation was not favoured, leading to ambivalent nucleophilic substitution of the 
anomeric centre. Additionally, whilst 127 was stable when stored under argon at less 
than 0°C, it was noticed over time the trichloroacetimidate was susceptible to 
degradation, particularly during reaction set up. Considering the issues with this 
synthetic strategy, and our shortcomings in the stereoselective production of 131, the 
focus of our efforts shifted to the development of a broader methodology for the 
"formation of “clickable” glycoconjugates between azidosugars and thiol-containing 
amino acids and peptides, and thus the functionalization of 131 by the CuAAC “click” 
reaction was not attempted. 
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4.5 Synthesis of Thioether-linked “Clickable” Glycoconjugate 
138 Using a “Click” Thiol-ene Approach 
 As described, problems were encountered in the attempted production of 
anomeric and 6-thioether linked derivatives (124 and 131), and it was also recognised 
that these strategies may not be so well suited for use in the formation of higher 
glycoconjugates. Challenges in producing 124 and 131 including reactivity, 
stereoselectivity and protecting group orthogonality could be overcome to yield 
thioether-linked glycoconjugates encompassing a single amino acid.  It is unlikely 
however whether this would be true for the synthesis of thioether-linked peptides or 
proteins. This is particular relevant in regards to protecting group orthogonality, as 
many glycosylating reagents (including SnCl4/TMSOTf) are not compatible with acid-
sensitive protecting groups. Additionally, reduction-labile protecting groups may 
compete with the 6-azido group during depotection, thus further limiting the access of 
produced synthons to solid or solution phase peptide synthesis. Furthermore, as many 
proteins and peptides require specific aqueous pH environments to maintain structure 
(and function) it is likely that the aciditiy of reagents could interfere with the coupling 
peptide or protein. Considering these arguments, a methodology that allowed for the 
ligation of azidosugars to thiol-containing peptides or proteins in benign conditions 
would be highly advantageous.  
Thus, an evaluation of the literature was undertaken to identify methods that 
could be utilized to readily produce “clickable” glycoconjugates between azidosugars 
and thiol-containing peptides or proteins. One such method that has grown in use for the 
labelling and tagging of peptides containing thiol groups is the thiol-ene reaction. 
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Encompassing the anti-Markovnikov addition of a free thiol group to an alkene, the 
result of this reaction is a saturated thioether.
208,209
 Mechanistically, the thiol-ene 
reaction can proceed via either an ionic or radical reaction mechanism. Under the ionic 
reaction conditions, the reaction is often performed in a buffered solvent at pH 6.5-7.5. 
At this pH, the thiol group may disproportionate to form the respective thiolate anion, 
which in the presence of an alkene will undergo addition, forming the desired thioether 
(Scheme 4.13, A).
208
 Alternatively to this, in the presence of a suitable radical initiator a 
thiyl radical may instead be produced from a thiol. In the presence of an alkene, anti-
Markovnikov addition across the double bond ensues, resulting in the formation of a 
thioether containing a stabilized secondary radical. In the propagation phase of the 
reaction, this radical can go on to form an additional sulfanyl radical, producing the 
desired thioether (Scheme 4.13, B).
 208 
 
Scheme 4.13: Ionic (A) and radical (B) mechanisms for the synthesis of thioethers via the 
thiol-ene reaction.
208
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 The use of relatively pH-netural, environmentally benign conditions in the ionic 
thiol-ene reaction have promoted its widespread use in synthetic biology.
210 
The 
utilization of maleimides as alkene donors drastically increases the reaction rate for the 
formation of thiol-enes, with these reactions finding widespread usage in the labelling 
of thiol-containing bioconjugates. As a result of its speed and efficiency in the 
formation of thioethers, the thiol-ene reaction is often referred to as a “click” reaction, 
and is often discussed alongside the CuAAC “click” reaction utilised in this work.
208
 
Examples such as the previously discussed development of [
18
F]-FDR by O’Hagan and 
co-workers (Chapter 1, Scheme 1.5),  have illustrated the utility of this method in the 
formation of bioconjugates. Utilizing a maleimide-containing hydroxylamine to attach 
to the thiol-containing tripeptide glutathione (γ-Glu-Cys-Gly), subsequent oxime 
formation resulted in the labelling of the bioconjugate with [
18
F]-FDR.
114
  
Beyond the usage of an oxime in this example, an abundance of literature for the 
introduction of maleimides into macromolecules using amide-coupling chemistry exists, 
linking maleimides through linkers bearing an amine or carboxylic acid.
210 
As described 
in chapter 2, the glc- and gal-sugar azido acids 60 and 65 were extensively derivatized 
using amide-coupling chemistry (Chapter 2, Pg 66-76), displaying broad scope for their 
usage in the synthesis of “clickable” glycoconjugates. Bearing these considerations in 
mind, if a maleimide bearing a free amine was produced and linked to a SAA using 
amide-coupling chemistry, this molecule could be subjected to the “click” thiol-ene 
reaction. The resulting thioether-linked “clickable” glycoconjugates could then be 
further derivatized at the free azide by the CuAAC “click” reaction (Scheme 4.14). 
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Scheme 4.14: Approach towards the synthesis and functionalization of thioether-linked “clickable” 
glycoconjugates utilizing the thiol-ene “click” reaction. 
 
4.5.1 Synthesis of Maleimide-Sugar Azido Acid-linked Derivative 136 
Thus, in order to synthesise glycoconjugates of this form, the synthesis of a 
maleimide bearing an amine-containing linker was required. An ethylenediamine-based 
linker was chosen for conjugation between the maleimide and sugar azido acid, with the 
short distance between the two limiting the likelihood of any issues due to linker 
folding. Additionally, the lack of cleavable functional groups on the linker would allow 
for the use of the glycoconjugate in a broad range of acidic or basic conditions. To form 
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the maleimide, N-Boc-ethylenediamine (133) was subject to reaction with maleic 
anhydride in diethyl ether in the presence of triethylamine. Subsequent refluxing in 
acetone with Ac2O followed by workup, resulted in the isolation of the desire 
N-Boc-ethylenediamine maleimide 134 in 50% yield (Scheme 4.15).
211
 With the desired 
maleimide core isolated, the Boc protecting group of 134 was subject to deprotection 
under standard TFA/dichloromethane conditions. Stirring for 1 hour, solvent 
evaporation followed by trituration with diethyl ether resulted in the isolation of 135 as 
a TFA salt in 95% yield (Scheme 4.15).
211
 The isolation of 135 was confirmed by the 
1
H NMR spectrum, where the disappearance of a signal from 1.42 ppm integrating for 
nine protons was indicative of the cleavage of the Boc protecting group, with both 
1
H and 
13
C NMR spectra for 135 consitent with those previously described in the 
literature.
211
 
 
 
Scheme 4.15: Synthesis of ethylenediamine maleimide 135. 
With 135 in hand, our focus now shifted to the formation of the maleimide-sugar 
azido acid glycoconjugate 136. Considering that the previously synthesised 131 was a 
glc-based derivative, it seemed fitting that the glc-sugar azido acid 60 should be used in 
Chapter 4: Thioether-linked “clickable” glycoconjugates 
 
137 | P a g e  
 
the formation of the required conjugate. Thus, under standard DCC/HOBt coupling 
conditions in acetonitrile, 60 was subjected to reaction with maleimide linker 135, with 
work up and flash column chromatography resulting in the isolation of the maleimide-
linked azido sugar 136 in a respectable 66% yield (Scheme 4.16).  
 
 
 
Scheme 4.16: Synthesis of maleimide-SAA linked derivative 136.  
In the 
1
H NMR spectrum of 136, the presence of a broad signal at 6.86 ppm 
accounting for one proton was indicative of the amide proton formed during the 
reaction, with a signal in the HR-ESIMS at m/z 490.1204 representing the desired 
product plus sodium (C18H21N5O10 + Na; 490.1186). Interestingly, the signals 
representing the hydrogens on the carbon adjacent to the amide bond in 136 are not split 
as they are in previous conjugates bearing CH2 groups adjacent to the amide (68 and 
88), with these protons forming a multiplet at 3.43 ppm. It is possible (but speculatory) 
that in the conditions of the 
1
H NMR (CDCl3, 25°C) the amide NH moiety present in 
136 may hydrogen bond with either of the ketones of the maleimide, forming a seven-
membered interaction that places both of these protons into identical chemical 
environments. The plausibility of this argument is justified by both the planarity and the 
α,β-unsaturated nature of the maleimide present in 136.  
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4.5.2 Thiol-ene “Click” Reaction of Maleimide-linked Derivative 136 
and Fmoc.HCys.OMe (130). 
With the maleimide-linked derivative 136 synthesised, its derivatization using 
the “click” thiol-ene reaction was subsequently evaluated. Instead of using a protected 
peptide (such as reduced L-glutathione), Fmoc.HCys.OMe (130) would instead be used 
to develop a methodology that could be used on protected thiol-bearing peptides. In 
addition to the ready availability of the homocysteine derivative 130, it was believed 
that the pKa of the thiol group of L-homocysteine (pKa 8.57) would provide a good 
comparison to the thiol groups present in other thiol-containing amino acids and 
peptides, such as L-cysteine (pKa 8.14) and reduced L-glutathione (pKa 9.2).
212–214
 
Thus, reaction between 136 and Fmoc.HCys.OMe (130) was trialled in a 
1:1 acetonitrile:water solution. Monitored by LR-ESIMS, after complete consumption 
of 136 (3 hours) the solvents were evaporated, with purification by flash column 
chromatography yielding thioether-linked glycoconjugate 137 as a mixture of 
diastereomers in 61% yield (Scheme 4.17). 
 
 
Scheme 4.17: Synthesis of thioether-linked “clickable” glycoconjugate 137 by “click” thiol-ene 
reaction of 136 and Fmoc.HCys.OMe (130). 
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 Whilst compound 137 was similar to the previously synthesized 131 in being a 
mixture of diastereomers, their presence in 137 was tolerated. This was because this 
strategy was targeted at the functionalization of thiol-containing peptides and proteins, 
with the relative chemistry of the linkage to the maleimide unlikely to affect the higher 
function and structure of peptides or proteins conjugated. The formation of 137 was 
supported by signals in the positive and negative ion modes of the LR-ESIMS of m/z 
861 and 873, with these masses represented the product (C38H42N6O14S) plus sodium 
and chloride, respectively. Furthermore, in the 
1
H NMR spectrum of 137, the 
disappearance of a signal from ~6.7 ppm ascribed to the maleimide methine protons 
highlights the formation of the glycoconjugate, illustrating the change in hybridization 
of the alkene carbons from Sp
2
 in 136 to Sp
3
 in 137.  
Interestingly in the 
1
H NMR spectrum, the signals representing the CH2 protons 
adjacent to the amide linking the succinimide in 137 have different chemical shifts of 
~3.35 ppm (H
β
) and ~3.71 ppm (H
α
). This directly compares to the starting 
maleimide-sugar azido acid 136, where these protons are represented by a single two-
proton multiplet (3.44 ppm). It is likely that the difference in the signals for these 
protons in the 
1
H NMR spectra of 136 and 137 may be due to the planarity of the 
maleimide in 136 versus the less planar succinimide in 137. Lacking symmetry in the 
succinimide of 137, the less planar succinimide ketones provide different chemical 
environments for the two geminal protons, resulting in two different signals in the 
1
H NMR spectrum of 137. (Figure 4.5).  
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Figure 4.5: Comparison between the chemical shift for H
β
 protons in the 
1
H NMR spectra of 136 
and 137, highlighting the effect of planarity and symmetry in the maleimide of 136 versus the 
succinimide of 137.  
 
4.6 Functionalization of Thioether-linked “Clickable” 
Glycoconjugate 137 
 With the production of the “clickable” glycoconjugate 137 through the ‘click” 
thiol-ene reaction successfully achieved, our attention now turned to its 
functionalization via the CuAAC “click” reaction. Utilizing the reaction conditions 
previously optimized for 74 in Chapter 2, reaction of 137 with 4-pentyn-1-ol resulted in 
the production of the functionalized thioether-linked glycoconjugate 138 in 76% yield, 
as a mixture of diastereomers (Scheme 4.17). The production of 138 was supported by 
LR-ESIMS of the isolated product, where a signal of m/z 946 calculated for a chemical 
formula C43H50N6O15S + Na was indicative of the desired compound. Additionally, 
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signals at 7.87 ppm in the 
1
H NMR spectrum and 120.2 ppm and 148.4 ppm in the 
13
C NMR spectrum of 138 were characteristic of the formed triazole ring. 
 
 
Scheme 4.18: Synthesis of the functionalized maleimide-linked glycoconjugate 136.
 
Alongside the previously synthesised “clickable” glycoconjugate 131, 137 
represents one of the first examples of a thioether-linked glycoconjugate that may be 
functionalized via the CuAAC “click” reaction. Thus in this chapter the synthesis of 
thioether-linked glycoconjugates formed by azidosugars and thiol-containing amino 
acids (HCys) was performed. Furthermore, the development of a methodology for the 
synthesis and functionalization of thioether-linked glycconjugates using the “click” 
thiol-ene reaction has also been described, allowing for its further use in the formation 
of glycoconjugates with thiol-containing peptides. In Chapter 5, the development of 
strategies towards the synthesis and functionalization of neoglycopeptides by the 
CuAAC “click” reaction will be discussed. 
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Chapter 5 : Strategies Towards the Synthesis 
and Functionalization of “Clickable” 
Neoglycopeptides  
 
 As illustrated in chapters 2, 3 and 4, the development of new carbohydrate 
molecules that can be readily incorporated into biologically-active peptides, and 
comprise functional groups that allow for further conjugation are greatly warranted. 
This chapter will focus on the development of sugar azido acid-containing 
neoglycopeptides; key intermediates in the production of “clickable” neoglycopeptides.  
 
5.1 Synthetic Rationale 
In earlier chapters, a broad range of azidosugars were conjugated to a range of 
different proteinogenic amino acids, to produce a library of different “clickable” 
glycoconjugates that were amenable to further functionalization via the CuAAC “click” 
reaction. To this end, the examples described thus far have been of azidosugars linked to 
the sidechain, α-amino group or carboxyl group of an amino acid. Hence, if these 
“clickable” glycoconjugates were to be incorporated into a peptide (such as in the 
KPV-glycopeptide derivative 88), the azidosugar would be external to the amino acid 
sequence of the synthesized peptide.  
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In the development of new peptidomimetics and glycoconjugates, keen interest 
has been shown in the imbedding of glycosides, including azidosugars, into the primary 
structure of both linear and cyclic peptides. Kessler and co-workers have illustrated this, 
producing a number of different neoglycopeptides – glycopeptides whereby the 
glycoside has been integrated into the peptide’s primary structure in an ‘unnatural’ 
fashion.
156,215–217
 Examples of linear neoglycopeptides include the sugar amino acid 
(SAA)-containing Leu-Enkephalin analogues 139 and 140, where a native Gly-Gly 
dipeptide motif was replaced with a sugar amino acid (Figure 5.1), with both of these 
analogues evaluated for their biological activity in a guinea pig ileum assay.
156
  
 
Figure 5.1: Leu-Enkephalin neoglycopeptide analogues 139 and 140, containing sugar amino acids 
(in red) -mimicking a Gly-Gly dipeptide motif.
156 
In addition, a number of SAAs have been incorporated into cyclic peptides, 
giving rise to different peptide secondary structures based on the differing substitution 
patterns of NH2 and COOH groups present in the glycosides used. These include SAA’s 
that impart linear (2,5-substituted, Figure 5.2, A) and flexible β-turn (1,6-substituted, 
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Figure 5.2, B) conformations to cyclic peptides, and more restricted β-turn 
(1,5-substituted, Figure 5.2, C), γ-turn (2,3 substituted, Figure 5.2, D) and homoproline 
peptide conformations (Figure 5.2, E).
156
 
 
Figure 5.2: Conformations induced by differing substitution patterns of various sugar amino acids 
embedded into cyclic peptides.
156
 
Based on these structural differences, a number of neoglycopeptides exploring 
these different motifs have been synthesised. In particular, much focus of their potential 
has been centred on biologically-derived scaffolds, with those such as the cyclic 
tetradecapeptide hormone somatostatin widely targeted.
156,215,217,218
 Subsequently, the 
synthesis of a number of cyclic petpide SAA derivatives displaying desirable biological 
activities has been achieved, including the furanosyl SAA-containing derivative 141 
(present in a homoproline conformation), which displayed IC50 values of 31 µM and 25 
µM against the drug-sensitive rat hepatoma carcinoma cell line Clone 2, and the 
multidrug resistant subclone Clone 2(10 x 80)T1, respectively (Figure 5.3).
215
 
Furthermore, the flexible β-turn containing cyclic neoglycopeptide 142 has also 
displayed great potential, (Figure 5.3), exhibiting inhibitory activity at an IC50 of 
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150 nM when displacing the receptor bound radioligand [
125
I]-Tyr
11
-somatostatin-14 in 
AtT20 epithelial-like tumour cell membranes.
156 
 
Figure 5.3: Cyclic neoglycopeptide derivatives 141, 142 and 143, as sugar amino acid (red) 
containing analogues of somatostatin.
156,215,217
  
In addition to these examples, the synthesis of glycoside-containing analogues of 
somatostatin has been extended to neoglycopeptides bearing other β-turn inducing 
glycosides, including the glu-sugar azido acid 60 previously synthesised in Chapter 2 
(Figure 5.3, 141).
156 
From a synthetic perspective, sugar azido acids such as 60 and 65 
are more readily accessible than the SAAs utilized in the cyclic somatotastatin 
derivatives 141 and 142, and hence show great promise as synthons in the production of 
substituted neoglycopeptides.
156
  
However, as seen in both the synthesis of sugar azido acids 60 and 65 in 
chapter 2, and in the synthesis of azidosugars in Chapters 3 and 4, selective substitution 
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of a secondary alcohol in a pyran based glycoside represents a significant challenge. 
Current protecting group strategies limit the selective substitution of secondary alcohols 
in glc-pyran ring systems, with the 2-, 3- and 4-positions of the pyran ring possessing 
comparable reactivity.  In order to selectively substitute these different positions, 
lengthy, atom uneconomical chemical manipulations are required.
218
 Hence, the 
development of an orthogonal protecting group strategy that could be used to selectively 
derivatize the secondary alcohols at either the 2-, 3- or 4-positions of a pyran ring would 
be highly advantageous.  
If these pyranosides are also incorporated an accessible amine and carboxylic 
acid (Scheme 5.1), they would additionally be compatible with amino acid coupling. 
This would produce neoglycopeptides that could be functionalized such that they can 
participate in the CuAAC “click” reaction (Scheme 5.1). Bearing such a handle for 
derivatization, these so-called “clickable” neoglycopeptides could be utilized to 
introduce a variety of different functional groups. These would provide an evaluation of 
the use of functionalized neoglycopeptides as molecular scaffolds, in addition to 
expanding the utility and chemical space surrounding the structure and function of 
linear and cyclic peptides (Scheme 5.1). 
 
Scheme 5.1: Proposed approach towards the synthesis of "clickable" neoglycopeptides. 
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5.2 Initial Synthetic Strategy 
5.2.1 Synthetic Criteria 
A number of different synthetic pathways could be employed to yield glycosides 
bearing handles capable of further ligation. One purported strategy is to synthesize and 
incorporate sugar diamino acids (SDAs), as previously described by Wittmann et al. 
(Figure 5.4, 144 & 145) and Gervay-Hague et al. (Figure 5.4, 146).
219–221
 
 
Figure 5.4: Sugar diamino acids (SDAs) reported by Wittmann et al. and Gervay-Hague et al.
219–221 
Containing an accessible amine and carboxylic acid substituted primarily at the 
1-,2- and 6-positions of the glycoside, these sugar amino acids also possess an 
additional amine or azide handles that can be further functionalized (Figure 5.4). Hence, 
these synthons represent an expansion of sugar amino acids that are amenable to amide 
coupling, and hence may be utilized to form either linear or cyclic neoglycopeptides. 
The may also participate in the CuAAC “click” reaction either directly, or through 
further chemical manipulation.  
Synthetically though, SDA analogues such as 144 and 145 are far from trivial to 
prepare, requiring 10 and 8 steps, respectively from an advanced intermediate.
219
 
Furthermore, the additional steps required to convert 144 and 145 to synthons that 
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contain a group available for use in the CuAAC “click” reaction, further decreases the 
feasibility of this approach. However, the greatest barrier to the successful use of these 
molecules is the limitation of the use of an azide as a “handle” for functionalization, 
which requires a rigorous orthogonal protecting group strategy in order to be introduced 
in the presence of another protected amine. Alternatively, an approach that allows for 
the late-stage introduction of a handle - potentially by a linker, would provide efficient 
access to a glycoside that can be introduced into linear or cyclic peptides and 
functionalized. Furthermore, this approach allows for the interchangeable usage of 
different handles (in this case, azide vs. alkyne), providing wider flexibility to the 
synthesis. Thus, an approach employing the late-stage derivatization was developed 
(Scheme 5.2).  
Based on the previous employment of a pyran-based sugar azido acid core 
(60 and 65), and its use in the somatostatin analogue 145,
156
 it was believed that the 
same core bearing an anomeric β-azide and 6-COOH would provide the easiest access 
to the targeted glc-sugar azido acid. Allowing for the introduction of the required handle 
at either the 2, 3- or 4-OH group of the glc-sugar azido acid, it was apparent that the 
4-position of the glycoside would provide the most easily accessible site for substitution 
through an orthogonal protecting group strategy, and hence was initially targeted. 
Adjacent to the primary 6-OH group on the pyran ring, both the 4-OH and 6-OH may be 
protected together as an acetal from a simple glycosyl azide (Scheme 5.2), with 
subsequent protection of the remaining 2,3-OH groups and deprotection of the acetal 
producing a 4,6-diol. This intermediate can be selectively protected using a sterically 
bulky protecting group (e.g. TBDPS, trityl, etc.) at the primary 6-OH, producing a free 
4-OH group (Scheme 5.2, Step A). Further protecting group manipulation would allow 
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for the protection of the 4-OH group, with deprotection, oxidation of the primary 6-OH 
and orthogonal deprotection of the 4-OH yielding a mono-hydroxylated glc-sugar azido 
acid (Scheme 5.2, Step B).  
Considering the potential length of this synthetic strategy, it was recognized that 
the coupling of this intermediate to an amino acid, producing a glycoconjugate that 
could be further derivatized using standard ester coupling conditions, also represented a 
key synthetic target (Scheme 5.2, Step C). Producing “clickable” neoglycopeptides that 
are structurally different to those previously studied (e.g.Type A, Scheme 5.2), the free 
β-azide of this target molecule would be available for functionalization via the CuAAC 
“click” reaction. As well as being a synthon in the production of Type A “clickable” 
neoglycopeptides, the orthogonal protection of the 4-OH group would provide an 
approach towards the synthesis of neoglycopeptides linked at the anomeric and 
6-positions, similar to those previously described (Scheme 5.2, Step D).
156
 Tandem 
reduction/amide coupling of the β-azide would yield a neoglycopeptide which following 
selective deprotection and functionalization of the 4-position would yield a “clickable” 
neoglycopeptide (Type B, Scheme 5.2).  
Synthetic approaches towards the development of both Type A and B 
neoglycoconjugates would have different biological purposes. If Type A derivatives of 
biologically-active neoglycopeptides were developed bearing different substitution 
patterns (i.e, 2,6-, 3,6- or 4,6-),  the effect of peptide conformation on biological activity 
could be evaluated. These studies could serve as a guide, providing a platform for the 
replacement of the ester linkage with a more stable linkage (i.e amide). Also, if the 
neoglycoconjugate synthesised bears relevance to nuclear imaging, the anomeric 
β-azide could be utilized for radiolabelling via the CuAAC “click” reaction. In regards 
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to Type B neoglycoconjugates, a synthetic approach for derivatives of this form will 
allow for the evaluation of cyclic peptides as nuclear imaging agents, again via labelling 
using the CuAAC “click” reaction. Examples of cyclic peptide derivatives that could be 
produced include labelled derivatives of the somatostatin mimics 141-143. Hence, in the 
current study our focus was on developing a synthetic strategy to both of these key 
synthetic targets, that would allow for the future synthesis of Type A and Type B 
“clickable” neoglycopeptides (Scheme 5.2). 
 
 
Scheme 5.2: Key strategy towards the development of "clickable" neoglycopeptides. 
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5.3 Synthesis of Orthogonally-protected Glycoconjugates 
5.3.1 Initial Pathway Towards 4-Protected Sugar Azido Acids
 
 En route to the synthesis of our key intermediate glc-sugar azido acid, the 
preparation of a glycoside with a selectively unmasked 4-OH group in the presence of 
2,3-OH protection was required. Hence, our synthesis of this target glycoside was 
initiated from D-glucose, where peracetylation yielded the known penta-acetylated 
glycoside 147 in 96% yield (Scheme 5.3).
222
 
 
 
Scheme 5.3: Synthesis of 2,3,4,6-tetra-O-β-D-glucopyranosyl azide (148) from D-glucose. 
Obtained as a white solid, evaluation of the 
1
H NMR spectrum of 147 
highlighted two doublets at 6.31 ppm (J = 3.9 Hz) and 5.72 ppm  (J = 8.2 Hz) indicative 
of the α- and β-anomers, respectively. Equally integrating for 0.5 protons, this suggests 
an equal abundance of both anomers present. Subsequently, the penta-acetate 147 was 
then subject to anomeric azidonation, under previously utilized SnCl4/TMSN3 
conditions. After 20 hours, subsequent work up yielded the known 2,3,4,6-tetra-O-
acetyl-β-D-glycopyranosyl azide (148) in 79% yield (Scheme 5.3).
153
 Compared to the 
SnCl4-mediated azidonation discussed in Chapter 2 (for compound 59), the longer time 
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period utilized here allows for epimerization of the anomeric α-acetate, with the 
presence of the 6-OAc providing a coordination site for SnCl4 with a much closer 
proximity than that described previously for the β-azido glucuronic acid allyl ester 59. 
The presence of a signal in the 
1
H NMR at 4.66 ppm was indicative of the  anomeric 
H1, with the downfield position of the signal indicative of shielding effects of the azide 
group, and a coupling constant of J = 8.8 Hz indicative of the trans stereochemistry that 
exists between the H3 and the β-H1 protons. This was consistent with data for 148 
previously reported.
223 
 With 148 in hand, our focus shifted to the regioselective formation of the 
4,6-benzylidene acetal, which is a key requirement of our orthogonal faprotection 
strategy. In order to install our acetal, 148 was subjected to classical Zemplen 
deacetylation conditions,
224
 with stirring in the presence of NaOMe dissolved in 
methanol yielding the β-D-glucopyanosyl azide intermediate 149 (Scheme 5.4). 
Subsequent heating of 149 under vacuum (~250 mbar) at 60°C for 4 hours in the 
presence of benzylidene dimethyl acetal and p-toluenesulfonic acid resulted in the 
formation of the requisite 4,6-benzylidene acetal, which upon isolation following flash 
column chromatography yielded 150 in 62% as a white solid (Scheme 5.4).
158,225 
 
Scheme 5.4: Synthesis of 4,6-benzylidene-β-D-glucopyranosyl azide (150).
 158,225
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 Mechanistically, in the presence of a catalytic quantity of p-TsOH a methoxy 
group of benzylidene dimethyl acetal is protonated. Subsequently, the primary 6-OH of 
149 may undergo nucleophilic attack of the α-carbon of benzylidene dimethyl acetal, 
resulting in the elimination of methanol and the proton of the primary alcohol. The 
remaining methoxy group can then be protonated, with nucleophilic substitution by the 
neighbouring 4-OH resulting in the elimination of a second molecule of MeOH, proton 
and the desired benzylidene acetal 150 (Scheme 5.5). 
 
 
Scheme 5.5: Mechanism for the acid catalysed formation of the 4,6-benzylidene acetal 150.  
 Producing an acetal only between the 4- and 6- positions, the regioselectivity of 
this reaction is a result of their direct proximity, with the acetal forming a 6-membered 
ring displaying a geometric chair arrangement. This is exemplified by a 2D NOESY 
NMR experiment of 150, where the proton situated on the α-carbon (5.55 ppm) present 
in the acetal shows a clear correlation with the H4 proton (3.56 ppm) present on the 
pyran ring, in addition to a H6 proton (Figure 5.5). 
Chapter 5: Towards fuctionalized neoglycopeptides 
 
155 | P a g e  
 
 
Figure 5.5: 2D NOESY experiment highlighting correlations between the acetal CH, and H4 and 
H6 in 150. 
 With the required acetal installed, the remaining 2-OH and 3-OH were subjected 
to protection. Considering the later introduction of our handle, multiple protecting group 
conditions were trialled to achieve the requisite 4,6-diol, with p-methoxybenzyl ethers 
(PMB) and benzoyl ester (Bz) protecting groups both utilized. Removed under 
concentrated acid, hydrogenolysis or oxidative conditions, the PMB ether allows for the 
introduction of our requisite handle through standard alkylation conditions, permitting 
the use of stronger hydride bases (NaH, KH).
159
 Conversely, the benzoyl ester is highly 
susceptible to base hydrolysis, a distinct disadvantage compared to the PMB ether, 
requiring the use of trichloroacetimidate chemistry to install the required handle at the 
4-OH. However, benzoyl esters display high compatibility to the reduction of anomeric 
β-azides to produce an amine, maintaining β-stereochemistry through neighbouring 
group participation, whilst PMB may be cleaved under such conditions.
159 
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 Thus to evaluate both of these protecting group strategies, the 2,3-OH groups of 
150 were protected. Using p-methoxybenzyl chloride (PMB-Cl) in the presence of 
tetrabutylammonium iodide (TBAI) as an activator, and NaH as base, the novel 
2,3-OPMB protected derivative 151 was synthesized in 77% yield (Scheme 5.6). This 
was confirmed by the LR-ESIMS spectrum of 151, where a signal at m/z 556 
(C29H31N3O7 + Na) represented the desired product plus sodium. Similarly, 150 was 
protected with benzoyl chloride (BzCl) in the presence of pyridine, with subsequent 
recrystallization yielding the novel 2,3-OBz protected derivative 152 in 81% yield 
(Scheme 5.6). The benzoyl protection of the 2,3-OH’s of 150 was highlighted in the 
1
H NMR spectrum, where signals at 5.81 ppm and 3.88 ppm were indicative of the H3 
and H2 protons of 152. These signals are in direct contrast to the corresponding protons 
in 150 (3.46 ppm, H3; 3.25 ppm, H2) with the benzoyl protecting group delocalizing the 
electrons of the oxygen at the 2- and 3-position significantly, reducing the shielding 
effect imparted on the neighbouring protons. 
 
 
Scheme 5.6: Synthesis of 2,3-protected-4,6-diol derivatives 153 and 154. 
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 With 151 and 152 in hand, the acetals of both were exposed to acidic 
deprotection conditions to unmask the 4-OH group. Initially, (-)-camphorsulphonic acid 
(CSA) was utilized in the deprotection of 151, with stirring in MeOH/CH2Cl2 (1:1) over 
24 hours resulting in cleavage of the acetal, to produce the 2,3-OPMB-4,6-diol 153 in 
67% yield (Scheme 5.6). Deprotection of the acetal was signified by the disappearance 
of a signal in the 
1
H NMR spectrum of the product 153 at 5.56 ppm, indicative of the 
axial proton present on the carbon linking the 4-OH and 6-OH. Subsequently, cleavage 
of the acetal of 152 was also performed under acidic conditions, with catalytic 
p-toluenesulfonic acid in MeOH/CH2Cl2 (4:1) producing the requisite diol 153 in 
73% yield after 3 hours. (Scheme 5.6) Though benzoyl esters are more prone to 
cleavage in acidic pH than PMB ethers,
159
 it was recognized that the catalytic use of a 
stronger acid such as p-TsOH, compared to CSA (pKA -2.5 vs. 0.9),
212
 would reduce 
the reaction time required for diol cleavage, limiting the formation of cleaved-ester 
by products. It must be noted though that TLC analysis of the formation of 154 also 
showed the slow cleavage of the benzoyl esters after 3 hours of reaction time.  
With both diols 153 and 154 synthesized, efforts were next made to selectively 
install the required 6-OH protecting group. For this purpose, protecting groups based on 
the triphenylmethyl (trityl -Trt) group were chosen, due to their steric bulk, ease of 
introduction and wide availability. Hence, using the PMB-protected diol 153 trials were 
initiated, with the use of Trt-Cl, NEt3 and DMAP over 48 hours resulting in the 
formation of the 6-OTrt derivative 155 in 31% yield (Scheme 5.7). 
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Scheme 5.7: Synthesis of 6-protected glycosides 155 and 156. 
 Utilizing a catalytic quantity of DMAP as an activator, the formation of a trityl-
DMAP intermediate ensued. In the presence of NEt3 as a proton scavenger, nucleophilic 
substitution of this intermediate by the 6-OH group of 153 resulted in the formation of 
the desired 6-OTrt protected 155, albeit in low yield. Thus, considering that this 
protection strategy may later be utilized in the 6-OH protection of the 2,3-OBz diol 154, 
efforts were made to improve this selective protection without requiring stronger basic 
conditions. Subsequently, the more-activated trityl donor 4-methoxytriphenyl chloride 
(MMTrt-Cl) was used in place of Trt-Cl, which under the previously used NEt3/DMAP 
conditions yielded the 6-OMMTr-protected derivative 156 in 61% yield (Scheme 5.7). 
The isolation of 156 was evidenced by the 
1
H NMR spectrum, whereby overlapping 
signals at 3.77 and 3.80 ppm accounted for the protons of the trityl-bound methoxy 
group and the p-methoxy groups of the PMB protecting groups present at the 2- and 3-
OH’s respectively (Figure 5.8).  
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Scheme 5.8: 
1
H NMR spectrum of 156, highlighting overlapping signals at 3.77 and 3.80 ppm that 
indicates the PMB and MMTr-methoxy groups, respectively. 
Interestingly, LR-ESIMS of 156 highlighted a signal at m/z 740 (C42H43N3O8Na; 
[M + Na
+
]) in a spectroscopically-pure sample of 156. Representing the molecular ion 
for this compound, this signal shows only ~25% intensity compared to the highest 
intensity signal present, highlighting the weak ionizability of the compound in the mass 
spectrometer. The MMTr-protecting group added significant mass to the overall 
compound, which when taken into account alongside the PMB groups introduced at the 
2- and 3- positions, accounted for a 245% increase in the molar mass of 156 from the 
4,6-acetal intermediate 150 (Scheme 5.9). Furthermore, in order to produce our requisite 
sugar azido acid bearing handles capable of further derivatization, it would require at 
least four additional synthetic steps, which alongside the six steps to produce 156 from 
D-glucose, signified a lengthy, atom-uneconomical synthesis (Scheme 5.9). Thus, based 
on these findings, alternate pathways towards our target glycoside were sought.  
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Scheme 5.9: Original synthetic pathway highlighting additional synthetic steps from 156 required 
to produce the desired sugar azido acid target. 
 
5.3.2. Improved Pathway Towards 4-Protected Sugar Azido Acids
 
In the development of a new strategy for the synthesis of orthogonally-protected 
sugar azido acids, a number of approaches were evaluated. One approach included the 
selective reduction of the benzylidene acetal of either 151 or 152, unmasking the 6-OH. 
This approach is effectively highlighted in the recently published work of Bera and 
Linhardt, whereby the 4-OH derivative 158 was produced en route to the synthesis of 
unnatural heparosan and chondroitin building blocks (Scheme 5.10).
226
 Synthesised in 
7 steps from phenyl-4,6-benzylidene-1-thio-β-D-glucopyranoside (157), this work 
demonstrates the usage of a 2,3-OBz  protecting group strategy in addition to the 
selective reductive opening of a benzylidene acetal. Oxidation of the 6-OH group to the 
carboxylic acid, and one-pot azidonation/4-deprotection result in the desired sugar azido 
acid bearing a free 4-OH group. This work represents a concise route to sugar azido 
Chapter 5: Towards fuctionalized neoglycopeptides 
 
161 | P a g e  
 
acids that can be derivatized with a handle and coupled to produce numerous 
glycoconjugates (Scheme 5.10).  
 
Scheme 5.10: Synthesis of 1-azido-2,3-O-benzoyl-β-D-glucuronic acid methyl ester (158) from 
phenyl-4,6-benzylidene-1-thio-β-D-glucopyranoside (157) published by Bera and Linhardt.
226 
Reflecting on our previous endeavours, there are clear distinctions between these 
two approaches – namely, the selective reduction of the benzylidene acetal and the 
timing of the introduction of the requisite anomeric β-azide. Whilst an attractive and 
noteworthy concept, the selective benzylidene reduction could potentially complicate 
the synthesis, with Bera and Linhardt highlighting that the removal of a 4-PMB group 
would require orthogonal protection of the carboxylic acid.
226 
Whilst more than 
adequate in this example, our requirement for coupling to the carboxylic acid would 
result in additional protection and deprotection steps. Instead, an approach that could 
Chapter 5: Towards fuctionalized neoglycopeptides 
 
162 | P a g e  
 
adapt the previously attempted synthesis of 4-OH bearing sugar azido acids would be 
highly advantageous.  
Considering the synthesis of the 2,3-OBz diol 154, it was recognized that a 
strategy where the required carboxylic acid could be produced selectively in the 
presence of a 4-OH would be optimal. Requiring minimal protecting group 
manipulation, the carboxylic acid could then be coupled to an amino acid with a free 
amine. Subsequently, the 4-OH could then be coupled to another amino acid bearing a 
free carboxylic acid, to produce a Type A “clickable” neoglycopeptide. Alternatively, 
the 4-OH group could be orthogonally protected, allowing for the coupling of another 
amino acid at the anomeric position following reduction of the azide to an amine (See 
Scheme 5.2). Indeed, previous studies by Van Den Bos and co-workers have 
highlighted the efficiency of oxidants such as TEMPO and bisacetoxyiodobenzene 
(PhI(OAc)2) in the selective oxidation of the primary alcohol of pyranosides carboxylic 
acids.
 227
  Encompassing a broad range of differently pyranosides bearing different 
mono- and dihydroxylated substitution patterns, these include a number of 4,6-OH 
bearing derivatives, such as 159 and 160 (Scheme 5.11). 
 
 
Scheme 5.11: Examples of selective oxidation of a primary alcohol present on a pyran-based 
glycoside previously described by Van Den Bos and coworkers.
227 
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Affording selective oxidation in the presence of a 4-OH in glucosyl-based 
examples, 159 and 160 show that the TEMPO/PhI(OAc)2 oxidation system can tolerate 
a variety of different protecting groups at the 2- and 3-positions, including benzyl and 
benzoyl groups.
227
 In relation to the previously synthesised 154, it was believed that this 
methodology could be utilized to produce a sugar azido acid that would also possess a 
4-OH free for further protection or derivatization, en route to the production of 
“clickable” neoglycopeptides. Therefore, 154 was subjected to TEMPO/PhI(OAc)2 
oxidation condition, with stirring in CH2Cl2/H2O (2:1).
227
 After 45 minutes, workup and 
purification by flash column chromatography resulted in the isolation of the partially-
deprotected sugar azido acid 161 in 88% yield (Scheme 5.12).   
 
 
 
Scheme 5.12: TEMPO/BAIB-mediated oxidation of diol 154 to form the sugar azido acid 161. 
The oxidation of 154 to form the sugar azido acid 161 was monitored by TLC, 
with the formation of a spot (solvent, 1:1 EtOAc/Hexane + 5% AcOH) much lower on 
the TLC plate (Rf 0.28) highlighting the transformation of 154 to the more polar 
carboxylic acid. Furthermore, the 
1
H NMR spectrum of 161 highlights the presence of 
five protons between 3.0 – 6.0 ppm as opposed to the seven protons observed in 154, 
indicative of the oxidation of the primary 6-OH to form a carboxylic acid (Figure  5.6). 
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Figure 5.6: Comparison of the 
1
H NMR spectra of 154 (A) and 161 (B), highlighting the loss of two 
protons (A – H6/H6’) through oxidation, resulting in the sugar azido acid (B).  
Utilizing a catalytic quantity of TEMPO, the reaction is initiated by an excess of 
PhI(OAc)2, resulting in the production of a piperidinium N-oxide intermediate 
(Scheme 5.13, A). In the presence of 154, the piperidinium N-oxide is subject to 
nucleophilic substitution by the alcohol, resulting in the formation of a dihydroxylamine 
intermediate (Scheme 5.13, B). Deprotonation at the C6 position of 154 drives the 
oxidation of the primary alcohol, resulting in the production of an intermediate 
aldehyde, in addition to a hydroxylamine derivative (Scheme 5.13, C).  
The biphasic solvent conditions present in the reaction are ideal for aldehyde 
hydration, resulting in the formation of a geminal diol intermediate (Scheme 5.13 D). 
Concurrently, the disproportionation of the hydroxylamine derivative back to TEMPO 
allows for its further usage in the catalytic cycle (Scheme 5.13, E). Secondary initiation 
of TEMPO by PhI(OAc)2 resulted in the reformation of the piperidinium N-oxide 
intermediate (Scheme 5.13, F). Finally, nucleophilic substitution by one of the geminal 
diols resulted in the production of a second dihydroxylamine intermediate, which 
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following oxidation yielded the desired carboxylic acid 161 (Scheme 5.13, G). It is 
likely that the tight transition state at the 6-OH, the steric bulk provided by the 
neighbouring 3-OBz group present on 154 and the mild/short reaction conditions 
utilized, significantly reduced the susceptibility of the 4-OH group of 154 to 
oxidation.
228–234
  
 
 
Scheme 5.13: Proposed mechanism for the oxidation of primary alcohols to carboxylic acids 
utilizing the TEMPO/PhI(OAc)2 oxidation protocol. 
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5.3.3 Synthesis of 4-Orthogonally Protected Intermediate 165
 
With access to the key intermediate sugar azido acid 161 achieved, our focus 
turned to the formation of a hydroxyl-bearing glycoconjugate, the first key synthetic 
target of this project. Orthogonal protection of the 4-OH of 161 prior to amino acid 
coupling would likely deliver the highest yielding approach to this target, providing 
future access to Type A and B neoglycopeptides. The presence of both an alcohol and 
carboxylic acid group in 161 though raises questions regarding protecting group 
selectivity, with the greater acidity of the carboxylic acid in comparison to the 4-OH of 
161 likely to favour carboxyl protection rather than alkylation. This is exemplified by 
the selective methylation of 161 by MeI and K2CO3 in DMF, which produced the ester 
162 in 64% yield, with this molecule displaying 
1
H and 
13
C NMR spectral data 
corresponding with those previously reported (Scheme 5.14).
226
  
 
 
Scheme 5.14: Synthesis of previously reported glucuronic acid methyl ester 162.
226 
Hence, as the presence of a 4-OH would be highly advantageous in the future 
production of Type A neoglycopeptides, direct coupling of 161 to a respective amino 
acid was performed prior to the protection of the 4-OH group. As a requirement of this 
strategy, suitably carboxyl-protected amino acids were required for coupling to the 
carboxylic acid group of 161.  As a result, L-alanine (Ala) was chosen as our model-
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coupling amino acid, with its simplicity in being N- or C-protected, and its minimal 
sidechain steric bulk making it ideal for the development of a broader strategy. Utilizing 
thionyl chloride in dry MeOH, the carboxylic acid of L-alanine was methylated, 
producing the carboxyl-protected derivative L-alanine methyl ester hydrochloride 
(H.Ala.OMe.HCl; 163) in near quantitative yield (Scheme 5.15). The 
1
H and 
13
C NMR 
spectral data for 163 were consistent with those previously reported.
235,236 
 
 
Scheme 5.15: Synthesis of L-alanine methyl ester hydrochloride (163). 
235,236 
With both 161 and our requisite amino acid in hand, coupling and protection was 
initiated. Utilizing the coupling reagent HBTU and 2.1 equivalents of DIPEA, 
H.Ala.OMe.HCl (163) was coupled to 161, selectively producing the novel 
glycopeptide 164 in 50% yield (Scheme 5.16). 
 
 
Scheme 5.16: Synthesis of alanine-sugar azido acid glycoconjugate 164 via amide coupling.  
An evaluation of the 
1
H NMR spectrum of 164, highlighted the presence of a 
doublet at 7.13 ppm (J = 6.9 Hz) integrating for one proton, which was indicative of the 
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amide nitrogen formed during coupling (Figure 5.7, A). Furthermore, when analysed 
with respect to a 2D gCOSY 
1
H NMR experiment of 164, correlations were observed 
between this signal and a triplet at 4.62 ppm (J = 7.5 Hz) integrating for one proton. 
Further correlations with a signal at 1.55 ppm highlighted sequential 3-bond couplings 
between the amide NH, H
α
 and H
β 
of the coupled amino acid in 164 (Figure 5.7, B). The 
first key objective of this project, to our knowledge the synthesis of 164 represents the 
first example of a glycoconjugate formed by the selective coupling of a sugar azido acid 
bearing a hindered alcohol. 
 
 
Figure 5.7: 
1
H NMR experiment (A) and 2D gCOSY experiment (B) of glycoconjugate 164. 
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Following the success encountered in producing the coupled product, efforts 
were undertaken to protect the 4-OH group of 164, and thus complete the second key 
objective of this project. Mindful of the need for an orthogonal protecting group, the 
tert-butyldimethylsilyl (TBS) group was chosen. Displaying favourable stability to 
reduction, and removed using mildly acidic conditions or through the use of fluoride 
donors such as tetrabutylammonium fluoride (TBAF),
159
 TBS-protection of 164 would 
provide access to the required neoglycopeptide, with selective deprotection unmasking 
the 4-OH group in order to introduce our handle for derivatization. Hence, 164 was 
subjected to TBS protection, with stirring in the presence of TBS-Cl and imidazole in 
DMF overnight resulting in the isolation of the 4-OTBS derivative 165 in 36% yield 
(Scheme 5.17). 
 
 
Scheme 5.17: Synthesis of the orthogonally-protected glyconjugate 165. 
The low yield gained for 165, was likely a result of the bulky nature of the TBS 
protecting group, with the surrounding benzoyl esters and linked amino acid hindering 
the approach of the active TBS-imidazole intermediate. Furthermore, the relative 
distance between the amide carbonyl of 164 and its corresponding 4-OH allows for 
hydrogen bonding, stabilizing the hydroxyl group and thus decreasing its 
nucleophilicity. As a result, even with an excess of TBS-Cl (2 eq.) and imidazole (4 eq.) 
present, protection of the 4-OH group of 164 would still have been highly unfavourable. 
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The formation of 165 was highlighted in the TLC by a dramatic increase in Rf (0.85, 
1:1 Hexane:EtOAc) from 164, with TBS protection greatly decreasing the polarity of 
the molecule. The effect of protecting the 4-OH group of 164 was also highlighted in 
the 
1
H NMR spectrum, where the signal representing the H4 proton of 165 shifted 
downfield (~0.3 ppm) compared to the corresponding proton in 164 (Figure 5.8). 
Attachment of the TBS group in 165 delocalizes electron density present on the 4-bound 
oxygen to the electropositive silicon atom of the TBS group, which as a result deshields 
the neighbouring H4, increasing the chemical shift (Figure 5.8). The second key 
objective of this project, the synthesis of 165 represents an important milestone in the 
development of Type B “clickable” neoglycopeptides. 
 
 
Figure 5.8: Comparison of the 
1
H NMR spectra of 164 (A) and 165 (B), highlighting the deshielding 
effect on the H4 of 165 through TBS-protection. 
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5.3.4 Synthesis of the 3-Orthogonally Protected Intermediate 170 
Building on the production 164 and 165 towards the development of “clickable” 
neoglycopeptides, it was recognised that the development of derivatives that could be 
functionalised at alternate positions of the glycoside would also be highly advantageous. 
Increasing the structural diversity of analogues, the development of differently-
substituted derivatives may also deliver a more concise route in the development of 
neoglycopeptides that may be functionalized by the CuAAC “click” reaction.  
The development of a more efficient approach was of particular importance, 
considering that the production of 165 from D-glucose required seven synthetic steps. 
Of these steps, the synthesis of the benzylidene acetal 150 and the low yielding 
production of the 4-OTBS glycoconjugate 165, stood out as those that would limit the 
scalability of this methodology. The use of p-toluenesulfonic acid, the same acid used to 
catalyze the acetals’ deprotection, made scaling up the production of 150 quite 
problematic, with the steric hinderance imposed by surrounding groups in 164 making 
the production of 165 highly unfavourable.  
Hence, in continuing on with the use of a sugar azido acid scaffold, an 
evaluation of the relevant literature was undertaken in order to develop an alternate 
route to development of orthogonally-protected neoglycopeptides that could be further 
functionalized by the CuAAC “click” reaction. During this process, a re-evaluation of 
the work of Tosin et al. highlighted that un-protected sugar azido 
acids (such as 53) can undergo intramolecular cyclisation to efficiently produce 
6,3-lactones (Scheme 5.18, 166).
157,237 
 
Chapter 5: Towards fuctionalized neoglycopeptides 
 
172 | P a g e  
 
 
Scheme 5.18: Conversion of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) to the 
6,3-lactone 166 reported by Tosin et al.
157,237
  
 In the presence of a strong nucleophilic base such as LiOH, global deprotection of 
the protected sugar azido acid 53 takes place, resulting in a glucuronic acid intermediate 
(Scheme 5.19). Present in an equatorial “chair” conformation, heating (85°C) results in 
conversion to a “half-chair” conformation, where the 3-OH and 6-COOH are more 
confined “axial” geometry relative to one another. In the presence of Ac2O, the 
formation of a mixed anhydride with the carboxyl group occurs. Prone to nucleophilic 
substitution from the 3-OH group, lactonization occurs, with the remaining 2- and 4-OH 
acetylated to yield the requisite protected 6,3-lactone product (Scheme 5.19). 
 
Scheme 5.19: Mechanism for the formation of 6,3-lactone 53 from 166, utilizing saponification and 
chair conformation interconversion. 
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Whilst not initially obvious, the importance of this conversion lies in the 
susceptibility of 6,3-lactones to nucleophilic attack, with Tosin et al. subjecting 166 to 
attack by weak nucleophiles such as allyl alcohol and aniline, producing the ester and 
amide derivatives 167 and 168 (Scheme 5.20).
157,237
 As a result of ring opening of the 
lactone, the 3-positions of both products 167 and 168 bear free-hydroxyl groups that 
may be further protected, alkylated or glycosylated (Scheme 5.20).
157,237 
 
 
 
Scheme 5.20: Nucleophilic substitution of the 6,3-lactone 164, resulting in the ester and amide 
derivatives 167 and 168 that bear unprotected 3-OH groups.
157,238 
In relation to the previously synthesised 4-OH-bearing intermediate 164, it could 
be envisaged that if an amino acid bearing an unprotected α-amino group, such as the 
previously used H.Ala.OMe.HCl (163), was reacted with 166, it may generate a 
respective glycoconjugate bearing a free 3-OH group (Scheme 5.21). Such a 
glycoconjugate would provide a mechanism for the production of Type A “clickable” 
neoglycopeptides linked to amino acids by the 3- and 6-positions. Additionally, 
protection of the 3-OH with a TBS-group akin to 165 would provide an orthogonally 
protected glycoconjugate that could be utilized as a key synthon in the development of 
Type B “clickable” neoglycoconjugates (Scheme 5.21).  
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Scheme 5.21: Proposed synthesis of glycoconjugates bearing a free 3-OH group from the 6,3-lactone 
166, towards the synthesis of “clickable” neoglycopeptides. 
With this in mind, efforts were undertaken to produce the requisite 3-OH and 
3-OTBS protected glycoconjugates, with the synthesis of the peracetylated azido 
glucuronic acid methyl ester 53, the precursor molecule to the 6,3-lactone 166, first 
targeted. Glucuronolactone (51) was utilized as starting material, with initial stirring in 
the presence of triethylamine in MeOH for 3 hours resulting in esterification and 
expansion of the furan ring of glucuronolactone to a pyran ring. Subsequently, workup 
followed by the addition of Ac2O and NaOAc, and stirring at room temperature for 
8 days resulted in the formation of the peracetylated methyl ester derivative 52, which 
was isolated by recrystallization in 38% yield (Scheme 5.22). 
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Scheme 5.22: Synthesis of 1,2,3,4-tetra-O-acetyl-β-D-glucuronic acid methyl ester (52) 
from  glucuronolactone. 
1
H and 
13
C NMR spectra for 52 synthesised were identical to those previously 
reported.
156 
Though produced in low yield due to the concurrent formation of the 
α-anomer of 52, the scalability of this reaction (>10 g product) and easy work up made 
it ideal for producing our requisite azidosugar. Hence, with 52 in hand, the β-azido 
group was introduced at the anomeric position. Using the TMSN3/SnCl4 conditions, the 
required 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) was 
synthesised, isolated in 81% yield (Scheme 5.23), with 
1
H and 
13
C NMR spectra, and 
LR-ESIMS data consistent with those previously described.
156
 
 
 
 
Scheme 5.23: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53).
156 
With the production of the required peracetylated precursor 53 achieved, efforts 
were made to produce the desired 3-OH glycoconjugate 169. Initially, saponification of 
the acetyl groups and methyl ester were performed under base hydrolysis, with 
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neutralization and lyophilisation, followed by heating in Ac2O at 85°C producing the 
desired 6,3-lactone intermediate 166. The formation of this intermediate was confirmed 
by TLC (Rf 0.45, 1:1 Hexane:EtOAc), with further evaluation of the crude 
1
H NMR 
spectrum of 166 (Figure 5.9, A) highlighting the presence of two signals at 2.18 and 
2.10 ppm each integrating for 3 protons. Furthermore, signals in the 
13
C NMR spectrum 
(Figure 5.9, B) at 169.0 and 168.9 ppm corresponding to the carbonyl carbons of the 
acetyl esters highlighted the presence of only two ester groups in 166. 
 
 
Figure 5.9: 
1
H (A) and 
13
C (B) NMR spectra of the crude 6,3-lactone 166,  highlighting the presence 
of 2 acetyl protecting groups at the 2- and 4- positions. 
Consequently, the 6,3-lactone 166 was subjected to nucleophilic substitution, 
utilizing H.Ala.OMe.HCl (163). Under stirring in dichloromethane, the addition of a 
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slight excess of triethylamine (1.2 equivalents) neutralised the hydrochloride salt of 163, 
liberating the α-amino group as a nucleophile. The subsequent nucleophilic attack of the 
lactone resulted in ring-opening, producing the desired 3-OH-bearing glycoconjugate 
169 in 42% yield from 53 (Scheme 5.24).  
 
 
 
Scheme 5.24: Synthesis of 3-OH bearing glycoconjugate 169 via ring-opening of the 6,3-lactone 166.   
The 
1
H NMR spectrum of 167 highlighted the formation of the amide linkage 
from ring-opening of the lactone, with a doublet at 6.93 ppm (J = 7.5 Hz) integrating for 
one proton indicative of the amide hydrogen (Figure 5.34). The formation of the amide 
bond was further established in the 
13
C NMR spectrum, where a signal at 165.9 ppm 
represented the carbonyl formerly constituting the lactone, bound to the α-amino group 
of the protected alanine (Figure 5.10). This signal appeared slightly shielded compared 
to that representing the same carbon in 166, the result of this carbon being bound to the 
comparatively less electronegative nitrogen atom, rather than the oxygen atom present 
in the lactone. The synthesis of 169 represents the first reported use of a 6,3-lactone, and 
only the second reported usage of lactone ring-opening in the preparation of 
glycoconjugates between a glycoside and a proteinogenic amino acid.
239
 Furthermore, 
169 represents a key intermediate in the production of Type A “clickable” 
glycoconjugates. 
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Figure 5.10: 
1
H and 
13
C NMR spectra of the 3-OH glycoconjugate 169, highlighting the formation 
of an bond resulting from the nucleophilic ring-opening of 164 by H.Ala.OMe.HCl. 
With the synthesis of 169 successfully completed, the 3-OH of 169 was 
subjected to TBS-protection. Utilizing TBS-Cl (2.0 equivalents) and imidazole 
(4.0 equivalents), the 3-OTBS glycoconjugate 170 was isolated in 66% yield 
(Scheme 5.25). Comparably to the previously synthesised 4-OH glycoconjugate 165, it 
is likely that the higher yield gained in the production of 170 is a result of the reduced 
steric hindrance present on the adjacent 2- and 4-positions, with the less-bulky acetyl 
groups allowing sufficient access to the 3-OH group by the TBS-imidazole reactive 
intermediate.  
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Scheme 5.25: Synthesis of the orthogonally-protected glycoconjugate 170. 
The production of 170 was confirmed by the 
1
H NMR spectrum, where the 
presence of singlets at 0.81 and 0.05 ppm integrating for nine and six protons 
respectively, were indicative of the tert-butyl and methyl protons of the TBS group. 
Furthermore, these signals correlated to two signals in the 
13
C NMR spectrum of 170 
at -4.6 and -4.9 ppm, both indicative of carbons linked to a silicon atom. A key 
intermediate in the production of Type B “clickable” glycoconjugates, the synthesis of 
170 from glucuronolactone represents a more concise and higher yielding approach to 
their production (8.5% over 6 steps), compared to the synthesis of 165 from D-glucose 
(4.4% over 9 steps). Nonetheless, the synthesis of 165 and 170 from D-glucose and 
glucuronolactone described in this chapter, have laid the foundation for the synthesis 
and development of Type A and Type B “clickable” neoglycocopeptides.  
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Chapter 6 : Conclusions and Future Directions 
 
6.1 Conclusions 
6.1.1 “Clickable” Glycoconjugates 
The CuAAC “click” reaction has greatly impacted on the synthesis and 
development of new bioconjugates.
240
Allowing for the rapid and stereoselective 
production of conjugates based on the 1,4-substituted triazole motif, until recently apart 
from metabolically incorporated azido sugars, the utilization of this ligation method in 
the synthesis and functionalization of bioconjugates incorporating carbohydrates has 
been limited. 
133,136
 In the study discussed herein, the scope and variety of 
glycoconjugates that can be formed between azidosugars and proteinogenic amino acids 
- and thus can participate in the CuAAC “click” reaction, has been significantly 
broadened. As a result, a number of glycoconjugates linked via ester (A, Scheme 6.1), 
amide (B and C, Scheme 6.1) and thioether linkages (D, Scheme 6.1) have been 
developed and further functionalized using the CuAAC “click” reaction.  
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Scheme 6.1: The diversity of “clickable” glycoconjugates synthesised from azidosugars, and 
functionalized using the CuAAC “click” reaction that have been described in the current study. 
Building on the successful production of glc- and gal-sugar azido acids 60 and 
65 from uronic acid precursors in Chapter 2, the variety of ester (66 and 67), sidechain 
(68 and 69) and α-amide (70-73) linked glycosyl azides produced highlighted the 
versatility of these molecules as scaffolds in the formation of glycoconjugates that can 
be functionalized using the CuAAC “click” reaction. This point was further 
demonstrated by the synthesis of the azide-bearing glycopeptide 88 as a key “click” 
precursor, promoting the use of this strategy in the synthesis and labelling of 
biologically-relevant peptides. 
In Chapter 3, the synthesis of “clickable” glycoconjugates linked via the 
sidechain or α-carboxyl group of an amino acid was investigated, with the conversion of 
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the azidoglucofuranose derivative 96 to the key intermediate azidoglucosylamine (102) 
achieved. Subsequently, the synthesis of amide-linked glycoconjugates 110 and 111 
through the coupling of 102 to the sidechain (Asp, Glu) groups of protected amino acids 
was also performed, along with their functionalization via the CuAAC “click” reaction. 
The synthesis and functionalization of 110 and 111 further demonstrated the versatility 
of azidosugars in forming amide-linked glycoconjugates with amino acids. In doing so, 
the development of glycoconjugates of this design has broadly extended the scope of 
this methodology to the formation of glycoconjugates between azidosugars and amino 
acids or peptides that bear a free sidechain-carboxyl group. 
Moving on from amide-linked examples, in chapter 4 the synthesis of thioether-
linked “clickable” glycoconjugates was also explored. In doing so, the challenges that 
exist in the production of thioether-linked conjugates with glycosides were highlighted. 
The individual reactivity of positions on a pyran-based glycoside (as illustrated in the 
attempted synthesis of 124), in addition to issues with stereoselectivity and scalability 
(131), significantly hindered the feasibility of producing glycoconjugates with 
individual thiol-containing amino acids. To address this issue, the development of the 
maleimide derivative 135 and the formation of glycoconjugate 136 by the “click” thiol-
ene reaction provided a concise method for the synthesis of thioether-linked “clickable” 
glycoconjugates. Utilizing the glc-sugar azido acid 60, the divergent nature of this 
synthesis added to the advantages that sugar azido acids possess in the formation of 
glycoconjugates that can be further derivatized by the CuAAC “click” reaction, 
endorsing their use in the development of glycoconjugates through the “click” 
thiol-ene reaction. 
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6.1.2 Functionalized Neoglycopeptides 
 In chapter 5, the development of a strategy towards the production of “clickable” 
neoglycopeptides based on sugar azido acids was also described. The development of an 
orthogonal protecting group strategy leading to the synthesis of the glycoconjugate 165 
was achieved (Scheme 6.2). Starting from D-glucose, an initial methodology utilizing 
acetal, p-methoxybenzyl, trityl and 4-methoxytrityl-protecting groups proved highly 
atom uneconomical. Revision of this methodology to utilize benzoyl protecting groups 
and selective TEMPO/BAIB oxidation conditions resulted in the partially protected 
glc-sugar azido acid derivative 164. Amide coupling followed by TBS protection 
subsequently yielded the desired orthogonally-protected 165. 
 
 
Scheme 6.2: The synthesis of orthogonally-protected glycoconjugates 165 and 170 from simple 
precursors (D-glucose; 165, and glucuronolactone; 170). 
Bearing a TBS protecting group at the 4-postion, the potential formation of 
differently-substituted derivatives, in addition to the efficiency of the synthesis of 163 
(4.4% over 9 steps) validated the investigation of an alternate method that may lead to 
the production of Type A and B “clickable” neoglycocpeptides. Subsequently, the 
design and synthesis of the orthogonally-protected glycoconjugate 170 was achieved, 
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with 170 instead bearing a TBS group at the 3-postion of the glycoconjugate 
(Scheme 6.2, 8.5% over 6 steps). Utilizing glucuronolactone (51), the formation of the 
key glycoconjugate 169 through nucleophilic substitution of a 6,3-lactone (166) 
represents a unique approach to the formation of glycoconjugates,  providing a concise, 
atom economical route to a key intermediate in the production of Type A and B 
“clickable” neoglycopeptides. The orthogonal protecting group strategies developed for 
the creation of 165 and 170 provides a mechanism for their further derivatization, which 
following protecting group manipulation would allow for their functionalization with a 
plethora of different functional groups.  
 
6.2 Future Directions 
6.2.1 Improved Access to Sugar Azido Acids From Protected 
Derivatives 
Key to the synthesis of “clickable” glycoconjugates performed in this study was 
the use of azidosugars, with sugar azido acids (such as the glc-sugar azido acid 60) 
shown to be exceedingly versatile in forming a variety of different linkages - directly or 
indirectly, with proteinogenic amino acids. One obvious drawback though in the 
production of sugar azido acids of this form is their scalability. This is predominantly a 
result of the utilization of allyl ester protection, as illustrated by the SAA precursors 59 
and 64. Both requiring Pd(0)-catalyzed de-allylation to produce the glc and gal-SAA’s 
60 and 65, the large quantities of catalyst (10 mol% loading) used in these processes is 
enough to limit their large scale production purely on economic grounds. However, the 
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competing reduction of the β-azide present in 60 and 65 by PPh3 that has leached from 
the catalyst is a much greater limitation, with the high variability in the quality of 
Pd(PPh3)4 that may be procured commercially reducing the consistency of yields 
obtained in the production of sugar azido acids.  
Thus, in order to scale up the synthesis of sugar azido acids and make their 
utility in the development of radiolabelled glycoconjugates more viable, an alternative 
strategy that doesn’t require the use of allyl esters or Pd(0) catalysis in their production 
would be required. Considering the ease and scale in which the methyl ester derivative 
53 was produced, an approach that used molecules of this form to produce sugar azido 
acids would be ideal. Generally cleaved under basic conditions akin to acetyl groups, 
reagents such as trimethyltin(IV) hydroxide have emerged as a mild alternative in the 
cleavage of methyl esters. This work has been pioneered by Nicolaou and co-workers, 
proving highly efficient and selective in the cleavage of methyl esters in the presence of 
acetyl groups.
241
 The development of such a strategy would have far reaching 
implications beyond the scope of our studies, generally improving accessibility to 
uronic acids for use in the development of biologically active molecules.  
 
6.2.2 Extension of the Synthesis of “Clickable” Glycoconjugates to 
Carboxyl and Thiol-containing Peptides 
In chapter 2, the synthesis of the neoglycopeptide 88 represented a key 
milestone in the development of glycoconjugates that may be derivatized by the 
CuAAC “click” reaction for the development of radiolabelled glycoconjugates. 
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Following on from the synthesis and functionalization of “clickable” glycoconjugates 
66-73, the production of 88 provided a substrate for the porting of this method to small, 
biologically-active peptides. The further functionalization of 88 to form 89 would 
illustrate the power of the CuAAC “click” reaction in the further derivatization of 
glycocopeptides.  In chapters 3 and 4, the formation of “clickable” glycoconjugates 
bearing thiol or carboxyl-containing amino acids was also achieved. In comparison 
though, the formation of glycoconjugates through these linkages was not extended to 
thiol or carboxyl-containing peptides. In order to validate the use of the CuAAC “click” 
reaction in the synthesis and labelling of glycoconjugates formed through these 
linkages, the methods developed in this project should be extended to peptides bearing 
these functional groups. Comparable to Ac.KPV.NH2 utilized in chapter 2, the synthesis 
of “clickable” glycoconjugates linked to small biologically-active tripeptides via an 
amide or thioether linkages would provide a good platform for the further utilization of 
conjugates linked in this manner.  
For amide-linked glycopeptides, the tripeptide motif LDV (H-Leu-Asp-Val-OH, 
171) represents a great example of a small peptide that could be utilized for this 
function. Commonly known as the Fibronectin Adhesion Motif, LDV motifs form key 
interactions with the α4β1 integrin, which has clinical implications in the promotion of 
tumour cell migration, invasion and metastasis.
100,242,243
 In addition to its biological 
relevance, the LDV motif bears both sidechain and terminal carboxyl groups, which 
through protecting group manipulation could be used to highlight the formation of 
“clickable” glycopeptides linked via either carboxyl group (Scheme 6.3). Additionally, 
the previously discussed thiol-containing peptide reduced-glutathione (172) would be 
ideally suited in validating the synthesis of “clickable” thioether-linked glycopeptides. 
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This is a result of its widespread use as model thiol-containing peptide in bioconjugate 
chemistry – particular when used in tandem with the “click” thiol-ene reaction, in 
addition to its important roles as an antioxidant in biological systems.
244
  
 
 
Scheme 6.3: The tripeptides Fibronectin Binding Motif (LDV; 171) and reduced-Glutathione (172), 
potential model peptides in the synthesis of amide and thioether-linked “clickable” glycopeptides. 
 
6.2.3 Synthesis of “Clickable” Neoglycopeptides 
 In chapter 5, the successful development of orthogonally-protected 
glycoconjugates 165 and 170 was described. Bearing TBS protecting groups at the 
3- and 4-positions, the basis for their production was to broaden the utility of sugar 
azido acids as molecular scaffolds in the synthesis of neoglycoconjugates. Considering 
that the general theme of this project was to develop glycoconjugates that were 
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amenable to the CuAAC “click” reaction, it seems appropriate that this ligation method 
could be applied to the functionalization of these neoglycopeptides formed from these 
precursors.  
If the 4- and 3-OH bearing derivatives 164 and 169 were subject to standard 
DCC/DMAP-mediated esterifcation, this would produce derivatives joined via an ester 
linkage (Scheme 6.4). As Type A “clickable” neoglycopeptides, these derivatives could 
then be further derivatized using the CuAAC “click” reaction. Alternatively, the 4- and 
3-OTBS derivatives 165 and 170 could be subjected to tandem azide reduction/amide 
coupling, to produce neoglycopeptides linked at the position (Scheme 6.4). The TBS 
groups of these derivatives are susceptible to selective cleavage by nucleophilic fluoride 
donors such as tetrabutylammonium fluoride (TBAF), which would unmask a free 
alcohol that could be derivatized (Scheme 6.4). Employing trichloroacetimidate 
chemistry akin to that used in the production of 128, azide-containing handles could be 
readily introduced, producing Type B “clickable” neoglycopeptides (Scheme 6.4). The 
utilization of this methodology would also allow for the functionalization of 
neoglycopeptides with a variety of different groups bearing a trichloroacetimidate, 
additional glycosides (such as 127). This could subsequently be ported to the 
development of a wider range of functionalized neoglycopeptides. 
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Scheme 6.4: Proposed synthetic strategy for the synthesis of Type A and B “clickable” 
neoglycopeptides from 164 and 169. 
 
6.2.4 Development and Synthesis of Radiolabelled Glycoconjugates 
Using the CuAAC “Click” Reaction 
With the development of “clickable” glycoconjugates achieved, the next step 
would be to examine this approach in the synthesis of radiolabelled glycoconjugate-
based molecular probes. In line with previous studies,
137
 a strategy utilizing fluorine-18 
as a radiolabel would represent the most viable approach to producing radiolabelled 
glycoconjugates. Such probes would be generated by the CuAAC “click” reaction of 
glycoconjugates to fluorine-18 containing species, with the subsequent purification of 
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these probes occurring prior to injection. This would limit  the possiblilty of copper 
toxicity, a problem encountered in in vivo CuAAC “click” imaging approaches such as 
live or whole cell imaging. 
Such derivatives would require cold standards, analogues of the radiolabelled 
compound containing fluorine-19, that provide a comparison for the radiolabelled 
derivative during purification.
84  
During our investigation into the production of 
“clickable” glycoconjugates based on the glc-sugar azido acid 60, the synthesis of 
fluorinated derivatives for the purpose of producing cold standards was explored. Using 
the methodology of Yin and co-workers,
245
 the fluorinated glycoconjugates 173 and 174 
were produced from the allyl ester 59,  and the methionine derivative 72 in 58% and 
49% yields, respectively (Scheme 6.5). These examples confirm the viability of 
fluorinated glycoconjugates of this form, validating the development of different 
[
18
F]-radiolabelled glycoconjugates using the CuAAC “click” reaction.   
 
 
 
 
Scheme 6.5: Synthesis of fluorinated glycoconjugates 173 and 174. 
In order to utilize this strategy in the development of radiolabelled 
glycoconjugates, the synthesized analogues must target biological function up-regulated 
in malignancies. Targets that may be suitable for this strategy include amino acid 
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transporters such as the neutral large amino acid transporter LAT-1 and the neutral 
small amino acid transporter ASCT-2.
246,247
 Key mediators of kinase signalling 
pathways such as PI3K, PKB and mTOR, these amino acid transporters coordinate 
cellular growth, metabolism and proliferation, and have been found to be up-regulated 
in metastases such as glioblastoma and non-small cell lung cancer (LAT-1).
248
 
Previously evaluated using radiolabelled derivatives of methionine
171,178
 and 
glutamine,
175
 the development of carbohydrate-containing derivatives of these 
analogues (such as 72, 73, 111 & 131) would probe both the effect of glycosylation on 
uptake of these amino acids, in addition to the pharmacokinetics of their excretion.  
In addition, the small scale nature of these conjugates would allow for the 
fine-tuning of radiofluorination conditions. This would subsequently allow for the 
extension of this methodology to more complex systems, including the formation of 
[
18
F]-radiolabelled glycoconjugates with peptides currently used in the evaluation of 
metastasis. These include those containing the RGD tripeptide motif targeting 
angiogenesis, those linked to the somatostatin analogue octreotide targeting 
neuroendocrine tumours, and full derivatives of α-MSH targeting melanoma. Herein, 
the foundation for the incorporation and utilization of azidosugars into a variety of 
peptides and other biomolecules has been laid. There is great scope for future work in 
this area, as azidosugars can be incorporated into a wide range of molecules (e.g. amino 
acids, peptides, proteins and lipids), and functionalised with a variety of different 
groups (e.g. with fluorophores, radiolabels). 
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Chapter 7 : Experimental 
 
7.1 Chemical Procedures 
7.1.1 General Experimental 
 All reactions were performed in standard glassware, acetone washed and oven 
dried prior to use. Solvents and reagents used were purchased from Sigma Aldrich 
Chemical Company (St Louis, MO, USA), Ajax Fine Chemicals (Taren Point, NSW), 
Thermofisher Scientifc (Waltham, MA, USA), Acros (Geel, Belgium), Alfa Aesar 
(Ward Hill, MA, USA), Carbosynth (Berkshire, UK) or Bachem (Bubendorf, 
Switzerland), and used as supplied. All solvents used were of analytical reagent (AR) 
grade or higher except for Hexane which was of LR grade, and was distilled for purity 
prior to use. The term petroleum spirit specifically refers to the solvent of the same 
name with a boiling point range of 40-60°C. The removal of large quantities of solvent 
in vacuo was carried out using Buchi and Heidolph rotary evaporators, at temperatures 
ranging from 35-65°C. When required, removal of trace quantities of solvent and drying 
in vacuo were performed using a CustomBlown Glassware high-vacuum manifold 
(Sydney, Australia), equipped with a JAVAC high vacuum pump.  
Sonication of reaction mixtures and solutions was performed using a Soniclean 
250HT ultrasonic bath (Thebarton, Victoria). Celite (Celite 545, particle size 0.02-
0.1 mm, Merck, Germany) was used to fliter out metal catalysts from reaction mixtures. 
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4Å molecular sieves (Sigma Aldrich) were used to dry reaction solvents, and Amberlite 
IR-120 or Dowex 50W cationic exchange resins (Sigma Aldrich) were utilized to 
neutralize basic aqueous solutions. All reactions were performed under an atmosphere 
of N2 or argon where possible. In particularly sensitive dry/inert reaction conditions, 
acetonitrile, CH2Cl2 and DMF used were supplied as pre-dried reagents.  All melting 
points were acquired using a Reichert and Buchi melting point apparati, standardised 
with (3,4-dimethoxyphenyl)acetic acid. All temperatures are recorded in °C, and are 
reported uncorrected.  
 
7.1.2 Chromatography 
All thin layer chromatography (TLC) was performed using Merck Silica Gel 60 
F254 aluminium backed plates. In general, all TLC plates used were stained to enhance 
visulaization using either vanillin, potassium permanganate, cerium molybdate or 
ninhydrin dips. For those bearing aromatic substituents, fluorescence was detected by 
exposure to ultraviolet (UV) light at a wavelength of (λ) 254 nm. Flash column 
chromatography was performed using Davisil
TM
 Silica Gel 60 (40-63 μm mesh) under 
air pressure. All eluents used for chromatographic purposes are indicated, with solvent 
proportions used given in volume: volume (v: v) ratios.  
 
7.1.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear magnetic resonance (NMR) spectra for all samples were acquired on a 
Varian VNMRS PS54  500 MHz spectrometer, with proton (
1
H) for all samples, and 
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carbon (
13
C) spectra for novel samples obtained at 500 MHz and 125 MHz, 
respectively. All spectra were obtained using a 5 mm PFG AutoX DB probe, at an 
operating temperature of 25.0 °C. Unless specifically stated, all samples subjected to 
NMR spectroscopy were dissolved in deuterated solvents, including chloroform 
(CDCl3), methanol (CD3OD), dimethylsulfoxide (d6-DMSO), acetonitrile (CD3CN) or 
water (D2O). Each provided internal references in 
1
H and 
13
C NMR spectra at δ 7.26 
ppm and 77.0 ppm (CDCl3), 3.31 ppm and 49.00 ppm (CD3OD), 3.50 ppm and 39.52 
ppm (d6-DMSO) 1.94 and 1.32 ppm (CD3CN) and 4.79 ppm (D2O, 
1
H only), 
respectively. Chemical shifts of peaks in NMR spectra are expressed in ppm with peak 
multiplicities reported as either singlets (s), doublets (d), triplets (t) or multiplets (m). 
Spectral data are assigned in the following format; (
1
H/
13
C NMR) (δ ppm) (m, iH, cc 
Hz, a) where m = multiplicity, i = integration, cc = coupling constant and a = 
assignment. All 
1
H and 
13
C NMR spectral assignments were assigned based on a 
combination of comparisons with literature data, 2D NMR spectral data, and using 
computer-aided identification methods. 
 
7.1.4 Mass Spectrometry 
Electrospray ionisation (ESI) mass spectra were obtained using both a 
Micromass Platform LCZ spectrometer and a Shimadzu Tandem LCMS-2010 liquid 
chromatograph mass spectrometer. For the majority of samples, High Resolution 
Electrospray Ionisation Mass Spectra (HRESI-MS) were performed on a Waters XEVO 
G2 Quadrapole Time-Of-Flight (Q-TOF) mass spectrometer, with leucine enkephalin 
(LeuEnk) used as an internal standard. 
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7.1.5 Chemical and Spectral Illustrations/Calculations 
 All figures, schemes and tables were drawn using ChemBioDraw Ultra 
versions 10.0-13.0 (CambridgeSoft/PerkinElmer, Waltham, MA, USA). All 
representations of 1D 
1
H and 
13
C NMR spectra, and 2D gCOSY/NOESY experiments   
were analysed and displayed using either MestReNova NMR Lite (Santiago, Chile) or 
ACD NMR Labs 12.00 (Toronto, Canada). All heat of formation ΔHf calculations were 
performed using ChemBio3D Ultra 11.00 (PerkinElmer) using the AM1 (semi-
empirical) level of theory. The following non-IUPAC structural abbreviations were used 
in the illustration of synthesised compounds: 
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7.2 Chapter 2 Experimental Data: 
1,2,3,4-tetra-O-acetyl-β-D-glucuronic acid (56)  
According to the method of Bergeon et al.,
160
 a round bottom 
flask containing D-glucuronic acid (55, 3.01 g, 15.50 mmol) 
was added acetic anhydride (50 mL), and the resulting 
suspension was chilled to 0°C. Solid I2 (0.215 g, 0.847 mmol) was added portionwise to 
the mixture, which was then allowed to stir at 0°C for 2 hours before being allowed to 
gradually warm to room temperature. After 5 hours, the reaction mixture was cooled 
back to 0°C, and dry MeOH (20 mL) was added dropwise to the solution, and allowed 
to stir overnight. The crude reaction mixture was then evaporated to dryness, 
resuspended in CH2Cl2 (50 mL) and washed sequentially with 0.1 M Na2S3O3 solution 
(2 x 20 mL) and brine (20 mL). The organic phases were combined, dried and 
evaporated, before recrystallization from Hexane/EtOAc yielded 56 as a white solid. 
(3.70 g, 58%), M.p. 153-155°C  (lit. 154 155°C)
249
 
1
H NMR (500 MHz, CDCl3) δ 5.79 
(d, 1H, J = 7.6 Hz, H1), 5.29 (m, 2H, H3/H4), 5.13 (m, 1H, H2), 4.24 (m, 1H, H5), 
2.11-2.02 (4s, 12H, CH3, 4 x OAc). 
13
C NMR (CDCl3, 125 MHz): 170.2 (C=O, OAc), 
169.9 (C=O, OAc), 169.5 (C=O, OAc), 169.1 (C=O, OAc), 91.5 (C1), 72.7 (C5), 72.1 
(C4), 70.4 (C3), 68.9 (C2), 20.9 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.6 
(CH3, OAc). LRMS (ESI): m/z 361 [M - H],
- 
HRMS (ESI): m/z calculated for 
C14H17O11 [M – H]
-
: 361.0771; Found 361.0774. 
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1,2,3,4-Tetra-O-acetyl-β-D-glucuronic acid allyl ester (57)  
According to the method of Tosin et al.,
157
 a solution of 56 
(4.65 g, 12.84 mmol) dissolved in dry CH2Cl2 (120 mL) was 
chilled to 0°C. Under an argon atmosphere, oxalyl chloride 
(1.2 mL, 1.68 g, 13.23 mmol) and DMF (0.60 mL) were added, and the reaction mixture 
was allowed to stir at 0°C for 30 minutes, before being allowed to warm to room 
temperature.  After 2 hours, the reaction mixture was cooled back down to 0°C, and in a 
separate dry round bottom flask, a solution of allyl alcohol (1.00 mL, 0.854 g, 
14.70 mmol), pyridine (3 mL)  and CH2Cl2 (20 mL) stirring in the presence of 
4Å molecular sieves was prepared. The solution containing the alcohol and pyridine 
was added dropwise to the reaction mixture, and allowed to stir at 0°C for 30 minutes 
before being warmed to room temperature. After a further 3 hours, the reaction mixture 
was diluted with CH2Cl2, before being quenched with sat. NaHCO3 solution (100 mL). 
The organic phases were washed with cold 0.1 M HCl (100 mL) and brine (50 mL), 
before being dried and evaporated. The resultant milky residue was triturated with 
petroleum spirit and left in the freezer overnight, to produce 57 as a waxy white solid. 
(4.81 g, 93%), M.p. 97-99°C (lit. 95-97°C)
157
  Rf 0.77 (1:1 Hexane:EtOAc.). 
1
H NMR 
(500 MHz, CDCl3) δ  5.89 (m, 1H, CH2-CH=CH2), 5.79 (d, 1H, J =7.7 Hz, H1), 
5.37 - 5.26 (m, 4H, CH2-CH=CH2, H3 and H4), 5.15 (dd, 1H, J = 8.7 Hz, H2), 4.61 (m, 
2H, CH2-CH=CH2), 4.20 (d, 1H, J = 9.4 Hz, H5),  2.12-2.02 (4s, 12H, CH3, 4 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 170.0 (C=O, OAc), 169.5 (C=O, 
OAc), 169.1 (C=O, OAc), 166.3 (C=O), 131.2 (CH2-CH=CH2), 119.8 (CH2-CH=CH2), 
91.6 (C1), 73.2 (C5), 72.1 (C4), 70.4 (C2), 69.1 (C3), 67.0 (CH2-CH=CH2), 21.0 (CH3, 
OAc), 20.7 (CH3,  OAc), 20.7 (CH3, OAc), 20.6 (CH3,  OAc). LRMS (ESI): m/z 425 
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[M + Na]
+  
HRMS (ESI): m/z calculated for C17H22O11Na [M + Na]
+ 
: 425.1060; 
Found 425.1050. 
 
1-Bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid, allyl ester (58) 
A solution of 57 (0.531 g, 1.33 mmol) dissolved in dry CH2Cl2 
(2 mL) was chilled to 0°C. 33% w/v HBr in AcOH (4 mL) was added 
dropwise to the solution, and upon addition the reaction mixture was 
allowed to gradually warm to room temperature under constant stirring. After 3 hours, 
the reaction mixture was diluted with CH2Cl2 (10 mL), and washed with H2O (5 mL), 
ice cold sat. NaHCO3 solution (5 mL) and brine (5 mL). The organic phases were then 
dried and evaporated, producing 58 as an orange oil that was used used without further 
purification.  (0.355 g, 67%), Rf 0.24 (3:1 Hexane:EtOAc). 
1
H NMR (500 MHz, 
CDCl3) δ  6.65 (d, 1H,  J  = 4.1 Hz, H1), 5.91 (m, 1H, CH2-CH=CH2), 5.61 (1H, t, 
J = 9.9 Hz, H3), 5.35 (m, 2H, CH2-CH=CH2), 5.24 (t, 1H J = 10.1 Hz, H4), 4.86 (dd, 
1H, J = 10.0 Hz, 4.1 Hz, H2), 4.62 (m, 3H, CH2-CH=CH2/H5), 2.12-2.01 (3s, 9H, CH3, 
3 x OAc). 
13
C NMR (CDCl3, 125 MHz): δ 169.7 (C=O, OAc), 169.6 (C=O, OAc), 
169.2 (C=O, OAc), 166.0 (C=O), 130.8 (CH2-CH=CH2), 119.9 (CH2-CH=CH2), 85.4 
(C1), 72.1 (C5), 70.3 (C4), 69.3 (C3), 68.5 (C2), 67.0 (CH2-CH=CH2), 20.6 (CH3, 
OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 423; 425 
[M + H]
+
Br
79
; Br
81 
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1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid, allyl ester (59)  
Method A: 58 (0.355 g, 0.85 mmol) was dissolved in dry DMF 
(3 mL), and the solution was cooled to 0°C. NaN3 (0.250 g, 
3.84 mmol) was added portion wise to the mixture, and allowed to 
stir at 0°C for 30 minutes, after which it was allowed to warm to room temperature. 
After 3 hours, the reaction mixture was diluted with H2O (5 mL), with the aqueous 
phase extracted with EtOAc (3 x 25 mL). The organic phases were dried and 
evaporated, with recrystallization from EtOAc/Hexanes producing 59 as a fluffy white 
solid. (0.223 g, 68%)  
Method B: According to the method of Tosin et al 
157
 57 (4.00 g, 9.95 mmol) was 
dissolved in dry CH2Cl2 (100 mL) under an atmosphere of argon. TMS-N3 (3.30 mL, 
2.89 g, 25.09 mmol) was added, and the resultant mixture was cooled to 0°C. SnCl4 
(0.60 mL, 1.34 g, 5.14 mmol) was added slowly to the cooled mixture and allowed to 
stir at 0°C for 15 minutes, after which the mixture was warmed to room temperature. 
After 4 hours, the mixture reaction mixture was diluted with CH2Cl2 (50 mL), and 
extracted with sat. NaHCO3 solution (2 x 50 mL) and brine (50 mL). The organic phase 
was dried and evaporated, with recrystallization from EtOAc/Hexanes yielding 59 as a 
fluffy white solid. (2.43 g, 63%), M.p. 132-133°C, Rf 0.81 
(1:1 Hexane:EtOAc).
1
H NMR (500 MHz, CDCl3) δ  5.91 (m, 1H, CH2-CH=CH2), 5.36-
5.26 (m, 4H, CH2-CH=CH2/ H3/H4), 4.97 (m, 1H, J = 9.5 Hz, 8.6 Hz, H2), 4.71 (d, 1H, 
H1), 4.63 (m, 2H, CH2-CH=CH2), 4.14 (d, 1H, J = 9.8 Hz, H5), 2.08-2.01 (3s, 9H, CH3, 
3 x OAc). 
13
C NMR (CDCl3, 125 MHz): 170.2 (C=O, OAc), 169.4 (C=O, OAc), 169.3 
(C=O, OAc), 166.1 (C=O), 131.2 (CH2-CH=CH2), 119.9 (CH2-CH=CH2), 88.3 (C1), 
74.6 (C5), 72.2 (C4), 70.7 (C2), 69.3 (C3), 67.0 (CH2-CH=CH2), 20.7 (CH3, OAc), 20.7 
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(CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 408 [M + Na]
+ 
HRMS (ESI): m/z 
calculated for C15H19N3O9Na [M + Na]
+
: 408.1019; Found 408.1039. 
 
1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60)  
According to the method of Tosin et al,
157
 59 (0.510 g, 
1.33 mmol) was dissolved in dry ACN (7 mL), and the reaction 
mixture was cooled to 0°C. To this solution, Pd(PPh3)4 (0.155 g, 
0.132 mmol)  was added, and the mixture was immersed in an atmosphere of argon. 
Pyrrolidine (0.12 mL, 1.34 mmol) was then added dropwise, and the reaction mixture 
was allowed to warm gradually to room temperature. After 1 hour, the reaction mixture 
was filtered through Celite, with the filtrate evaporated to dryness. The residue was re-
dissolved in EtOAc (20 mL), before extraction with H2O (2 x 20 mL). The aqueous 
phase was collected and acidified to pH 2 using Amberlite IR-120 resin, and 
subsequently extracted with EtOAc (3 x 40 mL). The organic phase was dried and 
evaporated, with the residue allowed to sit under high vacuum overnight, producing 60 
as a yellow foam. (0.303 g, 66%), 
1
H NMR 500 MHz, CD3OD) δ 5.36 (t, 1H, 
J = 9.4 Hz, H3), 5.19 (t, 1H, H4), 5.02 (d, 1H, J = 8.8 Hz, H1), 4.91 (t, 1H, J = 9.3 Hz, 
H2), 4.33 (d, 1H, J = 10.0 Hz, H5), 2.07-2.01 (3s, 9H, CH3, 3 x OAc). 
13
C NMR 
(CDCl3, 125 MHz): 173.2 (C=O, COOH), 172.5 (C=O, OAc), 172.4 (C=O, OAc), 172.4 
(C=O, OAc), 87.5 (C1), 74.7 (C5), 72.9 (C4), 71.2 (C2), 69.9 (C3), 20.3 (CH3, OAc), 
20.3 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 344 [M - H]
- 
HRMS (ESI): 
m/z calculated for C12H14N3O9 [M - H]
-
: 344.0730; Found 344.0746. 
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1,2,3,4-Tetra-O-acetyl-α-D-galacturonic acid (61)  
According to the method of Vogel et al.,
163
 a round bottom flask 
containing D-galactouronic acid (4.032 g, 19 mmol) was added 
acetic anhydride (25 mL), and the resulting suspension was chilled 
to 0°C. 70% perchloric acid (0.20 mL) was added dropwise over a 5 minute period, with 
the mixture allowed to gradually come to room temperature over a 30 minute period. 
After stirring at room temperature for 3 hours, the reaction mixture was cooled back to 
0°C, and dry MeOH (6 mL) was added dropwise to the solution. The reaction mixture 
was the diluted with H2O (20 mL), and subsequently extracted with CHCl3 (3 x 50 mL). 
The organic phases were dried (MgSO4), filtered and evaporated to dryness, producing a 
white residue which following recrystallization with EtOAc/Heptane produced 61 as a 
white solid. (2.46 g, 35%), M.p (103-105 °C) 
1
H NMR (500 MHz, CDCl3) δ  6.47 (d, 
1H, J = 2.9 Hz. H1), 5.84 (t, 1H, H4), 5.38 (t, 1H, J = 2.8 Hz, H3), 5.33 (dd,  lH, 
J = 9.5 Hz, 11.0 Hz, H2), 4.76 (d, 1H, J = 1.5 Hz, H5), 2.15-1.99 (4s, 12H, CH3, 
4 x OAc). 
13
C NMR (CDCl3, 125 MHz): 170.4 (C=O, OAc), 170.2 (C=O, OAc), 170.1 
(C=O, OAc), 169.1 (C=O, OAc), 168.6 (C=O), 89.5 (C1), 70.5 (C5), 68.7 (C4), 67.3 
(C3), 66.2 (C2), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, 
OAc). LRMS (ESI): m/z 361 [M – H]
- 
HRMS (ESI): m/z calculated for C14H17O11 
[M - H]
-
: 361.0771; Found 361.0778. 
 
1,2,3,4-Tetra-O-acetyl-α-D-galacturonic acid, allyl ester (62) 
 A solution of 61 (4.65 g, 12.84 mmol) dissolved in dry CH2Cl2 
(120 mL) was chilled to 0°C. Under an argon atmosphere, oxalyl 
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chloride (1.2 mL, 1.68 g, 13.23 mmol) and DMF (0.60 mL) were added, and the 
reaction mixture was allowed to stir at 0°C for 30 minutes, before being allowed to 
warm to room temperature.  After 2 hours, the reaction mixture was cooled back down 
to 0°C, and in a separate dry round bottom flask, a solution of allyl alcohol (1.00 mL, 
0.854 g, 14.70 mmol), pyridine (3 mL)  and CH2Cl2 (20 mL) stirring in the presence of 
4Å molecular sieves was prepared. The solution containing the alcohol and pyridine 
was added dropwise to the reaction mixture, and allowed to stir at 0°C for 30 minutes 
before being warmed to room temperature.  After a further 3 hours, the reaction mixture 
was diluted with CH2Cl2, before being quenched with sat. NaHCO3 solution (100 mL). 
The organic phases were washed with cold 0.1 M HCl (100 mL) and brine (50 mL), 
before being dried and evaporated. The resultant milky residue was triturated with 
petroleum spirit and left in the freezer overnight, to produce the novel 62 as an off-white 
solid. (4.38 g, 85%), M.p. 82-85°C Rf 0.80 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, 
CDCl3) δ 6.41 (d, 1H, J = 2.4 Hz, H1), 5.75 (m, 2H, CH2-CH=CH2/H4), 5.28 (m, 2H, 
H2/H3), 5.19 (dd, 2H, J = 10.3 Hz, 17.1 Hz, CH2-CH=CH2, 4.70 (m, 1H, H5), 4.56 (m, 
2H, CH2-CH=CH2), 2.07-1.91 (4s, 12H, CH3, 4 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 
170.1 (C=O, OAc), 169.8 (C=O, OAc), 169.8 (C=O, OAc), 168.8 (C=O, OAc), 165.9 
(C=O), 132.1 (CH2-CH=CH2), 120.0 (CH2-CH=CH2), 89.8 (C-1), 70.9 (C-5), 68.8 (C4), 
67.2 (C3), 66.7 (C2), 66.0 (CH2-CH=CH2), 20.4 (CH3, OAc), 20.2 (CH3, OAc), 20.1 
(CH3, OAc), 20.1 (CH3, OAc). LRMS (ESI): m/z 425 [M + Na]
+ 
HRMS (ESI): 
m/z calculated for C17H22O11Na [M + Na]
+
: 425.1060; Found 425.1063. 
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1-Bromo-2,3,4-tri-O-acetyl-α-D-galacturonic acid, allyl ester (63)  
 A solution of 62 (2.113 g, 5.24 mmol) dissolved in dry CH2Cl2 
(6 mL) was chilled to 0°C. 33% w/v HBr in AcOH (14 mL) was 
added dropwise to the solution, and upon addition the reaction 
mixture was allowed to gradually warm to room temperature under constant stirring. 
After 3 hours, the reaction mixture was diluted with CH2Cl2 (50 mL), and washed with 
H2O (50 mL), ice cold sat. NaHCO3 solution (50 mL) and brine (50 mL). The organic 
phases were then dried and evaporated, producing 63 as an orange oil that was used 
used without further purification (1.494 g, 66%), Rf 0.21 (3:1 
Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ  6.78 (d, 1H, J = 3.3 Hz, H1), 5.86 (m, 
2H, CH2-CH=CH2/H4), 5.46 (dd, 1H, J = 3.0 Hz, 9.5 Hz, H3), 5.32 (dd, 2H, J = 10.2 
Hz, 17.3 Hz, CH2-CH=CH2), 5.11 (dd, 1H, J = 2.9 Hz, 9.5 Hz, H2), 4.90 (m, 1H, H5), 
4.65 (m, 2H, CH2-CH=CH2), 2.14-2.01 (3s, 9H, CH3, 3 x OAc). 
13
C NMR (125 MHz, 
CDCl3) δ 170.1 (C=O, OAc), 169.9 (C=O, OAc), 169.6 (C=O, OAc), 165.2 (C=O), 
130.9 (CH2-CH=CH2), 120.3 (CH2-CH=CH2), 87.4 (C1), 72.6 (C5), 68.1 (C4), 67.8 
(C3), 67.3 (C2), 66.8 (CH2-CH=CH2), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, 
OAc). LRMS (ESI): m/z 423; 425 [M + H]
+
Br
79
; Br
81 
 
 
1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid, allyl ester (64) 
Method A: 62 (1.00 g, 2.48 mmol) was dissolved in dry CH2Cl2 
(30 mL) under an atmosphere of argon. TMS-N3 (0.83 mL, 
0.727 g, 6.31 mmol) was added, and the resultant mixture was 
cooled to 0°C. SnCl4 (0.15 mL, 0.335 g, 1.29 mmol) was added slowly to the cooled 
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mixture and allowed to stir at 0°C for 15 minutes, after which the mixture was warmed 
to room temperature. After 20 hours, the mixture reaction mixture was diluted with 
CH2Cl2 (20 mL), and extracted with sat. NaHCO3 solution (2 x 20 mL) and brine 
(20 mL). The organic phases were combined, dried and evaporated, with 
recrystallization from EtOAc/Hexanes yielding 64 as an off-white solid. (0.274 g, 29%) 
Method B: 63 (1.494 g, 3.54 mmol) was dissolved in dry DMF (10 mL), and the 
solution was cooled to 0°C. NaN3 (1.036 g, 15.98 mmol) was added portion wise to the 
mixture, and allowed to stir at 0°C for 30 minutes, after which it was allowed to warm 
to room temperature. After 3 hours, the reaction mixture was diluted with H2O (10 mL), 
with the aqueous phase extracted with EtOAc (3 x 50 mL). The organic phases were 
dried and evaporated, with recrystallization from EtOAc/Hexanes producing 64 as an 
off-white solid. (1.006 g, 70%), M.p. 113-114°C Rf 0.84 (1:1 Hexane:EtOAc.).
1
H NMR 
(500 MHz, CDCl3) δ  5.87 (m, 1H, CH2-CH=CH2), 5.76 (m, 1H, H4), 5.32 (dd, 2H, 
J = 10.4 Hz, 17.1 Hz, CH2-CH=CH2), 5.18 (t, 1H, J = 9.0 Hz, H2), 5.10 (m, 1H, H3), 
4.68-4.64 (m, 3H, CH2-CH=CH2/H1), 4.43 (m 1H, H5), 2.11-1.99 (3s, 9H, CH3, 
3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 169.9 (C=O, OAc), 169.4 
(C=O, OAc), 165.2 (C=O), 131.2 (CH2-CH=CH2), 120.1 (CH2-CH=CH2), 88.6 (C1), 
74.3 (C5), 70.6 (C4), 68.2 (C3), 67.8 (C2), 66.8 (CH2-CH=CH2), 20.9 (CH3, OAc),  
20.7 (CH3, OAc),  20.6 (CH3, OAc). LRMS (ESI): m/z 408 [M + Na]
+ 
HRMS (ESI): m/z calculated for C15H19N3O9Na [M + Na]
+
: 408.1019; Found 408.1024 
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1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65) 
64 (0.511 g, 1.33 mmol) was dissolved in dry ACN (7 mL), and 
the reaction mixture was cooled to 0°C. To this solution, 
Pd(PPh3)4 (0.155 g, 0.132 mmol)  was added, and the mixture was 
placed under an atmosphere of argon. Pyrrolidine (0.12 mL, 1.34 mmol) was then added 
dropwise, and the reaction mixture was allowed to warm gradually to room temperature. 
After 1 hour, the reaction mixture was filtered through Celite, with the filtrate 
evaporated to dryness. The residue was re-dissolved in EtOAc (20 mL), before 
extraction with H2O (2 x 20 mL). The aqueous phase was collected and acidified to 
pH 2 using Amberlite IR-120 resin, and subsequently extracted with EtOAc 
(3 x 40 mL). The organic phase was dried and evaporated, with the residue placed under 
high vacuum overnight, producing 65 as a yellow foam. (0.308 g, 67%).
1
H NMR (500 
MHz, CDCl3) δ 5.78 (m, 1H, H4), 5.16 (t, 1H, J = 8.5 Hz, H2), 5.12 (t, 1H, J = 8.5 Hz, 
H3, 4.71 (d, 1H, J = 8.8 Hz, H1), 4.44 (m, 1H, H5), 2.10, 2.09, 1.99 (3s, 9H, CH3, 3 x 
OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 170.0 (C=O, OAc), 169.4 
(C=O, OAc), 167.8 (C=O), 88.4 (C1), 74.0 (C5), 70.5 (C4), 68.0 (C3), 67.7 (C2), 20.7 
(CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 344 [M - H]
- 
HRMS (ESI): m/z calculated for C12H14N3O9 [M - H]
-
:344.0730; Found 344.0736.  
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N
α
-(tert-Butoxycarbonyl)-O-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-serine 
methyl ester (66) 
A solution of 60 (0.141 g, 0.41 mmol) and Boc.Ser.OMe 
(0.092 g, 0.41 mmol) in dry CH2Cl2 (10 mL) was cooled 
to 0°C. DCC (0.170 g, 0.81 mmol) and DMAP (0.010 g, 
0.08 mmol) were added, and the solution stirred at room 
temperature for 24 hours. Upon completion, the reaction mixture was filtered, and the 
filtrate was diluted with CH2Cl2 (10 mL). The organic phase was washed with sat. 
NaHCO3 solution (10 mL) and brine (10 mL), and dried and evaporated. The resulting 
residue was purified using flash column chromatography (2:1 Hexane: EtOAc) to 
produce 66 as a white solid. (0.172 g, 80%), M.p. 112-114°C Rf 0.18 
(2:1 Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ  5.40 (bs, 1H, NH), 5.26 (m, 2H, 
H3/H4), 4.96 (t, 1H, J = 8.7 Hz, H2), 4.73 (d, 1H, J = 8.1 Hz, H1), 4.58 (m, 2H, H
β
), 
4.41 (m, 1H, H
α
), 4.16 (d, 1H, J = 8.7 Hz, H5), 3.78 (s, 3H, OCH3), 2.08-2.02 (3s, 9H, 
CH3, 3 x OAc), 1.45 (s, 9H, Boc-H). 
13
C NMR (125 MHz, CDCl3) δ 170.1, (C=O, 
OAc), 169.9, (C=O, OAc), 169.6, (C=O, OAc), 169.3 (C=O, COOCH3), 165.9 (C=O), 
155.3 (C=O, Boc), 88.1 (C1), 80.6, (C(CH3)3), 74.3 (C5), 72.0 (C4), 70.5 (C3), 69.1 
(C2), 66.0 (C
β
), 53.1 (OCH3), 52.8 (C
α
), 28.4 (C(CH3)3), 20.7 (CH3, OAc), 20.7 (CH3, 
OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 569 [M + Na]
+ 
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N
α
-(tert-Butoxycarbonyl)-O-(1-azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-L-
serine methyl ester (67) 
 A solution of 60 (0.142 g, 0.410 mmol) and 
Boc.Ser.OMe (0.095 g, 0.430 mmol) in dry CH2Cl2 
(10 mL) was cooled to 0°C. DCC (0.170 g, 0.810 mmol) 
and DMAP (0.011 g, 0.080 mmol) were added, and the 
solution stirred at room temperature for 24 hours. Upon completion, the reaction 
mixture was filtered, and the filtrate was diluted with CH2Cl2 (10 mL). The organic 
phase was washed with sat. NaHCO3 solution (10 mL) and brine (10 mL), and dried and 
evaporated. The resulting residue was purified using flash column chromatography 
(2:1 Hexane: EtOAc) to produce 66 as a colourless oil. (0.138 g, 64%), 
Rf 0.22  (2:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ  5.69 (s, 1H, H4), 5.38 (d, 
1H, J = 7.3 Hz, NH), 5.16 (t, 1H, J = 8.7 Hz, H2), 5.08 (dd, 1H, J =  3.0 Hz, 10.3 Hz, 
H3), 4.64 (d, 1H, J = 8.7 Hz, H1), 4.55 (m, 1H, H
α
), 4.47 (m, 2H, H
β
), 4.38 (m, 1H, 
H5), 3.76 (s, 3H, OCH3), 2.07-1.98 (3s, 9H, CH3, 3 x OAc), 1.43 (s, 9H, CH3, Boc). 
13
C NMR (125 MHz, CDCl3) δ 170.2 (C=O, OAc), 170.0 (C=O, OAc), 169.8 (C=O, 
OAc), 169.4 (C=O, COOCH3), 165.0 (C=O), 155.4 (C=O, Boc), 88.5 (C1), 80.6 
(C(CH3)3), 74.0 (C5), 70.4 (C3), 68.0 (C4), 67.9 (C2), 66.1 (C
β
), 53.1 (OCH3), 52.9 
(C
α
), 28.5 (C(CH3)3), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc). 
LRMS (ESI): m/z 569 [M + Na]
+
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N
α
-(Acetyl)-N
ε
-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-lysine methyl ester 
(68) 
Method A: A solution of 60 (0.140 g, 0.40 mmol) 
and Ac.Lys.OMe.HCl (0.100 g, 0.41 mmol) in dry 
CH2Cl2 (10 mL) was cooled to 0°C. DCC 
(0.171 g, 0.81 mmol) and DMAP (0.16 g, 
0.13 mmol) were added, and the solution was allowed to stir at room temperature for 
24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was 
diluted with CH2Cl2 (10 mL). The organic phase was washed with sat. NaHCO3 
solution (10 mL) and brine (10 mL), and dried and evaporated. The resulting residue 
was purified using flash column chromatography (1:2 Hexane: EtOAc) to produce 68 as 
a light yellow oil. (0.67 g, 31%). 
Method B: 60, (0.141 g, 0.41 mmol) Ac.Lys.OMe.HCl (0.100 g, 0.41 mmol), DCC 
(0.175 g, 0.815 mmol) and HOBt (0.077 g, 0.528 mmol) were dissolved in DMF 
(5 mL), and the solution was cooled to 0°C. DIPEA (0.075 mL, 0.056 g, 0.446 mmol) 
was added dropwise to the solution, and the reaction mixture was allowed to warm to 
room temperature and stir for 24 hours. Upon completion, the reaction mixture was 
filtered, and the filtrate was diluted with EtOAc (20 mL), and extracted with H2O 
(5 mL). The organic phase was dried and evaporated, with the following residue 
purified by flash column chromatography (1:2 Hexane: EtOAc) to produce 68 as a light 
yellow solid. (0.163 g, 75%), M.p 145-148°C, Rf 0.16 (1:2 Hexane:EtOAc).
1
H NMR 
(500 MHz, CDCl3) δ  6.76 (bs, 1H, NH), 6.70 (bs, 1H, NH), 5.31 (t, 1H, J = 9.5 Hz, 
10.0 Hz, H4), 5.17 (t, 1H, J = 9.5 Hz, 10.0 Hz, H3), 4.95 (t, 1H, J = 9.2 Hz, H2), 4.83 
(d, 1H, J = 8.9 Hz, H1), 4.61 (m, 1H, CH
α
), 4.05 (d, 1H, J = 10.1 Hz, H5), 3.73 (s, 3H, 
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OCH3), 3.40 (m, 1H, CH
ε
), 3.15 (m, 1H, CH
ε
), 2.09-2.01 (4s, 12H, CH3, 
NHAc/3 x OAc), 1.79 (m, 1H, CH
β
), 1.72 (m, 1H, CH
β
), 1.55 (m, 2H, CH
δ
), 1.35 (m, 
2H, CH
γ
). 
13
C NMR (125 MHz, CDCl3) δ 173.1 (C=O, NHAc), 170.5 (C=O, OAc), 
170.3 (C=O, OAc), 169.9 (C=O, OAc), 169.4 (C=O, COOCH3), 166.2 (C=O), 88.1 
(C1), 74.6 (C5), 72.1 (C4), 70.8 (C3), 69.5 (C2), 52.5 (OCH3), 52.2 (CH
ε
), 38.7 (CH
α
), 
31.9 (CH
δ
), 29.1 (CH
β
), 23.1 (CH3, NHAc), 22.4 (CH
γ
), 20.8 (CH3, OAc), 20.7 (CH3, 
OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 552 [M + Na]
+ 
HRMS (ESI): m/z calculated 
for C21H31N5O11Na [M + Na]
+
: 552.1918; Found 552.1918. 
 
N
α
-(Acetyl)-N
ε
-(1-azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-L-lysine methyl ester 
(69) 
65 (0.141 g, 0.41 mmol) Ac.Lys.OMe.HCl 
(0.100 g, 0.42 mmol), DCC (0.176 g, 0.817 mmol) 
and HOBt (0.079 g, 0.530 mmol) were dissolved 
in DMF (5 mL), and the solution was cooled to 
0°C. DIPEA (0.075 mL, 0.056 g, 0.446 mmol) was added dropwise to the solution, and 
the reaction mixture was allowed to warm to room temperature and stir for 24 hours. 
Upon completion, the reaction mixture was filtered, and the filtrate was diluted with 
EtOAc (20 mL), and extracted with H2O (5 mL). The organic phases were combined, 
dried and evaporated, and the residue purified by flash column chromatography 
(1:2 Hexane: EtOAc) to produce 69 as a light yellow oil. (0.130 g, 60%), M.p. 154-
156°C (decomp.), Rf 0.18 (1:2 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  6.63 (t, 
1H, J = 6.2 Hz NH), 6.37 (d, 1H, J = 7.7 Hz, NH), 5.81 (m, 1H, H4), 5.14 (m 2H, 
H3/H2), 4.74 (m, 1H, H1), 4.54 (m, 1H, H
α
), 4.34 (m, 1H, H5), 3.74 (s, 3H, OCH3), 
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3.32-3.25 (m, 2H, CH
ε
), 2.10 -1.98 (4s, 12H, CH3, NHAc/3 x OAc), 1.83 (m, 1H, CH
β
), 
1.70 (m, 1H, CH
β
), 1.58 (m, 2H, CH
δ
), 1.37 (m, 2H, CH
γ
). 
13
C NMR (125 MHz, 
CDCl3) δ 173.0 (C=O, NHAc),  170.3 (C=O, OAc), 169.9 (C=O, OAc), 169.8 (C=O, 
OAc), 169.4 (C=O, COOCH3), 165.4 (C=O), 88.4 (C1), 76.8 (C4), 75.4 (C5), 70.4 (C3), 
67.8 (C2), 52.4 (OCH3), 52.0 (CH
ε
), 38.7 (CH
α
), 31.7 (CH
δ
), 29.2 (CH
β
), 23.1 (CH3 
NHAc), 22.4 (CH
γ
), 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.5 (CH3, OAc). 
LRMS (ESI): m/z 552 [M + Na]
+ 
HRMS (ESI): m/z calculated for C21H31N5O11Na 
[M + Na]
+
: 552.1918; Found 552.1935 
 
N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-leucine methyl ester (70) 
60 (0.173 g, 0.50 mmol), H.Leu.OMe.HCl (0.136 g, 
0.74 mmol) and HBTU (0.379 g, 1.00 mmol) were dissolved 
in DMF (5 mL), and the solution was cooled to 0°C. DIPEA 
(0.10 mL, 0.074 g, 0.55 mmol) was added dropwise to the 
solution, and the reaction mixture was allowed to warm to room temperature and stirred 
for 24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was 
diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The organic phase was 
dried and evaporated, and the residue purified by flash column chromatography 
(3:1 Hexane: EtOAc) to produce 71 as a white solid. (0.199 g, 84%), M.p. 122-124°C, 
Rf 0.72 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  6.70 (d, 1H, J = 8.4 Hz, 
NH), 5.28 (t, 1H, J = 9.4 Hz, H4), 5.15 (t, 1H, J = 9.8 Hz, H3), 4.96 (t, 1H, J = 9.1Hz, 
H2), 4.79 (d, 1H, J = 8.9 Hz, H1), 4.57 (m, 1H, H
α
), 4.04 (d, 1H, J = 10.1 Hz, H5), 3.74 
(s, 3H, OCH3), 2.08 – 2.01 (3s, 9H, CH3, 3 x OAc), 1.69 - 1.64 (m, 3H, H
β
/H
γ
), 0.95 (m, 
6H, CH3, 2 x H
δ
). 
13
C NMR (125 MHz, CDCl3) δ 172.8 C=O (COOCH3), 169.8 (C=O, 
Chapter 7: Experimental 
213 | P a g e  
 
OAc), 169.4 (C=O, OAc), 169.2 (C=O, OAc), 165.5 (C=O), 87.9 (C1), 74.2 (C5), 71.9 
(C4), 70.6 (C3), 69.1 (C2), 52.4 (C
α
), 50.4 (OCH3), 41.2 (C
β
), 24.8 (C
γ
), 22.8 (C
δ
), 21.8 
(C
δ
), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 495 
[M + Na]
+ 
HRMS (ESI): m/z calculated for C19H24N4O10Na [M + Na]
+
: 495.1703; 
Found 495.1697. 
 
N-(1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-L-leucine methyl ester (71)  
65 (0.173 g, 0.50 mmol), H.Leu.OMe.HCl (0.137 g, 
0.75 mmol) and HBTU (0.380 g, 1.00 mmol) were dissolved in 
DMF (5 mL), and the solution was cooled to 0°C. DIPEA 
(0.10 mL, 0.074 g, 0.55 mmol) was added dropwise to the 
solution, and the reaction mixture was allowed to warm to room temperature and stir for 
24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was 
diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The organic phase was 
dried and evaporated, with the following residue purified by flash column 
chromatography (2:1 Hexane: EtOAc) to produce 71 as a clear oil. (0.184 g, 78%), 
Rf 0.65 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 6. 82 (d, 1H, J = 7.6 Hz, 
NH), 5.83 (m, 1H, H4), 5.17 (m, 2H, H2/H3), 4.70 (m, 2H, H1/H
α
), 4.33 (m, 1H, H5), 
3.75 (s, 3H, OCH3), 2.11 – 1.99 (3s, 9H, CH3, 3 x OAc), 1.69 – 1.60 (m, 3H, H
β
/ H
γ
), 
0.95 (m, 6H, CH3, 2 x H
δ
). 
13
C NMR (125 MHz, CDCl3) δ  172.9 (C=O, COOCH3), 
170.0 (C=O, OAc), 169.6 (C=O, OAc), 169.3 (C=O, OAc), 164.9 (C=O), 88.4 (C1), 
75.4 (C5), 70.4 (C3), 67.7 (C2), 67.6 (C4),  52.5 (OCH3), 50.4 (C
α
), 41.4 (C
β
), 24.8 ( 
C
γ
), 22.9 (C
δ
), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 
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495 [M + Na]
+ 
HRMS (ESI): m/z calculated for C19H24N4O10Na [M + Na]
+
: 495.1703; 
Found 495.1696 
 
N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-methionine methyl ester (72) 
60 (0.342 g, 1.01 mmol), H.Met.OMe.HCl (0.302 g, 
1.51 mmol) and HBTU (0.764 g, 2.00 mmol) were 
dissolved in DMF (15 mL), and the solution was cooled to 
0°C. DIPEA (0.20 mL, 0.148 g, 1.1 mmol) was added 
dropwise to the solution, and the reaction mixture was allowed to warm to room 
temperature and stirred for 24 hours. Upon completion, the reaction mixture was 
filtered, and the filtrate was diluted with EtOAc (50 mL), and extracted with H2O (5 
mL). The organic phase was dried and evaporated, with the following residue purified 
by flash column chromatography (2:1 Hexane: EtOAc) to produce 72 as a fluffy white 
solid. (0.461 g, 95%), M.p. 106-107°C, Rf 0.71 (1:1 Hexane:EtOAc.).
1
H NMR 
(500 MHz, CDCl3)  δ  7.14 (bs, 1H, NH), 5.27 (t, 1H, J = 9.5 Hz, H3), 5.16 (t, 1H, 
J = 9.8 Hz, H4), 4.97 (t, 1H, J = 9.6 Hz, H2), 4.78 (d, 1H, J = 9.8Hz, H1), 4.68 (m, 1H, 
Hα), 4.02 (d, 1H, J = 9.8 Hz, H5),  3.78 (s, 3H, OCH3), 2.54 (t, 2H, J = 7.3 Hz, Hγ), 
2.19 (m, 2H, Hβ), 2.13 (s, 3H, S-CH3), 2.09-2.02 (3s, 9H, CH3, 3 x OAc). 
13
C NMR 
(125 MHz, CDCl3) δ 171.8 (COOCH3), 169.9 (C=O, OAc), 169.6 (C=O, OAc), 169.3 
(C=O, OAc), 165.7 (C=O), 87.9 (C1), 74.2 (C5), 71.7 (C4), 70.5 (C3), 69.1(C2), 52.7 
(C
α
), 51.2 (-OCH3), 31.2 (C
β
), 29.7(C
γ
), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3, 
OAc), 15.4 (SCH3). LRMS (ESI): m/z 513 [M + Na]
+  
HRMS (ESI): m/z calculated for 
C18H26N4O10SNa [M + Na]
+
: 513.1267; Found 513.1273. 
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N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-glutamine tert-butyl ester (73) 
60 (0.173 g, 0.50 mmol), H.Glu.OtBu.HCl (0.179 g, 
0.75 mmol) and HBTU (0.376 g, 0.99 mmol) were 
dissolved in DMF (5 mL), and the solution was cooled to 
0°C. DIPEA (0.10 mL, 0.074 g, 0.55 mmol) was added 
dropwise to the solution, and the reaction mixture was allowed to warm to room 
temperature and stir for 24 hours. Upon completion, the reaction mixture was filtered, 
and the filtrate was diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The 
organic phase was dried and evaporated, with the following residue purified by flash 
column chromatography (1:3 Hexane: EtOAc) to produce 73 as an off-white solid.  
(0.254 g, 96%), M.p. 129-130°C, Rf 0.24 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, 
CDCl3) δ 7.24 (d, 1H, J = 7.7 Hz, NH), 5.31 (t, 1H, J = 9.5 Hz, H3), 5.18 (t, 1H, J = 9.6 
Hz, H4), 4.98 (t, 1H, J = 9.4 Hz, H2), 4.82 (d, 1H, J = 9.0 Hz, H1), 4.45 (m, 1H, H
α
), 
4.02 (d, 1H, J = 9.9 Hz, H5), 2.35 - 2.28 (m, 2H, H
γ
), 2.20-1.90 (m, 2H, H
β
), 2.09 - 2.02 
(3s, 9H, CH3, 3 x OAc), 1.48 (s, 9H, OtBu).
13
C NMR (125 MHz, CDCl3) δ 174.9 
(CONH2), 170.6 (COOtBu), 170.2 (C=O, OAc), 169.7 (C=O, OAc), 169.2 (C=O, OAc) 
167.5 (C=O), 87.9 (C1), 83.0 (C(CH3)3), 74.2 (C5), 71.6 (C4), 70.6 (C3), 69.5(C2), 51.8 
(C
α
), 38.6 (C
γ
), 31.3 (C
β
), 27.9 (C(CH3)3), 20.8 (CH3, OAc), 20.5 (CH3, OAc), 20.5 
(CH3, OAc). LRMS (ESI): m/z 552 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C21H31N5O11Na [M + Na]
+
: 552.1918; Found 552.1922. 
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1-(4’-(2”-Hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic 
acid allyl ester (74) 
Method A: To a round bottom flask containing 59 
(0.100 g, 0.260 mmol), 3-butyn-1-ol (0.034 mL, 
0.037 g, 0.52 mmol), CuSO4.5H2O (0.013 g, 
0.052 mmol) and sodium ascorbate (0.010 g, 0.052 mmol) was added a 3:1 solution of 
ACN:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of 
nitrogen at room temperature for 8 hours. Upon completion, the reaction mixture was 
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). 
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a 
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to 
yield 74 as a light yellow oil. (0.044 g, 37%). 
Method B: As for Method A, except that a solution of 1:1 nBuOH: H2O was instead 
used, and the reaction mixture was stirred at 40°C for 4 hours. Work up and purification 
by flash column chromatography yielded 74 as a light yellow oil. (0.058 g, 49%). 
Method C: To a round bottom flask containing 59 (0.100 g, 0.260 mmol), 3-butyn-1-ol 
(0.067 mL, 0.073 g, 1.04 mmol), CuSO4.5H2O (0.013 g, 0.052 mmol) and sodium 
ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), 
with the solution stirred vigorously under an atmosphere of nitrogen at room 
temperature for 8 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography to yield 74 as a light yellow oil. 
(0.061 g, 52%) 
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Method D: As for Method C, except that CuOAc2.H2O (0.010 g, 0.052 mmol) was used 
instead of CuSO4.5H2O. Work up and purification by flash column chromatography 
yielded 74 as a light yellow oil. (0.065 g, 55%) 
Method E: As for Method D, except that the additive TBTA (0.028 g, 0.052 mmol) was 
added to the reaction mixture. Work up and purification by flash column 
chromatography yielded 74 as a light yellow oil. (0.071 g, 60%) 
Method F: To a round bottom flask containing 59 (0.100 g, 0.260 mmol), 3-butyn-1-ol 
(0.070 mL, 0.075 g, 1.06 mmol), CuOAc2.H2O (0.011 g, 0.056 mmol) and sodium 
ascorbate (0.022 g, 0.110 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), 
with the solution stirred vigorously under an atmosphere of nitrogen at room 
temperature for 24 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography to yield 74 as a light yellow solid  
(0.104 g, 88%), M.p. 116-118°C, Rf 0.29 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, 
CDCl3) δ  7.74 (s, 1H, Triazole-H), 5.93-5.86 (m, 2H, H1/CH2=CH-CH2), 5.48-5.25 (m, 
5H, H4/H3/H2/CH2=CH-CH2), 4.61 (m, 2H, CH2=CH-CH2), 4.35 (d, 1H,  J = 9.8 Hz, 
H5), 3.87 (m, 2H, CH2-CH2-OH), 2.92 (m, 2H, CH2-CH2-OH),  2.04-1.98 (3, 9H, CH3, 
3 x OAc). Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 169.9 (C=O, 
OAc), 169.5 (C=O, OAc), 169.2 (C=O, OAc), 165.7 (C=O), 147.9 (Triazole), 130.9 
(CH2-CH=CH2), 120.6 (Triazole), 120.0 (CH2-CH=CH2), 88.1 (C1), 74.9 (C5), 71.8 
(C4), 70.3 (C3), 69.1 (C2), 67.1 (CH2-CH=CH2), 61.5 (CH2-CH2-OH), 29.1 
(CH2-CH2-OH), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.3 (CH3, OAc). 
LRMS (ESI): m/z 478 [M + Na]
+ 
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 1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic 
acid allyl ester (75) 
 To a round bottom flask containing 59 (0.101 g, 
0.261 mmol), 4-pentyn-1-ol (0.097 mL, 0.087 g, 
1.04 mmol), CuOAc2.H2O (0.010 g, 
0.052 mmol) and sodium ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of 
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of 
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was 
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). 
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a 
residue which was purified by flash column chromatography to yield 75 as a white 
solid.  (0.114 g, 84%), M.p. 114-116°C, Rf 0.27 (1:3 Hexane:EtOAc). 
1
H NMR 
(500 MHz, CDCl3) δ  7.69 (s, 1H, Triazole-H), 5.95-5.84 (m, 2H, H1/CH2=CH-CH2), 
5.48-5.27 (m, 5H, H4/H3/H2/CH2=CH-CH2), 4.63 (m, 2H, CH2=CH-CH2), 4.37 (d, 1H,  
J = 9.8 Hz, H5), 3.67 (m, 2H, CH2-CH2-CH2-OH), 2.85 (m, 2H, CH2-CH2-CH2-OH),  
2.05 (s, 6H, CH3, 2 x OAc), 1.93 (m, 2H, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc). 
Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc), 
169.5 (C=O, OAc), 169.1 (C=O, OAc), 165.7 (C=O), 130.9 (Triazole C), 147.9 (CH2-
CH=CH2), 120.0 (Triazole C), 119.9 (CH2-CH=CH2), 85.5 (C1), 74.9 (C5), 72.0 (C4), 
70.1 (C3), 69.1 (C2), 67.1 (CH2-CH=CH2), 61.6 (CH2-CH2-CH2-OH), 31.7 (CH2-CH2-
CH2-OH), 22.0 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.2 (CH3, 
OAc). LRMS (ESI): m/z 492 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C20H27N3O10Na [M + Na]
+
: 492.1594; Found 492.1580. 
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1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-galacturonic 
acid allyl ester (76) 
 To a round bottom flask containing 64 
(0.101 g, 0.261 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 1.04 mmol), 
CuOAc2.H2O (0.010 g, 0.052 mmol) and 
sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O, 
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at 
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography to yield 76 as a light yellow oil.  (0.109 g, 
80%), Rf 0.30 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H, 
Triazole-H), 5.89-5.83 (m, 3H,  CH2-CH=CH2/H1/H3), 5.56 (t, 1H, J = 10.0 Hz, H2), 
5.30 (m, 3H, CH2-CH=CH2/H4), 4.68-4.61 (m, 3H, CH2-CH=CH2/H5), 3.68 (m, 2H, 
CH2-CH2-CH2-OH), 2.85 (m, 2H, CH2-CH2-CH2-OH), 2.02 (s, 6H, CH3, 2 x OAc), 1.95 
(m, 2H, CH2-CH2-CH2-OH), 1.89 (s, 3H, CH3, OAc). Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 169.8 (OAc), 169.6 (OAc), 169.2 (OAc), 164.7 (OAc), 
147.8 (Triazole C), 130.8 (CH2-CH=CH2), 120.2 (Triazole C), 119.7 (CH2-CH=CH2), 
85.9 (C1), 74.8 (C5), 70.4 (C4), 68.1 (C3), 67.6 (C2), 66.7 (CH2-CH=CH2), 61.5 (CH2-
CH2-CH2-OH), 31.7 (CH2-CH2-CH2-OH), 21.9 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 
20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 492 [M + Na]
+ 
HRMS (ESI): 
m/z calculated for C20H27N3O10Na [M + Na]
+
: 492.1594; Found 492.1597. 
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1-(4’-Phenyl-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic acid allyl ester 
(77) 
To a round bottom flask containing 59 
(0.101 g, 0.261 mmol), pheylacetylene 
(0.115 mL, 0.107 g, 1.04 mmol), 
CuOAc2.H2O (0.010 g, 0.052 mmol) and 
sodium ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of nBuOH:H2O, 
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at 
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography (2:1 Hexane: EtOAc) to yield 75 as a light 
yellow solid (0.108 g, 85%), M.p 207-210 °C (decomp.) Rf 0.25 (2:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  8.08 (s, 1H, Triazole-H), 7.82 (d, 2H, J = 7.3 Hz, 
Ar-H2/H6), 7.34-7.44 (m, 3H, Ar-H3/H4/H5),  6.00 (d, 1H, J = 8.2 Hz, H1), 5.90 (m, 
1H, CH2=CH-CH2), 5.52 (m, 2H, CH2=CH-CH2), 5.43-5.25 (3t (overlapping), 3H, 
J = 9.0 Hz, 9.9 Hz, H4/H3/H2), 4.63 (m, 2H, CH2=CH-CH2), 4.37 (d, 1H,  J = 9.7 Hz, 
H5), 2.04 (2s, 6H, CH3, 2 x OAc), 1.87 (s, 3H, CH3, OAc). 
13
C NMR (125 MHz, 
CDCl3) δ 170.4 (C=O, OAc), 169.9 (C=O, OAc), 169.5 (C=O, OAc), 166.1 (C=O), 
131.4 (CH2-CH=CH2), 130.4 (Triazole C), 129.5 (Ar-C), 129.2 (Ar-C), 126.5 (Ar-C), 
120.6 (Triazole C), 118.6 (CH2-CH=CH2), 86.1 (C1), 75.6 (C5), 72.6 (C4), 70.5 (C3), 
69.6 (C2), 67.6 (CH2-CH=CH2), 21.2 (CH3, OAc), 21.2 (CH3, OAc), 20.8 (CH3, OAc). 
LRMS (ESI): m/z 486 [M - H]
- 
HRMS (ESI): m/z calculated for C23H24N3O9 [M - H]
-
: 
486.1514; Found 486.1512. 
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N
α
-(tert-Butoxycarbonyl)-O-(1-(4’-(2”-hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-
tri-O-acetyl-β-D-glucuronyl)-L-serine methyl ester (78) 
 To a round bottom flask containing 66 
(0.143 g, 0.261 mmol), 3-butyn-1-ol 
(0.067 mL, 0.073 g, 1.04 mmol), 
CuOAc2.H2O (0.010 g, 0.052 mmol) and 
sodium ascorbate (0.022 g, 0.110 mmol) was added a 1:1 solution of nBuOH:H2O, 
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at 
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography (1:3 Hexane: EtOAc) to yield 78 as a light 
yellow solid.  (0.100 g, 62%), M.p. 146-148°C Rf 0.20 (1:3 
Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ  7.74 (s, 1H, Triazole-H), 5.88 (d, 1H, 
J = 8.9 Hz, (H1), 5.47-5.33 (m, 4H, H4/H3/H2/NH), 4.55 (m, 2H, H
β
), 4.37 (m, 2H, 
H
α
/H5), 3.92 (m, 2H, CH2-CH2-OH), 3.75 (s, 3H, OCH3), 2.96 (t, 2H, J = 6.9 Hz, CH2-
CH2-OH), 2.10-1.89 (3s, 9H, CH3, 3 x OAc), 1.44 (s, 9H, Boc-H). Exchangeable OH 
not detected. 
13
C NMR (125 MHz, CDCl3) δ 169.7, 169.7, 169.5 (C=O, OAc), 169.1 
(C=O, COOCH3), 165.4 (C=O), 155.6 (C=O, Boc), 149.4 (Triazole C), 118.6 
(Triazole C), 88.6 (C1), 80.6(C-CH3), 74.9 (C5), 71.7 (C4), 70.2 (C3), 69.0 (C2), 66.0 
(C
β
), 62.7 (CH2-CH2-OH), 53.0 (OCH3), 52.7 (C
α
), 34.0 (CH2-CH2-OH), 28.3 (C-CH3), 
20.5 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 639 [M + Na]
+
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N
α
-(tert-Butoxycarbonyl)-O-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-
tri-O-acetyl-β-D-glucuronyl)-L-serine methyl ester (79) 
 To a round bottom flask containing 
66 (0.144 g, 0.262 mmol), 
4-pentyn-1-ol (0.097 mL, 0.087 g, 
1.04 mmol), CuOAc2.H2O (0.010 g, 
0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of 
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of 
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was 
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). 
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a 
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to 
yield 79 as a light yellow solid. (0.096 g, 58%), M.p 174-176°C, Rf 0.16 (1:3 
Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  7.64 (s, 1H, Triazole-H), 5.88 (d, 1H, 
J = 8.7 Hz, H1), 5.44 (m, 2H, H4/H3), 5.33 (m, 2H, H2/NH), 4.59 (m, 1H, H
α
), 4.52 
(dd, 1H, J = 3.7 Hz, 11.4 Hz, H
β
), 4.40 (dd, 1H, J = 2.6 Hz, 11.2 Hz, H
β
), 4.31, (d, 1H, 
J = 9.9 Hz, H5), 3.76 (s, 3H, OCH3), 3.68 (m, 2H,  CH2-CH2-CH2-OH), 2.85 (t, 2H, 
J = 7.2 Hz, CH2-CH2-CH2-OH), 2.10, 2.05 (2s, 6H, CH3, 2 x OAc), 1.95 (t, 2H, J = 6.7 
Hz, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc), 1.44 (s, 9H, Boc). Exchangeable OH 
not detected. 
13
C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc), 169.9 (C=O, OAc), 
169.7 (C=O, OAc), 169.1 (C=O, COOCH3), 165.6 (C=O), 155.5 (C=O, Boc), 148.6 
(Triazole C), 119.6 (Triazole C), 85.6 (C1), 81.1(C-CH3), 75.1 (C5), 72.1 (C4), 70.2 
(C3), 69.2 (C2), 66.0 (C
β
), 61.8 (CH2-CH2-CH2-OH), 53.1 (OCH3), 52.9 (C
α
), 31.8 
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(CH2-CH2-CH2-OH), 28.5 (C-CH3), 22.2 (CH2-CH2-CH2-OH), 20.7 (CH3, OAc), 20.7 
(CH3, OAc), 20.3 (CH3, OAc). LRMS (ESI): m/z 653 [M + Na]
+
 
 
N
α
-(tert-Butoxycarbonyl)-O-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-
tri-O-acetyl-β-D-galacturonyl)-L-serine methyl ester (80) 
 To a round bottom flask containing 
67 (0.143 g, 0.261 mmol), 
4-pentyn-1-ol (0.097 mL, 0.087 g, 
1.04 mmol), CuOAc2.H2O (0.010 g, 
0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of 
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of 
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was 
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). 
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a 
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to 
yield 76 as a light yellow oil. (0.114 g, 69%), Rf 0.22 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.78 (bs,1H, Triazole-H) 5.87 (m, 2H, H3/H4), 5.58 (t, 
1H, J = 9.9 Hz, H2), 5.47 (d, 1H, J = 7.0 Hz, NH), 5.35 (d, 1H, J = 10.3 Hz, H1), 4.67 
(m, 1H, H5), 4.59 (m, 1H, H
α
), 4.48 (d, 1H, J = 9.7 Hz, H
β
), 3.78-3.73 (m, 
5H,OCH3/CH2-CH2-CH2-OH), 2.86 (m, 2H, CH2-CH2-CH2-OH), 2.21 (s, 3H, CH3, 
OAc), 2.04 (s, 3H, CH3, OAc), 1.97 (m, 2H, CH2-CH2-CH2-OH), 1.90 (s, 3H, CH3,  
OAc), 1.46 (s, 9H, Boc-H). Exchangeable OH not detected.
  13
C NMR (125 MHz, 
CDCl3) δ 169.9 (C=O, OAc), 169.7 (C=O, OAc), 169.6 (C=O, OAc), 169.1 (C=O, 
COOCH3), 164.6 (C=O), 155.2 (C=O, Boc), 148.3 (Triazole C), 120.0 (Triazole C), 
85.9 (C1), 80.5 (C(CH3)3), 74.6 (C4), 70.2 (C5), 67.8 (C3), 67.6 (C2), 66.1 (C
β
), 61.5 
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(CH2-CH2-CH2-OH), 52.9 (OCH3), 52.7 (C
α
), 31.6 (CH2-CH2-CH2-OH), 28.2 
(C(CH3)3), 22.0 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, 
OAc). LRMS (ESI): m/z 653 [M + Na]
+
 
  
N
α
-(Acetyl)-N
ε
-(1-(4’-(2”-hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-
β-D-glucuronyl)-L-lysine methyl ester (81) 
To a round bottom flask 
containing 68 (0.138 g, 0.261 
mmol), 3-butyn-1-ol (0.067 mL, 
0.073 g, 1.04 mmol), CuOAc2.H2O 
(0.010 g, 0.052 mmol) and sodium ascorbate (0.022 g, 0.110 mmol) was added a 
1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an 
atmosphere of nitrogen at room temperature for 24 hours. Upon completion, the reaction 
mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine 
(1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo 
resulted in a residue which was purified by flash column chromatography (EtOAc) to 
yield 81 as a light yellow oil (0.110 g, 70%). Rf 0.05 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.87 (s,1H, Triazole-H) 6.71 (bs, 1H, NH), 6.55 (d, 1H, 
J = 7.5 Hz, NH),  5.94 (d, 1H, J = 9.5 Hz, H1), 5.58 (t, 1H, J = 9.5 Hz, H4), 5.49 (t, 1H, 
J = 9.5 Hz, H3), 5.37 (t, 1H, J = 9.4 Hz, H2), 4.59 (m, 1H, CH
α
), 4.23 (d, 1H, 
J = 10.0 Hz, H5), 3.93 (m, 2H, CH2-CH2-OH), 3.74 (s, 3H, OCH3), 3.34 (m, 1H, CH
ε
), 
3.11 (m, 1H, CH
ε
), 2.98 (m, 2H, CH2-CH2-OH), 2.11-2.03 (3s, 9H, CH3, 2 x OAc, 
NHAc), 1.88 (s, 3H, CH3, OAc), 1.77 (m, 1H, CH
β
), 1.68 (m, 1H, CH
β
), 1.53 (m, 2H, 
CH
δ
), 1.34 (m, 2H, CH
γ
). Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) 
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δ 173.0 (C=O, NHAc), 170.6 (C=O, OAc), 170.0 (C=O, OAc), 169.7 (C=O, OAc), 
169.2 (C=O, COOCH3), 165.6 (C=O), 148.3 (Triazole C), 120.6 (Triazole C), 85.1 
(C1), 75.3 (C5), 72.0 (C4), 70.2 (C3), 69.1 (C2), 61.2 (CH2-CH2-OH), 52.5 (OCH3), 
51.7 (CH
ε
), 38.6 (CH
α
), 32.2 (CH
δ
), 28.8 (CH
β
), 28.3 (CH2-CH2-OH), 23.1(NHAc), 
22.1 (CH
γ
), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 
622 [M + Na]
+  
HRMS (ESI): m/z calculated for C25H37N5O12Na [M + Na]
+
: 622.2336; 
Found 622.2360. 
 
N
α
-(Acetyl)-N
ε
-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-
β-D-glucuronyl)-L-lysine methyl ester (82) 
To a round bottom flask 
containing 68 (0.137 g, 
0.261 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 
1.04 mmol), CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099 
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred 
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with 
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and 
evaporation in vacuo resulted in a residue which was purified by flash column 
chromatography (EtOAc) to yield 82 as a light yellow oil. (0.101 g, 63%), Rf 0.07 
(1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.79 (s,1H, Triazole-H) 6.77 (bs, 
1H, NH), 6.47 (bs, 1H, NH),  5.99 (d, 1H, J = 9.5 Hz, H1), 5.62 (t, 1H, J = 9.5 Hz, H4), 
5.50 (t, 1H, J = 9.5 Hz, H3), 5.39 (t, 1H, J = 9.4 Hz, H2), 4.58 (m, 1H, CH
α
), 4.27 (d, 
Chapter 7: Experimental 
226 | P a g e  
 
1H, J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 3.67 (m, 2H, CH2-CH2-CH2-OH),  3.34 (m, 
1H, CH
ε
), 3.11 (m, 1H, CH
ε
), 2.86 (m, 2H, CH2-CH2-CH2-OH), 2.11-2.02 (3s, 9H, CH3, 
2 x OAc, NHAc), 1.94 (m, 2H, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc), 1.77 
(m, 1H, CH
β
), 1.68 (m, 1H, CH
β
), 1.53 (m, 2H, CH
δ
), 1.34 (m, 2H, CH
γ
). Exchangeable 
OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 173.0 (C=O, NHAc), 170.7 (C=O, 
OAc), 170.0 (C=O, OAc), 169.9 (C=O, OAc), 169.0 (C=O, COOCH3), 165.8 (C=O), 
149.8 (Triazole C), 120.1 (Triazole C), 85.1 (C1), 75.4 (C5), 72.2 (C4), 70.1 (C3), 69.2 
(C2), 61.4 (CH2-CH2-CH2-OH), 52.4 (OCH3), 51.8 (CH
ε
), 38.6 (CH
α
), 32.1 (CH
δ
), 31.6 
(CH2-CH2-CH2-OH),  28.5 (CH
β
), 28.4 (CH2- CH2-CH2-OH), 23.0 (NHAc), 22.2 (CH
γ
), 
20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 636 [M + Na]
+ 
HRMS (ESI): m/z calculated for C26H39N5O12Na [M + Na]
+
: 636.2493; Found 
636.2520. 
 
N
α
-(Acetyl)-N
ε
-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-
β-D-galacturonyl)-L-lysine methyl ester (83) 
 To a round bottom flask 
containing 69 (0.137 g, 
0.261 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 1.04 
mmol), CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099 
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred 
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with 
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and 
evaporation in vacuo resulted in a residue which was purified by flash column 
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chromatography (EtOAc) to yield 83 as a light yellow oil. (0.121 g, 75%), Rf 0.05 
(1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  7.73 (s, 1H, Triazole-H), 6.47 (t, 
1H, J = 6.2 Hz NH), 6.23 (d, 1H, J = 7.7 Hz, NH), 5.94 (m, 2H, H4/H3), 5.65 (m 1H, 
H2), 5.33 (d, 1H, J = 9.9 Hz, H1), 4.57-4.51, (m, 2H, H5/H
α
), 3.72 (s, 3H, OCH3), 3.68 
(m, 2H, CH2-CH2-CH2-OH), 3.23 (m, 2H, H
ε
), 2.87 (m, 2H, CH2-CH2-CH2-OH), 2.10 
(s, 3H, CH3, NHAc), 2.01 (s, 6H, CH3, 2 x OAc), 1.95 (m, 2H, CH2-CH2-CH2-OH) 1.88 
(s, 3H, CH3, OAc), 1.81 (m, 1H, CH
β
), 1.68 (m, 1H, CH
β
), 1.50 (m, 2H, CH
δ
), 1.32 (m, 
2H, CH
γ
). Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 172.9 (C=O, 
NHAc),  170.3 (C=O, OAc), 169.7 (C=O, OAc), 169.2 (C=O, OAc), 169.1 (C=O, 
COOCH3), 164.9 (C=O), 148.4 (Triazole-C), 119.9 (Triazole-C), 85.7 (C1), 76.1 (C4), 
70.8 (C5), 67.7 (C2),  67.5 (C3),61.5 (CH2-CH2-CH2-OH),  52.4 (OCH3), 51.9 (CH
ε
), 
38.7 (CH
α
), 31.9 (CH2-CH2-CH2-OH), 31.7 (CH
δ
), 29.0 (CH
β
), 23.0 (CH3 NHAc), 22.5 
(CH
γ
), 22.0 (CH2-CH2-CH2-OH),  20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, 
OAc). LRMS (ESI): m/z 636 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C26H39N5O12Na [M + Na]
+
: 636.2493; Found 636.2493. 
 
N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-
glucuronoyl)-L-leucine methyl ester (84) 
 To a round bottom flask containing 70 (0.123 g, 
0.261 mmol), 4-pentyn-1-ol (0.097 mL, 0.087 g, 
1.04 mmol), CuOAc2.H2O (0.010 g, 
0.052 mmol) and sodium ascorbate (0.020 g, 
0.099 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution 
stirred vigorously under an atmosphere of nitrogen at room temperature for 24 hours. 
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Upon completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted 
with H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, 
and evaporation in vacuo resulted in a residue which was purified by flash column 
chromatography (1:2 Hexane: EtOAc) to yield 84 as a light yellow solid. (0.116 g, 
80%), M.p. 132-133°C, Rf 0.10 (1:2 Hexane:EtOAc.). 
1
H NMR (500 MHz, CD3OD) δ  
8.10 (s, 1H, triazole-H), 6.16 (d, 1H, J = 8.9 Hz, H1), 5.62-5.44 (2t (overlapping), 2H, 
J = 9.2 Hz, H4/H3), 5.39 (t, 1H, J = 9.7 Hz, H2), 4.46 (m, 2H, H5/H
α
), 3.67 (s, 3H, 
OCH3), 3.57 (m, 2H, CH2-CH2-CH2-OH), 2.79 (m, 2H, CH2-CH2-CH2-OH, 2.05 (s, 3H, 
CH3, OAc), 2.00 (2s, 6H, CH3, 2 x OAc), 1.87 (m, 2H, CH2-CH2-CH2-OH), 1.65-1.59 
(m, 3H, H
β
/H
γ
), 0.90 (m, 6H, 2 x CH3, H
δ
). Exchangeable OH not detected. 
13
C NMR 
(125 MHz, CD3OD) δ 172.7 (C=O, COOCH3), 170.3 (C=O, OAc), 169.8 (C=O, OAc), 
169.1 (C=O, OAc), 167.0 (C=O), 148.4 (Triazole C), 121.3 (Triazole C), 5.3 (C1), 75.4 
(C5), 72.6 (C4), 70.5 (C3), 69.4 (C2), 60.7 (CH2-CH2-CH2-OH),  51.6 (C
α
), 50.9 
(OCH3), 40.1 (C
β
), 31.9 (CH2-CH2-CH2-OH) 24.7 (C
γ
), 22.1 (C
δ
), 21.5 (CH2-CH2-CH2-
OH),  20.7 (C
δ’
),  19.5 (CH3, OAc), 19.3 (CH3, OAc), 18.9 (CH3, OAc). LRMS (ESI): 
m/z 579 [M + Na]
+
,
 
HRMS (ESI): m/z calculated for C24H36N4O11Na [M + Na]
+
: 
579.2278; Found 579.2271. 
 
N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-
galacturonoyl)-L-leucine methyl ester (85) 
To a round bottom flask containing 71 
(0.122 g, 0.261 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 1.04 mmol), CuOAc2.H2O 
(0.010 g, 0.052 mmol) and sodium ascorbate 
(0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the 
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solution stirred vigorously under an atmosphere of nitrogen at room temperature for 24 
hours. Upon completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and 
extracted with H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the 
organic phase, and evaporation in vacuo resulted in a residue which was purified by 
flash column chromatography (1:2 Hexane: EtOAc) to yield 85 as a light yellow oil. 
(0.109 g, 75%), Rf 0.12 (1:2 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.68 (s, 
1H, Triazole-H), 6.72 (d, 1H, J = 8.4 Hz, NH), 5.95 (m, 2H, H4/H3), 5.65 (t, 1H, J = 9.7 
Hz, H2), 5.36 (d, 1H, J = 10.1 Hz, H1), 4.62 (m, 1H, H
α
), 4.59 (m, 1H, H5), 3.76 (t, 2H, 
J = 6.0 Hz, CH2-CH2-CH2-OH), 3.69 (s, 3H, OCH3), 2.88 (t, 2H, J = 7.1 Hz, CH2-CH2-
CH2-OH), 2.32 (t, 2H, J = 2.1 Hz, 7.3 Hz, CH2-CH2-CH2-OH) 2.13 – 1.88 (3s, 9H, CH3, 
3 x OAc), 1.65 – 1.55 (m, 3H, H
β
/ H
γ
), 0.94 (m, 6H, 2CH3, H
δ
). Exchangeable OH not 
detected. 
13
C NMR (125 MHz, CDCl3) δ  172.7 (C=O, COOCH3), 169.6 (C=O, OAc), 
169.1(C=O, OAc), 169.1(C=O, OAc), 164.5 (C=O), 148.4 (Triazole-C), 119.9 
(Triazole-C) 85.7 (C1), 76.2 (C4), 70.7 (C5), 67.7 (C2), 67.5 (C3), 61.5 (CH2-CH2-CH2-
OH), 52.5 (OCH3), 50.5 (C
α
), 41.1 (C
β
), 31.7 (CH2-CH2-CH2-OH), 24.9 (C
γ
), 22.8 (C
δ
), 
22.0 (C
δ’
) 21.7 (CH2-CH2-CH2-OH), 20.5 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, 
OAc). LRMS (ESI): m/z 579 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C24H36N4O11Na [M + Na]
+
: 579.2278; Found 579.2274. 
 
N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-
glucuronoyl)-L-methionine methyl ester (86) 
To a round bottom flask containing 72 
(0.129 g, 0.261 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 1.04 mmol), 
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CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was 
added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred vigorously 
under an atmosphere of nitrogen at room temperature for 24 hours. Upon completion, 
the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), 
then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in 
vacuo resulted in a residue which was purified by flash column chromatography (1:3 
Hexane:EtOAc.) to yield 86 as a white solid. (0.128 g, 85%), M.p. 132-133°C Rf 0.10 
(1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H, Triazole-H), 7.06 (d, 
1H, J = 7.6 Hz, NH), 5.94 (d, 1H, J = 9.5 Hz, H1), 5.55 (t, 1H, J = 9.7 Hz, H3), 5.48 (t, 
1H, J = 9.7 Hz, H4), 5.35 (t, 1H, J = 9.7 Hz, H2), 4.64 (m, 1H, H
α
), 4.23 (d, 1H, 
J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 3.68 (t, 2H, J = 7.2 Hz, CH2CH2CH2OH), 2.86 (t, 
2H, J = 7.3 Hz, CH2CH2CH2OH), 2.51 (t, 1H, J = 7.2 Hz, H
γ
), 2.19-2.15 (m, 2H, H
β
), 
2.09-2.04 (2s, 9H, CH3, 3 x OAc), 2.04-1.99, (m, 2H, CH2CH2CH2OH), 1.89 (s, 3H, 
SCH3). Exchangeable OH not detected. 
13
C NMR (125 MHz, CD3OD) δ 173.1 
(COOCH3), 171.4 (C=O, OAc), 171.0 (C=O, OAc), 170.2 (C=O, OAc), 168.2 (C=O), 
149.9 (Triazole-C), 122.6 (Triazole-C), 86.3 (C1), 76.4 (C5), 73.6 (C2), 71.6 (C4), 70.5 
(C3), 61.8 (CH2-CH2-CH2-OH), 53.0 (C
α
), 52.6 (-OCH3), 33.0 (C
β
), (CH2-CH2-CH2-
OH) 31.0 (C
γ
), 22.7 (CH2-CH2-CH2-OH), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.1 
(CH3, OAc), 15.2 (SCH3). LRMS (ESI): m/z 597 [M + Na]
+ 
HRMS (ESI): 
m/z calculated for C23H34N4O11SNa [M + Na]
+
: 597.1842; Found 597.1857. 
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N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-
glucuronoyl)-L-glutamine tert-butyl ester (87) 
To a round bottom flask containing 73 
(0.137 g, 0.260 mmol), 4-pentyn-1-ol 
(0.097 mL, 0.087 g, 1.04 mmol), 
CuOAc2.H2O (0.010 g, 0.052 mmol) and 
sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O, 
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at 
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying 
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was 
purified by flash column chromatography (EtOAc) to yield 76 as a light yellow foam. 
(0.101 g, 63%), Rf 0.05 (1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CD3OD) δ 8.4 (d, 
1H, J = 7.8 Hz, NH), 8.15 (s, 1H, Triazole-H), 6.16 (d, 1H, J = 8.4 Hz, H1), 5.58 (m, 
2H, H3/H4), 5.37 (t, 1H,  J = 8.9 Hz, H2), 4.45 (d, 1H, J = 10.0 Hz, H5), 4.27 (m, 1H, 
H
α
), 3.58 (m, 2H, CH2-CH2-CH2-OH), 2.79 (m, 2H, CH2-CH2-CH2-OH), 2.34-2.26 (m, 
2H, H
γ
), 2.16-1.93 (m, 2H, H
β
), 2.05, 2.00 (s, 6H, 2x OAc), 1.89-1.86 (m, 2H, CH2-
CH2-CH2-OH),1.83 (s, 3H, OAc), 1.43 (s, 9H, OtBu). Exchangeable OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 177.6 (CONH2), 171.7 (C=O, OAc), 171.4 (C=O, 
OAc), 171.4 (C=O, OAc), 170.4 (COOtBu), 168.3 (C=O), 149.6 (Triazole-C), 
122.6 (Triazole C), 86.2 (C1), 83.3 (C(CH3)3), 76.3 (C5), 73.4 (C2), 71.7 (C4), 70.6 
(C3), 61.8 (CH2-CH2-CH2-OH), 54.0 (C
α
), 33.0 (CH2-CH2-CH2-OH) 33.0 (C
γ
), 31.3 
(C
β
), 28.2 (C(CH3)3), 22.6 (CH2-CH2-CH2=OH), 20.8 (CH3, OAc), 20.5 (CH3, OAc), 
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20.1 (CH3, OAc).LRMS (ESI): m/z 636 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C26H39N5O12Na [M + Na]
+
: 636.2493; Found 636.2501 
 
N
α
-Acetyl-N
ε
-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-lysine-L-proline-L-
valinamide (88) 
60 (0.041 g, 0.119 mmol), 
Ac.Lys.Pro.Val.NH2.HCl (0.050 
g, 0.119 mmol) and HBTU 
(0.068 g, 0.178 mmol) were 
dissolved in DMF (1 mL), and the solution was cooled to 0°C. DIPEA (0.228 mL, 0.017 
g, 0.131 mmol) was added dropwise to the solution, and the reaction mixture was 
allowed to warm to room temperature and stir for 24 hours. Upon completion, the 
reaction mixture was diluted with EtOAc (5 mL), and extracted with H2O (2 x 1 mL). 
The organic phase was dried and evaporated, with the following residue purified by 
flash column chromatography (EtOAc) to produce 88 as a light yellow foam (0.049 g, 
53%), Rf 0.29 (EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  6.89 (m, 2H, NH2), 6.83 (m, 
1H, NH), 6.44 (m, 1H, NH), 5.98 (m, 1H, NH), 5.27 (m, 2H, H3/H4), 4.97 (m, 1H, H2), 
4.78 (d, 1H, J = 8.8 Hz, H1), 4.75 (m, 1H, C
α
Pro), 4.47 (m, 1H, C
α
Lys), 4.31 (t, 1H, 
J = 6.1 Hz, C
α
Val), 4.04 (m, 1H, H5), 3.80 (m, 1H, C
δ
Pro), 3.67 (m, 1H, C
δ’
Pro), 3.38 
(m, 1H, C
ε
Lys), 3.05 (m, 1H, C
ε’
Lys), 2.16 (m, 1H, H
β
Val), 2.11 (m, 2H, H
β
Lys), 2.07-
1.99 (4s, 12H, CH3, 3 x Ac/NHAc), 1.72 (m, 2H, H
β
Pro), 1.50 (m, 2H, H
δ
Lys), 1.38 (m, 
2H, H
γ
Pro), 1.25 (m, 2H, H
γ
Lys), 0.95 (2q, 6H, J = 6.5 Hz, 2 x CH3). 
13
C NMR 
(125 MHz, CDCl3) δ 173.9 (C=O, CONH2), 172.5 (C=O, NHAc), 171.8 (C=O, CONH), 
170.6 (C=O, CONH), 170.1 (C=O, OAc), 170.1 (C=O, OAc), 169.6 (C=O, OAc), 166.4 
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(C=O), 88.3 (C1), 75.2 (C5), 72.2 (C4), 70.7 (C2), 69.6 (C3), 61.0 (C
α
Lys), 58.4 
(C
α
Val), 50.9 (C
α
Pro), 47.9 (C
ε
Lys), 38.9 (C
δ
Pro), 32.2 (C
β
Pro), 31.2 (C
β
Val), 29.5 
(C
γ
Lys), 28.7 (C
δ
Lys), 25.5 (C
β
Lys), 23.3 (CH3, NHAc), 22.1 (C
γ
Pro), 20.9 (CH3, 
OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 19.5 (C
γ
Val), 18.0 (C
γ
Val). LRMS (ESI): 
m/z 733 [M + Na]
+ 
 
7.3 Chapter 3 Experimental Data: 
1,2-Isopropylidene-α-D-glucofuranose (94)  
According to the method of Monrad and Madsen,
190
 a round 
bottom flask containing 1,2:5,6-di-isoproylidene-α-D-
glucofuranose (93, 5.00 g, 19.2 mmol) was added a solution of 
70% acetic acid (80 mL), and the reaction was stirred at room 
temperature for 24 hours. Upon completion, the solvent was evaporated in vacuo, with 
addition of water (50 mL) and azeotropic distillation resulting in 94 as a flaky white 
solid. (3.82 g, 90%), M.p. 157-160°C (Lit. 157-160°C )
190
  
1
H NMR (500 MHz, D2O) δ 
5.90 (d, 1H, J = 3.7 Hz, H1), 4.58 (d, 1H,  J = 3.7 Hz, H3), 4.20 (d, 1H,  J = 2.0  Hz, 
H2), 3.98 (dd, 1H, J = 2.5, 9.0 Hz, H4), 3.80 (m, 1H, H5), 3.70 (ddd, 1H J = 1.3 Hz, 2.7 
Hz, 12.0 Hz, H6), 3.53 (ddd, 1H, J = 1.3 Hz, 6.0 Hz, 12.1 Hz, H6’), 1.41 (s, 3H, CH3), 
1.26 (s, 3H, CH3). 
13
C NMR (125 MHz, D2O) δ 113.5 (CH(CH3)2), 105.6 (C1), 85.3 
(C4), 80.6 (C2), 74.5 (C3), 69.3 (C5), 64.4 (C6), 26.4 (CH3), 26.0 (CH3). LRMS (ESI): 
m/z 255 [M + Cl]
- 
HRMS (ESI): m/z calculated for C9H16O6Cl [M + Cl]
-
: 255.0635; 
Found 255.0625. 
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6-p-Toluenesulfonyl-1,2-isopropylidene-α-D-glucofuranose (95) 
To a round bottom flask containing 94 (3.00 g, 13.62 mmol) 
was added pyridine (30 mL), and the mixture was cooled to 
0°C. Under stirring, p-toluenesulfonyl chloride (3.12 g, 
16.34 mmol) was added to the solution portionwise, with the 
reaction mixture allowed to warm to room temperature and stir for an additional 18 
hours. Upon completion, the reaction mixture was evaporated in vacuo. The resulting 
slurry was subject to recrystallization from ethanol, to produce 95 as an amorphous 
white solid. (3.77 g, 73%), Rf 0.29 (1:1 Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ 
7.79 (d, 2H, J = 7.9 Hz, Ar-H), 7.33 (d, 2H, J = 7.9 Hz, Ar-H),  5.88 (m, 1H, H1), 4.50 
(m, 1H, H2), 4.34 (m, 1H, H3), 4.28 (d, 1H, J =  9.5 Hz, H4), 4.19 (m, 1H, H5), 4.11 
(m, 1H, H6), 4.01 (m, 1H, H6’), 2.43 (s, 3H, Ar-CH3),  1.45 (s, 3H, CH3), 1.29 (s, 3H, 
CH3). 
13
C NMR (125 MHz, CDCl3) δ 148.9 (Ar-C1), 145.1 (Ar-C4), 130.0 
(Ar-C3/C5), 128.0 (Ar-C2/C6), 111.9 (CH(CH3)2), 105.1 (C1), 85.1 (C4), 79.3 (C2), 
74.7 (C3), 72.4 (C5), 67.6 (C6), 26.8 (CH3), 26.2 (CH3), 21.6 (Ar-CH3). 
LRMS (ESI): m/z 409 [M + Cl]
-
 
 
6-Azido-6-deoxy-1,2-isopropylidene-α-D-glucofuranose (96) 
To a round bottom flask containing 95 (3.00 g, 8.01 mmol), was 
added NaN3 (2.08 g, 32.04 mmol). The solids suspended in 
DMF (30 mL), and stirred under an argon atmosphere at 40°C 
for 72 hours. Upon completion, the reaction mixture was diluted 
with ethyl acetate (50 mL), and washed with water (2 x 25 mL). Subsequently, the 
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aqueous phases was washed with ethyl acetate (3 x 50 mL), and the combined organic 
fractions were dried (MgSO4) and evaporated in vacuo. Flash column chromatography 
(2:1 Hexane: EtOAc) of the mixture yielded the product 96 as a fine white solid,  
(1.46 g, 74%), M.p. 98-99°C (Lit. 104°C)
250
 Rf 0.45 (1:1 Hexane:EtOAc.). 
1
H NMR 
(500 MHz, CDCl3) δ 5.94 (d, 1H, J = 7.6 Hz, H1), 4.53 (d, 1H,  J = 3.7 Hz, H3), 4.36 
(m, 1H, H2), 4.15 (m, 1H, H5), 3.80 (dd, 1H, J = 2.3 Hz, 6.6 Hz, H4), 3.59-3.54 (m, 
2H, H6/H6’), 3.30 (bs, 1H, OH), 3.13 (bs, 1H, OH), 1.49 (s, 3H, CH3), 1.32 (s, 3H, 
CH3). 
13
C NMR (125 MHz, CDCl3) δ 112.0 (CH(CH3)2), 104.9 (C1), 85.2 (C4), 79.7 
(C2), 75.3 (C3), 6943 (C5), 54.0 (C6), 26.8 (CH3), 26.2 (CH3). LRMS (ESI): m/z 280 
[M + Cl]
- 
HRMS (ESI): m/z calculated for C9H15N3O5Cl [M + Cl]
-
: 280.0700; 
Found 280.0710. 
 
6-Azido-6-deoxy-1-amino-N-(2’,2’-diethoxycarbonylvinyl)-β-D-glucose (101)  
 In a round bottom flask, 96 (1.00 g, 4.08 mmol) was 
dissolved in 80% acetic acid (20 mL). The mixture 
was heated to 80°C, and stirred for 18 hours. After 
this period, the reaction mixture was cooled to room temperature, and the solvent 
removed in vacuo using water as an azeotrope. The resulting oil was then re-dissolved 
in a saturated solution of NH4HCO3 (50 mL), and stirred at 40°C for a further 4 days. 
Additional solid NH4HCO3 (2 g) was added to the reaction mixture every 24 hours to 
maintain saturation. Upon completion monitored using LR-ESIMS, the reaction mixture 
was evaporated to half volume at 20°C and then subject to lyophilisation overnight. The 
resultant foam was resuspended in MeOH (10 mL), and diethyl 
ethoxymethylenemalonate (1.24 mL, 1.32 g, 6.12 mmol) was added and allowed to stir 
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at room temperature for 48 hours. Upon completion, the reaction mixture was 
evaporated to dryness, and the residue subject to column chromatography (45:5:3 
EtOAc/EtOH/H2O), producing 101 as a colourless oil. (0.809 g, 53%), Rf 0.54 (45:5:3 
EtOAc/EtOH/H2O). 
1
H NMR (500 MHz, CD3OD) δ 9.40 (m, 1H, NH), 8.22 (d, 1H, 
J = 13.7 Hz, CH=C), 4.57 (t, 1H, J = 8.3 Hz, H1), 4.28-4.10 (2q, 4H, J = 7.0 Hz, 2 x 
CH2CH3), 3.62 (m, 1H, H3), 3.57 (m, 1H, H4), 3.49-3.31 (m, 4H, H6/H6’/H2/H5), 1.28 
(t, 6H, J = 7.1 Hz, CH2CH3). 
13
C NMR (125 MHz, CDCl3) δ 168.1 (C=O), 166.3 
(C=O), 158.5 (CH=C), 91.6 (CH=C), 88.2 (C1), 77.3 (C4), 76.7 (C5), 73.2 (C2), 70.4 
(C3), 59.7 (C6), 51.1 (CH2CH3), 13.3 (CH2CH3). LRMS (ESI): m/z 409 [M + Cl]
- 
HRMS (ESI): m/z calculated for C14H22N4O8Cl [M + Cl]
-
: 409.1126; Found 409.1120. 
Data gained in the production of this compound was not consistent with that published 
elsewhere.
187 
 
6-Azido-6-deoxy-1-amino-N-(2’,2’-diethoxycarbonylvinyl)-2,3,4-tri-O-acetyl-β-D-
glucose (102) 
To a round bottom flask containing 101 (0.400 g, 
1.07 mmol), was added acetic anhydride (10 mL) 
and pyridine (10 mL), and the reaction mixture was 
stirred at room temperature for 2 hours. Upon completion, the reaction mixture was 
evaporated to dryness, with flash column chromatography (2:1 Hexane: EtOAc) of the 
crude mixture producing 102 as a white solid. (0.491 g, 92%), M.p. 88-91°C, Rf 0.75 
(1:1 Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ 9.22 (m, 1H, NH), 7.94 (d, 1H, J = 
13.7 Hz, CH=C), 5.29 (t, 1H, J = 9.3 Hz, H3), 5.06 (t, 1H, J = 9.5 Hz, H2), 5.04 (t, 1H, 
J = 9.5 Hz, H4), 4.59 (t, 1H, J = 8.5 Hz, H1) 4.26-4.18 (2q, 4H, J = 7.1 Hz, 2 x 
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CH2CH3),  3.77 (m, 1H, H5), 3.38 (m, 2H, H6/H6’), 2.08-2.03 (3s, 9H, CH3, 3 x OAc), 
1.30 (t, 6H, J = 7.1 Hz, CH2CH3). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 
169.6 (C=O, OAc), 169.4 (C=O, OAc), 167.6 (C=O), 165.5 (C=O), 157.2 (CH=C), 95.2 
(CH=C), 86.9 (C1), 75.0 (C5), 72.4 (C3), 70.5 (C2), 69.2 (C4), 60.4 (CH2CH3), 60.2 
(CH2CH3), 50.8 (C6), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc),  14.4 
(CH2CH3), 14.2 (CH2CH3).   LRMS (ESI): m/z 523 [M + Na]
+ 
HRMS (ESI): 
m/z calculated for C20H28N4O11Na [M + Na]
+
: 523.1652; Found 523.1663. 
 
6-Azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucose hydrobromide (103) 
In a round bottom flask, 100 (0.300 g 0.60 mmol) was 
dissolved in CH2Cl2 (5 mL) and cooled to 0°C. Br2 (0.060 mL, 
0.186 g, 1.16 mmol) was then added dropwise, followed by 
the addition of H2O (0.20 mL) and the reaction mixture was stirred at 0°C for 1 hour. 
Upon completion, the reaction mixture was evaporated in vacuo, resulting in an orange 
residue. Subsequent trituration and storage of the residue at -20°C overnight in diethyl 
ether (5 mL) resulted in the isolation of 103 as an orange solid. (0.181 g, 73%), 
1
H  NMR (500 MHz, CD3OD) δ 5.36 (t,1H, J = 9.5 Hz, H3), 5.12 (m, 2H, H2/H4) 5.02 
(m, 1H, H1), 4.09 (m,1H, H5), 3.60 (m, 1H, H6), 3.42 (m, 1H, H6’), 2.09-1.98 (3s, 9H, 
3 x OAc). 
13
C NMR (125 MHz, CD3OD) δ 171.4 (C=O, OAc), 171.3 (C=O, OAc), 
171.1 (C=O, OAc), 80.5 (C1), 76.3 (C5), 73.6 (C3), 71.3 (C2), 69.5 (C4), 51.6 (C6), 
20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 331 
[M + H-Br]
+
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N-(tert-Butoxycarbonyl)-4-benzyl-L-aspartic acid, methyl ester (106) 
To a round bottom flask containing BocAsp.(OBn).OH (104, 
0.648 g, 2.00 mmol) and THF (10 mL) was added K2CO3 
(1.106 g, 8.00 mmol), and the solution was allowed to cool to 
0°C under stirring. MeI (0.182 mL, 0.415 g, 3.00 mmol) was added dropwise to the 
solution, and stirred for 30 minutes at 0°C, before warming to room temperature. After 
18 hours, the reaction was diluted with THF (10 mL), and washed with sat. NaHCO3 
solution (10 mL) and brine (10 mL). The organic phases were dried (MgSO4) and 
evaporated in vacuo, with recrystallization from EtOH/Hexanes producing 106 as a 
white solid. (0.576 g, 85%), M.p 64-66°C. (Lit. 61-62°C)
251
 Rf 0.90 
(1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  7.35 (m, 5H, Ar-H),  5.49 (d, 1H, 
J = 7.6 Hz, NH), 5.13 (s, 2H, CH2Ph), 4.59 (m, 1H, H
α
), 3.70(s, 3H, OCH3), 3.03 (dd, 
1H, J = 3.6 Hz, 16.7 Hz,  H
β
),2.86 (dd, 1H, J = 3.6 Hz, 16.7 Hz,  H
β’
), 1.44 (s, 9 H, 
Boc-H). 
13
C NMR (125 MHz, CDCl3) δ 171.7 (C=O, OBn), 171.1 (C=O, OBn), 155.8 
(C=O, Boc), 135.6 (Ar-C1), 128.8 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C),  80.4 (CCH3), 
67.0 (CH2Ph), 52.9 (C
α
), 50.2 (OCH3), 37.1 (C
β
), 28.5 (CCH3). LRMS (ESI): m/z 360 
[M + Na]
+ 
HRMS (ESI): m/z calculated for C17H23NO6Na [M + Na]
+
: 360.1423; Found 
360.1430. 
 
N-(tert-Butoxycarbonyl)-5-benzyl-L-glutamic acid, methyl ester (107) 
To a round bottom flask containing BocGlu.(OBn).OH 
(105, 0.671 g, 1.99 mmol) and THF (10 mL) was added 
K2CO3 (1.106 g, 8.00 mmol), and the solution was 
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allowed to cool to 0°C under stirring. MeI (0.182 mL, 0.415 g, 3.00 mmol) was added 
dropwise to the solution, and stirred for 30 minutes at 0°C, before warming to room 
temperature. After 18 hours, the reaction was diluted with THF (10 mL), and washed 
with sat. NaHCO3 solution (10 mL) and brine (10 mL). The organic phases were dried 
(MgSO4) and evaporated in vacuo, with recrystallization from EtOH/Hexanes producing 
107 as a white solid. (0.644 g, 92%), M.p. 42-45°C (Lit 38-41°C),
252
 Rf 0.85 (1:1 
Hexane:EtOAc.). 
1
H NMR (500 MHz, DMSO-d6) δ  7.39 - 7.28 (m, 5H, Ar-H), 5.09 (s, 
2H, CH2Ph), 4.02 - 3.90 (m, 1H, Hα), 3.62 (s, 3H, OCH3), 2.47 - 2.42 (m, 2H, Hγ), 2.02 
- 1.94 (m, 1H, Hβ), 1.86 - 1.76 (m, 1H, Hβ), 1.37 (s, 9 H, Boc-H). 
13
C NMR (125 MHz, 
DMSO-d6) δ 172.6 (C=O), 172.1 (C=O), 155.5 (C=O, Boc), 136.2 (Ar-C1), 128.4 (Ar-
C), 128.0 (Ar-C), 127.9 (Ar-C), 78.3 (CCH3), 65.5 (CH2Ph), 52.6 (Cα), 51.8 (OCH3), 
29.9 (Cγ), 28.1 (Cβ), 25.9 (CCH3). LRMS (ESI): m/z 374 [M + Na]
+ 
HRMS (ESI): 
m/z calculated for C18H25NO6Na [M + Na]
+
: 374.1580; Found 374.1572. 
 
N-(tert-Butoxycarbonyl)- L-aspartic acid, methyl ester (108) 
To a round bottom flask containing 106 (0.400 g, 1.19 mmol) 
dissolved in THF (10 mL), 10% palladium on carbon (0.100 g) 
was added. The reaction mixture was placed under an 
atmosphere of H2 gas, and stirred for 18 hours. Upon completion, the H2 atmosphere 
was removed, and the reaction mixture was filtered through a pad of Celite, with the pad 
washed with EtOAc (4 x 20 mL). Subsequent evaporation to dryness of the filtrate 
resulted in the isolation of 108 as an off-white solid. (0.248 g, 84%), M.p. 80-82°C 
(Lit. 79-81°C).
253
 
1
H NMR (500 MHz, CD3OD) δ 4.48 (m, 1H, H
α
), 3.71 (s, 3H, 
OCH3), 2.80-2.72 (m, 1H, H
β
), 1.43 (s, 9H, Boc-H). 
13
C NMR (125 MHz, CD3OD) δ 
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172.7 (C=O, COOH), 172.1 (C=O, COOCH3), 156.3 (C=O, NHBoc), 79.4 (C(CH3)3), 
51.5 (C
α
), 50.1 (OCH3), 30.1 (C
γ
), 35.8 (C
β
), 27.2 (C(CH3)3). LRMS (ESI): m/z 270 [M 
+ Na]
+ 
HRMS (ESI): m/z calculated for C10H17NO6Na [M + Na]
+
: 270.0954; Found 
270.0962. 
 
N-(tert-Butoxycarbonyl)- L-glutamic acid, methyl ester (109) 
 To a round bottom flask containing 107 (0.450 g, 
1.28 mmol) dissolved in THF (10 mL), 10% Palladium 
on carbon (0.120 g) was added. The reaction mixture 
was then subject to an atmosphere of H2 gas, and stirred for 18 hours. Upon completion, 
the H2 atmosphere was removed, and the reaction mixture was filtered through a pad of 
Celite, with the pad washed with EtOAc (4 x 20 mL). Subsequent evaporation to 
dryness of the filtrate resulted in the isolation of 109 as an off-white solid. (0.288 g, 
86%),  M.p. 41-42°C (Lit. 42-45°C).
252
 
1
H NMR (500 MHz, CDCl3) δ 5.17 (d, 1H, 
J = 7.1 Hz, NH), 4.36 (m, 1H, H
α
), 3.74 (s, 3H, OCH3), 2.52-2.35 (m, 1H, H
γ
), 2.21-
2.15 (m, 1H, H
β
), 2.01-1.90 (m, 1H, H
β’
), 1.43 (s, 9H, Boc-H). 
13
C NMR (125 MHz, 
CDCl3) δ 177.7 (C=O, COOH), 173.8 (C=O, COOCH3), 155.8 (C=O, NHBoc), 80.3 
(C(CH3)3), 52.8 (C
α
), 52.5 (OCH3), 30.1 (C
γ
), 28.3 (C(CH3)3), 27.7 (C
β
). LRMS (ESI): 
m/z 284 [M + Na]
+ 
HRMS (ESI): m/z calculated for C11H19NO6Na [M + Na]
+
: 
284.1110; Found 284.1124.  
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N
α
-(tert-Butoxycarbonyl)-N
γ
-(6-azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-
glucosyl)-L-aspartic acid, methyl ester (110) 
103 (0.070 g, 0.17 mmol), Boc.Asp.OMe (108, 
0.063 g, 0.254 mmol) and HBTU (0.0965 g, 
0.254 mmol) were dissolved in DMF (1 mL), 
and the solution was cooled to 0°C. DIPEA 
(0.060 mL, 0.080 g, 0.625 mmol) was added dropwise to the solution, and the reaction 
mixture was allowed to warm to room temperature and stirred for 24 hours. Upon 
completion, the reaction mixture was filtered, and the filtrate was diluted with EtOAc 
(10 mL), and extracted with H2O (2 x 1 mL). The organic phase was dried and 
evaporated, and the resulting residue purified by flash column chromatography 
(2:1 Hexane:EtOAc) to produce 110 as a clear oil. (0.066 g, 70%), Rf 0.30 
(1:1 Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ 6.54 (d, 1H, J = 9.0 Hz, NH), 5.68 
(d, 1H, J =  9.0 Hz, NHBoc), 5.25 (d/t, 2H, J = 9.9 Hz, 9.0 Hz, H1/H3), 5.05 (t, 1H, J = 
9.6 Hz, H4), 4.93 (t, 1H, J = 9.0 Hz, H2), 4.56 (m, 1H, H
α
), 3.78 (m, 1H, H5), 3.74 (s, 
3H, OCH3), 3.40 (dd, 1H, J = 5.4 Hz, 12.4 Hz, H6), 3.31 (dd, 1H, J = 2.1 Hz, 12.4 Hz, 
H6’), 2.87 (dd, 1H, J = 4.2 Hz, 16.5 Hz, H
β
), 2.72 (dd, 1H, J = 4.2 Hz, 16.5 Hz, H
β’
), 
2.09-2.02 (3s, 9H, CH3, 3 x OAc), 1.44 (s, 9H, Boc-H). 
13
C NMR (125 MHz, CDCl3) δ 
171.7 (C=O, CONH2), 171.2 (C=O, COOCH3), 170.9 (C=O, OAc), 169.9 (C=O, OAc), 
169.6 (C=O, OAc), 155.6 (C=O, Boc), 80.2 (C1), 77.9 (C(CH3)3), 74.6 (C5), 72.5 (C3), 
70.4 (C2), 69.2 (C4), 52.7 (C
α
), 50.6 (C6), 50.0 (OCH3) 38.0 (C
β
), 28.3 (C(CH3)3), 20.6 
(CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3, OAc).  LRMS (ESI): m/z 582 [M + Na]
+ 
HRMS (ESI): m/z calculated for C22H33N5O12Na [M + Na]
+
: 582.2023; Found 
582.2029.  
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N
α
-(tert-Butoxycarbonyl)-N
δ
-(6-azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-
glucosyl)-L-glutamic acid, methyl ester (111) 
103 (0.071 g, 0.17 mmol), Boc.Glu.OMe 
(109, 0.067 g, 0.254 mmol) and HBTU 
(0.067 g, 0.255 mmol) were dissolved in 
DMF (1 mL), and the solution was cooled to 
0°C. DIPEA (0.060 mL, 0.080 g, 0.625 mmol) was added dropwise to the solution, and 
the reaction mixture was allowed to warm to room temperature and stirred for 24 hours. 
Upon completion, the reaction mixture was filtered, and the filtrate was diluted with 
EtOAc (10 mL), and extracted with H2O (2 x 1 mL). The organic phase was dried and 
evaporated, with the following residue purified by flash column chromatography 
(2:1 Hexane: EtOAc) to produce 111 as a clear oil. (0.061 g, 62%), Rf 0.35 
(1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 6.85 (d, 1H, J = 9.0 Hz, NH), 5.28 
(m, 3H, NHBoc, H1/H3), 5.06 (t, 1H, J = 9.6 Hz, H4), 4.94 (t, 1H, J = 9.0 Hz, H2), 4.26 
(m, 1H, H
α
), 3.81 (m, 1H, H5), 3.75 (s, 3H, OCH3), 3.43 (dd, 1H, J = 2.0 Hz, 13.0 Hz, 
H6), 3.29 (dd, 1H, J = 4.5 Hz, 13.0 Hz, H6’), 2.31 (m, 2H, H
γ
), 2.17 (m, 1H, H
β
), 2.04-
2.01 (3s, 9H, CH3, 3 x OAc), 1.88 (m, 1H, H
β
), 1.44 (s, 9H, Boc-H). 
13
C NMR 
(125 MHz, CDCl3) δ 172.7 (C=O, CONH2), 172.5 (C=O, COOCH3), 170.7 (C=O, 
OAc), 170.0 (C=O, OAc), 169.5 (C=O, OAc), 155.7 (C=O, Boc), 80.3 (C1), 78.0 
(C(CH3)3), 74.5 (C5), 72.9 (C3), 70.4 (C2), 69.3 (C4), 52.7 (C
α
), 52.4 (C6), 50.6 (C6), 
32.3 (C
γ
), 28.6 (C
β
), 28.3 (C(CH3)3), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3, 
OAc).  LRMS (ESI): m/z 596 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C25H35N5O12Na [M + Na]
+
: 596.2180; Found 596.2204.  
 
 
Chapter 7: Experimental 
243 | P a g e  
 
N
α
-(tert-Butoxycarbonyl)-N
ε
-(6-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-6-
deoxy-1-amino-2,3,4-tri-O-acetyl -β-D-glucosyl)-L-aspartic acid, methyl ester (112) 
 To a round bottom flask containing 110 
(0.061 g, 0.131 mmol), 4-pentyn-1-ol 
(0.050 mL, 0.045 g, 0.54 mmol), 
CuOAc2.H2O (0.005 g, 0.026 mmol) 
and sodium ascorbate (0.010 g, 0.049 
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred 
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (10 mL), and extracted with 
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and 
evaporation in vacuo resulted in a residue which was purified by flash column 
chromatography (EtOAc.) to yield 112 as a clear oil (0.057 g, 70%), Rf 0.15 (1:3 
Hexane:EtOAc.).
 1
H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H, Triazole-H), 6.79 (d, 1H, 
J = 8.9 Hz, NH), 5.77 (d, 1H, J =  9.0 Hz, NHBoc), 5.30 (t, 1H, J = 9.0 Hz, H1), 5.12 (t, 
1H, J = 9.5 Hz, H3), 4.90 (t, 1H, J = 9.0 Hz, H2), 4.83 (t, 1H, J   9.6 Hz, H4), 4.51-4.64 
(dd, 2H, J = 5.2 Hz, 11.5 Hz, H6/H6’), 4.30 (m, 1H, H
α
), 3.88 (m, 1H, H5), 3.75 (s, 3H, 
OCH3), 3.68 (m, 2H, CH2-CH2-CH2-OH), 3.31 (dd, 1H, J
 
= 2.1 Hz, 12.4 Hz, H6’), 2.87 
(m, 2H, CH2-CH2-CH2-OH), 2.78 (dd, 2H, J = 4.0 Hz, 16.4 Hz, H
β’
), 2.10-2.00 (3s, 9H, 
CH3, 3 x OAc), 1.96 (m, 2H, CH2-CH2-CH2-OH), 1.46 (s, 9H, Boc-H). Exchangeable 
OH not detected. 
13
C NMR (125 MHz, CDCl3) δ 171.7 (C=O, CONH2), 171.3 (C=O, 
COOCH3), 171.0 (C=O, OAc), 169.7 (C=O, OAc), 169.7 (C=O, OAc), 155.6 (C=O, 
Boc), 147.9 (Triazole-C), 122.0 (Triazole-C),  80.5 (C1), 78.4 (C(CH3)3), 74.2 (C5), 
72.3 (C3), 70.3 (C2), 69.4 (C4), 61.4 (CH2-CH2-CH2-OH), 52.8 (C
α
), 50.5 (C6), 50.2 
(OCH3), 38.2 (C
β
), 31.6 (CH2-CH2-CH2-OH), 28.3 (C(CH3)3), 21.9 (CH2-CH2-CH2-
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OH), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc).  LRMS (ESI): m/z 666 
[M + Na]
+ 
HRMS (ESI): m/z calculated for C27H41N5O13Na [M + Na]
+
: 666.2599; 
Found 666.2621 
 
N
α
-(tert-Butoxycarbonyl)-N
ε
-(6-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-6-
deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucosyl)-L-glutamic acid, methyl ester (113) 
 To a round bottom flask containing 111 
(0.075 g, 0.131 mmol), 4-pentyn-1-ol 
(0.050 mL, 0.045 g, 0.54 mmol), 
CuOAc2.H2O (0.005 g, 0.026 mmol) and 
sodium ascorbate (0.010 g, 0.049 mmol) 
was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred 
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (10 mL), and extracted with 
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and 
evaporation in vacuo resulted in a residue which was purified by flash column 
chromatography (EtOAc.)  to yield 113 as a clear oil (0.053 g, 62%), Rf 0.26 
(1:3 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.71 (bs,1H, Triazole-H), 7.16 (d, 
1H, J = 8.7 Hz, NH), 5.35 (m, 2H, NHBoc/H1), 5.19 (t. 1H, J = 9.4 Hz, H3), 4.96 (t, 
1H, J = 9.5 Hz, H4), 4.89 (t, 1H, J = 9.3 Hz, H2), 4.68 (m, 1H, H6), 4.37 (m, 2H, 
H
α
/H6’), 3.95 (m, 1H, H5), 3.79 (s, 3H, OCH3), 3.70 (m, 2H, CH2-CH2-CH2-OH), 2.86 
(m, 2H, CH2-CH2-CH2-OH), 2.34 (m, 4H, H
γ
/ CH2-CH2-CH2-OH),   (dd, 1H, 
J = 2.0 Hz, 13.0 Hz, H6), 3.29 (dd, 1H, J = 4.5 Hz, 13.0 Hz, H6’),  2.20 (m, 1H, H
β
), 
2.12-2.04 (3s, 9H, CH3, 3 x OAc), 1.95 (m, 1H, H
β
), 1.44 (s, 9H, Boc-H). Exchangeable 
OH not detected.
13
C NMR (125 MHz, CDCl3) δ 173.3 (C=O, CONH2), 172.7 (C=O, 
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COOCH3), 171.0 (C=O, OAc), 170.0 (C=O, OAc), 169.9 (C=O, OAc), 156.0 (C=O, 
Boc), 147.4 (Triazole-C), 119.9 (Triazole-C), 80.7 (C1), 78.7 (C(CH3)3), 74.5 (C5), 72.9 
(C3), 70.4 (C2), 69.3 (C4), 61.3 (CH2-CH2-CH2-OH),  52.8 (C
α
), 50.7 (OCH3), 32.6 
(C
γ
), 31.1 (CH2-CH2-CH2-OH), 28.9 (C
β
), 28.5 (C(CH3)3), 22.9 (CH2-CH2-CH2-OH), 
20.9 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 680 [M + Na]
+ 
HRMS (ESI): m/z calculated for C28H43N5O13Na [M + Na]
+
: 680.2755; 
Found 680.2793.  
 
7.4 Chapter 4 Experimental Data: 
6-p-Toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose (114)  
According to the method of Nishimura et al.,
196
 a round 
bottom flask containing D-glucose (10.0 g, 55 mmol), pyridine 
(150 mL) was added. The reaction mixture was cooled to 0°C, 
and p-toluenesulfonyl chloride (11.00 g, 58 mmol) was added portionwise to the 
reaction mixture, forming a yellow/green solution. The reaction mixture was slowly 
brought to room temperature, and allowed to stir for 16 hours. Following this time, 
acetic anhydride (40 mL) was added and the reaction mixture was stirred for an 
additional 1 hour. Upon completion, the reaction mixture was evaporated, with the 
resulting residue subject to recrystallization from ethanol, producing the desired product 
114 as a white solid. (11.08 g, 40%), M.p. 192-196°C (decomp.), 
Rf 0.71 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.75 (d, 4H, J = 8.3 Hz, 
Ar-H), 7.33 (d, 4H, J = 8.3 Hz, Ar-H), 5.71-5.63 (d, 2H, J = 8.2 Hz, H1α/β), 5.20-5.16 
(m, 1H, H3α/β), 5.04-5.01 (m, 8H, H2α/β, H4α/β), 4.12-4.09 (m, 4H, H6α/β/H6’α/β), 
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3.83 (d, 2H, J = 8.3 Hz, H5α/β), 2.44 (s, 6H, CH3-Ar), 2.09-1.97 (4s, 24H, CH3, 
4 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 169.3 (C=O, OAc), 169.1 
(C=O, OAc), 168.8 (C=O, OAc), 145.2 (Ar-C1), 132.4 (Ar-C4), 129.9 (Ar-C2/C6), 
128.2 (Ar-C3/C5), 91.7 (C1α), 91.5 (C1β), 72.6 (C5), 72.2 (C3), 70.0 (C2), 67.9 (C4), 
66.8 (C6),  21.7 (ArCH3), 20.7 (Ar-CH3), 20.5 (OAc), 20.5 (OAc), 20.5 (OAc). LRMS 
(ESI): m/z 525 [M + Na]
+  
HRMS (ESI): m/z calculated for C21H26O12SNa [M + Na]
+
: 
525.1043; Found 525.1062. 
 
6-p-Toluenesulfonyl-1,2,3-tri-O-acetyl-β,D-glucosyl azide (116)  
 A solution of 114 (2.25 g, 4.48 mmol) dissolved in dry CH2Cl2 
(5 mL) was chilled to 0°C. 33% w/v HBr in AcOH (12 mL) was 
added dropwise to the solution, and upon addition the reaction 
mixture was allowed to gradually warm to room temperature under constant stirring. 
After 3 hours, the reaction mixture was diluted with CH2Cl2 (50 mL), and washed with 
H2O (10 mL), ice cold sat. NaHCO3 solution (2 x 10 mL) and brine (10 mL). The 
organic phases were then dried and evaporated, producing the bromo intermediate 115 
as a orange oil that was used without further purification. 115 was subsequently 
dissolved in dry DMF (20 mL), and the solution was cooled to 0°C. NaN3 (1.166 g, 
17.92 mmol) was added portion wise to the mixture, and allowed to stir at 0°C for 30 
minutes, after which it was allowed to warm to room temperature. After 3 hours, the 
reaction mixture was diluted with H2O (20 mL), with the aqueous phase extracted with 
EtOAc (3 x 50 mL). The organic phase was dried and evaporated, with recrystallization 
from EtOAc/Hexanes producing 116 as an off-white solid. (1.42 g, 65%), M.p. 
137-138°C, Rf 0.76 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.80 (d, 2H, 
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J = 8.2 Hz, Ar-H), 7.36 (d, 2H, J = 8.2 Hz, Ar-H), 5.18 (t, 1H, J = 9.4 Hz, H3), 4.96 (t, 
1H, J = 9.9 Hz, H2), 4.85 (t, 1H, J = 8.8 Hz, 9.4 Hz, H4), 4.56 (d, 1H, J = 9.8 Hz, H1), 
4.15 (dd, 1H, J = 2.2 Hz, 11.0 Hz, H6), 4.09 (dd, 1H, J = 5.2 Hz, 11.0 Hz, H6’), 3.83 
(m, 1H, H5), 2.46 (s, 3H, ArCH3), 2.06-1.99 (3s, 9H, CH3, 3 x OAc).  
13
C NMR 
(125 MHz, CDCl3) δ 170.0 (C=O, OAc), 169.3 (C=O, OAc), 169.1 (C=O, OAc), 145.3 
(Ar-C1), 132.2 (Ar-C4), 129.9 (Ar-C2/C6), 128.1 (Ar-C3/C5), 87.7 (C1), 73.6 (C3), 
72.3 (C2), 70.4 (C4), 68.1 (C5), 67.2 (C6), 21.7 (ArCH3), 20.5 (OAc), 20.5 (OAc), 20.5 
(OAc). LRMS (ESI): m/z 508 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C19H23N3O10SNa  [M + Na]
+
: 508.1002; Found 508.0997. 
 
6-Iodo-6-deoxy-1,2,3-tri-O-acetyl-β,D-glucosyl azide (117) 
To a round bottom flask containing 116 (1.01 g, 2.08 mmol) and 
sodium iodide (1.25 g, 8.32 mmol), acetone (25 mL) was added. 
The resulting suspension was heated under at reflux and stirred 
for 48 hours. After completion, the reaction mixture was evaporated to dryness, with the 
resulting residue suspended in ice cold H2O (100 mL). Filtration of the precipitate, 
followed by recrystallization from ethanol resulted in the isolation of 117 as a white 
solid. (0.572 g, 62%), M.p. 127-128°C Rf 0.81 (1:1 Hexane:EtOAc.). 
1
H NMR 
(500 MHz, CDCl3) δ 5.22 (t, 1H, J =  9.5 Hz,  H3), 4.97 (t overlapping, 2H, J = 9.5 Hz, 
H2/4), 4.70 (d, 1H, J = 9.6 Hz, H1), 3.56 (dt, 1H, J = 2.5 Hz, 8.0 Hz, H5), 3.36-3.32 
(dd, 1H, J
 
= 7.1 Hz, 11.1 Hz,  H6), 3.21-3.18 (dd, 1H, J
 
= 7.2 Hz, 11.0 Hz, H6’), 
2.07-2.01 (3s, 9H, CH3, 3 x OAc).  
13
C NMR (125 MHz, CDCl3) δ 170.0 (C=O, OAc), 
169.9 (C=O, OAc), 169.8, (C=O, OAc), 87.6 (C1), 72.2 (C3), 69.7 (C2), 69.6 (C4), 68.3 
(C5), 20.1 (OAc), 19.0 (OAc), 18.9 (OAc), 3.6 (C6). LRMS (ESI): m/z 464 [M + Na]
+ 
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N,N-(tert-Butoxycarbonyl)-L-homocystine (118)
  
According to the method of Zhu et al.,
197
 a 
round bottom flask containing L,L-homocystine 
(2.68 g, 10.0 mmol) was added a 10% sodium 
carbonate solution (90 mL) and 1,4-dioxane (80 mL). The resultant suspension was 
cooled to 0°C and di-t-butyl dicarbonate (4.80 g, 22.2 mmol) was added. The reaction 
mixture was allowed to warm to room temperature and stirred for 18 hours. Following 
this time, 10% ascorbic acid was added to adjust the solution to pH 4, and the reaction 
mixture was extracted with ethyl acetate (3 x 50 ml). The organic layers were then 
combined, washed with brine (25 mL), dried (MgSO4) and evaporated in vacuo, 
producing 118 as a white solid, (4.20 g, 90%),  M.p. 162-164°C (decomp.)(Lit. 158-
159°C).
178
 
1
H NMR (500 MHz, CD3OD) δ  4.20 (m, 2H, H
α
), 2.74 (m, 4H, H
γ
), 2.20 
(m, 2H, H
β
), 1.96 (m, 2H, Hβ’), 1.42 (s,18H, Boc-H). 
13
C NMR (125 MHz, CD3OD) δ 
175.7 (COOH), 158.2 (C=O, Boc), 80.7 (C(CH3)3, 53.7 (C
α
), 35.8 (C
γ
), 32.5 (C
β
), 28.8 
(C(CH3)3).  LRMS (ESI): m/z 491 [M + Na]
+
, HRMS (ESI): m/z calculated for 
C18H32N2O8S2Na [M + Na]
+
: 491.1498; Found 491.1470. 
 
N,N-(tert-Butoxycarbonyl)-L-homocystine ditert-butyl ester (119)  
According to the method of Bourdier 
et al., 
178
 a solution of 118 (0.895 g, 
1.92 mmol) dissolved in CH2Cl2 (10 mL) 
under argon was added tert-butyl-2,2,2-trichloroacetimidate (2.20 g, 9.55 mmol). The 
reaction mixture was allowed to stir at room temperature for 18 hours, after which 
evaporation in vacuo, followed by flash column chromatography (6:1 Hexane: EtOAc) 
yielded the product 119 as a white solid.
  
(1.108 g, 99%), M.p. 66-69°C (Lit. 
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66-68°C),
178
 Rf 0.60 (4:1 Hexane:EtOAc.).
1
H NMR (500 MHz, CDCl3) δ  5.22 (m, 2H, 
NH), 4.24 (m, 2H, Hα), 2.70 (m, 4H, Hγ), 2.19 (m, 2H, Hβ), 1.97 (m, 2H, Hβ’), 1.48 (s, 
18H, tBu), 1.45 (s, 18H, Boc-H).  
13
C NMR (125 MHz, CDCl3) δ 171.5 (C=O), 155.7 
(C=O, Boc), 82.5 (C(CH3)3), 80.1 (Boc C-CH3), 53.6 (Cα), 34.9 (Cγ), 33.1 (Cβ), 28.7 
(C(CH3)3), 28.3(Boc C-CH3).  LRMS (ESI): m/z 603 [M + Na]
+  
HRMS (ESI): 
m/z calculated for C26H48N2O8S2Na [M + Na]
+
: 603.2750; Found 603.2771. 
 
N-(Tert-butoxycarbonyl)-L-homocysetine tert-butyl ester (120)  
 According to the method of Bourdier et al.,
178
  a solution of 119 
(0.321 g, 0.551 mmol) in DMF (5 mL) under argon, was added 
H2O (0.500 mL) and tributylphosphine (0.160 mL, 0.131 g, 
0.631 mmol). The reaction mixture was allowed to stir at room temperature for 18 
hours, after which the reaction was quenched with H2O (50 mL). The aqueous phase 
was washed with EtOAc (3 x 25 mL), which was subsequently washed with brine (25 
mL), dried (MgSO4) and evaporated in vacuo. Purification by flash column 
chromatography (6:1 Hexane: EtOAc) resulted in the isolation of 120 as a clear solid. 
(0.274 g, 85%). M.p. 38-40°C, Rf 0.75 (4:1 Hexane:EtOAc.).
1
H NMR (500 MHz, 
CDCl3) δ  5.17 (d, 1H, J = 6.9 Hz, NH), 4.29 (m, 1H, Hα), 2.56 (m, 2H, Hγ), 2.06 (m, 
1H, Hβ), 1.95 (m, 1H, Hβ’), 1.55 (t, 1H, J = 5.2 Hz, SH), 1.48 (s, 9H, tBu), 1.45 (s, 9H, 
Boc-H) 
13
C NMR (125 MHz, CDCl3) δ 171.7 (C=O), 155.7 (C=O, Boc), 82.5 
(C(CH3)3), 80.1 (Boc C-CH3), 53.3 (Cα), 38.0 (Cβ), 28.7 (C(CH3)3), 28.3(Boc C-CH3) 
21.1 (Cγ). LRMS (ESI): m/z 314 [M + Na]
+  
HRMS (ESI): m/z calculated for 
C13H25NO4SNa [M + Na]
+
: 314.1402; Found 314.1390 
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Attempted synthesis of N
α
-(tert-Butoxycarbonyl)-S-(1-azido-1-deoxy-2,3,4-tri-O-
acetyl-6-thio-β-D-glucosyl)-L-homocysteine tert-butyl ester (124) 
 
Method A: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu 
(120; 0.132 g, 0.454 mmol) was dissolved in THF (5 mL). NEt3 (0.065 mL, 0.047 g, 
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature. 
Periodic monitoring by TLC highlighted the formation of the side product 121, with the 
desired product 124 not detected. After 48 hours, the reaction mixture was evaporated in 
vacuo and dissolved in EtOAc (10 ml). After washing with H2O (5 mL) and brine (5 
mL), the organic phases were then dried and evaporated in vacuo with the resulting 
residue purified by flash column chromatography (3:1 Hexane: EtOAc), resulting in the 
isolation of the side product 121 as a white solid. (0.054g, 39%) 
Method B: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu 
(120; 0.132 g, 0.454 mmol) was dissolved in THF (5 mL). DBU (0.070 mL, 0.069 g, 
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature. 
Periodic monitoring by TLC highlighted the formation of the side product 121, with the 
desired product 124 not detected. After 48 hours, the reaction mixture was evaporated in 
vacuo and dissolved in EtOAc (5 ml). After washing with H2O (5 mL) and brine 
(5 mL), the organic phases were then dried and evaporated in vacuo with the resulting 
residue purified by flash column chromatography (3:1 Hexane: EtOAc), resulting in the 
isolation of the side product 121 as a white solid. (0.066 g, 48%) 
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Method C: In a round bottom flask, 117 (0.102 g, 0.228 mmol) and Boc.HCys.OtBu 
(120; 0.130 g, 0.453 mmol) was dissolved in DMF (5 mL). Cs2CO3 (0.148 g, 
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature. 
Periodic monitoring by TLC highlighted the formation of the side product 121, with the 
desired product 124 not detected. After 48 hours, the reaction mixture was diluted with 
EtOAc (5 ml). After washing with H2O (5 mL) and brine (5 mL), the organic phases 
were then dried and evaporated in vacuo with the resulting residue purified by flash 
column chromatography (3:1 Hexane: EtOAc), resulting in the isolation of the side 
product 121 as a white solid. (0.068 g, 49%) 
Method D: In a round bottom flask, 117 (0.101 g, 0.227 mmol) and Boc.HCys.OtBu 
(120; 0.131 g, 0.454 mmol) was dissolved in DMF (5 mL). Ag2O (0.210 g, 0.906 mmol) 
was added to the reaction mixture the reaction glassware was covered in foil and 
allowed to stir at room temperature in the dark for 4 days. Periodically monitored by 
TLC, neither the formation of side product 121, or the desired product 124 were 
detected.  As a result, the reaction was terminated, and a work up was not performed. 
Method E: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu 
(120; 0.130 g, 0.453 mmol) was dissolved in THF (5 mL). Ag20 (0.213 g, 0.908 mmol) 
was added to the reaction mixture and allowed to stir at room temperature in the dark. 
Periodical monitoring by TLC highlighted the formation of the side product 121, with 
the desired product 124 not detected. After 8 days, the reaction mixture was evaporated 
in vacuo and dissolved in EtOAc (5 ml). After washing with H2O (5 mL) and brine 
(5 mL), the organic phases were then dried and evaporated. 
1
H NMR of the reaction 
worked up displayed trace quantities of the side product 121. As a result, the reaction 
mixture was discarded and no isolation of 121 was performed. 
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Analytical data for (121): Rf 0.41 (1:1 Hexane EtOAc), M.p. 84-86°C. 
1
H NMR 
(500 MHz, CDCl3) δ 5.50 (d, 1H, J = 7.6 Hz, H4), 5.08 (t, 1H,  J =  7.8 Hz, H3), 4.96 (t, 
1H, J  = 7.9 Hz, H2), 4.90 (overlapping d, 2H, J  = 7.5 Hz, H1/CH), 4.64 (m, 1H, CH),  
2.10-2.02 (3s, 9H, CH3, 3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc), 
169.4 (C=O, OAc), 169.3 (C=O, OAc), 150.8 (C5), 98.4, (C6) 88.3 (C1), 71.6 (C4), 
70.9 (C3), 68.7 (C2), 20.9 (CH3, OAc), 20.8 (CH3, OAc), 20.8 (CH3, OAc). LRMS 
(ESI): m/z 336 [M + Na]
+
 HRMS (ESI): m/z calculated for C12H15N3O7 [M + Na]
+
: 
336.0808, Found 336.0820. 
 
6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl--D-glucose (125) 
To a round bottom flask containing 114 (4.00 g, 7.96 mmol) 
was added NaN3 (1.55 g, 23.88 mmol) and DMF (20 mL). 
The resulting suspension was heated to 50°C and stirred 
under nitrogen for 24 hours, after which the solution was concentrated. The resulting 
residue was suspended in H2O (10 mL), and subsequently washed with EtOAc 
(3 x 50 mL). The organic phases were collected, dried and evaporated, with the 
resulting residue subjected to flash column chromatography (3:1 Hexane: EtOAc). 
Further recrystallization by EtOAc/Hexanes yielded 125 as a white solid present as a 
1:1 mixture of α and β anomers. (1.71 g, 57%), M.p. 130-133°C, Rf 0.79 (1:1 
Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ α-anomer: 6.36 (d, 1H, J = 8.2 Hz, 
H1α), 5.43 (t, 1H, J =  9.2 Hz,  H3α), 5.17-5.05 (m, 2H, H2/H4), 4.05 (dt, 1H, 
J = 9.1 Hz, H5α), 3.36-3.32 (m, 2H, H6α/H6α’), 2.24-1.99 (4s, 12H, CH3, 4 x OAc). β-
anomer:  5.70 (d, 1H, J = 8.0 Hz,  H1β), 5.22 (t, 1H, J = 8.4 Hz,  H3β), 5.10 (m, 2H, 
H2/H4), 3.80 (dt, 1H, J = 9.3 Hz, H5β), 3.36-3.32 (m, 2H, H6β/H6β’), 2.24-2.04 (4s, 
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12H, CH3, 4 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.1 (C=O, CH3), 169.6 (C=O, 
CH3), 169.4 (C=O, CH3), 168.7 (C=O, CH3), 91.4 (C1
β
), 88.8 (C1
α
), 73.8 (C5), 72.5 
(C3
β
), 70.8 (C3
β
), 70.1 (C2
β
), 69.7 (C5
β
), 69.1 (C4
β
), 68.9 (C4), 50.6 (C6), 20.8 (CH3, 
OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 396 
[M + Na]
+ 
HRMS (ESI): m/z calculated for C14H19N3O9Na [M + Na]
+
: 396.1019; 
Found 396.1019. 
 
6-Azido-6-deoxy-1,2,3-tri-O-acetyl-α,D-glucosyl trichloroacetimidate (127)  
To a round bottom flask containing 125 (1.80 g, 4.80 mmol) 
DMF (40 mL) was added. The resultant was cooled to 0°C.  
Hydrazine acetate (0.60 g, 7.20 mmol) was then added 
portion wise to the reaction mixture, which was allowed to 
gradually warm to room temperature and stir for 3 hours. 
Upon completion, the reaction mixture was evaporated to dryness and subject to flash 
column chromatography (1:1 Hexane: EtOAc), producing the lactol intermediate 126 
(1.270 g, 80%).  Subsequently, 126 was re-dissolved in dry CH2Cl2 (15 mL) under 
argon with trichloroacetonitrile (3.00 mL, 4.32 g, 29.92 mmol). The mixture was cooled 
to 0°C, and DBU (1.08 mL, 1.10 g, 7.23 mmol) was added to the mixture dropwise, 
with the reaction warmed to room temperature and allowed to stir for a further 3 hours. 
Upon completion, the reaction mixture was diluted with CH2Cl2, (15 mL) washed with 
sat. NaHCO3 solution (25 mL) and brine (25 mL), dried (MgSO4) and evaporated in 
vacuo. The resulting residue was subjected to flash column chromatography 
(2:1 Hexane: EtOAc), yielding 127 as an off-white solid. (1.37 g, 75%), M.p. 76-78°C, 
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Rf 0.55 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ  8.76 (s, 1H, NHCCl3), 
6.63 (d, 1H, J = 3.7 Hz, H1), 5.51 (t, 1H, J = 9.5 Hz, H3), 5.19-5.16 (m, 2H, H2/H4), 
4.22 (ddd, 1H, J = 10.2 Hz, H5), 3.46 (dd, 1H, J = 3.0 Hz, H6’), 3.36 (dd, 1H, J  = 5.5 
Hz, 13.5 Hz, H6), 2.10-2.05 (3s, 9H, CH3, 3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 
170.0, 169.8, 169.5 (C=O, OAc), 92.8 (C1), 71.1 (C5), 69.7 (C2), 69.6 (C3), 68.9 (C4), 
50.6 (C6), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 
498 [M + Na]
+
. 
 
L-Homocystine dimethyl ester dihydrochloride (128)  
To a round bottom flask containing 
homocystine (0.786 g, 2.93 mmol) was added 
methanol (10 mL). The resulting suspension 
was cooled to 0°C, and thionyl chloride (0.240 mL, 0.383 g, 3.223 mmol) was added 
dropwise. Upon addition, the reaction mixture was allowed to gradually warm to room 
temperature, and was left to stir for 18 hours. Upon completion, the reaction solvents 
were removed in vacuo, producing the dimethyl ester dihydrochloride salt 128 as a light 
yellow oil. (1.076 g, 99%). 
1
H NMR (500 MHz, CDCl3) δ  4.17 (t, 2H, J = 6.6 Hz, Hα) 
3.82 (s, 6H, NH3), 3.69 (s, 6H, OCH3), 2.81 (t, 4H, J = 7.3 Hz, Hγ), 2.37 (m, 4H, Hβ). 
13
C NMR (125 MHz, D2O) δ 170.2 (C=O, COOCH3), 53.7 (C
α
), 51.44 (OCH3), 
32.0 (C
β
), 28.9 (C
γ
). LRMS (ESI): m/z 297 [M +H]
+ 
 
 
 
 
Chapter 7: Experimental 
255 | P a g e  
 
N,N-(Fluorenylmethylcarbonyl)-L-homocystine dimethyl ester (129)  
According to the method of Kelleman 
et al.,
203
 a round bottom flask containing 128 
(0.594 g, 1.61 mmol), was added solid 
K2CO3 (1.02 g, 7.25 mmol). H2O (10 mL) and 1,4-dioxane (5 mL) were also added, and 
the mixture was gently stirred at room temperature. Solid Fmoc-Cl (1.039 g, 4.03 
mmol) was added to the reaction mixture portion wise, and the reaction mixture was 
allowed to stir vigorously at room temperature for 18 hours. After this time, the reaction 
mixture was subjected to sonication then filtered. The isolated solid was subjected to 
flash column chromatography (4:1 Hexane: EtOAc), resulting in the isolation of 129 as 
a light yellow solid. (0.884 g, 74%),  M.p. 89-91°C, Rf 0.15 (4:1 Hexane:EtOAc.). 
1
H 
NMR (500 MHz, CDCl3) δ 7.74 (d, 4H, J
 
= 7.3 Hz, Fmoc-H) 7.57 (d, 4H,  J =  7.3 Hz, 
Fmoc-H), 7.39 (t, 4H, J  = 7.3 Hz, Fmoc-H), 7.24 (t, 4H, J  = 7.3 Hz, Fmoc-H), 5.51 (d, 
2H, J = 8.0 Hz, NH),  4.48 (m, 2H, Hα), 4.40 (m, 4H, OCH2), 4.19 (t, 2H, J = 6.7 Hz),  
3.75 (s, 6H, OCH3),  2.70 (t, 4H, J = 7.3 Hz,  Hγ), 2.17 (m, 4H, Hβ). 
13
C NMR (125 
MHz, CDCl3) δ 172.4 (C=O, COOCH3), 155.9 (C=O, Fmoc),  143.8 (Fmoc Ar-C1), 
143.4 (Fmoc Ar-C1), 141.3 (Fmoc Ar-C6), 127.7 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 
125.0 (Fmoc Ar-C3), 120.0 (Fmoc Ar-C2), 67.0 (OCH2CH), 52.7, 52.6 (OCH3/C
α
), 47.2 
(OCH2CH), 34.5 (C
β
), 32.4 (C
γ
). LRMS (ESI): m/z 763 [M + Na]
+  
HRMS (ESI): m/z 
calculated for C40H40N2O8S2Na [M + Na]
+
: 763.2124; Found 763.2151. 
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N-(Fluorenylmethylcarbonyl)-L-homocysteine methyl ester (130)  
According to the method of Kelleman et al.,
203
  a round 
bottom flask containing 129 (0.519 g, 0.700 mmol) under 
argon, was added CH2Cl2 (20 mL) and MeOH (60 mL). To the 
flask, zinc dust (0.250 g, 3.50 mmol) was added followed by TFA (2.20 mL, 3.278 g, 
28.75 mmol) dropwise. Subsequently, the flask was again flushed with argon, and the 
reaction mixture was allowed to stir at room temperature for 18 hours. Following this, 
the reaction mixture was filtered and evaporated in vacuo, with the resulting residues 
dissolved in EtOAc (50 mL). Subsequent washes with H2O (10 mL) and brine (10 mL), 
followed by drying (MgSO4) and concentration, resulted in the isolation of 130 as a 
light yellow solid. (0.370 g, 71%),  M.p. 87-90°C, Rf 0.42 (4:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.74 (d, 2H, J = 7.3 Hz, Fmoc-H) 7.59 (d, 2H,  J =  7.3 
Hz, Fmoc-H), 7.39 (t, 2H, J  = 7.3 Hz, Fmoc-H), 7.23 (t, 2H, J  = 7.3 Hz, Fmoc-H), 5.34 
(d, 1H, J = 8.0 Hz, NH),  4.54 (m, 1H, Hα), 4.44 (m, 2H, OCH2), 4.22 (t, 1H, J = 6.7 
Hz),  3.76 (s, 3H, OCH3),  2.55 (t, 2H, J = 7.3 Hz,  H
γ
), 2.13 (m, 1H, H
β
), 1.97 (m, 1H, 
H
β’
), 1.55 (t, 1H, J = 8.1 Hz, SH). 
13
C NMR (125 MHz, CDCl3) δ 172.5 (COOCH3), 
156.0 (C=O, Fmoc), 143.9 (Fmoc Ar-C1), 143.6 (Fmoc Ar-C1), 141.4 (Fmoc Ar-C6), 
127.8 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.0 (Fmoc Ar-C3), 120.0 (Fmoc Ar-C2), 
67.0 (OCH2CH), 52.7, 52.6 (OCH3/C
α
), 47.2 (OCH2CH), 37.0 (C
β
), 20.6 (C
γ
). LRMS 
(ESI): m/z 394 [M + Na]
+ 
HRMS (ESI): m/z calculated for C20H21NO4SNa [M + Na]
+
: 
394.1089; Found 394.1082. 
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N
α
-(Fluorenylmethylcarbonyl)-S-(6-azido-6-deoxy-1-thio-2,3,4-tri-O-acetyl-D-
glucosyl)-L-homocysteine methyl ester (131) 
 Method A: To a round bottom flask containing 
125 (0.100 g, 0.268 mmol) and Fmoc.HCys.OMe 
(130, 0.250 g, 0.670 mmol) under argon, was 
added dry CH2Cl2 (5 mL). The mixture was 
cooled to 0°C, and SnCl4 (0.020 ml, 0.045 g, 
0.0171 mmol) was added to the solution. The reaction mixture was subsequently 
allowed to warm to room temperature, and stirred overnight. Upon completion, the 
reaction mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. NaHCO3 
solution (5 mL). The organic phases where then washed with H2O (5 mL) and brine (10 
mL), dried (Na2SO4) and evaporated in vacuo with the resulting residues purified by 
flash column chromatography (3.5:1 Hexane: EtOAc), producing 131  as an amorphous 
solid present in a ~2:1 ratio of α and β-anomers. (0.094 g, 51%).  
Method B: A round bottom flask containing 127 (0.127 g, 0.268 mmol), 
Fmoc.HCys.OMe (128, 0.248 g, 0.669 mmol) and 4Å molecular sieves (0.100 g) was 
dried under high vacuum overnight. Upon drying, the flask was immersed in an 
atmosphere of argon and dry CH2Cl2 (2 mL) was added. The reaction mixture was 
cooled to -20°C, and stirred at this temperature for 30 minutes. After this time, TMSOTf 
(0.005 mL, 0.006 g, 0.027 mmol) was added to the reaction mixture dropwise, and the 
flask was stirred vigorously for an additional 1 hour.  Upon reaction completion, the 
reaction mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. NaHCO3 
solution (1 mL). The organic phases where then washed with H2O (5 mL) and brine 
(5 mL), dried (Na2SO4) and evaporated in vacuo with the resulting residues purified by 
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flash column chromatography (3.5:1 Hexane: EtOAc), producing 131 as a white foam 
present as a 1:1 mixture of α and β-anomers. (0.071 g, 38%). 
α-anomer;  Rf 0.30 (2:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.75 (m, 2H, 
Fmoc-H), 7.57 (m, 2H, Fmoc-H), 7.37 (m, 2H, Fmoc-H), 7.29 (m, 2H, Fmoc-H), 6.36 
(d, 2H, J = 4.0 Hz, H1), 5.47 (overlapping t, 2H, J = 9.9 Hz, NH/H3), 5.10 (m, 2H, 
H2/H4), 4.48 (m, 1H, H
α
), 4.39 (m, 2H, OCH2-CH), 4.19 (m, 1H, OCH2-CH), 4.08 (m, 
1H, H5), 3.76 (s, 3H, OCH3), 3.39 (dd, 1H, J = 2.6, 13.6 Hz, H6), 3.30 (dd, 1H, J =  5.5; 
13.4 Hz, H6’), 2.70 (m, 2H, H
γ
), 2 24 (m, 1H, H
β
), 2.10 (m, 1H, H
β
), 2.02-2.06 (3s, 9H, 
CH3, 3 x OAc).  
13
C NMR (125 MHz, CDCl3) δ 172.5 (C=O, COOCH3), 170.4 (C=O, 
OAc), 169.8 (C=O, OAc), 168.9 (C=O, OAc), 156.2 (C=O, Fmoc), 143.9 (Fmoc Ar-
C1), 141.6 (Fmoc Ar-C6), 128.1 (Fmoc Ar-C4), 127.2 (Fmoc Ar-C5), 125.4 (Fmoc Ar-
C3), 120.3 (Fmoc Ar-C2), 89.2 (C1), 71.2 (C5) 71.0 (C3), 69.9 (C2), 69.5 (C4), 67.3 
(OCH2CH), 53.1 (C
α
), 52.7 (OCH3), 51.0 (C6),  47.4 (OCH2CH), 34.7 (C
β
), 21.1 (C
γ
), 
20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc).  
β-anomer, Rf 0.23 (2:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.76 (m, 2H, 
Fmoc-H), 7.61 (m, 2H, Fmoc-H), 7.40 (m, 2H, Fmoc-H), 7.32 (m, 2H, Fmoc-H), 5.45 
(m, 1H, NH), 5.22 (t, 1H, J = 9.9 Hz, H3), 5.02 (m, 2H, H2/H4), 4.51 (d, 1H, J = 9.8 
Hz, H1), 4.48 (m, 1H, H
α
), 4.42 (d, 2H, J = 8.1 Hz, OCH2CH), 4.23 (t, 1H, J = 8.2 Hz, 
OCH2CH), 3.77 (s, 2H, OCH3), 3.67 (m, 1H, H5), 3.32 (m, 2H, H6/H6’), 2.80 (m, 1H, 
H
γ
), 2.67 (m, 1H, H
γ’
), 2.18 (m, 1H, H
β
), 2.07 (m, 1H, H
β’
), 2.01-2.05 (3s, 9H, CH3, 
3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 172.3 (C=O, COOCH3), 170.1 (C=O, OAc), 
169.4 (C=O, OAc), 169.4 (C=O, OAc), 155.9 (C=O, Fmoc), 143.8 (Fmoc Ar-C1), 141.3 
(Fmoc Ar-C6), 127.7 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.1 (Fmoc Ar-C3), 120.0 
(Fmoc Ar-C2), 83.4 (C1), 77.0 (C5), 73.6 (C3) 69.6 (C2), 69.4 (C4), 67.0 (OCH2CH), 
53.0 (C
α
), 52.6 (OCH3), 51.1 (C6),  47.2 (OCH2CH), 32.8 (C
β
), 21.0 (C
γ
), 20.7 (CH3, 
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OAc), 20.6 (CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 707 [M + Na]
+ 
HRMS 
(ESI): m/z calculated for C32H36N4O11SNa [M + Na]
+
: 707.1999; Found 707.2008 
 
N-(tert-Butoxycarbonyl)ethylenediamine maleimide (134)  
According to the method of Richter et al.,
211
 round bottom 
flask containing N-Boc-ethylenediamine (133, 0.50 mL, 
0.510 g, 3.20 mmol) and NEt3 (0.66 mL) was suspended in 
Et2O (5 mL) and cooled to 0°C.  Maleic anhydride (0.311 g, 3.20 mmol) dissolved in 
Et2O (5 mL) was added dropwise to the reaction mixture, after which it was allowed to 
stir for 4 hours gradually warming to room temperature. After this time, the reaction 
mixture was concentrated, and the resulting residue was dissolved in acetone (15 mL). 
NEt3 (1.0 mL) and Ac2O (0.500 mL) was added, and the mixture was heated to reflux 
for a further 20 hours. Upon completion, solvent evaporation resulted in a brown 
residue, which following flash column chromatography resulted in the isolation of the 
desired product 134 as a white solid. (0.388 g. 50%). M.p. 126-128°C, Rf 0.80 (1:1 
Hexane: EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 6.70 (m, 2H, CH=CH), 4.78 (bs, 1H, 
NH), 3.64 (m, 2H, CH2-CH3-NHBoc), 3.31 (m, 2H, CH2-CH3-NHBoc), 1.39 (s, 9H, 
Boc-H) 
13
C NMR (125 MHz, CDCl3) δ 170.8 (C=O, maleimide), 155.9 (C=O, Boc), 
134.2 (CH=CH), 79.5 (C(CH3)3), 39.4 (CH2-CH2-NHBoc), 38.0 (CH2-CH2-NHBoc), 
28.3 (C(CH3)3). LRMS (ESI): m/z 263 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C11H16N2O4Na [M + Na]
+
: 263.1008; Found 263.1061. 
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N-Ethylenediamine maleimide trifluoroacetate (135) 
 According to the method of Richter et al.,
211
 a round bottom 
flask containing 134 (0.150 g, 0.624 mmol) was added dry 
CH2Cl2 (5 mL). The flask was cooled to 0°C, and TFA (2.50 
mL, 3.725 g, 32.67 mmol) was added to the solution dropwise. Upon addition, the 
reaction mixture was stirred for 1 hour, during which it was allowed to warm to room 
temperature. Upon completion, the reaction mixture was evaporated to dryness, with 
flushing of the mixture with ice-cold Et2O (5 mL) resulting in precipitation of 
thedesired product. Trituration with additional Et2O (4 x 5 mL) followed by filtration 
resulting in the isolation of 135 as a white solid. (0.141 g, 95%). M.p. 133-134°C. 
1
H NMR (500 MHz, D2O) δ 6.95 (s, 2H, CH=CH), 3.88 (t, 2H, J = 5.7 Hz, CH2-CH2-
NHBoc), 3.28 (t, 2H, J = 5.7 Hz, CH2-CH2-NHBoc). 
13
C NMR (125 MHz, D2O) δ 
172.7 (C=O), 134.7 (CH=CH), 38.4 (CH2-CH2-NHBoc), 35.0 (CH2-CH2-NHBoc). 
LRMS (ESI): m/z 141 [M – TFA +H]
+ 
 
 N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-ethylenediamine maleimide (136) 
135 (0.076 g, 0.322 mmol), 60 (0.075 g, 0.215 mmol), and 
DCC (0.066 g, 0.321 mmol) were dissolved in ACN 
(2 mL), and the solution was cooled to 0°C. HOBt 
(0.043 g, 3.21 mmol) was added portionwise to the 
reaction mixture, and allowed to warm to room temperature and stir for 8 hours. Upon 
completion, the reaction mixture was filtered, and the filtrate was evaporated to dryness. 
The resulting residue was subject to purification by flash column chromatography 
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(1:1 Hexane: EtOAc), producing the desired compound 136 as a white solid (0.066 g, 
66%). M.p. 196-198°C (Decomp.), Rf 0.20 (1:1 Hexane:EtOAc). 
1
H NMR (500 MHz, 
CDCl3) δ 6.84 (m, 1H, NH), 6.74 (s, 2H, CH=CH), 5.27 (t, 1H, J = 9.5 Hz, H3), 5.12 (t, 
1H, J = 9.6 Hz, H4), 4.95 (t, 1H, J = 9.0 Hz, H2), 4.73 (d, 1H, J = 8.8 Hz, H1), 3.71 (m, 
2H, CH2-CH2-NH), 3.43 (m, 2H, CH2-CH2-NH), 2.08-2.01 (3s, 9H, CH3, 3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.9 (C=O, maleimide), 169.9 (C=O, OAc), 169.6 
(C=O, OAc), 169.2 (C=O, OAc), 166.4 (C=O, CONH), 134.3 (CH=CH), 87.8 (C1), 
74.1 (C5), 71.9 (C2), 70.5 (C3), 69.0 (C4), 38.9 (CH2-CH2-NH), 37.0 (CH2-CH2-NH), 
20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 490 [M + Na]
+ 
HRMS (ESI): m/z calculated for C18H21N5O10Na [M + Na]
+
: 490.1186; 
Found 490.1204. 
 
N
α
-(Fluorenylmethylcarbonyl)-S-(N-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-
ethylenediamine succinimido)-L-Homocysteine methyl ester (137) 
To a round bottom flask containing 137 
(0.020 g, 0.0428 mmol) and Fmoc.HCys.OMe 
(130, 0.016 g, 0.0428 mmol) was added a 
1:1 solution of ACN:H2O (0.5 mL). The 
reaction mixture was left to stir at room 
temperature for 3 hours, with periodic monitoring of product formation by LR-ESIMS. 
Upon completion the reaction mixture was evaporated to dryness, with the resulting 
residue purified by flash column chromatography (1:1 Hexane EtOAc) to yield the 
desired product 137 as a light yellow oil, present as a mixture of diastereomers 
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(0.022g, 62%). Rf  0.25 (1:1 Hexane: EtOAc) 
1
H NMR (500 MHz, CDCl3) δ 7.76 (d, 
2H, J = 7.3 Hz, Fmoc-H), 7.62 (d, 2H,  J =  7.2 Hz, Fmoc-H), 7.41 (t, 2H, J  = 7.3 Hz, 
Fmoc-H), 7.32 (t, 2H, J  = 7.3 Hz, Fmoc-H), 6.82 (m,1H, CH2-CH2-NH),  5.67 (m, 1H, 
Fmoc-NH), 5.27 (m, 1H, C3), 5.08 (m, 1H, C4), 4.94 (t, 1 H, J = 9.0 Hz, H2), 4.70 (t, 
1H, J = 9 Hz, H1), 4.54 (m, 1H, H
α
), 4.41 (m, 2H, OCH2-CH), 4.24 (t, 1H, J = 6.5 Hz, 
OCH2CH), 3.96 (m, 1H, H5), 3.77 (m, 3.5H, Succinimide-CH/OCH3), 3.71 (m, 2H, 
CH2-CH2-NH), 3.59 (m, 1H, CH2-CH2-NH), 3.36 (m, 1H, CH2-CH2-NH), 3.20-3.24 (m, 
2H, Succinimide-CH2), 3.03 (m, 1H, H
γ
), 2.75-2.87 (dm, 1H, H
γ
), 2.49 (m, 0.5H, 
Succinimide-CH), 2.10-2.25 (dm, 2H, H
β
), 2.00-2.08 (3s, 9H, CH3, 3 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 177.3 (C=O, Succinimide), 175.3 (C=O, Succinimide), 
175.0 (C=O, Succinimide), 172.2 (C=O, CONH), 169.8 (C=O, OAc), 169.5 (C=O, 
OAc), 169.5 (C=O, OAc), 166.5 (C=O, CO COOCH3), 156.1 (C=O, Fmoc), 143.8 
(Fmoc Ar-C1), 141.3 (Fmoc Ar-C6), 127.8 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.1 
(Fmoc Ar-C3), 120.0 (Fmoc Ar-C2), 87.8 (C1), 74.2 (C5), 71.8 (C3), 70.5 (C2), 69.1 
(C4), 67.2 (OCH2CH), 52.9 (C
α
), 52.7 (OCH3), 47.1 (OCH2CH), 39.2 
(Succinimide-CH), 38.9 (Succinimide-CH), 38.6 (CH2-CH2-NH), 38.3 (CH2-CH2-NH), 
35.8 (Succinimide-CH2), 32.0 (C
β
), 27.8 (C
γ
), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.5 
(CH3, OAc). LRMS (ESI): m/z 861 [M + Na]
+ 
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N
α
-(Fluorenylmethylcarbonyl)-S-(N-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-
1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-ethylenediamine succinimido)-L-
homocysteine methyl ester (138) 
To a round bottom flask 
containing 137 (0.030 g, 
0.036 mmol), 4-pentyn-1-ol 
(0.015 mL, 0.013 g, 
0.143 mmol), CuOAc2 
(0.002 g, 0.010 mmol) and sodium ascorbate (0.003 g, 0.015 mmol) was added a 
1:1 solution of n-BuOH:H2O, (0.250 mL), with the solution stirred vigorously under an 
atmosphere of nitrogen at  room temperature for 24 hours. Upon completion, the 
reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then 
brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in 
vacuo resulted in a residue which was purified by flash column chromatography 
(1:3 Hexane: EtoAc) to yield 138 as a light yellow oil. (0.025 g, 76%). Rf 0.15  
(1:3 Hexane: EtOAc). 1H NMR (500 MHz, CD3CN) δ 7.87 (m, 3H, Fmoc-H/Triazole-
H), 7.72 (m, 2H, Fmoc-H), 7.46 (t, 4H, J  = 7.3 Hz, Fmoc-H), 7.38 (t, 4H, J  = 7.3 Hz, 
Fmoc-H), 7.01 (m, 1H, NH), 6.27 (m, 1H, Fmoc-NH), 6.05 (d, 1H, J = 8.5 Hz, H1), 
5.51-5.60 (m, 2H, H3/H2), 5.33 (m, 1H, H4), 4.37 (m, 3H, H
α
/OCH2CH). 4.29 (m, 2H, 
OCH2CH/H5), 3.80 (m, 0.5H, Succinimide-H), 3.73 (s, 3H, OCH3) 3.49-3.62 (m, 4H, 
CH2-CH2-NH/CH2-CH2-CH2-OH). 3.32 (m, 2H, CH2-CH2-NH), 3.10 (m, 2H, 
Succinimide-H), 2.93 (m, 1H, H
γ
), 2.81 (m, 1H, H
γ
), 2.77 (t, 2H, J = 7.1 Hz, CH2-CH2-
CH2-OH), 2.46 (m, 0.5H, Succinimide-H), 2.27 (m, 2H, H
β
), 2.00-2.03 (2s, 6H, CH3, 2 
x OAc), 1.98 (m, 2H, CH2-CH2-CH2-OH), 1.81 (s, 3H, CH3, OAc). Exchangeable OH 
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not detected. 
13
C NMR (125 MHz, CD3CN) δ 177.2 (C=O, Succinimide), 175.3 (C=O, 
Succinimide), 175.3 (C=O, Succinimide), 172.6 (C=O, CONH), 170.0 (C=O, OAc), 
169.7 (C=O, OAc), 169.0 (C=O, OAc), 166.6 (C=O, CONH), 156.4 (C=O, Fmoc), 
148.4 (Triazole-C), 144.4 (Fmoc Ar-C1), 141.4 (Fmoc Ar-C6), 127.8 (Fmoc Ar-C4), 
127.3 (Fmoc Ar-C5), 125.4 (Fmoc Ar-C3), 120.8 (Triazole-C), 120.2 (Fmoc Ar-C2), 
84.8 (C1), 74.6 (C5), 72.1 (C3), 70.3 (C2), 69.2 (C4), 66.6 (OCH2CH), 60.9 (CH2-CH2-
CH2-OH) 53.2 (C
α
), 52.3 (OCH3), 47.3 (OCH2CH), 40.0 (Succinimide-CH), 39.7 
(Succinimide-CH), 38.2 (CH2-CH2-NH), 36.7 (CH2-CH2-NH), 36.2 (Succinimide-CH2), 
32.6 (CH2-CH2-CH2-OH), 32.2 (C
β
), 30.2 (CH2-CH2-CH2-OH), 27.8 (C
γ
), 20.1 (CH3, 
OAc), 20.0 (CH3, OAc), 19.6 (CH3, OAc). LRMS (ESI): m/z 945 [M + Na]
+
  
 
7.5 Chapter 5 Experimental Data: 
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (147) 
To a round bottom flask containing D-glucose (2.54g, 
14.1 mmol) was added pyridine (10 mL) and Ac2O (7.00 mL, 
7.52 g, 73.7 mmol), with the reaction mixture allowed to stir at 
room temperature for 72 hours. After which, the reaction mixture was diluted with 
CH2Cl2 (30 mL) and washed with 1% CuSO4 solution (2 x 50 mL). The organic layers 
were further washed with water, dried with Na2SO4 and concentrated, with the resultant 
solid recrystallised from EtOAc to produce 147 as white crystals, present as a mixture 
of α/β anomers. (5.42 g, 96%). Mp 96-97°C (Lit 100-102°C),
222
 Rf 0.65 
(1:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 6.31 (d, 1H, J = 3.9 Hz, H1α), 
5.72 (d,1H,  J = 8.2 Hz, H1β) 5.47 (m, 1H, J = 9.8 Hz, H3α) 5.26 (m, 1H, J = 9.6Hz, 
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H3β) 5.16-5.10 (m, 4H, H2αβ/H4αβ) 4.30-4.25 (m, 2H) 4.14-4.09 (m, 3H, H5α/H6αβ ), 
3.84 (m, 1H, H5), 2.18 (s, 3H, OAc), 2.11-2.02 (5s, 15H, CH3, 5 x OAc).
 3
C NMR 
(CDCl3, 125 MHz): 170.4 (C=O, OAc), 170.1 (C=O, OAc), 169.5 (C=O, OAc), 169.3 
(C=O, OAc), 168.6 (C=O, OAc), 92.0 (C1β), 89.4 (C1α), 73.2 (C3), 70.6 (C2α), 70.2 
(C2β), 69.5 (C4), 68.2 (C5), 61.7 (C6), 21.0 (CH3, OAc), 20.9 (CH3, OAc), 
20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 413 [M + Na]
+
  
 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide (148) 
To a solution of 147 (1.17g, 2.99 mmol) in CH2Cl2 (30 mL) 
under a nitrogen atmosphere, were added sequentially TMSN3 
(0.500 mL, 0.458 g, 3.97 mmol) and SnCl4 (0.200 mL, 0.444 g, 
1.71 mmol), with the reaction mixture allowed to stir at room temperature for 24 hours. 
Upon completion, the reaction mixture was diluted further with DCM (50 mL), washed 
with aq. NaHCO3 solution (50 mL) and H2O (50 mL), dried with Na2SO4 and 
concentrated. The resultant solid was recrystallised from EtOH to produce 148 as a fine 
white powder. (0.728 g, 65%). Mp 128-130°C (Lit. 128.5°C),
254
 Rf 0.75 
(1:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 5.22 (t, 1H, J = 9.4 Hz, H3 ) 5.10 
(t, 1H, J = 9.1 Hz, H4 ) 4.96 (t, 1H, J = 9.4 Hz, 9.1 Hz, H2 ) 4.66 (d, 1H, J = 8.8 Hz, 
H1) 4.27 (dd, 1H, J = 12.2 Hz, 4.8 Hz, H6) 4.16 (dd, 1H, J = 12.4 Hz, 2.5 Hz, H6’) 3.79 
(m, 1H, H5) 2.10-2.01 (4s, 12H, CH3, 4 x OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.6 
(C=O, OAc), 170.1 (C=O, OAc), 169.3 (C=O, OAc), 169.2 (C=O, OAc), 87.9 (C1), 
73.6 (C3), 72.5 (C2), 70.6 (C4), 67.8 (C5), 61.6 (C6), 20.7 (CH3, OAc), 20.6 (CH3, 
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OAc), 20.5 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 396 [M + Na]
+ 
HRMS 
(ESI): m/z calculated for C17H19N3O9Na [M + Na]
+
: 396.1019; Found 396.1026. 
 
4,6-Benzylidene-β-D-glucopyranosyl azide (150)  
According to the method of D’Onofrio et al.,
158
 To a round 
bottom flask containing 148 (0.351 g, 940 mmol) in MeOH 
(9.50 mL) was added 0.500 mL of a 0.5M solution of 
NaOCH3 in MeOH, with the reaction mixture allowed to stir at room temperature for 
0.5 hours. The reaction mixture was neutralised with Dowex 50 x 4 [H
+
] resin, filtered 
and concentrated to dryness. The resultant residue (149) was dissolved in dry DMF 
(6 mL), treated with benzylidene dimethyl acetal (0.318 g, 0.320 mL, 2.09 mmol) and 
dry p-TsOH (0.020 g, 0.116 mmol), and allowed to stir under aspirator vacuum pressure 
at 60°C for 5 hours. Upon completion, the reaction mixture was concentrated, and 
purified using flash column chromatography (1:9 Acetone: CH2Cl2) to yield 150 as an 
amorphous white solid. (0.239 g, 87%) Mp 155-157°C (Lit. 152-153°C),
225
 Rf  0.27 
(1:9 Acetone: CH2Cl2). 
1
H NMR (500 MHz, CD3OD) δ 7.48 (m, 2H, Ar-H), 7.37 (m, 
3H, Ar-H), 5.55 (s, 1H, PhCH), 4.68 (d, 1H, J = 8.9 Hz, H1), 4.30 (dd, 1H, J = 4.8 Hz, 
9.2 Hz, H6), 3.81 (m, 1H, H3/H6’),  3.56 (t, 1H, J = 9.2 Hz, 8.5 Hz, H4), 3.55 (m, 1H, 
H5), 3.46 (t, 1H, J = 9.1 Hz, 8.8 Hz, H3), 3.25 (t, 1H, J = 8.8 Hz, 8.4 Hz, H2).
13
C NMR 
(125 MHz, CDCl3) δ 137.1 (Ar-C1), 129.6 (Ar-C4), 128.6 (Ar-C3/5), 126.5 (Ar-C2/6), 
102.2 (PhCH), 90.8 (C1), 80.4 (C4), 74.4 (C5), 73.8 (C3), 68.6 (C6), 68.6 (C2). LRMS 
(ESI): m/z 328 [M + Cl]
-
 HRMS (ESI): m/z calculated for C13H15N3O5Cl: 328.0700 [M 
+ Cl]
-
; Found 328.0708. 
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2,3-Di-O-p-methoxybenzyl-4,6-benzylidene-β-D-glucopyranosyl azide (151) 
To a round bottom flask containing 150 (0.200 g, 0.682 mmol) 
was added p-methoxybenzyl chloride (0.530 mL, 0.614 g, 
3.92 mmol), tert-butylammonium iodide (150 g, 0.406 mmol) 
and anhydrous DMF (10 mL). The reaction mixture was cooled to 0°C, before NaH – 
60% dispersed in mineral oil (0.161 g, 3.93 mmol) was added portion wise. The reaction 
mixture was then allowed to warm to room temperature, and was left to stir for 
24 hours. Upon completion, the reaction mixture was diluted with NH3Cl and 
evaporated in vacuo. The residue was dissolved in CHCl3 (20 mL), washed with water 
(2 x 20 mL), dried with Na2SO4 and evaporated. The resultant residue was purified 
using flash column chromatography (4:1 Hexane:EtOAc.), furnishing 151 as a fluffy 
white solid. (0.264 g, 73%). M.p. 132-133°C Rf 0.61 (4:1 Hexane:EtOAc.) 
1
H NMR 
(500 MHz, CDCl3) δ 7.48 (d, 2H, J = 7.6 Hz, PhH2/6), 7.36 (m, 3H, PhH3/4/5), 7.26 
(dd, 4H, J= 3.1 Hz, 5.5 Hz, PMB-H3/5), 6.84 (dd, 4H, J= 8.5 Hz, 5.5 Hz, PMB-H2/6), 
5.54 (s, 1H, Ph-CH), 4.84 (d, 1H, J = 11.0 Hz, CH2Ph), 4.74 (m, 2H, CH2Ph), 4.71 (d, 
1H, J = 11.0 Hz, CH2Ph), 4.65 (d, 1H, J = 11.0 Hz, Ch2Ph), 4.34 (dd, 1H, J = 5.0 Hz, 
10.5 Hz, H6), 3.76 (m, 7H, 2 x OCH3, H3), 3.73 (dd, 1H, J = 4.4 Hz, 10.3 Hz, H6’), 
3.63 (t, 1H, J = 9.1 Hz, H4), 3.45 (m, 1H, H5), 3.34 (t, 1H, J = 8.5 Hz, H2). 
13
C NMR 
(125 MHz, CDCl3) δ 159.8 (PMB-C4), 159.6 (PMB-C4’), 137.4 (Ph-C1), 130.7 (PMB-
C1/C1’), 130.2 (PMB-C2/C6), 130.0 (PMB-C2’/C6’), 129.3 (Ph-C4), 128.6 (Ph-
C3/C5), 126.3(Ph-C2/C6), 114.2 (PMB-C3/C5), 114.1(PMB-C3’/C5’), 101.5 (Ph-C-O), 
91.0 (C1), 81.5(C3), 81.3 (C2), 81.1 (C4), 75.5 (O-CH2Ph), 75.1 (O-CH2Ph), 68.7 (C5), 
68.4 (C6), 55.5 (OCH3). LRMS (ESI): m/z 556 [M + Na]
+  
HRMS (ESI): m/z 
calculated for C29H31N3O7Na [M + Na]
+
: 556.2060, Found: 556.2078. 
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2,3-Di-O-benzoyl-4,6-benzylidene-β-D-glucopyranosyl azide (152) 
To a round bottom flask containing 150 (1.63 g, 5.54 mmol) 
was added pyridine (20 mL). The reaction mixture was cooled 
to 0°C, and benzoyl chloride (1.55 mL, 1.98 g, 13.33 mmol) 
was added dropwise to the solution. The reaction mixture was subsequently allowed to 
warm to room temperature, and stirred for 3 hours. Upon completion, the reaction 
mixture was concentrated in vacuo, with the resulting residue recrystallized from 
EtOAc/Hexanes to produce 152 as a fine white solid. (2.79 g, 63%). M.p. 162-164°C 
(decomp.), Rf 0.90 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 7.96 (m, 4H, 
Bz-H2/H6), 7.47-7.53 (m, 2H, Bz-C4). 7.31-7.40 (m, 9H, Ar-H), 5.81 (t, 1H, J = 9.5 
Hz, H3), 5.56 (s, 1H, PhCH), 5.42 (t, 1H, J = 9.2 Hz, H4), 4.92 (d, 1H, J = 8.7 Hz, H1), 
4.48 (m, 1H, H6), 3.88-3.97 (m, 2H, H2/H6’), 3.80 (m, 1H, H5). 
13
C NMR (125 MHz, 
CD3OD) δ 165.5 (C=O), 165.2 (C=O), 136.5 (Ar-C1), 133.6 (Ar-C4), 133.3 (Ar-C4), 
129.9 (Ar-C2/C6), 129.8 (Ar-C2/C6), 129.2 (Ar-C1), 128.7 (Ar-C4), 128.5 (Ar-C3/C5), 
128.4 (Ar-C3/C5), 128.2 (Ar-C3/C5), 126.1 (Ar-C2/C6), 101.6 (PhCH), 88.9 (C1, 78.5 
(C4), 71.9 (C3), 71.8 (C5), 68.9 (C2), 68.3 (C6). LRMS (ESI): m/z 540 [M + K]
+ 
HRMS (ESI): m/z calculated for C27H23N3O7K [M + K]
+
: 540.1173 Found 540.1173. 
 
2,3-Di-O-p-methoxybenzyl-β-D-glucopyranosyl azide (153) 
To a round bottom flask containing 151 (0.169 g, 0. 318 mmol) 
in MeOH: CHCl3 (5:1, 12 mL) was added dry p-TsOH (0.045 g, 
0.261 mmol), with the reaction allowed to stir for 24 hours at 
room temperature. Upon completion, solvent was removed and the resultant residue was 
purified using flash column chromatography (1:1 Hexane:EtOAc) providing 153 as a 
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waxy solid. (0.102 g, 72%), M.p 112-115°C Rf 0.31 (1:1 Hexane:EtOAc). 
1
H NMR 
(500 MHz, CD3OD) δ 7.24 (m, 4H, J = 8.5 Hz, PMB-H3/H5), 6.84 (d, 4H, J = 8.5 Hz, 
PMB-H2/H6), 4.84-4.61 (m, 5H, CH2-Ph, H1), 3.87(dd, 1H, J = 2.2 Hz, 12.1 Hz, H6), 
3.77 (s, 6H, -OCH3), 3.68 (dd, 1H, J = 5.1 Hz, 12.2 Hz, H6’), 3.47-3.36 (m, 2H, 
H3/H5), 3.30 (m, 1H, H4), 3.20 (t, 1H, J = 8.5 Hz, H2). 
13
C NMR (125 MHz, CD3OD) 
δ 159.6 (PMB-C4), 159.5 (PMB-C4’), 130.9 (PMB-C1), 130.3 (PMB-C1’), 129.5 
(PMB-C2/C6), 129.5 (PMB-C2’/C6’), 90.2 (C1), 84.6 (C3), 81.0 (C2), 78.8 (C4), 74.9 
(CH2-Ph), 74.4 (CH2-Ph), 70.1 (C5), 61.1 (C6), 54.4 (OCH3). LRMS (ESI): m/z 479 
[M + HCOO]
-
  
 
2,3-Di-O-benzoyl-β-D-glucopyranosyl azide (154) 
To a round bottom flask containing 152 (0.528 g, 1.054 mmol), 
was added a solution of CH2Cl2 and CH3OH (1:4, 5 mL). The 
resulting suspension was cooled to 0°C, and p-TsOH (0.091 g, 
0.526 mmol) was added portionwise to the solution. The reaction mixture was then 
allowed to warm to room temperature, and stirred for 3 hours. Subsequently, the 
reaction mixture was quenched with sat. NaHCO3 solution (5 mL), and extracted with 
CH2Cl2 (2 x 50 mL). The organic layers were pooled together, dried (MgSO4) and 
concentrated in vacuo, with the resulting residue subject to flash column 
chromatography (1:1 Hexane:EtOAc), producing 154 as a clear oil. (0.320 g, 73%). 
Rf 0.25 (1:1 Hexane:EtOAc).  
1
H NMR (500 MHz, CDCl3) δ 7.95 (t, 4H, 7.0 Hz, Ar-
H2/H6), 7.51 (m, 2H, Ar-H4), 7.35 (m, 4H, Ar-H3/H5), 5.51 (t, 1H, J = 9.5 Hz, H3), 
5.34 (t, 1H, J = 9.0 Hz, H2), 4.87 (d, 1H, J = 8.9 Hz, H1), 3.98 (m, 2H, H4/H6), 3.91 
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(dd, 1H, J = 3.0 Hz, 12.1 Hz, H6’), 3.90 (bs, 1H, OH), 3.69 (m, 1H, H5), 2.65 (bs, 1H, 
OH). 
13
C NMR (125 MHz, CDCl3) δ 167.3 (C=O), 165.5 (C=O), 133.9 (Ar-C4), 133.8 
(Ar-C4), 130.1 (Ar-C2/C6), 130.1 (Ar-C2/C6), 129.0 (Ar-C1), 128.7 (Ar-C3/C5), 128.7 
(Ar-C3/C5), 88.4 (C1), 78.4 (C3), 76.6 (C2), 71.3 (C5), 69.4 (C4), 62.1 (C6). LRMS 
(ESI): m/z 458 [M + HCOO]
-  
 
2,3-Di-O-p-methoxybenzyl-6-trityl-β-D-glucopyranosyl azide (155) 
To a round bottom flask 153 (0.100 g, 0.145 mmol) was added 
trityl chloride (0.061 g, 0.218 mmol) and pyridine (5 mL), with 
the reaction allowed to stir at room temperature for 48 hours. 
Upon completion, the reaction mixture was co-evaporated with toluene (2 x 25 mL). 
The resultant residue was purified using flash column chromatography (4:1 
Hexane:EtOAc), producing 155 as a white amorphous solid. (0.048 g, 31%) Rf 0.28 (4:1 
Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 7.45 (d, 4H, J = 8.5 Hz, PMB-H3/H5), 
7.30-7.20 (m, 15H, Ar-H), 6.86 (m, 4H, J = 8.5 Hz, PMB-H2/H6), 4.82 (m, 2H, 
J = 11.1 Hz, CH2-Ph, H1), 4.70 (d, 1H, J = 5.7 Hz, CH2-Ph), 4.64 (d, 1H, J = 6.3 Hz, 
CH2-Ph), 4.61 (d, 1H, J = 8.1 Hz, CH2-Ph), 3.79 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 
3.67 (t, 1H, J = 5.5 Hz, H3), 3.45-3.30 (m, 5H, H2/H4/H5/H6/H6’). 
13
C NMR (125 
MHz, CDCl3) δ 159.8 (PMB-C4/C4’), 143.9 (Trt-C1), 130.8 (Ar-C), 130.3 (Ar-C), 
130.2 (Ar-C), 130.0 (Ar-C), 129.0 (Ar-C), 128.2 (Ar-C), 127.5 (Ar-C), 114.3 (PMB-
C3/C5), 114.2 (Ar-C3’/C5’), 90.2 (C1), 87.2 (Ph-C), 84.3 (C3), 81.4 (C2), 76.6 (C4), 
75.5 (CH2-Ph), 75.1 (CH2-Ph), 71.5 (C5), 63.8 (C6), 55.6 (OCH3). LRMS (ESI): 
m/z 710 [M + Na]
+ 
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2,3-O-p-Methoxybenzyl-6-(p-methoxytrityl)-β-D-glucopyranosyl azide (156) 
To a round bottom flask 153 (0.101 g, 0.146 mmole) was added 
4-methoxytrityl chloride (0.068 g, 0.220 mmol) and pyridine 
(5 mL), with the reaction allowed to stir at room temperature for 
48 hours. Upon completion, the reaction mixture was co-evaporated with toluene 
(2 x 25 mL). The resultant residue was purified using flash column chromatography 
(4:1 Hexane: EtOAc) producing 156 as a white amorphous solid. (0.099 g, 61%), 
Rf 0.35 (4:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 7.45 (d, 6H, J = 8.5 Hz, 
PMB-H3/H5), 7.20-7.34 (m, 10H, Ar-H), 6.82-6.88 (m, 6H, PMB-H2/H6), 4.81 (d, 2H, 
CH2-Ph), 4.69 (m, 2H, CH2-Ph), 4.61 (d, 1H, J = 8.8 Hz, H1), 3.79 (3s, 9H, OCH3), 
3.67 (t, 1H, J = 9.0 Hz, H3), 3.33-3.45 (m, 5H, H2/H4/H5/H6/H6’). 
13
C NMR 
(125 MHz, CDCl3) δ 159.5 (PMB-C4) 159.4 (PMB-C4’), 158.7 (PMB-Trt-C4), 144.2 
(Trt-C1/C1’), 135.3 (PMB-Trt-C1), 130.4 (Ar-C), 130.1 (Ar-C), 129.9 (Ar-C), 
129.7 (Ar-C), 128.4 (Ar-C), 127.9 (Ar-C), 127.1 (Ar-C), 114.0 (PMB-C3/C5), 113.9 
(PMB-C3’/C5’), 113.3 (PMB-Trt-C3’/C5’), 90.0 (C1), 86.7 (Ph-C), 84.0 (C3), 81.1 
(C2), 76.3 (C4), 75.2 (CH2-Ph), 74.8 (CH2-Ph), 71.4 (C5), 63.6 (C6), 55.3 (OCH3), 55.3 
(OCH3), 55.2 (OCH3).  LRMS (ESI): m/z 740 [M + Na]
+ 
 
 
2,3-Di-O-benzoyl-1-azido-β-D-glucuronic acid (161)  
According to the method of van den Bos et al., 
227
 a round bottom 
flask containing 154 (0.120 g, 0.29 mmol), was added a solution of 
CH2Cl2 and H2O (2:1; 1.50 mL)). The biphasic solution was cooled 
to 0°C, and TEMPO (0.010 g, 0.640 mmol) and PhIOAc2 (0.242 g, 0.751 mmol) was 
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added to the reaction mixture portion wise, after which the reaction mixture was 
warmed to room temperature, and stirred vigorously for 45 minutes. After this time, the 
reaction was diluted with 10% sodium thiosulphate solution (5 mL), and extracted with 
EtOAc (2 x 10 mL). The combined organic layers were washed with brine (5 mL), dried 
(MgSO4) and evaporated in vacuo, with purification by flash column chromatography 
(5% AcOH in 1:1 Hexane:EtOAc) yielding the product 161 as a light yellow oil. (0.109 
g, 88%). Rf 0.28 (5% AcOH in 1:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CD3OD) δ 
7.91 (t, 2H, 7.0 Hz, Ar-H2/H6), 7.51 (m, 2H, Ar-H4), 7.37 (m, 4H, Ar-H3/H5), 5.61 (t, 
1H, J = 9.3 Hz, H3), 5.25 (t, 1H, J = 9.0 Hz, H2), 5.16 (d, 1H, J = 8.7 Hz, H1), 4.24 (d, 
1H,, J = 9.7 Hz, H5), 4.09 (t, 1H, J = 9.6 Hz, H4). 
13
C NMR (125 MHz, CD3OD) δ 
169.7 (C=O, COOH), 165.9 (C=O), 165.2 (C=O), 133.3 (Ar-C4), 133.1 (Ar-C4), 129.3 
(Ar-C2/C6), 129.3 (Ar-C2/C6), 128.8 (Ar-C1), 128.2 (Ar-C3/C5), 128.1 (Ar-C3/C5), 
87.9 (C1), 77.0 (C3), 75.0 (C2), 71.4 (C5), 69.7 (C4). LRMS (ESI): m/z 426 [M - H]
- 
HRMS (ESI): m/z calculated for C20H16N3O8 [M - H]
-
: 426.0937; Found 426.0946 
 
2,3-Di-O-benzoyl-1-azido-β-D-glucuronic acid methyl ester (162) 
To a round bottom flask containing 161 (0.109 g, 0.255 mmol) in 
DMF (2 mL), was added K2CO3 (0.141 g, 1.02 mmol). The 
solution was stirred for 5 minutes, before being brought down to 
0°C. MeI (0.024 mL, 0.054 g, 0.382 mmol) was subsequently added to the stirring 
solution dropwise, with the reaction mixture allowed to warm gradually to room 
temperature and stir for an additional 16 hours. Following completion, the reaction was 
diluted with H2O (5 mL), and extracted with EtOAc (10 mL). The organic layers were 
collected, washed with brine (5 mL), dried (Na2SO4) and evaporated in vacuo, yielding 
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a residue that following flash column chromatography (2:1 Hexane:EtOAc.) resulted in 
the isolation of 162 as a clear oil. (0.072 g, 64%). Rf 0.35 (2:1 Hexane:EtOAc.).   
1
H NMR (500 MHz, CDCl3) δ 7.95 (m, 4H, Ar-H2/H6), 7.50 (m, 2H, Ar-H4), 7.37 (m, 
4H, Ar-H3/H5), 5.60 (m, 1H, H3), 5.38 (t, 1H, J = 9.5 Hz, H2), 4.91 (d, 1H, J = 8.7 Hz, 
H1), 4.20 (m, 2H, H4/H5), 3.87 (s, 3H, OCH3), 3.51 (bs, 1H, OH).
13
C NMR (125 MHz, 
CDCl3) 168.5 (C=O, COOCH3), 166.4 (C=O), 165.1 (C=O), 133.6 (Ar-C4), 133.6 (Ar-
C4), 129.9 (Ar-C2/C6), 129.9 (Ar-C2/C6), 128.8 (Ar-C3/C5), 128.6 (Ar-C3/C5), 128.6 
(Ar-C1), 128.5 (Ar-C1), 88.6 (C1), 76.2 (C3), 74.6 (C2), 70.5 (C5), 70.2 (C4), 53.1 
(OCH3). LRMS (ESI): m/z 464 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C21H19N3O8Na [M + Na]
+
: 464.1070; Found 464.1092. Data gained in the production of 
this compound was not consistent with that published elsewhere.
226 
 
L-Alanine methyl ester hydrochloride (163)  
To a round bottom flask containing L-alanine (1.7 g, 19 mmol), 
was added MeOH (20 mL) and placed under an atmosphere of 
argon. The reaction mixture was cooled to 0°C, and thionyl 
chloride (1.45 mL, 2.37 g, 20 mmol) was subsequently added to the reaction mixture 
dropwise. After 30 minutes, the round bottom flask was allowed to warm to room 
temperature, and the reaction mixture was stirred for an additional 18 hours. Upon 
completion, the reaction mixture was concentrated in vacuo, producing 163 as an off-
white crystalline solid. (2.64 g, 99%). M.p. 104-106°C (Lit. 107-110°C)
255
 
1
H NMR 
(500 MHz, DMSO-d6) δ 8.54 (bs, 1H, NH3), 4.05 (m, 1H, H
α
), 3.73 (s, 3H, OCH3), 1.43 
(d, 3H, J = 7.3 Hz, H
β
). 
13
C NMR (125 MHz, DMSO-d6) 170.4 (C=O, COOCH3), 52.7 
(OCH3), 47.8 (C
α
), 15.6 (C
β
). LRMS (ESI): m/z 104 [M –Cl + H]
+ 
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N-(1-Azido-2,3-di-O-benzoyl-β-D-glucopyranuronoyl)-L-alanine methyl ester (164) 
161 (0.100 g, 0.234 mmol), HBTU (0.178 g, 0.468 mmol) and 
L-alanine methyl ester hydrochloride (163, 0.049 g, 0.351 mmol) 
were placed in a round bottom flask. DMF (5 mL) was added to 
the flask, and the resulting solution was cooled to 0°C. DIPEA 
(0.045 mL, 0.033 g, 0.257 mmol) was then added, and the reaction mixture was allowed 
to warm to room temperature, stirring for 24 hours. Upon completion, the reaction 
mixture was diluted with H2O (5 mL), and the aqueous solution was washed with 
EtOAc (20 mL). The organic phases were pooled together and washed with brine 
(5 mL), dried (NaSO4) and evaporated in vacuo. The resulting residue was then 
subjected to flash column chromatography (1:3 Hexane: EtOAc), resulting in the 
isolation of 164 as a clear oil. (0.060 g, 50%). Rf 0.05 (1:1 Hexane:EtOAc.). 
1
H NMR 
(500 MHz, CDCl3) δ 7.95 (m, 4H, Ar-H2/H6), 7.51 (m, 2H, Ar-H4), 7.37 (m, 4H, 
Ar-H3/H5), 7.15 (d, 1H, J = 7.4 Hz, NH), 5.68 (t, 1H, J = 9.4 Hz, H3), 5.36 (t, 
1H, J = 9.5 Hz, H2), 4.94 (d, 1H, J = 8.9 Hz, H1), 4.64 (m, 1H, H
α
), 4.11 (m, 2H, 
H4/H5), 3.80 (s, 3H, OCH3), 1.51 (d, 3H, J = 7.5 Hz, H
β
). 
13
C NMR (125 MHz, CDCl3) 
172.5 (C=O, COOCH3), 168.9 (C=O, CONH), 165.7 (C=O), 165.1 (C=O), 133.6 
(Ar-C4), 133.3 (Ar-C4), 129.9 (Ar-C2/H6), 129.8 (Ar-C2/H6), 129.0 (Ar-C1), 128.6 
(Ar-C1), 128.5 (Ar-C3/C5), 128.3 (Ar-C3/C5), 88.3 (C1), 74.4 (C5), 73.9 (C3), 70.6 
(C2), 70.4 (C4), 52.8 (OCH3), 47.9 (C
α
), 18.1 (C
β
). LRMS (ESI): m/z 547 [M + Cl]
-
. 
HRMS (ESI): m/z calculated for C24H24N4O9Cl [M + Cl]
-
: 547.1232; Found 547.1238. 
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N-(1-Azido-2,3-di-O-benzoyl-4-t-butyldimethylsilyl-β-D-glucopyranuronoyl)-L-
alanine methyl ester (165) 
164 (0.105 g, 0.205 mmol) and imidazole (0.070 g, 1.03 mmol) 
were dissolved in dry DMF (1 mL) in a round bottom flask. The 
reaction mixture was cooled to 0°C, and t-butyldimethylsilyl 
chloride (0.077 g, 0.511 mmol) was added portion wise. The 
reaction mixture was then flushed with argon, warmed to room temperature and allowed 
to stir for 18 hours. Upon completion, the reaction mixture was diluted with H2O (2 mL) 
and extracted with EtOAc (10 mL). The organic layers were washed with brine (2 mL), 
dried (Na2SO4) and evaporated in vacuo, with the resulting residue subjected to flash 
column chromatography (1:1 Hexane: EtOAc), producing 165 as a clear oil. (0.046 g, 
36%). Rf 0.55 (1:1 Hexane:EtOAc.).  
1
H NMR (500 MHz, CDCl3) δ 7.92 (m, 4H, Ar-
H2/H6), 7.50 (m, 2H, Ar-H4), 7.37 (m, 4H, Ar-H3/H5), 6.87 (d, 1H, J = 7.4 Hz, NH), 
5.48 (t, 1H, J = 9.4 Hz, H3), 5.29 (t, 1H, J = 9.5 Hz, H2), 5.09 (d, 1H, J = 8.9 Hz, H1), 
4.53 (m, 1H, H
α
), 4.38 (t, 1H, J = 9.4 Hz, H4), 4.17 (d, 1H, J = 6.5 Hz, H5), 3.76 (s, 3H, 
OCH3), 1.39 (d, 3H, J = 7.0 Hz, H
β
), 0.79 (s, 9H, CH3, Si-t-Bu), 0.04 (s, 3H, Si-
CH3), -0.08 (s, 3H, Si-CH3). 
13
C NMR (125 MHz, CDCl3) 172.9 (C=O, COOCH3), 
166.5 (C=O, CONH), 165.3 (C=O), 165.1 (C=O), 133.5 (Ar-C4), 133.4 (Ar-C4), 129.9 
(Ar-C2/H6), 129.8 (Ar-C2/H6), 129.3 (Ar-C1), 128.8 (Ar-C1), 128.4 (Ar-C3/C5), 128.4 
(Ar-C3/C5), 87.6 (C1), 79.7 (C5), 74.9 (C3), 71.8 (C2), 70.4 (C4), 52.6 (OCH3), 48.1 
(C
α
), 30.9 (Si-C), 25.6 (C(CH3)3), 18.4 (C
β
), -4.6 (Si-C), -4.9 (Si-CH3). LRMS (ESI): 
m/z 649 [M + Na]
+
. HRMS (ESI): m/z calculated for C30H38N4O9SiNa: 649.2306 
[M + Na]
+
; Found 649.2302 
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1,2,3,4-Tetra-O-acetyl-β-D-glucopyranuronic acid methyl ester (52)  
According to the method of Graff von Roedern et al.,
156
 
Glucuronolactone (51, 12.90 g, 72 mmol) was suspended in dry 
MeOH (400 mL), and triethylamine (0.6 mL) was added. The 
reaction mixture was stirred for 3 hours until the glucuronolactone was dissolved. The 
solvent was evaporated and the resulting solid was used without further purification. 
The solid was then suspended in Ac2O (63.0 mL, 67.8 g, 660 mmol) and NaOAc 
(6.30 g, 72.0 mmol) were added, and the suspension was stirred for 8 days. The reaction 
mixture was then poured onto ice water (300 mL) and stirred overnight. The resulting 
white solid was isolated by filtration, washed with water (50 mL), and recrystallized 
from EtOAc/Hexanes to afford the desired product 52 solely present as the β anomer. 
(10.59 g, 38%) Mp 179-180 °C. (Lit.179-180°C).
164
 Rf 0.75 (1:1 Hexane:EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 6.02 (d, 1H, J = 8.1 Hz, H1), 5.51 (dd, 1H J = 9.4 Hz, 
H3), 5.01 (t, 1H, J = 9.6 Hz, H4), 4.97 (t, 1H, J = 8.2 Hz, H2), 4.67 (d, 1H, J = 9.8 Hz, 
H5), 3.63 (s, 3H, OCH3β), 2.08-1.97 (4s, 12H, OAc). 
13
C NMR (125 MHz, CDCl3) 
170.1 (C=O, OAc), 169.6 (C=O, OAc), 169.4 (C=O, OAc), 169.0 (C=O, OAc), 167.0 
(C=O, COOCH3), 91.6 (C1), 73.2 (C5), 72.0 (C4), 70.4 (C3), 69.1 (C2), 53.2 (OCH3), 
21.0 (CH3, OAc), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI): 
m/z 399 [M + Na]
+
. HRMS (ESI): m/z calculated for C15H20O11Na [M + Na]
+
: 
399.0903; Found 399.0917. 
 
 1-Azido-1-deoxy-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53)  
To a solution of 52 (5.00g, 2.65 mmol) in CH2Cl2 (50 mL) under 
a N2 atmosphere, were added sequentially TMS-N3 (2.50 mL, 
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2.290 g, 19.85 mmol) and SnCl4 (1.00 mL, 2.22 g, 8.55 mmol), with the reaction 
mixture allowed to stir at room temperature for 3 hours. Upon completion, the reaction 
mixture was diluted further with CH2Cl2 (100 mL), washed with sat. NaHCO3 solution 
(100 mL) and brine (100 mL), dried with Na2SO4 and concentrated. The resultant solid 
was recrystallised from EtOAc/Hexanes to produce 53 as a fine white powder. (3.89 g, 
81%) Mp 154-157 °C (Lit. 152-153°C),
153
 Rf 0.85 (1:1 Hexane:EtOAc).  
1
H NMR (500 
MHz, CDCl3) δ  5.40 (dd, 1H, J = 9.6 Hz, H3), 5.19 (d, 1H,  J = 8.8 Hz, H1), 5.05 (dd, 
1H,  J = 9.8 Hz, H4), 4.87 (dd, 1H,  J = 9.2 Hz, H2), 4.57 (d,1H,  J = 9.9 Hz, H5), 3.66 
(s, 3H, OCH3), 2.04-1.98 (3s, 9H, OAc). ). 
13
C NMR (125 MHz, CDCl3) δ 170.2 (C=O, 
OAc), 169.4 (C=O, OAc), 169.3 (C=O, OAc), 167.1 (C=O), 88.1 (C1), 74.3 (C5), 72.0 
(C4), 70.5 (C2), 69.1 (C3), 53.2 (OCH3) 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, 
OAc). LRMS (ESI): m/z 382 [M + Na]
+ 
HRMS (ESI): m/z calculated for 
C13H17N3O9Na [M + Na]
+
: 382.0862; Found 382.0867. 
 
2,4-Di-O-acetyl-β-D-glucopyranuronyl azide-3,6-lactone (166)  
According to the method of Tosin et al.,
157
 To a round bottom flask 
containing 53 (0.985 g, 2.74 mmol) was added a solution of LiOH 
(0.3 M, 60 mL) at 0°C, with the resulting suspension allowed to stir for 
3.5 hours. Following this time, the pH of the solution was adjusted to 2 
using Amberlite IR-120 resin, the solution was filtered, and concentrated in vacuo, 
before being subjected to lyophilisation overnight. The resulting white powder was 
suspended in Ac2O (20.0 mL) and 4Å molecular sieves were added, with the reaction 
mixture placed under argon and allowed to stir at 85°C for 2 hours. After this time, 
filtration followed by concentration in vacuo and consecutive azeotropic distillation 
with toluene, resulted in the isolation of 166 as yellow oil that was directly used in the 
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next step without further purification. (0.586 g, 75%), Rf 0.31 (1:1 Hexane:EtOAc.).  
1
H NMR (500 MHz, CDCl3) δ 5.44 (m, 1H, H1), 5.07 (m, 1H, H3), 4.93 (m, 2H, 
H2/H4), 4.36 (m, 1H, H5), 2.19 (s, 3H, CH3, OAc), 2.10 (s, 3H, CH3, OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.2 (C=O), 169.0 (C=O, OAc), 168.9 (C=O, OAc), 
88.5 (C1), 71.4 (C5), 68.9 (C4), 68.6 (C3), 67.5 (C2), 20.7 (CH3, OAc), 20.7 
(CH3, OAc).  
 
N-(1-Azido-2,4-di-O-acetyl-β-D-glucopyranuronoyl)-L-alanine methyl ester (169) 
To a round bottom flask containing 166 (0.586 g, 2.05 mmol), was 
added L-alanine methyl ester hydrochloride (163, 0.430 g, 
3.08 mmol) and dry CH2Cl2 (10 ml). The reaction mixture was 
cooled to 0°C, and NEt3 (0.311 g, 0.430 mL, 3.08 mmol) was 
added dropwise, with the resulting suspension allowed to warm to room temperature 
and stirred for 18 hours. Upon completion, the reaction mixture was diluted with 
CH2Cl2 (10 mL), and the organic phase was washed with H2O (5 mL) and brine (5 mL). 
Drying (Na2SO4) and evaporation in vacuo, followed by flash column chromatography 
resulted in the isolation of 169 as a white solid. (0.447 g, 56%), M.p. 162-163°C 
(decomp.) Rf 0.25 (1:1 Hexane:EtOAc.). 
1
H NMR (500 MHz, CDCl3) δ 6.93 (d, 1H, 
J = 7.1 Hz, NH), 5.04 (t, 1H, J = 9.6 Hz, H4), 4.87 (t, 1H, J = 8.9 Hz, H2), 4.69 (d, 1H, 
J = 8.8 Hz, H1), 4.54 (m, 1H, H
α
), 3.94 (d, 1H, J = 9.9 Hz, H5), 3.83 (t, 1H, J = 9.2 Hz, 
H4), 3.76 (s, 3H, OCH3),  2.16 (s, 3H, CH3, OAc), 2.13 (s, 3H, CH3, OAc), 1.43 (d, 3H, 
J = 7.1 Hz, H
β
). 
13
C NMR (125 MHz, CDCl3) 172.9 (C=O), 170.3 (C=O, OAc), 170.2 
(C=O, OAc), 165.8 (C=O, CONH), 87.9 (C1), 74.4 (C5), 72.9 (C4), 72.8 (C2), 71.5 
(C3), 52.6 (OCH3), 47.8 (C
α
), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 18.1 (C
β
). 
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LRMS (ESI): m/z 411 [M + Na]
+ 
HRMS (ESI): m/z calculated for C14H20N4O9Na 
[M + Na]
+
: 411.1128; Found 411.1165. 
 
N-(1-Azido-2,4-di-O-acetyl-3-t-butyldimethylsilyl-β-D-glucopyranuronoyl)-L-
alanine methyl ester (170) 
169 (0.400 g, 1.03 mmol) and imidazole (0.281 g, 4.12 mmol) 
were dissolved in dry DMF (10 mL) in a round bottom flask. The 
reaction mixture was cooled to 0°C, and t-butyldimethylsilyl 
chloride (0.310 g, 2.06 mmol) was added portionwise. The 
reaction mixture was then flushed with argon, warmed to room temperature and allowed 
to stir for 18 hours. Upon completion, the reaction mixture was diluted with H2O 
(10 mL) and extracted with EtOAc (2 x 25 mL). The organic layers were pooled and 
washed with brine (10 mL), dried (Na2SO4) and evaporated in vacuo, with the resulting 
residue subjected to flash column chromatography, producing 170 as a white solid. 
(0.343 g, 66%), M.p. 152-153°C Rf 0.85 (1:1 Hexane:EtOAc.)  
1
H NMR (500 MHz, 
CDCl3) δ 6.94 (d, 1H, J = 7.1 Hz, NH), 5.01 (t, 1H, J = 9.6 Hz, H4), 4.93 (t, 1H, 
J = 8.9 Hz, H2), 4.53 (m, 2H, H1/H
α
), 3.88 (m, 2H, H4/H5), 3.75 (s, 3H, OCH3),  2.13 
(s, 3H, CH3, OAc), 2.10 (s, 3H, CH3, OAc), 1.42 (d, 3H, J = 7.1 Hz, H
β
), 0.81 (s, 9H, 
Si-tBu), 0.05 (s, 6H, 2 x Si-CH3). 
13
C NMR (125 MHz, CDCl3) 173.0 (C=O), 169.9 
(C=O, OAc), 169.4 (C=O, OAc), 166.1 (C=O, CONH), 88.2 (C1), 74.9 (C5), 73.0 (C4), 
72.9 (C2), 72.0 (C3), 52.8 (OCH3), 47.9 (C
α
), 25.6 (C(CH3)3),  21.3 (CH3, OAc), 21.2 
(CH3, OAc), 18.3 (C
β
), 18.0 (C(CH3)3), -4.4 (Si-CH3). LRMS (ESI): m/z 525 [M + Na]
+ 
HRMS (ESI): m/z calculated for C20H34N4O9SiNa [M + Na]
+
: 525.1993; 
Found 525.2014. 
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1-(4’-(3”-Fluoropropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic 
acid allyl ester (173) 
To a round bottom flask containing 74 (0.101 g, 
0.215 mmol) dissolved in ACN (5 mL), was 
added C4F9SO2F (0.132 g, 0.080 mL, 
0.433 mmol) NEt3.3HF (0.069 g, 0.070 mL, 
0.430 mmol) and NEt3 (0.131 g, 0.180 mL, 1.30 mmol). Under an argon atmosphere, 
the reaction mixture was stirred at room temperature for 24 hours. Upon completion, the 
reaction mixture was filtered through a short silica plug. The resulting solution was then 
evaporated in vacuo, with purification by flash column chromatography (1:1 Hexane: 
EtOAc) producing the desired product 173 as a light yellow solid.  (0.059 g, 58 %). Rf 
0.15 (1:1 Hexane:EtOAc), M.p 114-116°C. 
 1
H NMR (500 MHz, CDCl3) δ  7.65 (s, 1H, 
Triazole-H), 5.94-5.81 (m, 2H, H1/CH2=CH-CH2), 5.48-5.27 (m, 5H, 
H4/H3/H2/CH2=CH-CH2), 4.65 (m, 2H, CH2=CH-CH2), 4.51-4.42 (dt, 2H, J = 6.1 Hz, 
47 Hz, CH2-CH2-CH2-F), 4.36 (d,1H,  J = 9.8 Hz, H5), 2.87 (m, 2H, CH2-CH2-CH2-F), 
2.17 (m, 2H, CH2-CH2-CH2-F),  2.05 (2s, 6H, OAc), 1.88 (s, 3H, OAc). 
13
C NMR (125 
MHz, CDCl3) δ 170.0 (C=O, OAc), 169.6 (C=O, OAc), 169.1 (C=O, OAc), 165.8 
(C=O), 147.9 (Triazole C), 131.0 (CH2-CH=CH2), 120.1 (Triazole C), 119.7(CH2-
CH=CH2), 85.6 (C1), 83.8-82.4 (d, J = 164.9 Hz, CH2-CH2-CH2-F),  75.1 (C5), 72.1 
(C4), 70.2 (C3), 69.2 (C2), 67.2 (CH2-CH=CH2),  30.0-29.8 (d, J = 20.1 Hz, CH2-CH2-
CH2-F), 21.5 (CH2-CH2-CH2-F), 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.3 (CH3, OAc). 
LRMS (ESI): m/z 494 [M + Na]
+ 
HRMS (ESI): m/z calculated for C20H26FN3O9Na 
[M + Na]
+
: 494.1551; Found 494.1574. 
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N-(1-(4’-(3”-Fluoropropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-
glucuronoyl)-L-methionine methyl ester (174) 
To a round bottom flask containing 86 (0.100 g, 
0.174 mmol) dissolved in ACN (5 mL), was 
added C4F9SO2F (0.105 g, 0.063 mL, 
0.348 mmol) NEt3.3HF (0.059 g, 0.060 mL, 
0.352 mmol) and NEt3 (0.105 g, 0.145 mL, 1.04 mmol). Under an argon atmosphere, 
the reaction mixture was stirred at room temperature for 24 hours. Upon completion, the 
reaction mixture was filtered through a short silica plug. The resulting solution was then 
evaporated in vacuo, with purification of the residue by flash column chromatography 
(1:1 Hexane: EtOAc) producing the desired product 174 as a white solid (0.049mg, 
49%). Rf 0.35 (1:1 Hexane:EtOAc), M.p 198-199°C. 
 1
H NMR (500 MHz, CDCl3) δ 
7.63 (s, 1H, Triazole-H), 7.06 (d, 1H, J = 7.6 Hz, NH), 5.94 (d, 1H, J = 9.5 Hz, H1), 
5.55 (t, 1H, J = 9.7 Hz, H3), 5.49 (t, 1H, J = 9.7 Hz, H4), 5.35 (t, 1H, J = 9.7 Hz, H2), 
4.64 (m, 1H, H
α
), 4.27-4.25 (dt, 2H, J = 5.8 Hz, 52.9 Hz, CH2-CH2-CH2-F),  4.25 (d, 
1H, J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 2.89 (t, 2H, J = 7.3 Hz, CH2-CH2-CH2-F), 
2.51 (t, 1H, J = 7.2 Hz, H
γ
), 2.17-2.15 (m, 2H, H
β
), 2.09-2.04 (2s, 9H, 3 x OAc), 2.04-
1.99, (m, 2H, CH2-CH2-CH2-F), 1.89 (s, 3H, SCH3). 
13
C NMR (125 MHz, CD3OD) δ 
172.1 (COOCH3), 169.9 (C=O, OAc), 169.7 (C=O, OAc), 169.1 (C=O, OAc), 165.4 
(C=O), 148.0 (Triazole-C), 119.9 (Triazole-C), 85.3 (C1),  83.7-82.4 (d, J = 164.6 Hz, 
CH2-CH2-CH2-F), 75.4 (C5), 72.2 (C2), 70.2 (C4), 69.2 (C3), 52.9 (C
α
), 51.6 (-OCH3), 
31.2 (C
β
), 30.0 (C
γ
), 30.0-29.8 (d, J = 20.5 Hz, CH2-CH2-CH2-F), 21.7 (CH2-CH2-CH2-
F), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.3 (CH3, OAc), 15.5 (SCH3). 
LRMS (ESI): m/z 599 [M + Na]
+ 
HRMS (ESI): m/z calculated for C23H33FN4O10SNa 
[M + Na]
+
: 599.1799; Found 599.1808. 
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